ID   SCN1A_HUMAN             Reviewed;        2009 AA.
AC   P35498; E9PG49; Q16172; Q585T7; Q8IUJ6; Q96LA3; Q9C008;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   08-DEC-2000, sequence version 2.
DT   15-FEB-2017, entry version 186.
DE   RecName: Full=Sodium channel protein type 1 subunit alpha;
DE   AltName: Full=Sodium channel protein brain I subunit alpha;
DE   AltName: Full=Sodium channel protein type I subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.1;
GN   Name=SCN1A; Synonyms=NAC1, SCN1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANTS GEFS+2 MET-875
RP   AND HIS-1648.
RX   PubMed=10742094; DOI=10.1038/74159;
RA   Escayg A., MacDonald B.T., Meisler M.H., Baulac S., Huberfeld G.,
RA   An-Gourfinkel I., Brice A., LeGuern E., Moulard B., Chaigne D.,
RA   Buresi C., Malafosse A.;
RT   "Mutations of SCN1A, encoding a neuronal sodium channel, in two
RT   families with GEFS+2.";
RL   Nat. Genet. 24:343-345(2000).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RA   Jeong S.-Y., Goto J., Kanazawa I.;
RT   "Cloning of cDNA for human voltage-gated sodium channel alpha subunit,
RT   SCN1A.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Sugawara T., Mazaki E.M., Yamakawa K.;
RT   "Homo sapiens neuronal voltage-gated sodium channel type I (Nav1.1)
RT   mRNA.";
RL   Submitted (JUL-2001) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1; 2 AND 3), VARIANT THR-1067,
RP   AND ALTERNATIVE SPLICING.
RC   TISSUE=Brain;
RA   Ouchida M., Ohmori I.;
RT   "Isoforms of human sodium channel SCN1A gene.";
RL   Submitted (OCT-2002) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1335-1428.
RX   PubMed=8062593;
RA   Malo M.S., Blanchard B.J., Andresen J.M., Srivastava K., Chen X.N.,
RA   Li X., Jabs E.W., Korenberg J.R., Ingram V.M.;
RT   "Localization of a putative human brain sodium channel gene (SCN1A) to
RT   chromosome band 2q24.";
RL   Cytogenet. Cell Genet. 67:178-186(1994).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1518-1940.
RC   TISSUE=Brain;
RX   PubMed=1317301; DOI=10.1016/0014-5793(92)80476-W;
RA   Lu C.-M., Han J., Rado T.A., Brown G.B.;
RT   "Differential expression of two sodium channel subtypes in human
RT   brain.";
RL   FEBS Lett. 303:53-58(1992).
RN   [8]
RP   INTERACTION WITH FGF13.
RX   PubMed=21566136; DOI=10.1074/jbc.M111.245803;
RA   Wang C., Wang C., Hoch E.G., Pitt G.S.;
RT   "Identification of novel interaction sites that determine specificity
RT   between fibroblast growth factor homologous factors and voltage-gated
RT   sodium channels.";
RL   J. Biol. Chem. 286:24253-24263(2011).
RN   [9]
RP   INTERACTION WITH THE CONOTOXIN GVIIJ.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G.,
RA   Wickenden A.D., Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [10]
RP   VARIANTS GEFS+2 VAL-188; LEU-1353 AND MET-1656, AND VARIANTS THR-1067
RP   AND GLY-1928.
RX   PubMed=11254444; DOI=10.1086/319516;
RA   Wallace R.H., Scheffer I.E., Barnett S., Richards M., Dibbens L.,
RA   Desai R.R., Lerman-Sagie T., Lev D., Mazarib A., Brand N.,
RA   Ben-Zeev B., Goikhman I., Singh R., Kremmidiotis G., Gardner A.,
RA   Sutherland G.R., George A.L. Jr., Mulley J.C., Berkovic S.F.;
RT   "Neuronal sodium-channel alpha1-subunit mutations in generalized
RT   epilepsy with febrile seizures plus.";
RL   Am. J. Hum. Genet. 68:859-865(2001).
RN   [11]
RP   VARIANT GEFS+2 ARG-1204.
RX   PubMed=11254445; DOI=10.1086/319524;
RA   Escayg A., Heils A., MacDonald B.T., Haug K., Sander T., Meisler M.H.;
RT   "A novel SCN1A mutation associated with generalized epilepsy with
RT   febrile seizures plus -- and prevalence of variants in patients with
RT   epilepsy.";
RL   Am. J. Hum. Genet. 68:866-873(2001).
RN   [12]
RP   VARIANT EIEE6 PHE-986.
RX   PubMed=11359211; DOI=10.1086/320609;
RA   Claes L., Del-Favero J., Ceulemans B., Lagae L., Van Broeckhoven C.,
RA   De Jonghe P.;
RT   "De novo mutations in the sodium-channel gene SCN1A cause severe
RT   myoclonic epilepsy of infancy.";
RL   Am. J. Hum. Genet. 68:1327-1332(2001).
RN   [13]
RP   VARIANTS GEFS+2 ALA-1428 AND VAL-1685.
RX   PubMed=11524484; DOI=10.1212/WNL.57.4.703;
RA   Sugawara T., Mazaki-Miyazaki E., Ito M., Nagafuji H., Fukuma G.,
RA   Mitsudome A., Wada K., Kaneko S., Hirose S., Yamakawa K.;
RT   "Na(v)1.1 mutations cause febrile seizures associated with afebrile
RT   partial seizures.";
RL   Neurology 57:703-705(2001).
RN   [14]
RP   VARIANT GEFS+2 THR-1270.
RX   PubMed=11756608; DOI=10.1212/WNL.57.12.2265;
RA   Abou-Khalil B., Ge Q., Desai R., Ryther R., Bazyk A., Bailey R.,
RA   Haines J.L., Sutcliffe J.S., George A.L. Jr.;
RT   "Partial and generalized epilepsy with febrile seizures plus and a
RT   novel SCN1A mutation.";
RL   Neurology 57:2265-2272(2001).
RN   [15]
RP   VARIANTS EIEE6 CYS-902; CYS-931; PRO-1265; PHE-1289 DEL; MET-1390;
RP   ARG-1434; ARG-1450; CYS-1648 AND ARG-1674 AND ILE-1909, AND VARIANT
RP   THR-1067.
RX   PubMed=12083760; DOI=10.1016/S0006-291X(02)00617-4;
RA   Ohmori I., Ouchida M., Ohtsuka Y., Oka E., Shimizu K.;
RT   "Significant correlation of the SCN1A mutations and severe myoclonic
RT   epilepsy in infancy.";
RL   Biochem. Biophys. Res. Commun. 295:17-23(2002).
RN   [16]
RP   VARIANTS EIEE6 GLY-103; ILE-112; TRP-265; ASP-343; VAL-960; ILE-985;
RP   ARG-1231; LEU-1263; ASP-1685; 1807-MET--GLU-1810 DEL; GLY-1812 AND
RP   SER-1831, VARIANTS ICEGTC SER-808; ARG-979; ALA-983; ILE-1011;
RP   PHE-1611; SER-1632; ILE-1709 AND LEU-1808, AND VARIANT THR-1067.
RX   PubMed=12566275; DOI=10.1093/brain/awg053;
RA   Fujiwara T., Sugawara T., Mazaki-Miyazaki E., Takahashi Y.,
RA   Fukushima K., Watanabe M., Hara K., Morikawa T., Yagi K., Yamakawa K.,
RA   Inoue Y.;
RT   "Mutations of sodium channel alpha subunit type 1 (SCN1A) in
RT   intractable childhood epilepsies with frequent generalized tonic-
RT   clonic seizures.";
RL   Brain 126:531-546(2003).
RN   [17]
RP   VARIANTS GEFS+2 CYS-790 AND THR-1852.
RX   PubMed=12919402; DOI=10.1046/j.1528-1157.2003.22503.x;
RA   Annesi G., Gambardella A., Carrideo S., Incorpora G., Labate A.,
RA   Pasqua A.A., Civitelli D., Polizzi A., Annesi F., Spadafora P.,
RA   Tarantino P., Ciro Candiano I.C., Romeo N., De Marco E.V., Ventura P.,
RA   LePiane E., Zappia M., Aguglia U., Pavone L., Quattrone A.;
RT   "Two novel SCN1A missense mutations in generalized epilepsy with
RT   febrile seizures plus.";
RL   Epilepsia 44:1257-1258(2003).
RN   [18]
RP   VARIANT GEFS+2 VAL-188, AND CHARACTERIZATION OF VARIANT GEFS+2
RP   VAL-188.
RX   PubMed=12576172; DOI=10.1016/S0920-1211(02)00259-0;
RA   Cossette P., Loukas A., Lafreniere R.G., Rochefort D.,
RA   Harvey-Girard E., Ragsdale D.S., Dunn R.J., Rouleau G.A.;
RT   "Functional characterization of the D188V mutation in neuronal
RT   voltage-gated sodium channel causing generalized epilepsy with febrile
RT   seizures plus (GEFS).";
RL   Epilepsy Res. 53:107-117(2003).
RN   [19]
RP   VARIANTS EIEE6 HIS-393; GLN-939; ARG-959; ARG-1434; SER-1661 AND
RP   GLU-1749.
RX   PubMed=12754708; DOI=10.1002/humu.10217;
RA   Claes L., Ceulemans B., Audenaert D., Smets K., Loefgren A.,
RA   Del-Favero J., Ala-Mello S., Basel-Vanagaite L., Plecko B., Raskin S.,
RA   Thiry P., Wolf N.I., Van Broeckhoven C., De Jonghe P.;
RT   "De novo SCN1A mutations are a major cause of severe myoclonic
RT   epilepsy of infancy.";
RL   Hum. Mutat. 21:615-621(2003).
RN   [20]
RP   VARIANT GEFS+2 CYS-1657, CHARACTERIZATION OF VARIANTS GEFS+2 LEU-1353;
RP   MET-1656; CYS-1657 AND VAL-1685, AND CHARACTERIZATION OF VARIANT EIEE6
RP   PHE-986.
RX   PubMed=14672992;
RA   Lossin C., Rhodes T.H., Desai R.R., Vanoye C.G., Wang D., Carniciu S.,
RA   Devinsky O., George A.L. Jr.;
RT   "Epilepsy-associated dysfunction in the voltage-gated neuronal sodium
RT   channel SCN1A.";
RL   J. Neurosci. 23:11289-11295(2003).
RN   [21]
RP   VARIANTS GLN-542; THR-1034; LEU-1038; THR-1067 AND THR-1955.
RX   PubMed=12610651; DOI=10.1038/sj.mp.4001241;
RA   Weiss L.A., Escayg A., Kearney J.A., Trudeau M., MacDonald B.T.,
RA   Mori M., Reichert J., Buxbaum J.D., Meisler M.H.;
RT   "Sodium channels SCN1A, SCN2A and SCN3A in familial autism.";
RL   Mol. Psychiatry 8:186-194(2003).
RN   [22]
RP   VARIANTS EIEE6 ASP-78; GLU-177; SER-227; ARG-280; ILE-297; ASN-426;
RP   ARG-1233; ILE-1461; SER-1463; ALA-1668; THR-1780 AND
RP   1812-TRP--LYS-1815 DELINS CYS.
RX   PubMed=12821740; DOI=10.1212/01.WNL.0000069463.41870.2F;
RA   Nabbout R., Gennaro E., Dalla Bernardina B., Dulac O., Madia F.,
RA   Bertini E., Capovilla G., Chiron C., Cristofori G., Elia M.,
RA   Fontana E., Gaggero R., Granata T., Guerrini R., Loi M., La Selva L.,
RA   Lispi M.L., Matricardi A., Romeo A., Tzolas V., Valseriati D.,
RA   Veggiotti P., Vigevano F., Vallee L., Dagna Bricarelli F., Bianchi A.,
RA   Zara F.;
RT   "Spectrum of SCN1A mutations in severe myoclonic epilepsy of
RT   infancy.";
RL   Neurology 60:1961-1967(2003).
RN   [23]
RP   VARIANTS EIEE6 PRO-1326 AND ASP-1881, AND VARIANT INFANTILE SPASMS
RP   GLY-1957.
RX   PubMed=14504318; DOI=10.1212/01.WNL.0000086379.71183.78;
RA   Wallace R.H., Hodgson B.L., Grinton B.E., Gardiner R.M., Robinson R.,
RA   Rodriguez-Casero V., Sadleir L., Morgan J., Harkin L.A., Dibbens L.M.,
RA   Yamamoto T., Andermann E., Mulley J.C., Berkovic S.F., Scheffer I.E.;
RT   "Sodium channel alpha1-subunit mutations in severe myoclonic epilepsy
RT   of infancy and infantile spasms.";
RL   Neurology 61:765-769(2003).
RN   [24]
RP   CHARACTERIZATION OF VARIANT GEFS+2 ARG-1204.
RX   PubMed=12535936; DOI=10.1016/S0306-4522(02)00698-X;
RA   Spampanato J., Escayg A., Meisler M.H., Goldin A.L.;
RT   "Generalized epilepsy with febrile seizures plus type 2 mutation
RT   W1204R alters voltage-dependent gating of Na(v)1.1 sodium channels.";
RL   Neuroscience 116:37-48(2003).
RN   [25]
RP   VARIANTS EIEE6 GLN-101; ARG-190; ILE-934; ALA-944; CYS-946; HIS-946;
RP   PRO-1355; MET-1559 DEL; SER-1692; CYS-1694; PHE-1766 DEL AND CYS-1781.
RX   PubMed=14738421; DOI=10.1111/j.0013-9580.2004.15103.x;
RA   Fukuma G., Oguni H., Shirasaka Y., Watanabe K., Miyajima T.,
RA   Yasumoto S., Ohfu M., Inoue T., Watanachai A., Kira R., Matsuo M.,
RA   Muranaka H., Sofue F., Zhang B., Kaneko S., Mitsudome A., Hirose S.;
RT   "Mutations of neuronal voltage-gated Na+ channel alpha 1 subunit gene
RT   SCN1A in core severe myoclonic epilepsy in infancy (SMEI) and in
RT   borderline SMEI (SMEB).";
RL   Epilepsia 45:140-148(2004).
RN   [26]
RP   VARIANT GEFS+2 TYR-1866, CHARACTERIZATION OF VARIANT GEFS+2 TYR-1866,
RP   AND INTERACTION WITH SCN1B.
RX   PubMed=15525788; DOI=10.1523/JNEUROSCI.2034-04.2004;
RA   Spampanato J., Kearney J.A., de Haan G., McEwen D.P., Escayg A.,
RA   Aradi I., MacDonald B.T., Levin S.I., Soltesz I., Benna P.,
RA   Montalenti E., Isom L.L., Goldin A.L., Meisler M.H.;
RT   "A novel epilepsy mutation in the sodium channel SCN1A identifies a
RT   cytoplasmic domain for beta subunit interaction.";
RL   J. Neurosci. 24:10022-10034(2004).
RN   [27]
RP   VARIANT EIEE6 ASN-252.
RX   PubMed=15087100; DOI=10.1016/j.pediatrneurol.2003.10.012;
RA   Ceulemans B.P.G.M., Claes L.R.F., Lagae L.G.;
RT   "Clinical correlations of mutations in the SCN1A gene: from febrile
RT   seizures to severe myoclonic epilepsy in infancy.";
RL   Pediatr. Neurol. 30:236-243(2004).
RN   [28]
RP   VARIANT EIEE6 ASN-1713, AND VARIANT THR-1067.
RX   PubMed=16122630; DOI=10.1016/j.braindev.2004.11.005;
RA   Kimura K., Sugawara T., Mazaki-Miyazaki E., Hoshino K., Nomura Y.,
RA   Tateno A., Hachimori K., Yamakawa K., Segawa M.;
RT   "A missense mutation in SCN1A in brothers with severe myoclonic
RT   epilepsy in infancy (SMEI) inherited from a father with febrile
RT   seizures.";
RL   Brain Dev. 27:424-430(2005).
RN   [29]
RP   VARIANT GEFS+2 LEU-1857.
RX   PubMed=15715999; DOI=10.1016/j.eplepsyres.2004.11.005;
RA   Nagao Y., Mazaki-Miyazaki E., Okamura N., Takagi M., Igarashi T.,
RA   Yamakawa K.;
RT   "A family of generalized epilepsy with febrile seizures plus type 2-a
RT   new missense mutation of SCN1A found in the pedigree of several
RT   patients with complex febrile seizures.";
RL   Epilepsy Res. 63:151-156(2005).
RN   [30]
RP   VARIANTS ICEGTC SER-808 AND ILE-1011, AND CHARACTERIZATION OF VARIANTS
RP   ICEGTC SER-808; ARG-979; ALA-983; ILE-1011; PHE-1611; SER-1632;
RP   ILE-1709 AND LEU-1808.
RX   PubMed=16210358; DOI=10.1113/jphysiol.2005.094326;
RA   Rhodes T.H., Vanoye C.G., Ohmori I., Ogiwara I., Yamakawa K.,
RA   George A.L. Jr.;
RT   "Sodium channel dysfunction in intractable childhood epilepsy with
RT   generalized tonic-clonic seizures.";
RL   J. Physiol. (Lond.) 569:433-445(2005).
RN   [31]
RP   VARIANT FHM3 LYS-1489.
RX   PubMed=16054936; DOI=10.1016/S0140-6736(05)66786-4;
RA   Dichgans M., Freilinger T., Eckstein G., Babini E.,
RA   Lorenz-Depiereux B., Biskup S., Ferrari M.D., Herzog J.,
RA   van den Maagdenberg A.M.J.M., Pusch M., Strom T.M.;
RT   "Mutation in the neuronal voltage-gated sodium channel SCN1A in
RT   familial hemiplegic migraine.";
RL   Lancet 366:371-377(2005).
RN   [32]
RP   VARIANT EIEE6 SER-946.
RX   PubMed=15944908; DOI=10.1055/s-2005-865607;
RA   Ebach K., Joos H., Doose H., Stephani U., Kurlemann G., Fiedler B.,
RA   Hahn A., Hauser E., Hundt K., Holthausen H., Mueller U.,
RA   Neubauer B.A.;
RT   "SCN1A mutation analysis in myoclonic astatic epilepsy and severe
RT   idiopathic generalized epilepsy of infancy with generalized tonic-
RT   clonic seizures.";
RL   Neuropediatrics 36:210-213(2005).
RN   [33]
RP   VARIANT FEB3A THR-145, AND CHARACTERIZATION OF VARIANT FEB3A THR-145.
RX   PubMed=16326807; DOI=10.1073/pnas.0506818102;
RA   Mantegazza M., Gambardella A., Rusconi R., Schiavon E., Annesi F.,
RA   Cassulini R.R., Labate A., Carrideo S., Chifari R., Canevini M.P.,
RA   Canger R., Franceschetti S., Annesi G., Wanke E., Quattrone A.;
RT   "Identification of an Nav1.1 sodium channel (SCN1A) loss-of-function
RT   mutation associated with familial simple febrile seizures.";
RL   Proc. Natl. Acad. Sci. U.S.A. 102:18177-18182(2005).
RN   [34]
RP   VARIANT GEFS+2 GLY-1742.
RX   PubMed=15694566; DOI=10.1016/j.seizure.2004.12.007;
RA   Pineda-Trujillo N., Carrizosa J., Cornejo W., Arias W., Franco C.,
RA   Cabrera D., Bedoya G., Ruiz-Linares A.;
RT   "A novel SCN1A mutation associated with severe GEFS+ in a large South
RT   American pedigree.";
RL   Seizure 14:123-128(2005).
RN   [35]
RP   VARIANT EIEE6 PRO-1393.
RX   PubMed=17129991; DOI=10.1080/08035250600778628;
RA   Stefanaki E., Aggelakou V., Orfanou M., Kokori E., Boutoufianakis S.;
RT   "Epilepsy with a de novo missense mutation in the sodium channel a1
RT   subunit: a case report.";
RL   Acta Paediatr. 95:1703-1706(2006).
RN   [36]
RP   VARIANTS EIEE6 ASP-78; PRO-162; ASN-194; LYS-217; SER-227; ARG-280;
RP   LEU-383; CYS-393; SER-393; ASN-426; ARG-812; LYS-846; PRO-942;
RP   ARG-1233; GLN-1245; CYS-1422; ARG-1426; LEU-1451; SER-1463; SER-1475;
RP   ALA-1668; ARG-1714; GLU-1762; PHE-1773 AND THR-1780.
RX   PubMed=17054684; DOI=10.1111/j.1528-1167.2006.00641.x;
RA   Mancardi M.M., Striano P., Gennaro E., Madia F., Paravidino R.,
RA   Scapolan S., Dalla Bernardina B., Bertini E., Bianchi A.,
RA   Capovilla G., Darra F., Elia M., Freri E., Gobbi G., Granata T.,
RA   Guerrini R., Pantaleoni C., Parmeggiani A., Romeo A., Santucci M.,
RA   Vecchi M., Veggiotti P., Vigevano F., Pistorio A., Gaggero R.,
RA   Zara F.;
RT   "Familial occurrence of febrile seizures and epilepsy in severe
RT   myoclonic epilepsy of infancy (SMEI) patients with SCN1A mutations.";
RL   Epilepsia 47:1629-1635(2006).
RN   [37]
RP   CHARACTERIZATION OF VARIANTS EIEE6 GLU-177; SER-227; HIS-393; ASN-426;
RP   GLN-939; ARG-959; PHE-1289 DEL AND ILE-1909.
RX   PubMed=17054685; DOI=10.1111/j.1528-1167.2006.00643.x;
RA   Ohmori I., Kahlig K.M., Rhodes T.H., Wang D.W., George A.L. Jr.;
RT   "Nonfunctional SCN1A is common in severe myoclonic epilepsy of
RT   infancy.";
RL   Epilepsia 47:1636-1642(2006).
RN   [38]
RP   VARIANT GEFS+2 CYS-859, AND CHARACTERIZATION OF VARIANT GEFS+2
RP   CYS-859.
RX   PubMed=16525050; DOI=10.1523/JNEUROSCI.2977-05.2006;
RA   Barela A.J., Waddy S.P., Lickfett J.G., Hunter J., Anido A.,
RA   Helmers S.L., Goldin A.L., Escayg A.;
RT   "An epilepsy mutation in the sodium channel SCN1A that decreases
RT   channel excitability.";
RL   J. Neurosci. 26:2714-2723(2006).
RN   [39]
RP   VARIANTS EIEE6 LEU-403; ASN-413; HIS-946; ASP-1238; GLY-1396 AND
RP   GLN-1645.
RX   PubMed=16713920; DOI=10.1016/S1474-4422(06)70446-X;
RA   Berkovic S.F., Harkin L., McMahon J.M., Pelekanos J.T., Zuberi S.M.,
RA   Wirrell E.C., Gill D.S., Iona X., Mulley J.C., Scheffer I.E.;
RT   "De-novo mutations of the sodium channel gene SCN1A in alleged vaccine
RT   encephalopathy: a retrospective study.";
RL   Lancet Neurol. 5:488-492(2006).
RN   [40]
RP   VARIANT EIEE6 THR-1231.
RX   PubMed=16458823; DOI=10.1016/j.pediatrneurol.2005.07.009;
RA   Kearney J.A., Wiste A.K., Stephani U., Trudeau M.M., Siegel A.,
RA   Ramachandrannair R., Elterman R.D., Muhle H., Reinsdorf J.,
RA   Shields W.D., Meisler M.H., Escayg A.;
RT   "Recurrent de novo mutations of SCN1A in severe myoclonic epilepsy of
RT   infancy.";
RL   Pediatr. Neurol. 34:116-120(2006).
RN   [41]
RP   VARIANTS CYS-393; PRO-395; GLU-422; GLY-626; VAL-1480; SER-1543;
RP   GLN-1636 AND HIS-1657, VARIANTS EIEE6 HIS-79; CYS-84; TRP-101;
RP   ARG-199; MET-226; THR-239; LEU-403; ASN-413; GLY-674; PRO-783;
RP   GLU-944; LEU-945; GLU-950; ASP-1238; MET-1390; GLY-1396; PRO-1441;
RP   VAL-1545; CYS-1596; GLN-1645; VAL-1707; ARG-1721 AND THR-1922, AND
RP   VARIANT GEFS+2 VAL-973.
RX   PubMed=17347258; DOI=10.1093/brain/awm002;
RG   The infantile epileptic encephalopathy referral consortium;
RA   Harkin L.A., McMahon J.M., Iona X., Dibbens L., Pelekanos J.T.,
RA   Zuberi S.M., Sadleir L.G., Andermann E., Gill D., Farrell K.,
RA   Connolly M., Stanley T., Harbord M., Andermann F., Wang J.,
RA   Batish S.D., Jones J.G., Seltzer W.K., Gardner A., Sutherland G.,
RA   Berkovic S.F., Mulley J.C., Scheffer I.E.;
RT   "The spectrum of SCN1A-related infantile epileptic encephalopathies.";
RL   Brain 130:843-852(2007).
RN   [42]
RP   VARIANTS EIEE6 GLN-101; ILE-322; GLY-356; THR-358; CYS-393; HIS-393;
RP   LEU-957; TYR-1414; TRP-1470; ARG-1588; TYR-1608; MET-1630; ARG-1658;
RP   ARG-1716; VAL-1783 AND LYS-1787, AND VARIANTS GEFS+2 PRO-74; ARG-1204
RP   AND SER-1687.
RX   PubMed=17561957; DOI=10.1111/j.1528-1167.2007.01122.x;
RA   Marini C., Mei D., Temudo T., Ferrari A.R., Buti D., Dravet C.,
RA   Dias A.I., Moreira A., Calado E., Seri S., Neville B., Narbona J.,
RA   Reid E., Michelucci R., Sicca F., Cross H.J., Guerrini R.;
RT   "Idiopathic epilepsies with seizures precipitated by fever and SCN1A
RT   abnormalities.";
RL   Epilepsia 48:1678-1685(2007).
RN   [43]
RP   VARIANT GEFS+2 ILE-1366, AND VARIANT ICEGTC ILE-1366.
RX   PubMed=17507202; DOI=10.1016/j.eplepsyres.2007.03.018;
RA   Osaka H., Ogiwara I., Mazaki E., Okamura N., Yamashita S., Iai M.,
RA   Yamada M., Kurosawa K., Iwamoto H., Yasui-Furukori N., Kaneko S.,
RA   Fujiwara T., Inoue Y., Yamakawa K.;
RT   "Patients with a sodium channel alpha 1 gene mutation show wide
RT   phenotypic variation.";
RL   Epilepsy Res. 75:46-51(2007).
RN   [44]
RP   VARIANT FHM3 GLN-1649.
RX   PubMed=17397047; DOI=10.1002/humu.9486;
RA   Vanmolkot K.R., Babini E., de Vries B., Stam A.H., Freilinger T.,
RA   Terwindt G.M., Norris L., Haan J., Frants R.R., Ramadan N.M.,
RA   Ferrari M.D., Pusch M., van den Maagdenberg A.M., Dichgans M.;
RT   "The novel p.L1649Q mutation in the SCN1A epilepsy gene is associated
RT   with familial hemiplegic migraine: genetic and functional studies.
RT   Mutation in brief #957. Online.";
RL   Hum. Mutat. 28:522-522(2007).
RN   [45]
RP   CHARACTERIZATION OF VARIANT GEFS+2 THR-1852, SUBCELLULAR LOCATION, AND
RP   INTERACTION WITH SCN1B.
RX   PubMed=17928445; DOI=10.1523/JNEUROSCI.3515-07.2007;
RA   Rusconi R., Scalmani P., Cassulini R.R., Giunti G., Gambardella A.,
RA   Franceschetti S., Annesi G., Wanke E., Mantegazza M.;
RT   "Modulatory proteins can rescue a trafficking defective epileptogenic
RT   Nav1.1 Na+ channel mutant.";
RL   J. Neurosci. 27:11037-11046(2007).
RN   [46]
RP   VARIANT PHE-790, AND POSSIBLE INVOLVEMENT IN PANAYIOTOPOULOS SYNDROME.
RX   PubMed=17679682; DOI=10.1212/01.wnl.0000266666.10404.53;
RA   Grosso S., Orrico A., Galli L., Di Bartolo R., Sorrentino V.,
RA   Balestri P.;
RT   "SCN1A mutation associated with atypical Panayiotopoulos syndrome.";
RL   Neurology 69:609-611(2007).
RN   [47]
RP   VARIANT FOCAL EPILEPSY PHE-1771.
RX   PubMed=18330841; DOI=10.1055/s-2008-1062703;
RA   Okumura A., Kurahashi H., Hirose S., Okawa N., Watanabe K.;
RT   "Focal epilepsy resulting from a de novo SCN1A mutation.";
RL   Neuropediatrics 38:253-256(2007).
RN   [48]
RP   VARIANT FHM3 SER-1174.
RX   PubMed=18021921; DOI=10.1016/j.pediatrneurol.2007.06.016;
RA   Gargus J.J., Tournay A.;
RT   "Novel mutation confirms seizure locus SCN1A is also familial
RT   hemiplegic migraine locus FHM3.";
RL   Pediatr. Neurol. 37:407-410(2007).
RN   [49]
RP   VARIANT GEFS+2 MET-978.
RX   PubMed=17927801; DOI=10.1111/j.1600-0404.2007.00941.x;
RA   Selmer K.K., Egeland T., Solaas M.H., Nakken K.O., Kjeldsen M.J.,
RA   Friis M.L., Brandal K., Corey L.A., Undlien D.E.;
RT   "Genetic screening of Scandinavian families with febrile seizures and
RT   epilepsy or GEFS+.";
RL   Acta Neurol. Scand. 117:289-292(2008).
RN   [50]
RP   VARIANTS EIEE6 SER-118; GLU-366; PRO-1207; MET-1335; SER-1358 AND
RP   CYS-1462, VARIANT GEFS+2 GLN-377, AND VARIANT GLY-1928.
RX   PubMed=18413471; DOI=10.1001/archneur.65.4.489;
RA   Zucca C., Redaelli F., Epifanio R., Zanotta N., Romeo A., Lodi M.,
RA   Veggiotti P., Airoldi G., Panzeri C., Romaniello R., De Polo G.,
RA   Bonanni P., Cardinali S., Baschirotto C., Martorell L., Borgatti R.,
RA   Bresolin N., Bassi M.T.;
RT   "Cryptogenic epileptic syndromes related to SCN1A: twelve novel
RT   mutations identified.";
RL   Arch. Neurol. 65:489-494(2008).
RN   [51]
RP   VARIANT GEFS+2 THR-1867.
RX   PubMed=18251839; DOI=10.1111/j.1528-1167.2007.01439_2.x;
RA   Hindocha N., Nashef L., Elmslie F., Birch R., Zuberi S.,
RA   Al-Chalabi A., Crotti L., Schwartz P.J., Makoff A.;
RT   "Two cases of sudden unexpected death in epilepsy in a GEFS+ family
RT   with an SCN1A mutation.";
RL   Epilepsia 49:360-365(2008).
RN   [52]
RP   VARIANT CYS-1575.
RX   PubMed=18031552; DOI=10.1111/j.1528-1167.2007.01411.x;
RA   Ohmori I., Ouchida M., Kobayashi K., Jitsumori Y., Inoue T.,
RA   Shimizu K., Matsui H., Ohtsuka Y., Maegaki Y.;
RT   "Rasmussen encephalitis associated with SCN 1 A mutation.";
RL   Epilepsia 49:521-526(2008).
RN   [53]
RP   VARIANT GEFS+2 HIS-935.
RX   PubMed=18566737; DOI=10.1007/s10038-008-0306-y;
RA   Sun H., Zhang Y., Liang J., Liu X., Ma X., Wu H., Xu K., Qin J.,
RA   Qi Y., Wu X.;
RT   "SCN1A, SCN1B, and GABRG2 gene mutation analysis in Chinese families
RT   with generalized epilepsy with febrile seizures plus.";
RL   J. Hum. Genet. 53:769-774(2008).
RN   [54]
RP   VARIANT EIEE6 CYS-280.
RX   PubMed=18639757; DOI=10.1016/j.pediatrneurol.2008.04.003;
RA   Miyama S., Goto T., Inoue Y., Yamakawa K.;
RT   "Monozygotic twins with severe myoclonic epilepsy in infancy
RT   discordant for clinical features.";
RL   Pediatr. Neurol. 39:120-122(2008).
RN   [55]
RP   VARIANT THR-1067.
RX   PubMed=19694741; DOI=10.1111/j.1365-2125.2009.03437.x;
RA   Lakhan R., Kumari R., Misra U.K., Kalita J., Pradhan S., Mittal B.;
RT   "Differential role of sodium channels SCN1A and SCN2A gene
RT   polymorphisms with epilepsy and multiple drug resistance in the north
RT   Indian population.";
RL   Br. J. Clin. Pharmacol. 68:214-220(2009).
RN   [56]
RP   VARIANT EIEE6 LYS-1503.
RX   PubMed=19783390; DOI=10.1016/j.braindev.2009.08.009;
RA   Shi X., Yasumoto S., Nakagawa E., Fukasawa T., Uchiya S., Hirose S.;
RT   "Missense mutation of the sodium channel gene SCN2A causes Dravet
RT   syndrome.";
RL   Brain Dev. 31:758-762(2009).
RN   [57]
RP   VARIANTS GLN-542 AND PHE-790, VARIANT FEB3A ASP-1308, VARIANT EIEE6
RP   CYS-1648, VARIANTS GEFS+2 THR-899; ILE-976; ASN-1249 AND MET-1250, AND
RP   POSSIBLE INVOLVEMENT IN PANAYIOTOPOULOS SYNDROME.
RX   PubMed=19522081; DOI=10.1111/j.1399-0004.2009.01155.x;
RA   Orrico A., Galli L., Grosso S., Buoni S., Pianigiani R., Balestri P.,
RA   Sorrentino V.;
RT   "Mutational analysis of the SCN1A, SCN1B and GABRG2 genes in 150
RT   Italian patients with idiopathic childhood epilepsies.";
RL   Clin. Genet. 75:579-581(2009).
RN   [58]
RP   VARIANT GEFS+2 LEU-218, AND POSSIBLE INVOLVEMENT IN PANAYIOTOPOULOS
RP   SYNDROME.
RX   PubMed=19339291; DOI=10.1177/0883073808324537;
RA   Livingston J.H., Cross J.H., Mclellan A., Birch R., Zuberi S.M.;
RT   "A novel inherited mutation in the voltage sensor region of SCN1A is
RT   associated with Panayiotopoulos syndrome in siblings and generalized
RT   epilepsy with febrile seizures plus.";
RL   J. Child Neurol. 24:503-508(2009).
RN   [59]
RP   VARIANTS GLN-542; HIS-604; THR-924; ILE-1079; THR-1109; ASP-1308;
RP   CYS-1575 AND GLY-1928, AND VARIANTS EIEE6 VAL-58; PHE-61; HIS-79;
RP   GLN-101; TRP-101; ASN-124; ARG-171; VAL-175; LYS-191; TYR-191;
RP   GLY-194; GLU-223; SER-227; SER-232; TYR-243; ARG-277; LEU-281;
RP   SER-281; ILE-322; PHE-340; ASP-343; ARG-345; ASP-355; ILE-357;
RP   GLN-378; CYS-393; MET-400 DEL; CYS-426; PHE-525; GLY-626; ARG-843;
RP   CYS-859; LYS-875; LEU-896; PHE-927; CYS-931; ILE-934; PRO-939;
RP   ASN-943; SER-949; TYR-949; LYS-973; PRO-986; GLY-998; LYS-1068;
RP   GLY-1239; TYR-1239; ASP-1255; VAL-1275; SER-1284; PHE-1289 DEL;
RP   SER-1316; PRO-1328; LYS-1367; SER-1391; GLY-1416; ILE-1431; MET-1437;
RP   PHE-1473 DEL; ILE-1483 DEL; GLY-1484; ILE-1538; ALA-1544; LYS-1561;
RP   GLU-1579; GLU-1586; CYS-1596; LEU-1596; ILE-1612; GLY-1639; HIS-1648;
RP   ARG-1658; MET-1658; LYS-1664; ARG-1675; PHE-1677; LYS-1714; CYS-1725;
RP   ASN-1771; THR-1780; HIS-1781; MET-1782; SER-1782; THR-1783; VAL-1783;
RP   LYS-1788; ILE-1808; SER-1812; 1813-GLU--PHE-1815 DEL AND PHE-1835.
RX   PubMed=18930999; DOI=10.1136/jmg.2008.062323;
RA   Depienne C., Trouillard O., Saint-Martin C., Gourfinkel-An I.,
RA   Bouteiller D., Carpentier W., Keren B., Abert B., Gautier A.,
RA   Baulac S., Arzimanoglou A., Cazeneuve C., Nabbout R., LeGuern E.;
RT   "Spectrum of SCN1A gene mutations associated with Dravet syndrome:
RT   analysis of 333 patients.";
RL   J. Med. Genet. 46:183-191(2009).
RN   [60]
RP   VARIANTS FHM3 HIS-1489 AND LEU-1499.
RX   PubMed=19332696; DOI=10.1212/01.wnl.0000345393.53132.8c;
RA   Vahedi K., Depienne C., Le Fort D., Riant F., Chaine P.,
RA   Trouillard O., Gaudric A., Morris M.A., LeGuern E.,
RA   Tournier-Lasserve E., Bousser M.-G.;
RT   "Elicited repetitive daily blindness: a new phenotype associated with
RT   hemiplegic migraine and SCN1A mutations.";
RL   Neurology 72:1178-1183(2009).
RN   [61]
RP   VARIANT GEFS+2 HIS-388.
RX   PubMed=19464195; DOI=10.1016/j.seizure.2009.04.009;
RA   Mahoney K., Moore S.J., Buckley D., Alam M., Parfrey P., Penney S.,
RA   Merner N., Hodgkinson K., Young T.L.;
RT   "Variable neurologic phenotype in a GEFS+ family with a novel mutation
RT   in SCN1A.";
RL   Seizure 18:492-497(2009).
RN   [62]
RP   VARIANT THR-1067.
RX   PubMed=20682179; DOI=10.1016/j.arcmed.2010.04.007;
RA   Ebrahimi A., Houshmand M., Tonekaboni S.H.,
RA   Fallah Mahboob Passand M.S., Zainali S., Moghadasi M.;
RT   "Two novel mutations in SCN1A gene in Iranian patients with
RT   epilepsy.";
RL   Arch. Med. Res. 41:207-214(2010).
RN   [63]
RP   VARIANTS GEFS+2 HIS-946 AND LEU-1765, AND CHARACTERIZATION OF VARIANTS
RP   GEFS+2 HIS-946 AND LEU-1765.
RX   PubMed=20550552; DOI=10.1111/j.1528-1167.2010.02645.x;
RA   Liao W.P., Shi Y.W., Long Y.S., Zeng Y., Li T., Yu M.J., Su T.,
RA   Deng P., Lei Z.G., Xu S.J., Deng W.Y., Liu X.R., Sun W.W., Yi Y.H.,
RA   Xu Z.C., Duan S.;
RT   "Partial epilepsy with antecedent febrile seizures and seizure
RT   aggravation by antiepileptic drugs: associated with loss of function
RT   of Na(v) 1.1.";
RL   Epilepsia 51:1669-1678(2010).
RN   [64]
RP   VARIANTS EIEE6 ILE-1612 AND GLY-1756.
RX   PubMed=20452746; DOI=10.1016/j.eplepsyres.2010.04.003;
RA   Herini E.S., Gunadi Harahap I.S., Yusoff S., Morikawa S., Patria S.Y.,
RA   Nishimura N., Sunartini Sutaryo S., Takada S., Matsuo M., Nishio H.;
RT   "Generalized epilepsy with febrile seizures plus (GEFS+) spectrum:
RT   clinical manifestations and SCN1A mutations in Indonesian patients.";
RL   Epilepsy Res. 90:132-139(2010).
RN   [65]
RP   VARIANT GLU-1637.
RX   PubMed=20392657; DOI=10.1016/j.ejpn.2010.03.002;
RA   Nishri D., Blumkin L., Lev D., Leshinsky-Silver E., Abu-Rashid M.,
RA   Birch R., Zuberi S.M., Lerman-Sagie T.;
RT   "Hepatic coma culminating in severe brain damage in a child with a
RT   SCN1A mutation.";
RL   Eur. J. Paediatr. Neurol. 14:456-459(2010).
RN   [66]
RP   VARIANTS EIEE6 GLN-862 AND LYS-954.
RX   PubMed=20110217; DOI=10.1177/0883073809357241;
RA   Arlier Z., Bayri Y., Kolb L.E., Erturk O., Ozturk A.K., Bayrakli F.,
RA   Bilguvar K., Moliterno J.A., Dervent A., Demirbilek V., Yalcinkaya C.,
RA   Korkmaz B., Tuysuz B., Gunel M.;
RT   "Four novel SCN1A mutations in Turkish patients with severe myoclonic
RT   epilepsy of infancy (SMEI).";
RL   J. Child Neurol. 25:1265-1268(2010).
RN   [67]
RP   VARIANT GEFS+2 THR-27, VARIANTS EIEE6 LEU-63; VAL-239 AND ARG-1433,
RP   AND VARIANT ASP-1308.
RX   PubMed=20729507; DOI=10.1177/0883073810365737;
RA   Nicita F., Spalice A., Papetti L., Ursitti F., Parisi P., Gennaro E.,
RA   Zara F., Iannetti P.;
RT   "Genotype-phenotype correlations in a group of 15 SCN1A-mutated
RT   Italian patients with GEFS+ spectrum (seizures plus, classical and
RT   borderline severe myoclonic epilepsy of infancy).";
RL   J. Child Neurol. 25:1369-1376(2010).
RN   [68]
RP   VARIANTS EIEE6 SER-90; THR-91; TRP-101; GLN-101; THR-239; ARG-259;
RP   HIS-393; TYR-939; GLY-952; LYS-1210; PRO-1260; PRO-1287; MET-1335;
RP   MET-1390; GLU-1433; GLU-1586 AND THR-1783.
RX   PubMed=20431604; DOI=10.1038/jhg.2010.39;
RA   Sun H., Zhang Y., Liu X., Ma X., Yang Z., Qin J., Jiang Y., Qi Y.,
RA   Wu X.;
RT   "Analysis of SCN1A mutation and parental origin in patients with
RT   Dravet syndrome.";
RL   J. Hum. Genet. 55:421-427(2010).
RN   [69]
RP   VARIANTS EIEE6 CYS-84; GLN-101; LYS-171; THR-175; ASN-194; SER-227;
RP   PHE-406; ASN-413; PRO-783; GLU-944; LEU-945; HIS-946; GLU-950;
RP   GLY-1396; LYS-1450; VAL-1545; GLN-1645; ARG-1726 AND THR-1783, AND
RP   VARIANTS HIS-604; GLN-1636 AND HIS-1657.
RX   PubMed=19589774; DOI=10.1136/jmg.2008.065912;
RA   Heron S.E., Scheffer I.E., Iona X., Zuberi S.M., Birch R.,
RA   McMahon J.M., Bruce C.M., Berkovic S.F., Mulley J.C.;
RT   "De novo SCN1A mutations in Dravet syndrome and related epileptic
RT   encephalopathies are largely of paternal origin.";
RL   J. Med. Genet. 47:137-141(2010).
RN   [70]
RP   VARIANTS EIEE6 ASN-124; TYR-191; LYS-875; LYS-1367; SER-1514;
RP   HIS-1648; MET-1658; LYS-1664 AND MET-1782.
RX   PubMed=20522430; DOI=10.1136/jmg.2009.074328;
RA   Depienne C., Trouillard O., Gourfinkel-An I., Saint-Martin C.,
RA   Bouteiller D., Graber D., Barthez-Carpentier M.A., Gautier A.,
RA   Villeneuve N., Dravet C., Livet M.O., Rivier-Ringenbach C., Adam C.,
RA   Dupont S., Baulac S., Heron D., Nabbout R., Leguern E.;
RT   "Mechanisms for variable expressivity of inherited SCN1A mutations
RT   causing Dravet syndrome.";
RL   J. Med. Genet. 47:404-410(2010).
RN   [71]
RP   VARIANT GEFS+2 LYS-1795.
RX   PubMed=20600615; DOI=10.1016/j.neulet.2010.06.040;
RA   Li N., Zhang J., Guo J.F., Yan X.X., Xia K., Tang B.S.;
RT   "Novel mutation of SCN1A in familial generalized epilepsy with febrile
RT   seizures plus.";
RL   Neurosci. Lett. 480:211-214(2010).
RN   [72]
RP   VARIANTS EIEE6 ILE-1612 AND GLY-1756.
RX   PubMed=19563458; DOI=10.1111/j.1442-200X.2009.02916.x;
RA   Herini E.S., Gunadi H., van Kempen M.J., Yusoff S., Sutaryo S.,
RA   Patria S.Y., Matsuo M., Lindhout D., Nishio H.;
RT   "Novel SCN1A mutations in Indonesian patients with severe myoclonic
RT   epilepsy in infancy.";
RL   Pediatr. Int. 52:234-239(2010).
RN   [73]
RP   VARIANT GEFS+2 PHE-1309.
RX   PubMed=20117752; DOI=10.1016/j.pediatrneurol.2009.09.007;
RA   Dimova P.S., Yordanova I., Bojinova V., Jordanova A., Kremenski I.;
RT   "Generalized epilepsy with febrile seizures plus: novel SCN1A
RT   mutation.";
RL   Pediatr. Neurol. 42:137-140(2010).
RN   [74]
RP   VARIANT GEFS+2 HIS-859, VARIANT EIEE6 GLY-865, CHARACTERIZATION OF
RP   VARIANT GEFS+2 HIS-859, AND CHARACTERIZATION OF VARIANTS EIEE6
RP   GLY-865; CYS-946 AND HIS-946.
RX   PubMed=21864321; DOI=10.1111/j.1460-9568.2011.07826.x;
RA   Volkers L., Kahlig K.M., Verbeek N.E., Das J.H., van Kempen M.J.,
RA   Stroink H., Augustijn P., van Nieuwenhuizen O., Lindhout D.,
RA   George A.L. Jr., Koeleman B.P., Rook M.B.;
RT   "Nav 1.1 dysfunction in genetic epilepsy with febrile seizures-plus or
RT   Dravet syndrome.";
RL   Eur. J. Neurosci. 34:1268-1275(2011).
RN   [75]
RP   VARIANTS EIEE6 PHE-17 DEL; THR-68; ASN-79; CYS-84; PRO-98; GLN-101;
RP   TRP-101; ARG-108; ASP-127; ARG-199; SER-227; THR-227; SER-232;
RP   ARG-233; VAL-342; ASP-343; TRP-351; SER-359; ARG-363; ARG-384;
RP   CYS-393; HIS-393; VAL-400; VAL-403; PHE-406; GLY-626; ASP-762;
RP   THR-785; ILE-812; ARG-842; 854-GLY-LEU-855 DEL; CYS-859; GLN-862;
RP   PRO-890; CYS-932; PRO-933; CYS-946; HIS-946; ARG-950; LYS-954;
RP   LYS-956; LEU-957; ILE-976; VAL-979; ARG-993; 999-ASN-LEU-1000 DELINS
RP   LEU-ILE-SER; LYS-1208; LYS-1221; PHE-1230; ASP-1238; ALA-1266;
RP   ASN-1288; VAL-1320; PRO-1326; GLY-1350; ARG-1358; PRO-1370; HIS-1378;
RP   THR-1378; ILE-1394; TYR-1396; SER-1417; PHE-1423; ALA-1429 DEL;
RP   VAL-1433; LYS-1450; SER-1451; LYS-1454; HIS-1462; LYS-1476; LYS-1503;
RP   GLY-1544; GLU-1586; ARG-1588; HIS-1592; PRO-1592; SER-1605; GLU-1637;
RP   THR-1638; CYS-1648; GLU-1653; PRO-1660; PRO-1667; LEU-1668; ILE-1672;
RP   THR-1673; THR-1683; ASP-1684; TRP-1688; ARG-1714; ASN-1763; ASN-1770;
RP   PHE-1770; THR-1770; THR-1780; VAL-1783; LYS-1787; PRO-1832; LYS-1852;
RP   LEU-1855; GLU-1880; THR-1909 DEL AND ARG-1927 DELINS ILE-ILE-GLN,
RP   VARIANTS GEFS+2 LEU-218; ILE-254; GLY-291; THR-960; VAL-973; SER-1204;
RP   PHE-1230; ASP-1414; HIS-1596; LEU-1739 AND THR-1867, AND VARIANTS
RP   ASN-45; VAL-333; ASN-382; HIS-604; ILE-699; THR-924; HIS-931;
RP   GLU-1006; ILE-1079; THR-1109; ASP-1308; ASP-1326; MET-1483 AND
RP   PHE-1683.
RX   PubMed=21248271; DOI=10.1212/WNL.0b013e31820c309b;
RA   Zuberi S.M., Brunklaus A., Birch R., Reavey E., Duncan J.,
RA   Forbes G.H.;
RT   "Genotype-phenotype associations in SCN1A-related epilepsies.";
RL   Neurology 76:594-600(2011).
RN   [76]
RP   VARIANTS EIEE6 VAL-1339 AND LEU-1630.
RX   PubMed=22092154; DOI=10.1111/j.1528-1167.2011.03311.x;
RA   Okumura A., Uematsu M., Imataka G., Tanaka M., Okanishi T., Kubota T.,
RA   Sudo A., Tohyama J., Tsuji M., Ohmori I., Naiki M., Hiraiwa-Sofue A.,
RA   Sato H., Saitoh S., Shimizu T.;
RT   "Acute encephalopathy in children with Dravet syndrome.";
RL   Epilepsia 53:79-86(2012).
RN   [77]
RP   VARIANTS LEU-982; CYS-1575 AND LEU-1977.
RX   PubMed=22309220; DOI=10.1111/j.1528-1167.2011.03402.x;
RA   Saitoh M., Shinohara M., Hoshino H., Kubota M., Amemiya K.,
RA   Takanashi J.L., Hwang S.K., Hirose S., Mizuguchi M.;
RT   "Mutations of the SCN1A gene in acute encephalopathy.";
RL   Epilepsia 53:558-564(2012).
RN   [78]
RP   VARIANTS EIEE6 VAL-289; ARG-379 AND HIS-393.
RX   PubMed=22612257; DOI=10.1111/j.1528-1167.2012.03516.x;
RA   Lemke J.R., Riesch E., Scheurenbrand T., Schubach M., Wilhelm C.,
RA   Steiner I., Hansen J., Courage C., Gallati S., Buerki S., Strozzi S.,
RA   Simonetti B.G., Grunt S., Steinlin M., Alber M., Wolff M.,
RA   Klopstock T., Prott E.C., Lorenz R., Spaich C., Rona S.,
RA   Lakshminarasimhan M., Kroell J., Dorn T., Kraemer G., Synofzik M.,
RA   Becker F., Weber Y.G., Lerche H., Boehm D., Biskup S.;
RT   "Targeted next generation sequencing as a diagnostic tool in epileptic
RT   disorders.";
RL   Epilepsia 53:1387-1398(2012).
RN   [79]
RP   VARIANT ALA-1275.
RX   PubMed=23647072; DOI=10.1111/epi.12201;
RA   Veeramah K.R., Johnstone L., Karafet T.M., Wolf D., Sprissler R.,
RA   Salogiannis J., Barth-Maron A., Greenberg M.E., Stuhlmann T.,
RA   Weinert S., Jentsch T.J., Pazzi M., Restifo L.L., Talwar D.,
RA   Erickson R.P., Hammer M.F.;
RT   "Exome sequencing reveals new causal mutations in children with
RT   epileptic encephalopathies.";
RL   Epilepsia 54:1270-1281(2013).
RN   [80]
RP   VARIANTS EIEE6 CYS-84; GLN-101; TRP-101; ILE-105; ARG-179; ARG-190;
RP   ARG-226; SER-227; ARG-259; ARG-280; ALA-281; PRO-363; ARG-384;
RP   HIS-393; TRP-409; CYS-426; MET-875; ILE-876; PHE-896; ILE-934;
RP   PHE-940; CYS-946; HIS-946; LEU-987; GLY-1316; VAL-1339; MET-1344;
RP   PRO-1355; VAL-1385; GLY-1418; PRO-1427; CYS-1453; HIS-1462; SER-1472;
RP   TYR-1485; GLU-1503 DEL; LYS-1503; VAL-1545; ARG-1555; GLY-1608;
RP   LEU-1630; ASN-1638; SER-1642; VAL-1662; PRO-1667; PHE-1677; THR-1683;
RP   SER-1692; CYS-1694; GLY-1727; ARG-1741; PHE-1766 DEL; PHE-1771;
RP   THR-1783; VAL-1783 AND THR-1792, VARIANTS ICEGTC SER-90; GLN-101;
RP   SER-178; MET-252; ARG-290; HIS-393; ILE-896; ALA-944; GLN-1213;
RP   CYS-1254; THR-1325; PRO-1328; LEU-1357; ARG-1376; ASP-1429; HIS-1462;
RP   LYS-1511; VAL-1619; SER-1684; PRO-1724; CYS-1781 AND TRP-1861, AND
RP   VARIANTS GLN-542; HIS- AND CYS-1575.
RX   PubMed=23195492; DOI=10.1016/j.eplepsyres.2012.06.006;
RA   Wang J.W., Shi X.Y., Kurahashi H., Hwang S.K., Ishii A., Higurashi N.,
RA   Kaneko S., Hirose S.;
RT   "Prevalence of SCN1A mutations in children with suspected Dravet
RT   syndrome and intractable childhood epilepsy.";
RL   Epilepsy Res. 102:195-200(2012).
RN   [81]
RP   VARIANTS LEU-982; CYS-1575 AND SER-1674.
RX   PubMed=26311622; DOI=10.1016/j.eplepsyres.2015.08.001;
RA   Saitoh M., Ishii A., Ihara Y., Hoshino A., Terashima H., Kubota M.,
RA   Kikuchi K., Yamanaka G., Amemiya K., Hirose S., Mizuguchi M.;
RT   "Missense mutations in sodium channel SCN1A and SCN2A predispose
RT   children to encephalopathy with severe febrile seizures.";
RL   Epilepsy Res. 117:1-6(2015).
CC   -!- FUNCTION: Mediates the voltage-dependent sodium ion permeability
CC       of excitable membranes. Assuming opened or closed conformations in
CC       response to the voltage difference across the membrane, the
CC       protein forms a sodium-selective channel through which Na(+) ions
CC       may pass in accordance with their electrochemical gradient. Plays
CC       a key role in brain, probably by regulating the moment when
CC       neurotransmitters are released in neurons. Involved in sensory
CC       perception of mechanical pain: activation in somatosensory neurons
CC       induces pain without neurogenic inflammation and produces
CC       hypersensitivity to mechanical, but not thermal stimuli.
CC       {ECO:0000250|UniProtKB:A2APX8}.
CC   -!- ENZYME REGULATION: Inactivation of this channel is specifically
CC       inhibited by the spider toxins Hm1a and Hm1b (H.maculata, AC
CC       P60992 and AC P0DOC5) in somatosensory neurons to elicit acute
CC       pain and mechanical allodynia. {ECO:0000250|UniProtKB:A2APX8}.
CC   -!- SUBUNIT: The voltage-sensitive sodium channel consists of an ion
CC       conducting pore forming alpha-subunit regulated by one or more
CC       beta-1 (SCN1B), beta-2 (SCN2B), beta-3 (SCN3B) and/or beta-4
CC       (SCN4B). Beta-1 (SCN1B) and beta-3 (SCN3B) are non-covalently
CC       associated with alpha, while beta-2 (SCN2B) and beta-4 (SCN4B) are
CC       covalently linked by disulfide bonds. Interacts with FGF13
CC       (PubMed:21566136). Interacts with SCN1B (PubMed:17928445,
CC       PubMed:15525788). Interacts with the conotoxin GVIIJ
CC       (PubMed:24497506). {ECO:0000269|PubMed:15525788,
CC       ECO:0000269|PubMed:17928445, ECO:0000269|PubMed:21566136,
CC       ECO:0000269|PubMed:24497506}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17928445};
CC       Multi-pass membrane protein {ECO:0000255}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=P35498-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=P35498-2; Sequence=VSP_001031;
CC       Name=3;
CC         IsoId=P35498-3; Sequence=VSP_045399;
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- DOMAIN: The S3b-S4 and S1-S2 loops of repeat IV are targeted by
CC       H.maculata toxins Hm1a and Hm1b, leading to inhibit fast
CC       inactivation of Nav1.1/SCN1A. Selectivity for H.maculata toxins
CC       Hm1a and Hm1b depends on S1-S2 loops of repeat IV.
CC       {ECO:0000250|UniProtKB:A2APX8}.
CC   -!- PTM: Phosphorylation at Ser-1516 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents. {ECO:0000250|UniProtKB:P04775}.
CC   -!- DISEASE: Generalized epilepsy with febrile seizures plus 2
CC       (GEFS+2) [MIM:604403]: A rare autosomal dominant, familial
CC       condition with incomplete penetrance and large intrafamilial
CC       variability. Patients display febrile seizures persisting
CC       sometimes beyond the age of 6 years and/or a variety of afebrile
CC       seizure types. This disease combines febrile seizures, generalized
CC       seizures often precipitated by fever at age 6 years or more, and
CC       partial seizures, with a variable degree of severity.
CC       {ECO:0000269|PubMed:10742094, ECO:0000269|PubMed:11254444,
CC       ECO:0000269|PubMed:11254445, ECO:0000269|PubMed:11524484,
CC       ECO:0000269|PubMed:11756608, ECO:0000269|PubMed:12535936,
CC       ECO:0000269|PubMed:12576172, ECO:0000269|PubMed:12919402,
CC       ECO:0000269|PubMed:14672992, ECO:0000269|PubMed:15525788,
CC       ECO:0000269|PubMed:15694566, ECO:0000269|PubMed:15715999,
CC       ECO:0000269|PubMed:16525050, ECO:0000269|PubMed:17347258,
CC       ECO:0000269|PubMed:17507202, ECO:0000269|PubMed:17561957,
CC       ECO:0000269|PubMed:17927801, ECO:0000269|PubMed:17928445,
CC       ECO:0000269|PubMed:18251839, ECO:0000269|PubMed:18413471,
CC       ECO:0000269|PubMed:18566737, ECO:0000269|PubMed:19339291,
CC       ECO:0000269|PubMed:19464195, ECO:0000269|PubMed:19522081,
CC       ECO:0000269|PubMed:20117752, ECO:0000269|PubMed:20550552,
CC       ECO:0000269|PubMed:20600615, ECO:0000269|PubMed:20729507,
CC       ECO:0000269|PubMed:21248271, ECO:0000269|PubMed:21864321}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 6 (EIEE6)
CC       [MIM:607208]: A severe form of epileptic encephalopathy
CC       characterized by generalized tonic, clonic, and tonic-clonic
CC       seizures that are initially induced by fever and begin during the
CC       first year of life. Later, patients also manifest other seizure
CC       types, including absence, myoclonic, and simple and complex
CC       partial seizures. Psychomotor development delay is observed around
CC       the second year of life. Some patients manifest a borderline
CC       disease phenotype and do not necessarily fulfill all diagnostic
CC       criteria for core EIEE6. EIEE6 is considered to be the most severe
CC       phenotype within the spectrum of generalized epilepsies with
CC       febrile seizures-plus. {ECO:0000269|PubMed:11359211,
CC       ECO:0000269|PubMed:12083760, ECO:0000269|PubMed:12566275,
CC       ECO:0000269|PubMed:12754708, ECO:0000269|PubMed:12821740,
CC       ECO:0000269|PubMed:14504318, ECO:0000269|PubMed:14672992,
CC       ECO:0000269|PubMed:14738421, ECO:0000269|PubMed:15087100,
CC       ECO:0000269|PubMed:15944908, ECO:0000269|PubMed:16122630,
CC       ECO:0000269|PubMed:16458823, ECO:0000269|PubMed:16713920,
CC       ECO:0000269|PubMed:17054684, ECO:0000269|PubMed:17054685,
CC       ECO:0000269|PubMed:17129991, ECO:0000269|PubMed:17347258,
CC       ECO:0000269|PubMed:17561957, ECO:0000269|PubMed:18413471,
CC       ECO:0000269|PubMed:18639757, ECO:0000269|PubMed:18930999,
CC       ECO:0000269|PubMed:19522081, ECO:0000269|PubMed:19563458,
CC       ECO:0000269|PubMed:19589774, ECO:0000269|PubMed:19783390,
CC       ECO:0000269|PubMed:20110217, ECO:0000269|PubMed:20431604,
CC       ECO:0000269|PubMed:20452746, ECO:0000269|PubMed:20522430,
CC       ECO:0000269|PubMed:20729507, ECO:0000269|PubMed:21248271,
CC       ECO:0000269|PubMed:21864321, ECO:0000269|PubMed:22092154,
CC       ECO:0000269|PubMed:22612257, ECO:0000269|PubMed:23195492}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Intractable childhood epilepsy with generalized tonic-
CC       clonic seizures (ICEGTC) [MIM:607208]: A disorder characterized by
CC       generalized tonic-clonic seizures beginning usually in infancy and
CC       induced by fever. Seizures are associated with subsequent mental
CC       decline, as well as ataxia or hypotonia. ICEGTC is similar to
CC       SMEI, except for the absence of myoclonic seizures.
CC       {ECO:0000269|PubMed:12566275, ECO:0000269|PubMed:16210358,
CC       ECO:0000269|PubMed:17507202, ECO:0000269|PubMed:23195492}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Migraine, familial hemiplegic, 3 (FHM3) [MIM:609634]: A
CC       subtype of migraine associated with transient blindness in some
CC       families. Migraine is a disabling symptom complex of periodic
CC       headaches, usually temporal and unilateral. Headaches are often
CC       accompanied by irritability, nausea, vomiting and photophobia,
CC       preceded by constriction of the cranial arteries. The two major
CC       subtypes are common migraine (migraine without aura) and classic
CC       migraine (migraine with aura). Classic migraine is characterized
CC       by recurrent attacks of reversible neurological symptoms (aura)
CC       that precede or accompany the headache. Aura may include a
CC       combination of sensory disturbances, such as blurred vision,
CC       hallucinations, vertigo, numbness and difficulty in concentrating
CC       and speaking. {ECO:0000269|PubMed:16054936,
CC       ECO:0000269|PubMed:17397047, ECO:0000269|PubMed:18021921,
CC       ECO:0000269|PubMed:19332696}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Febrile seizures, familial, 3A (FEB3A) [MIM:604403]:
CC       Seizures associated with febrile episodes in childhood without any
CC       evidence of intracranial infection or defined pathologic or
CC       traumatic cause. It is a common condition, affecting 2-5% of
CC       children aged 3 months to 5 years. The majority are simple febrile
CC       seizures (generally defined as generalized onset, single seizures
CC       with a duration of less than 30 minutes). Complex febrile seizures
CC       are characterized by focal onset, duration greater than 30
CC       minutes, and/or more than one seizure in a 24 hour period. The
CC       likelihood of developing epilepsy following simple febrile
CC       seizures is low. Complex febrile seizures are associated with a
CC       moderately increased incidence of epilepsy.
CC       {ECO:0000269|PubMed:16326807, ECO:0000269|PubMed:19522081}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=SCN1A mutations may be involved in Panayiotopoulos
CC       syndrome, a benign age-related focal seizure disorder occurring in
CC       early and mid-childhood. It is characterized by seizures, often
CC       prolonged, with predominantly autonomic symptoms, and by an
CC       electroencephalogram that shows shifting and/or multiple foci,
CC       often with occipital predominance. Autonomic seizures in
CC       Panayiotopoulos syndrome consist of episodes of disturbed
CC       autonomic function with emesis as the predominant symptom.
CC       Cardiorespiratory arrest is exceptional.
CC       {ECO:0000269|PubMed:17679682, ECO:0000269|PubMed:19339291,
CC       ECO:0000269|PubMed:19522081}.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.1/SCN1A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF225985; AAK00217.1; -; mRNA.
DR   EMBL; AY043484; AAK95360.1; -; mRNA.
DR   EMBL; AB093548; BAC21101.1; -; mRNA.
DR   EMBL; AB093549; BAC21102.1; -; mRNA.
DR   EMBL; AB098335; BAC45228.1; -; mRNA.
DR   EMBL; AC010127; AAX81984.1; -; Genomic_DNA.
DR   EMBL; S71446; AAB31605.1; -; Genomic_DNA.
DR   EMBL; X65362; CAA46439.1; -; mRNA.
DR   EMBL; M91803; -; NOT_ANNOTATED_CDS; mRNA.
DR   CCDS; CCDS33316.1; -. [P35498-2]
DR   CCDS; CCDS54413.1; -. [P35498-1]
DR   CCDS; CCDS54414.1; -. [P35498-3]
DR   PIR; I52964; I52964.
DR   PIR; S29184; S29184.
DR   RefSeq; NP_001159435.1; NM_001165963.1. [P35498-1]
DR   RefSeq; NP_001159436.1; NM_001165964.1. [P35498-3]
DR   RefSeq; NP_001189364.1; NM_001202435.1. [P35498-1]
DR   RefSeq; NP_008851.3; NM_006920.4. [P35498-2]
DR   RefSeq; XP_011509904.1; XM_011511602.2. [P35498-1]
DR   RefSeq; XP_011509906.1; XM_011511604.2. [P35498-2]
DR   RefSeq; XP_011509908.1; XM_011511606.2. [P35498-3]
DR   RefSeq; XP_016860133.1; XM_017004644.1. [P35498-1]
DR   RefSeq; XP_016860134.1; XM_017004645.1. [P35498-2]
DR   RefSeq; XP_016860135.1; XM_017004646.1. [P35498-2]
DR   RefSeq; XP_016860136.1; XM_017004647.1. [P35498-2]
DR   RefSeq; XP_016860137.1; XM_017004648.1. [P35498-2]
DR   RefSeq; XP_016860138.1; XM_017004649.1. [P35498-2]
DR   RefSeq; XP_016860140.1; XM_017004651.1. [P35498-3]
DR   RefSeq; XP_016860141.1; XM_017004652.1. [P35498-3]
DR   UniGene; Hs.22654; -.
DR   UniGene; Hs.629873; -.
DR   UniGene; Hs.693440; -.
DR   UniGene; Hs.740081; -.
DR   ProteinModelPortal; P35498; -.
DR   BioGrid; 112228; 3.
DR   DIP; DIP-59851N; -.
DR   IntAct; P35498; 2.
DR   MINT; MINT-6542725; -.
DR   STRING; 9606.ENSP00000303540; -.
DR   BindingDB; P35498; -.
DR   ChEMBL; CHEMBL1845; -.
DR   DrugBank; DB04855; Dronedarone.
DR   DrugBank; DB01595; Nitrazepam.
DR   DrugBank; DB04930; Permethrin.
DR   DrugBank; DB01121; Phenacemide.
DR   DrugBank; DB01438; Phenazopyridine.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB00273; Topiramate.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 578; -.
DR   TCDB; 1.A.1.10.7; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; P35498; -.
DR   PhosphoSitePlus; P35498; -.
DR   BioMuta; SCN1A; -.
DR   DMDM; 12644229; -.
DR   PaxDb; P35498; -.
DR   PeptideAtlas; P35498; -.
DR   PRIDE; P35498; -.
DR   Ensembl; ENST00000303395; ENSP00000303540; ENSG00000144285. [P35498-1]
DR   Ensembl; ENST00000375405; ENSP00000364554; ENSG00000144285. [P35498-2]
DR   Ensembl; ENST00000409050; ENSP00000386312; ENSG00000144285. [P35498-3]
DR   Ensembl; ENST00000423058; ENSP00000407030; ENSG00000144285. [P35498-1]
DR   Ensembl; ENST00000635750; ENSP00000490799; ENSG00000144285. [P35498-2]
DR   Ensembl; ENST00000637988; ENSP00000490780; ENSG00000144285. [P35498-2]
DR   GeneID; 6323; -.
DR   KEGG; hsa:6323; -.
DR   UCSC; uc061pes.1; human. [P35498-1]
DR   CTD; 6323; -.
DR   DisGeNET; 6323; -.
DR   GeneCards; SCN1A; -.
DR   GeneReviews; SCN1A; -.
DR   HGNC; HGNC:10585; SCN1A.
DR   HPA; HPA078664; -.
DR   MalaCards; SCN1A; -.
DR   MIM; 182389; gene.
DR   MIM; 604403; phenotype.
DR   MIM; 607208; phenotype.
DR   MIM; 609634; phenotype.
DR   neXtProt; NX_P35498; -.
DR   OpenTargets; ENSG00000144285; -.
DR   Orphanet; 33069; Dravet syndrome.
DR   Orphanet; 569; Familial or sporadic hemiplegic migraine.
DR   Orphanet; 36387; Generalized epilepsy with febrile seizures-plus.
DR   Orphanet; 2382; Lennox-Gastaut syndrome.
DR   Orphanet; 293181; Malignant migrating partial seizures of infancy.
DR   PharmGKB; PA301; -.
DR   eggNOG; ENOG410INF8; Eukaryota.
DR   eggNOG; COG1226; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOGENOM; HOG000231755; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; P35498; -.
DR   KO; K04833; -.
DR   OMA; DNCMSNH; -.
DR   OrthoDB; EOG0903014J; -.
DR   PhylomeDB; P35498; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   GeneWiki; Nav1.1; -.
DR   GenomeRNAi; 6323; -.
DR   PRO; PR:P35498; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000144285; -.
DR   CleanEx; HS_SCN1A; -.
DR   Genevisible; P35498; HS.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0030018; C:Z disc; ISS:BHF-UCL.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; ISS:UniProtKB.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; IMP:BHF-UCL.
DR   GO; GO:0050966; P:detection of mechanical stimulus involved in sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0006814; P:sodium ion transport; ISS:UniProtKB.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR008051; Na_channel_a1su.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PRINTS; PR01664; NACHANNEL1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Autism; Autism spectrum disorder; Cell membrane;
KW   Complete proteome; Disease mutation; Disulfide bond; Epilepsy;
KW   Glycoprotein; Ion channel; Ion transport; Membrane; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Sodium; Sodium channel;
KW   Sodium transport; Transmembrane; Transmembrane helix; Transport;
KW   Voltage-gated channel.
FT   CHAIN         1   2009       Sodium channel protein type 1 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048489.
FT   TOPO_DOM      1    123       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    124    147       Helical; Name=S1 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    148    155       Extracellular. {ECO:0000255}.
FT   TRANSMEM    156    175       Helical; Name=S2 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    176    188       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    189    207       Helical; Name=S3 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    208    213       Extracellular. {ECO:0000255}.
FT   TRANSMEM    214    233       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000250}.
FT   TOPO_DOM    234    249       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    250    273       Helical; Name=S5 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    274    399       Extracellular. {ECO:0000255}.
FT   TRANSMEM    400    425       Helical; Name=S6 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    426    762       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    763    787       Helical; Name=S1 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    788    798       Extracellular. {ECO:0000255}.
FT   TRANSMEM    799    822       Helical; Name=S2 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    823    830       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    831    850       Helical; Name=S3 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    851    856       Extracellular. {ECO:0000255}.
FT   TRANSMEM    857    876       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000250}.
FT   TOPO_DOM    877    892       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    893    913       Helical; Name=S5 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    914    966       Extracellular. {ECO:0000255}.
FT   TRANSMEM    967    992       Helical; Name=S6 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    993   1213       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1214   1237       Helical; Name=S1 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1238   1250       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1251   1276       Helical; Name=S2 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1277   1282       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1283   1304       Helical; Name=S3 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1305   1308       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1309   1330       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000250}.
FT   TOPO_DOM   1331   1349       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1350   1377       Helical; Name=S5 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1378   1456       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1457   1483       Helical; Name=S6 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1484   1536       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1537   1560       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1561   1571       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1572   1595       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1596   1601       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1602   1625       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1626   1635       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1636   1657       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000250}.
FT   TOPO_DOM   1658   1672       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1673   1695       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1696   1761       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1762   1786       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1787   2009       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      110    454       I. {ECO:0000305}.
FT   REPEAT      750   1022       II. {ECO:0000305}.
FT   REPEAT     1200   1514       III. {ECO:0000305}.
FT   REPEAT     1523   1821       IV. {ECO:0000305}.
FT   DOMAIN     1915   1944       IQ.
FT   REGION     1561   1571       S1-S2 loop of repeat IV.
FT                                {ECO:0000250|UniProtKB:A2APX8}.
FT   REGION     1619   1636       S3b-S4 loop of repeat IV.
FT                                {ECO:0000250|UniProtKB:A2APX8}.
FT   MOD_RES     470    470       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04774}.
FT   MOD_RES     523    523       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04774}.
FT   MOD_RES     525    525       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04774}.
FT   MOD_RES     550    550       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04774}.
FT   MOD_RES     551    551       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:A2APX8}.
FT   MOD_RES     607    607       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04774}.
FT   MOD_RES     730    730       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04774}.
FT   MOD_RES    1516   1516       Phosphoserine; by PKC.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   CARBOHYD    211    211       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    284    284       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    295    295       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    301    301       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    306    306       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1378   1378       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1392   1392       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1403   1403       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    919    919       Interchain; with SCN2B or SCN4B.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   DISULFID    919    919       Interchain; with the conotoxin GVIIJ
FT                                (when the channel is not linked to SCN2B
FT                                or SCN4B; the bond to SCN2B or SCN4B
FT                                protects the channel from the inhibition
FT                                by toxin).
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   VAR_SEQ     654    681       Missing (in isoform 3).
FT                                {ECO:0000303|Ref.4}.
FT                                /FTId=VSP_045399.
FT   VAR_SEQ     671    681       Missing (in isoform 2).
FT                                {ECO:0000303|Ref.2, ECO:0000303|Ref.3,
FT                                ECO:0000303|Ref.4}.
FT                                /FTId=VSP_001031.
FT   VARIANT      17     17       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073441.
FT   VARIANT      27     27       R -> T (in GEFS+2; dbSNP:rs121917906).
FT                                {ECO:0000269|PubMed:20729507}.
FT                                /FTId=VAR_064229.
FT   VARIANT      45     45       D -> N (probable disease-associated
FT                                mutation found in a patient with an
FT                                unclassified form of epilepsy;
FT                                dbSNP:rs531894715).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073442.
FT   VARIANT      58     58       G -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073443.
FT   VARIANT      61     61       L -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073444.
FT   VARIANT      63     63       F -> L (in EIEE6; dbSNP:rs121917907).
FT                                {ECO:0000269|PubMed:20729507}.
FT                                /FTId=VAR_064230.
FT   VARIANT      68     68       I -> T (in EIEE6; borderline phenotype;
FT                                dbSNP:rs758871507).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073445.
FT   VARIANT      74     74       S -> P (in GEFS+2; dbSNP:rs121917931).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064295.
FT   VARIANT      78     78       E -> D (in EIEE6; dbSNP:rs121917933).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_029660.
FT   VARIANT      79     79       D -> H (in EIEE6; borderline phenotype;
FT                                dbSNP:rs121917982).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_064346.
FT   VARIANT      79     79       D -> N (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073446.
FT   VARIANT      84     84       Y -> C (in EIEE6; dbSNP:rs121917964).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_043349.
FT   VARIANT      90     90       F -> S (in EIEE6 and ICEGTC;
FT                                dbSNP:rs121918733).
FT                                {ECO:0000269|PubMed:20431604,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_064231.
FT   VARIANT      91     91       I -> T (in EIEE6; dbSNP:rs121918734).
FT                                {ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_064232.
FT   VARIANT      98     98       A -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073447.
FT   VARIANT     101    101       R -> Q (in EIEE6 and ICEGTC;
FT                                dbSNP:rs121917918).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:20431604,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029661.
FT   VARIANT     101    101       R -> W (in EIEE6; dbSNP:rs121917965).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20431604,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_064233.
FT   VARIANT     103    103       S -> G (in EIEE6; dbSNP:rs121918743).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029662.
FT   VARIANT     105    105       T -> I (in EIEE6; dbSNP:rs796053089).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073448.
FT   VARIANT     108    108       L -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073449.
FT   VARIANT     112    112       T -> I (in EIEE6; dbSNP:rs121918745).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029663.
FT   VARIANT     118    118       R -> S (in EIEE6; dbSNP:rs121917959).
FT                                {ECO:0000269|PubMed:18413471}.
FT                                /FTId=VAR_043350.
FT   VARIANT     124    124       I -> N (in EIEE6; dbSNP:rs121918761).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064234.
FT   VARIANT     127    127       H -> D (in EIEE6; borderline phenotype;
FT                                dbSNP:rs148442069).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073450.
FT   VARIANT     145    145       M -> T (in FEB3A; loss of function;
FT                                dbSNP:rs121918631).
FT                                {ECO:0000269|PubMed:16326807}.
FT                                /FTId=VAR_025366.
FT   VARIANT     162    162       T -> P (in EIEE6; dbSNP:rs121917934).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064296.
FT   VARIANT     171    171       I -> K (in EIEE6; dbSNP:rs121918766).
FT                                {ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064235.
FT   VARIANT     171    171       I -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073451.
FT   VARIANT     175    175       A -> T (in EIEE6; dbSNP:rs121918767).
FT                                {ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064236.
FT   VARIANT     175    175       A -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073452.
FT   VARIANT     177    177       G -> E (in EIEE6; results in a non-
FT                                functional channel; dbSNP:rs121918770).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054685}.
FT                                /FTId=VAR_029664.
FT   VARIANT     178    178       F -> S (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073453.
FT   VARIANT     179    179       C -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073454.
FT   VARIANT     188    188       D -> V (in GEFS+2; results in increased
FT                                membrane excitability as suggested by
FT                                increased resistance to cumulative
FT                                inactivation during high frequency
FT                                activation; dbSNP:rs121917953).
FT                                {ECO:0000269|PubMed:11254444,
FT                                ECO:0000269|PubMed:12576172}.
FT                                /FTId=VAR_014267.
FT   VARIANT     190    190       W -> R (in EIEE6; dbSNP:rs121918773).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029665.
FT   VARIANT     191    191       N -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073455.
FT   VARIANT     191    191       N -> Y (in EIEE6; dbSNP:rs121918762).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064237.
FT   VARIANT     194    194       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073456.
FT   VARIANT     194    194       D -> N (in EIEE6; dbSNP:rs121917935).
FT                                {ECO:0000269|PubMed:17054684,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064238.
FT   VARIANT     199    199       T -> R (in EIEE6; borderline phenotype
FT                                with spike wave activity;
FT                                dbSNP:rs121917983).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064347.
FT   VARIANT     217    217       T -> K (in EIEE6; dbSNP:rs121917936).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064297.
FT   VARIANT     218    218       F -> L (in GEFS+2; also found in patients
FT                                with Panayiotopoulos syndrome).
FT                                {ECO:0000269|PubMed:19339291,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073457.
FT   VARIANT     223    223       A -> E (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073458.
FT   VARIANT     226    226       T -> M (in EIEE6; borderline phenotype;
FT                                also found in a patient with cryptogenic
FT                                generalized epilepsy; dbSNP:rs121917984).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_043351.
FT   VARIANT     226    226       T -> R (in EIEE6; dbSNP:rs121917984).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073459.
FT   VARIANT     227    227       I -> S (in EIEE6; borderline phenotype
FT                                with spike wave activity in some
FT                                patients; results in a non-functional
FT                                channel; dbSNP:rs121917937).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684,
FT                                ECO:0000269|PubMed:17054685,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029666.
FT   VARIANT     227    227       I -> T (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073460.
FT   VARIANT     232    232       G -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073461.
FT   VARIANT     233    233       L -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073462.
FT   VARIANT     239    239       A -> T (in EIEE6; borderline phenotype
FT                                with spike wave activity in some
FT                                patients; dbSNP:rs121917985).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_043352.
FT   VARIANT     239    239       A -> V (in EIEE6; dbSNP:rs121917909).
FT                                {ECO:0000269|PubMed:20729507}.
FT                                /FTId=VAR_064239.
FT   VARIANT     243    243       S -> Y (in EIEE6; dbSNP:rs794726755).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073463.
FT   VARIANT     252    252       I -> M (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073464.
FT   VARIANT     252    252       I -> N (in EIEE6; dbSNP:rs121918780).
FT                                {ECO:0000269|PubMed:15087100}.
FT                                /FTId=VAR_029667.
FT   VARIANT     254    254       T -> I (in GEFS+2).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073465.
FT   VARIANT     259    259       S -> R (in EIEE6; dbSNP:rs121918735).
FT                                {ECO:0000269|PubMed:20431604,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_064240.
FT   VARIANT     265    265       G -> W (in EIEE6; dbSNP:rs121918749).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029668.
FT   VARIANT     277    277       C -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073466.
FT   VARIANT     280    280       W -> C (in EIEE6).
FT                                {ECO:0000269|PubMed:18639757}.
FT                                /FTId=VAR_073467.
FT   VARIANT     280    280       W -> R (in EIEE6; dbSNP:rs121917938).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029669.
FT   VARIANT     281    281       P -> A (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073468.
FT   VARIANT     281    281       P -> L (in EIEE6; dbSNP:rs796052964).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073469.
FT   VARIANT     281    281       P -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073470.
FT   VARIANT     289    289       E -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:22612257}.
FT                                /FTId=VAR_072743.
FT   VARIANT     290    290       H -> R (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073471.
FT   VARIANT     291    291       S -> G (in GEFS+2).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073472.
FT   VARIANT     297    297       T -> I (in EIEE6; dbSNP:rs121918771).
FT                                {ECO:0000269|PubMed:12821740}.
FT                                /FTId=VAR_029670.
FT   VARIANT     322    322       R -> I (in EIEE6; dbSNP:rs121917928).
FT                                {ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_064298.
FT   VARIANT     333    333       A -> V. {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073473.
FT   VARIANT     340    340       S -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073474.
FT   VARIANT     342    342       A -> V (in EIEE6; dbSNP:rs794726797).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073475.
FT   VARIANT     343    343       G -> D (in EIEE6; dbSNP:rs121918753).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_029671.
FT   VARIANT     345    345       C -> R (in EIEE6; dbSNP:rs794726782).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073476.
FT   VARIANT     351    351       C -> W (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073477.
FT   VARIANT     355    355       G -> D (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073478.
FT   VARIANT     356    356       R -> G (in EIEE6; dbSNP:rs121917920).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064299.
FT   VARIANT     357    357       N -> I (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073479.
FT   VARIANT     358    358       P -> T (in EIEE6; dbSNP:rs121917923).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064300.
FT   VARIANT     359    359       N -> S (in EIEE6; dbSNP:rs794726713).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073480.
FT   VARIANT     363    363       T -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073481.
FT   VARIANT     363    363       T -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073482.
FT   VARIANT     366    366       D -> E (in EIEE6; dbSNP:rs121917958).
FT                                {ECO:0000269|PubMed:18413471}.
FT                                /FTId=VAR_043353.
FT   VARIANT     377    377       R -> Q (in GEFS+2; dbSNP:rs121917957).
FT                                {ECO:0000269|PubMed:18413471}.
FT                                /FTId=VAR_043354.
FT   VARIANT     378    378       L -> Q (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073483.
FT   VARIANT     379    379       M -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:22612257}.
FT                                /FTId=VAR_072744.
FT   VARIANT     382    382       D -> N (probable disease-associated
FT                                mutation found in a patient with an
FT                                unclassified form of epilepsy).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073484.
FT   VARIANT     383    383       F -> L (in EIEE6; dbSNP:rs121917939).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064301.
FT   VARIANT     384    384       W -> R (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073485.
FT   VARIANT     388    388       Y -> H (in GEFS+2; dbSNP:rs121918781).
FT                                {ECO:0000269|PubMed:19464195}.
FT                                /FTId=VAR_064241.
FT   VARIANT     393    393       R -> C (in EIEE6; also in a patient with
FT                                myoclonic astatic epilepsy;
FT                                dbSNP:rs121917929).
FT                                {ECO:0000269|PubMed:17054684,
FT                                ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_043355.
FT   VARIANT     393    393       R -> H (in EIEE6 and ICEGTC; results in a
FT                                non-functional channel;
FT                                dbSNP:rs121917927).
FT                                {ECO:0000269|PubMed:12754708,
FT                                ECO:0000269|PubMed:17054685,
FT                                ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:20431604,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:22612257,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029672.
FT   VARIANT     393    393       R -> S (in EIEE6; dbSNP:rs121917929).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064302.
FT   VARIANT     395    395       A -> P (probable disease-associated
FT                                mutation found in a patient with
FT                                cryptogenic generalized epilepsy;
FT                                dbSNP:rs121917988).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_043356.
FT   VARIANT     400    400       M -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073486.
FT   VARIANT     400    400       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073487.
FT   VARIANT     403    403       F -> L (in EIEE6; dbSNP:rs121917966).
FT                                {ECO:0000269|PubMed:16713920,
FT                                ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_064303.
FT   VARIANT     403    403       F -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073488.
FT   VARIANT     406    406       V -> F (in EIEE6; dbSNP:rs121918768).
FT                                {ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064242.
FT   VARIANT     409    409       L -> W (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073489.
FT   VARIANT     413    413       Y -> N (in EIEE6; dbSNP:rs121917967).
FT                                {ECO:0000269|PubMed:16713920,
FT                                ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064243.
FT   VARIANT     422    422       V -> E (probable disease-associated
FT                                mutation found in a patient with
FT                                cryptogenic generalized epilepsy;
FT                                dbSNP:rs121917989).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_043357.
FT   VARIANT     426    426       Y -> C (in EIEE6; dbSNP:rs796052973).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073490.
FT   VARIANT     426    426       Y -> N (in EIEE6; results in decreased
FT                                peak current densities; causes a negative
FT                                shift in the half-maximal steady-state
FT                                inactivation and delayed recovery from
FT                                fast inactivation; dbSNP:rs121917940).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684,
FT                                ECO:0000269|PubMed:17054685}.
FT                                /FTId=VAR_029673.
FT   VARIANT     525    525       S -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073491.
FT   VARIANT     542    542       R -> Q (found in a patient with
FT                                intractable epilepsy and in a patient
FT                                with generalized epilepsy with febril
FT                                seizures; also found in patients with
FT                                autism; unknown pathological
FT                                significance; dbSNP:rs121918817).
FT                                {ECO:0000269|PubMed:12610651,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:19522081,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029674.
FT   VARIANT     604    604       R -> H (rare variant; found in patients
FT                                with early infantile epileptic
FT                                encephalopathy and in patients with
FT                                intractable epilepsy; unknown
FT                                pathological significance;
FT                                dbSNP:rs121918769).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_064244.
FT   VARIANT     626    626       S -> G (in EIEE6; also found in a patient
FT                                with cryptogenic generalized epilepsy;
FT                                dbSNP:rs121917990).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_043358.
FT   VARIANT     674    674       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_073492.
FT   VARIANT     699    699       V -> I. {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073493.
FT   VARIANT     762    762       N -> D (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073494.
FT   VARIANT     783    783       L -> P (in EIEE6; dbSNP:rs121917968).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064245.
FT   VARIANT     785    785       M -> T (in EIEE6; dbSNP:rs796053095).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073495.
FT   VARIANT     790    790       Y -> C (in GEFS+2; dbSNP:rs121918782).
FT                                {ECO:0000269|PubMed:12919402}.
FT                                /FTId=VAR_029675.
FT   VARIANT     790    790       Y -> F (probable disease-associated
FT                                mutation found in patients with
FT                                Panayiotopoulos syndrome;
FT                                dbSNP:rs121918782).
FT                                {ECO:0000269|PubMed:17679682,
FT                                ECO:0000269|PubMed:19522081}.
FT                                /FTId=VAR_073496.
FT   VARIANT     808    808       T -> S (in ICEGTC; results in increased
FT                                peak current density and delayed slow
FT                                inactivation onset; recovery from slow
FT                                inactivation is delayed;
FT                                dbSNP:rs121918758).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029676.
FT   VARIANT     812    812       T -> I (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073497.
FT   VARIANT     812    812       T -> R (in EIEE6; dbSNP:rs121917941).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064304.
FT   VARIANT     842    842       L -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073498.
FT   VARIANT     843    843       S -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073499.
FT   VARIANT     846    846       E -> K (in EIEE6; dbSNP:rs121917942).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064305.
FT   VARIANT     854    855       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073500.
FT   VARIANT     859    859       R -> C (in GEFS+2 and EIEE6; causes a
FT                                positive shift in the voltage dependence
FT                                of channel activation, slower recovery
FT                                from slow inactivation and lower levels
FT                                of current compared with the wild-type
FT                                channel; dbSNP:rs121918784).
FT                                {ECO:0000269|PubMed:16525050,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064306.
FT   VARIANT     859    859       R -> H (in GEFS+2; results in impaired
FT                                channel fast inactivation and
FT                                significantly increased persistent
FT                                current; dbSNP:rs398123588).
FT                                {ECO:0000269|PubMed:21864321}.
FT                                /FTId=VAR_073501.
FT   VARIANT     862    862       R -> Q (in EIEE6; dbSNP:rs121918785).
FT                                {ECO:0000269|PubMed:20110217,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064246.
FT   VARIANT     865    865       R -> G (in EIEE6; results in impaired
FT                                channel fast inactivation and
FT                                significantly increased persistent
FT                                current). {ECO:0000269|PubMed:21864321}.
FT                                /FTId=VAR_073502.
FT   VARIANT     875    875       T -> K (in EIEE6; dbSNP:rs121918623).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064247.
FT   VARIANT     875    875       T -> M (in GEFS+2 and EIEE6; borderline
FT                                phenotype; dbSNP:rs121918623).
FT                                {ECO:0000269|PubMed:10742094,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_010110.
FT   VARIANT     876    876       L -> I (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073503.
FT   VARIANT     890    890       L -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073504.
FT   VARIANT     896    896       V -> F (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073505.
FT   VARIANT     896    896       V -> I (in ICEGTC; dbSNP:rs745378416).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073506.
FT   VARIANT     896    896       V -> L (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073507.
FT   VARIANT     899    899       I -> T (in GEFS+2).
FT                                {ECO:0000269|PubMed:19522081}.
FT                                /FTId=VAR_073508.
FT   VARIANT     902    902       F -> C (in EIEE6; dbSNP:rs121918787).
FT                                {ECO:0000269|PubMed:12083760}.
FT                                /FTId=VAR_029677.
FT   VARIANT     924    924       A -> T (in dbSNP:rs141950573).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073509.
FT   VARIANT     927    927       C -> F (in EIEE6; dbSNP:rs794726811).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073510.
FT   VARIANT     931    931       R -> C (in EIEE6; dbSNP:rs121918788).
FT                                {ECO:0000269|PubMed:12083760,
FT                                ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_029678.
FT   VARIANT     931    931       R -> H (probable disease-associated
FT                                mutation found in a patient with an
FT                                unclassified form of epilepsy;
FT                                dbSNP:rs794726718).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073511.
FT   VARIANT     932    932       W -> C (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073512.
FT   VARIANT     933    933       H -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073513.
FT   VARIANT     934    934       M -> I (in EIEE6; dbSNP:rs121918774).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029679.
FT   VARIANT     935    935       N -> H (in GEFS+2).
FT                                {ECO:0000269|PubMed:18566737}.
FT                                /FTId=VAR_073514.
FT   VARIANT     939    939       H -> P (in EIEE6; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073515.
FT   VARIANT     939    939       H -> Q (in EIEE6; results in a non-
FT                                functional channel; dbSNP:rs121918795).
FT                                {ECO:0000269|PubMed:12754708,
FT                                ECO:0000269|PubMed:17054685}.
FT                                /FTId=VAR_029680.
FT   VARIANT     939    939       H -> Y (in EIEE6; dbSNP:rs121918736).
FT                                {ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_064248.
FT   VARIANT     940    940       S -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073516.
FT   VARIANT     942    942       L -> P (in EIEE6; dbSNP:rs121917943).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064307.
FT   VARIANT     943    943       I -> N (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073517.
FT   VARIANT     944    944       V -> A (in EIEE6 and ICEGTC;
FT                                dbSNP:rs121917969).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029681.
FT   VARIANT     944    944       V -> E (in EIEE6).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064249.
FT   VARIANT     945    945       F -> L (in EIEE6; dbSNP:rs121917970).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064250.
FT   VARIANT     946    946       R -> C (in EIEE6; loss-of-function
FT                                mutation resulting in complete absence of
FT                                sodium current; dbSNP:rs121918775).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:21864321,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029682.
FT   VARIANT     946    946       R -> H (in EIEE6 and GEFS+2; GEFS+2
FT                                phenotype consists of partial epilepsy
FT                                with antecedent febrile seizures and
FT                                seizure aggravation by antiepileptic
FT                                drugs; loss-of-function mutation
FT                                resulting in complete absence of sodium
FT                                current; dbSNP:rs121917971).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:16713920,
FT                                ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:20550552,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:21864321,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029683.
FT   VARIANT     946    946       R -> S (in EIEE6; dbSNP:rs121918775).
FT                                {ECO:0000269|PubMed:15944908}.
FT                                /FTId=VAR_057995.
FT   VARIANT     949    949       C -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073518.
FT   VARIANT     949    949       C -> Y (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073519.
FT   VARIANT     950    950       G -> E (in EIEE6; dbSNP:rs121917972).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064251.
FT   VARIANT     950    950       G -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073520.
FT   VARIANT     952    952       W -> G (in EIEE6; dbSNP:rs121918737).
FT                                {ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_064252.
FT   VARIANT     954    954       E -> K (in EIEE6; dbSNP:rs121918786).
FT                                {ECO:0000269|PubMed:20110217,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064253.
FT   VARIANT     956    956       M -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073521.
FT   VARIANT     957    957       W -> L (in EIEE6; dbSNP:rs121917917).
FT                                {ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064308.
FT   VARIANT     959    959       C -> R (in EIEE6; results in a non-
FT                                functional channel; dbSNP:rs121918796).
FT                                {ECO:0000269|PubMed:12754708,
FT                                ECO:0000269|PubMed:17054685}.
FT                                /FTId=VAR_029684.
FT   VARIANT     960    960       M -> T (in GEFS+2).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073522.
FT   VARIANT     960    960       M -> V (in EIEE6; dbSNP:rs121918750).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029685.
FT   VARIANT     973    973       M -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073523.
FT   VARIANT     973    973       M -> V (in GEFS+2; dbSNP:rs121917991).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_043359.
FT   VARIANT     976    976       M -> I (in EIEE6 and GEFS+2).
FT                                {ECO:0000269|PubMed:19522081,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073524.
FT   VARIANT     978    978       I -> M (in GEFS+2; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:17927801}.
FT                                /FTId=VAR_073525.
FT   VARIANT     979    979       G -> R (in ICEGTC; loss-of-function
FT                                mutation resulting in absence of sodium
FT                                current; dbSNP:rs121918754).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029686.
FT   VARIANT     979    979       G -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073526.
FT   VARIANT     982    982       V -> L (found in a patient with acute
FT                                encephalopathy with biphasic seizures and
FT                                late reduced diffusion; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:22309220,
FT                                ECO:0000269|PubMed:26311622}.
FT                                /FTId=VAR_075569.
FT   VARIANT     983    983       V -> A (in ICEGTC; reduced function;
FT                                decreased peak current density; results
FT                                in a negative shift of inactivation and
FT                                positive shift of activation;
FT                                dbSNP:rs121918756).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029687.
FT   VARIANT     985    985       N -> I (in EIEE6; dbSNP:rs121918747).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029688.
FT   VARIANT     986    986       L -> F (in EIEE6; complete loss of
FT                                function; dbSNP:rs121918625).
FT                                {ECO:0000269|PubMed:11359211,
FT                                ECO:0000269|PubMed:14672992}.
FT                                /FTId=VAR_014268.
FT   VARIANT     986    986       L -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073527.
FT   VARIANT     987    987       F -> L (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073528.
FT   VARIANT     993    993       S -> R (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073529.
FT   VARIANT     998    998       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073530.
FT   VARIANT     999   1000       NL -> LIS (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073531.
FT   VARIANT    1006   1006       D -> E (probable disease-associated
FT                                mutation found in a patient with an
FT                                unclassified form of epilepsy;
FT                                dbSNP:rs375909896).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073532.
FT   VARIANT    1011   1011       N -> I (in ICEGTC; results in reduced
FT                                peak current density and hyperpolarizing
FT                                shift in inactivation;
FT                                dbSNP:rs121918759).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029689.
FT   VARIANT    1034   1034       I -> T (associated with autism;
FT                                dbSNP:rs121918818).
FT                                {ECO:0000269|PubMed:12610651}.
FT                                /FTId=VAR_029690.
FT   VARIANT    1038   1038       F -> L (associated with autism).
FT                                {ECO:0000269|PubMed:12610651}.
FT                                /FTId=VAR_029691.
FT   VARIANT    1067   1067       A -> T (in dbSNP:rs2298771).
FT                                {ECO:0000269|PubMed:11254444,
FT                                ECO:0000269|PubMed:12083760,
FT                                ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:12610651,
FT                                ECO:0000269|PubMed:16122630,
FT                                ECO:0000269|PubMed:19694741,
FT                                ECO:0000269|PubMed:20682179,
FT                                ECO:0000269|Ref.4}.
FT                                /FTId=VAR_014269.
FT   VARIANT    1068   1068       E -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073533.
FT   VARIANT    1079   1079       V -> I. {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073534.
FT   VARIANT    1109   1109       P -> T (in dbSNP:rs753452775).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073535.
FT   VARIANT    1174   1174       T -> S (in FHM3; dbSNP:rs121918799).
FT                                {ECO:0000269|PubMed:18021921}.
FT                                /FTId=VAR_064309.
FT   VARIANT    1204   1204       W -> R (in GEFS+2; causes hyperpolarized
FT                                shifts in the voltage dependence of
FT                                activation and steady-state inactivation;
FT                                dbSNP:rs121917930).
FT                                {ECO:0000269|PubMed:11254445,
FT                                ECO:0000269|PubMed:12535936,
FT                                ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_014270.
FT   VARIANT    1204   1204       W -> S (in GEFS+2).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073536.
FT   VARIANT    1207   1207       L -> P (in EIEE6; dbSNP:rs121917963).
FT                                {ECO:0000269|PubMed:18413471}.
FT                                /FTId=VAR_043360.
FT   VARIANT    1208   1208       R -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073537.
FT   VARIANT    1210   1210       T -> K (in EIEE6; dbSNP:rs121918738).
FT                                {ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_064254.
FT   VARIANT    1213   1213       R -> Q (in ICEGTC; dbSNP:rs566081370).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073538.
FT   VARIANT    1221   1221       E -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073539.
FT   VARIANT    1230   1230       L -> F (in EIEE6 and GEFS+2).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073540.
FT   VARIANT    1231   1231       S -> R (in EIEE6; dbSNP:rs121918746).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029692.
FT   VARIANT    1231   1231       S -> T (in EIEE6; dbSNP:rs121918800).
FT                                {ECO:0000269|PubMed:16458823}.
FT                                /FTId=VAR_064310.
FT   VARIANT    1233   1233       G -> R (in EIEE6; dbSNP:rs121917911).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_029693.
FT   VARIANT    1238   1238       E -> D (in EIEE6; dbSNP:rs121917973).
FT                                {ECO:0000269|PubMed:16713920,
FT                                ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_043361.
FT   VARIANT    1239   1239       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073541.
FT   VARIANT    1239   1239       D -> Y (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073542.
FT   VARIANT    1245   1245       R -> Q (in EIEE6; dbSNP:rs121917912).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064311.
FT   VARIANT    1249   1249       K -> N (in GEFS+2).
FT                                {ECO:0000269|PubMed:19522081}.
FT                                /FTId=VAR_073543.
FT   VARIANT    1250   1250       T -> M (in GEFS+2; dbSNP:rs140731963).
FT                                {ECO:0000269|PubMed:19522081}.
FT                                /FTId=VAR_073544.
FT   VARIANT    1254   1254       Y -> C (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073545.
FT   VARIANT    1255   1255       A -> D (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073546.
FT   VARIANT    1260   1260       T -> P (in EIEE6; dbSNP:rs121918739).
FT                                {ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_064255.
FT   VARIANT    1263   1263       F -> L (in EIEE6; dbSNP:rs121918752).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029694.
FT   VARIANT    1265   1265       L -> P (in EIEE6; dbSNP:rs121918794).
FT                                {ECO:0000269|PubMed:12083760}.
FT                                /FTId=VAR_029695.
FT   VARIANT    1266   1266       E -> A (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073547.
FT   VARIANT    1270   1270       K -> T (in GEFS+2; dbSNP:rs121918626).
FT                                {ECO:0000269|PubMed:11756608}.
FT                                /FTId=VAR_014271.
FT   VARIANT    1275   1275       G -> A (found in a child with sporadic
FT                                epilepsy; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:23647072}.
FT                                /FTId=VAR_077831.
FT   VARIANT    1275   1275       G -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073548.
FT   VARIANT    1284   1284       W -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073549.
FT   VARIANT    1287   1287       L -> P (in EIEE6; dbSNP:rs121918740).
FT                                {ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_064256.
FT   VARIANT    1288   1288       D -> N (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073550.
FT   VARIANT    1289   1289       Missing (in EIEE6; results in a non-
FT                                functional channel).
FT                                {ECO:0000269|PubMed:12083760,
FT                                ECO:0000269|PubMed:17054685,
FT                                ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_029696.
FT   VARIANT    1308   1308       E -> D (in FEB3A; also found in patients
FT                                with early infantile epileptic
FT                                encephalopathy; unknown pathological
FT                                significance; dbSNP:rs121917910).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:19522081,
FT                                ECO:0000269|PubMed:20729507,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064257.
FT   VARIANT    1309   1309       L -> F (in GEFS+2; dbSNP:rs121918801).
FT                                {ECO:0000269|PubMed:20117752}.
FT                                /FTId=VAR_064258.
FT   VARIANT    1316   1316       R -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073551.
FT   VARIANT    1316   1316       R -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073552.
FT   VARIANT    1320   1320       A -> V (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073553.
FT   VARIANT    1325   1325       R -> T (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073554.
FT   VARIANT    1326   1326       A -> D (probable disease-associated
FT                                mutation found in a patient with an
FT                                unclassified form of epilepsy).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073555.
FT   VARIANT    1326   1326       A -> P (in EIEE6; dbSNP:rs121918803).
FT                                {ECO:0000269|PubMed:14504318,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_029698.
FT   VARIANT    1328   1328       S -> P (in ICEGTC and EIEE6).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073556.
FT   VARIANT    1335   1335       V -> M (in EIEE6; dbSNP:rs121917960).
FT                                {ECO:0000269|PubMed:18413471,
FT                                ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_043362.
FT   VARIANT    1339   1339       A -> V (in EIEE6; dbSNP:rs794726789).
FT                                {ECO:0000269|PubMed:22092154,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073557.
FT   VARIANT    1344   1344       I -> M (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073558.
FT   VARIANT    1350   1350       V -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073559.
FT   VARIANT    1353   1353       V -> L (in GEFS+2; complete loss of
FT                                function; dbSNP:rs121917954).
FT                                {ECO:0000269|PubMed:11254444,
FT                                ECO:0000269|PubMed:14672992}.
FT                                /FTId=VAR_014272.
FT   VARIANT    1355   1355       L -> P (in EIEE6; dbSNP:rs121918776).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029697.
FT   VARIANT    1357   1357       F -> L (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073560.
FT   VARIANT    1358   1358       W -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073561.
FT   VARIANT    1358   1358       W -> S (in EIEE6; dbSNP:rs121917961).
FT                                {ECO:0000269|PubMed:18413471}.
FT                                /FTId=VAR_043363.
FT   VARIANT    1366   1366       V -> I (in GEFS+2 and ICEGTC;
FT                                dbSNP:rs121918805).
FT                                {ECO:0000269|PubMed:17507202}.
FT                                /FTId=VAR_043364.
FT   VARIANT    1367   1367       N -> K (in EIEE6; dbSNP:rs121918760).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064259.
FT   VARIANT    1370   1370       A -> P (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073562.
FT   VARIANT    1376   1376       C -> R (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073563.
FT   VARIANT    1378   1378       N -> H (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073564.
FT   VARIANT    1378   1378       N -> T (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073565.
FT   VARIANT    1385   1385       F -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073566.
FT   VARIANT    1390   1390       V -> M (in EIEE6; some patients have a
FT                                borderline EIEE6 phenotype;
FT                                dbSNP:rs121917986).
FT                                {ECO:0000269|PubMed:12083760,
FT                                ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_029699.
FT   VARIANT    1391   1391       N -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073567.
FT   VARIANT    1393   1393       H -> P (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:17129991}.
FT                                /FTId=VAR_073568.
FT   VARIANT    1394   1394       T -> I (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073569.
FT   VARIANT    1396   1396       C -> G (in EIEE6; some patients have a
FT                                borderline EIEE6 phenotype;
FT                                dbSNP:rs121917987).
FT                                {ECO:0000269|PubMed:16713920,
FT                                ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064260.
FT   VARIANT    1396   1396       C -> Y (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073570.
FT   VARIANT    1414   1414       N -> D (in GEFS+2).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073571.
FT   VARIANT    1414   1414       N -> Y (in EIEE6; dbSNP:rs121917925).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064312.
FT   VARIANT    1416   1416       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073572.
FT   VARIANT    1417   1417       N -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073573.
FT   VARIANT    1418   1418       V -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073574.
FT   VARIANT    1422   1422       Y -> C (in EIEE6; dbSNP:rs121917913).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064313.
FT   VARIANT    1423   1423       L -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073575.
FT   VARIANT    1426   1426       L -> R (in EIEE6; dbSNP:rs121917944).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064314.
FT   VARIANT    1427   1427       Q -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073576.
FT   VARIANT    1428   1428       V -> A (in GEFS+2; dbSNP:rs121918627).
FT                                {ECO:0000269|PubMed:11524484}.
FT                                /FTId=VAR_029700.
FT   VARIANT    1429   1429       A -> D (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073577.
FT   VARIANT    1429   1429       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073578.
FT   VARIANT    1431   1431       F -> I (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073579.
FT   VARIANT    1433   1433       G -> E (in EIEE6; dbSNP:rs121918741).
FT                                {ECO:0000269|PubMed:20431604}.
FT                                /FTId=VAR_064261.
FT   VARIANT    1433   1433       G -> R (in EIEE6; dbSNP:rs121917908).
FT                                {ECO:0000269|PubMed:20729507}.
FT                                /FTId=VAR_064262.
FT   VARIANT    1433   1433       G -> V (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073580.
FT   VARIANT    1434   1434       W -> R (in EIEE6; dbSNP:rs121918789).
FT                                {ECO:0000269|PubMed:12083760,
FT                                ECO:0000269|PubMed:12754708}.
FT                                /FTId=VAR_029701.
FT   VARIANT    1437   1437       I -> M (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073581.
FT   VARIANT    1441   1441       A -> P (in EIEE6; dbSNP:rs121917974).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_064348.
FT   VARIANT    1450   1450       Q -> K (in EIEE6; dbSNP:rs121918806).
FT                                {ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064263.
FT   VARIANT    1450   1450       Q -> R (in EIEE6; dbSNP:rs121918790).
FT                                {ECO:0000269|PubMed:12083760}.
FT                                /FTId=VAR_029702.
FT   VARIANT    1451   1451       P -> L (in EIEE6; dbSNP:rs121917945).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064315.
FT   VARIANT    1451   1451       P -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073582.
FT   VARIANT    1453   1453       Y -> C (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073583.
FT   VARIANT    1454   1454       E -> K (in EIEE6; dbSNP:rs796053012).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073584.
FT   VARIANT    1461   1461       L -> I (in EIEE6; dbSNP:rs121918772).
FT                                {ECO:0000269|PubMed:12821740}.
FT                                /FTId=VAR_029703.
FT   VARIANT    1462   1462       Y -> C (in EIEE6; dbSNP:rs121917962).
FT                                {ECO:0000269|PubMed:18413471}.
FT                                /FTId=VAR_043365.
FT   VARIANT    1462   1462       Y -> H (in EIEE6 and ICEGTC; borderline
FT                                EIEE6 phenotype).
FT                                {ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073585.
FT   VARIANT    1463   1463       F -> S (in EIEE6; dbSNP:rs121917946).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_029704.
FT   VARIANT    1470   1470       G -> W (in EIEE6; dbSNP:rs121917924).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064316.
FT   VARIANT    1472   1472       F -> S (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073586.
FT   VARIANT    1473   1473       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073587.
FT   VARIANT    1475   1475       L -> S (in EIEE6; dbSNP:rs121917947).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064317.
FT   VARIANT    1476   1476       N -> K (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073588.
FT   VARIANT    1480   1480       G -> V (probable disease-associated
FT                                mutation found in a patient with
FT                                myoclonic astatic epilepsy;
FT                                dbSNP:rs121917996).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_043366.
FT   VARIANT    1483   1483       I -> M (probable disease-associated
FT                                mutation found in a patient with an
FT                                unclassified form of epilepsy).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073589.
FT   VARIANT    1483   1483       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073590.
FT   VARIANT    1484   1484       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073591.
FT   VARIANT    1485   1485       N -> Y (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073592.
FT   VARIANT    1489   1489       Q -> H (in FHM3; dbSNP:rs121918633).
FT                                {ECO:0000269|PubMed:19332696}.
FT                                /FTId=VAR_057996.
FT   VARIANT    1489   1489       Q -> K (in FHM3; dbSNP:rs121918628).
FT                                {ECO:0000269|PubMed:16054936}.
FT                                /FTId=VAR_025281.
FT   VARIANT    1499   1499       F -> L (in FHM3; dbSNP:rs121918632).
FT                                {ECO:0000269|PubMed:19332696}.
FT                                /FTId=VAR_057997.
FT   VARIANT    1503   1503       E -> K (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:19783390,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073593.
FT   VARIANT    1503   1503       Missing (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073594.
FT   VARIANT    1511   1511       M -> K (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073595.
FT   VARIANT    1514   1514       L -> S (in EIEE6; dbSNP:rs121918764).
FT                                {ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064264.
FT   VARIANT    1538   1538       V -> I (in EIEE6; dbSNP:rs780360360).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073596.
FT   VARIANT    1543   1543       F -> S (in a patient with cryptogenic
FT                                focal epilepsy; dbSNP:rs121917992).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_043367.
FT   VARIANT    1544   1544       D -> A (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073597.
FT   VARIANT    1544   1544       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073598.
FT   VARIANT    1545   1545       I -> V (in EIEE6; dbSNP:rs121917975).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_064265.
FT   VARIANT    1555   1555       M -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073599.
FT   VARIANT    1559   1559       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:14738421}.
FT                                /FTId=VAR_029705.
FT   VARIANT    1561   1561       E -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073600.
FT   VARIANT    1575   1575       R -> C (found in a patient with
FT                                intractable epilepsy and patients with
FT                                Dravet syndrome; found in a patient with
FT                                acute necrotizing encephalopathy and also
FT                                found in a patient with acute
FT                                encephalopathy with biphasic seizures and
FT                                late reduced diffusion; unknown
FT                                pathological significance;
FT                                dbSNP:rs121918807).
FT                                {ECO:0000269|PubMed:18031552,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:22309220,
FT                                ECO:0000269|PubMed:23195492,
FT                                ECO:0000269|PubMed:26311622}.
FT                                /FTId=VAR_064318.
FT   VARIANT    1579   1579       V -> E (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073601.
FT   VARIANT    1586   1586       G -> E (in EIEE6; dbSNP:rs121918742).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20431604,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064266.
FT   VARIANT    1588   1588       C -> R (in EIEE6; dbSNP:rs121917919).
FT                                {ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064319.
FT   VARIANT    1592   1592       L -> H (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073602.
FT   VARIANT    1592   1592       L -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073603.
FT   VARIANT    1596   1596       R -> C (in EIEE6; also found in a patient
FT                                with cryptogenic focal epilepsy;
FT                                dbSNP:rs121917993).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_043368.
FT   VARIANT    1596   1596       R -> H (in GEFS+2; dbSNP:rs575368466).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073604.
FT   VARIANT    1596   1596       R -> L (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073605.
FT   VARIANT    1605   1605       N -> S (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073606.
FT   VARIANT    1608   1608       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073607.
FT   VARIANT    1608   1608       D -> Y (in EIEE6; dbSNP:rs121917915).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064320.
FT   VARIANT    1611   1611       V -> F (in ICEGTC; results in greater
FT                                levels of persistent non-inactivating
FT                                current compared to wild-type;
FT                                dbSNP:rs121918630).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029706.
FT   VARIANT    1612   1612       V -> I (in EIEE6; dbSNP:rs121918808).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:19563458,
FT                                ECO:0000269|PubMed:20452746}.
FT                                /FTId=VAR_064267.
FT   VARIANT    1619   1619       M -> V (in ICEGTC; dbSNP:rs373967247).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073608.
FT   VARIANT    1630   1630       V -> L (in EIEE6; borderline phenotype in
FT                                some patients).
FT                                {ECO:0000269|PubMed:22092154,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073609.
FT   VARIANT    1630   1630       V -> M (in EIEE6; dbSNP:rs121917914).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064321.
FT   VARIANT    1632   1632       P -> S (in ICEGTC; results in greater
FT                                levels of persistent non-inactivating
FT                                current compared to wild-type;
FT                                dbSNP:rs121918755).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029707.
FT   VARIANT    1636   1636       R -> Q (probable disease-associated
FT                                mutation found in a patient with Lennon-
FT                                Gastaut syndrome; dbSNP:rs121917995).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_043369.
FT   VARIANT    1637   1637       V -> E (in EIEE6; also found in a child
FT                                with febrile status epilepticus who
FT                                developed liver failure;
FT                                dbSNP:rs121918810).
FT                                {ECO:0000269|PubMed:20392657,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064268.
FT   VARIANT    1638   1638       I -> N (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073610.
FT   VARIANT    1638   1638       I -> T (in EIEE6; also found in a patient
FT                                with an unclassified form of epilepsy).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073611.
FT   VARIANT    1639   1639       R -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073612.
FT   VARIANT    1642   1642       R -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073613.
FT   VARIANT    1645   1645       R -> Q (in EIEE6; dbSNP:rs121917976).
FT                                {ECO:0000269|PubMed:16713920,
FT                                ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064269.
FT   VARIANT    1648   1648       R -> C (in EIEE6; dbSNP:rs121918791).
FT                                {ECO:0000269|PubMed:12083760,
FT                                ECO:0000269|PubMed:19522081,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_029708.
FT   VARIANT    1648   1648       R -> H (in GEFS+2 and EIEE6;
FT                                dbSNP:rs121918622).
FT                                {ECO:0000269|PubMed:10742094,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_010111.
FT   VARIANT    1649   1649       L -> Q (in FHM3).
FT                                {ECO:0000269|PubMed:17397047}.
FT                                /FTId=VAR_064322.
FT   VARIANT    1653   1653       A -> E (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073614.
FT   VARIANT    1656   1656       I -> M (in GEFS+2; exhibits a
FT                                depolarizing shift in the voltage
FT                                dependence of activation;
FT                                dbSNP:rs121917955).
FT                                {ECO:0000269|PubMed:11254444,
FT                                ECO:0000269|PubMed:14672992}.
FT                                /FTId=VAR_014273.
FT   VARIANT    1657   1657       R -> C (in GEFS+2; exhibits a
FT                                depolarizing shift in the voltage
FT                                dependence of activation; shows a 50%
FT                                reduction in current density and
FT                                accelerates recovery from slow
FT                                inactivation; dbSNP:rs121918811).
FT                                {ECO:0000269|PubMed:14672992}.
FT                                /FTId=VAR_029709.
FT   VARIANT    1657   1657       R -> H (probable disease-associated
FT                                mutation found in a patient with
FT                                cryptogenic focal epilepsy;
FT                                dbSNP:rs121917994).
FT                                {ECO:0000269|PubMed:17347258,
FT                                ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_043370.
FT   VARIANT    1658   1658       T -> M (in EIEE6; dbSNP:rs121917922).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064270.
FT   VARIANT    1658   1658       T -> R (in EIEE6; dbSNP:rs121917922).
FT                                {ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_064323.
FT   VARIANT    1660   1660       L -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073615.
FT   VARIANT    1661   1661       F -> S (in EIEE6; dbSNP:rs121918797).
FT                                {ECO:0000269|PubMed:12754708}.
FT                                /FTId=VAR_029710.
FT   VARIANT    1662   1662       A -> V (in EIEE6; borderline phenotype;
FT                                dbSNP:rs794726839).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073616.
FT   VARIANT    1664   1664       M -> K (in EIEE6; dbSNP:rs121918765).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064271.
FT   VARIANT    1667   1667       L -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073617.
FT   VARIANT    1668   1668       P -> A (in EIEE6; dbSNP:rs121917948).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_029711.
FT   VARIANT    1668   1668       P -> L (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073618.
FT   VARIANT    1672   1672       N -> I (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073619.
FT   VARIANT    1673   1673       I -> T (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073620.
FT   VARIANT    1674   1674       G -> R (in EIEE6; dbSNP:rs121918792).
FT                                {ECO:0000269|PubMed:12083760}.
FT                                /FTId=VAR_029712.
FT   VARIANT    1674   1674       G -> S (found in a patient acute
FT                                encephalopathy with biphasic seizures and
FT                                late reduced diffusion; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:26311622}.
FT                                /FTId=VAR_075570.
FT   VARIANT    1675   1675       L -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073621.
FT   VARIANT    1677   1677       L -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073622.
FT   VARIANT    1683   1683       I -> F (probable disease-associated
FT                                mutation found in a patient with an
FT                                unclassified form of epilepsy).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073623.
FT   VARIANT    1683   1683       I -> T (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073624.
FT   VARIANT    1684   1684       Y -> D (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073625.
FT   VARIANT    1684   1684       Y -> S (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073626.
FT   VARIANT    1685   1685       A -> D (in EIEE6; dbSNP:rs121918744).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029714.
FT   VARIANT    1685   1685       A -> V (in GEFS+2; complete loss of
FT                                function; dbSNP:rs121918744).
FT                                {ECO:0000269|PubMed:11524484,
FT                                ECO:0000269|PubMed:14672992}.
FT                                /FTId=VAR_029715.
FT   VARIANT    1687   1687       F -> S (in GEFS+2; dbSNP:rs121917932).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064324.
FT   VARIANT    1688   1688       G -> W (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073627.
FT   VARIANT    1692   1692       F -> S (in EIEE6; dbSNP:rs121918778).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029716.
FT   VARIANT    1694   1694       Y -> C (in EIEE6; dbSNP:rs121918777).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029713.
FT   VARIANT    1707   1707       F -> V (in EIEE6; dbSNP:rs121917977).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_064349.
FT   VARIANT    1709   1709       T -> I (in ICEGTC; loss-of-function
FT                                mutation resulting in absence of sodium
FT                                current; dbSNP:rs121918629).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029717.
FT   VARIANT    1713   1713       S -> N (in EIEE6; dbSNP:rs121918816).
FT                                {ECO:0000269|PubMed:16122630}.
FT                                /FTId=VAR_064325.
FT   VARIANT    1714   1714       M -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073628.
FT   VARIANT    1714   1714       M -> R (in EIEE6; dbSNP:rs121917949).
FT                                {ECO:0000269|PubMed:17054684,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064326.
FT   VARIANT    1716   1716       C -> R (in EIEE6; dbSNP:rs121917926).
FT                                {ECO:0000269|PubMed:17561957}.
FT                                /FTId=VAR_064327.
FT   VARIANT    1721   1721       T -> R (in EIEE6; dbSNP:rs121917978).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_064350.
FT   VARIANT    1724   1724       A -> P (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073629.
FT   VARIANT    1725   1725       G -> C (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073630.
FT   VARIANT    1726   1726       W -> R (in EIEE6; dbSNP:rs121917979).
FT                                {ECO:0000269|PubMed:19589774}.
FT                                /FTId=VAR_064272.
FT   VARIANT    1727   1727       D -> G (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073631.
FT   VARIANT    1739   1739       P -> L (in GEFS+2).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073632.
FT   VARIANT    1741   1741       C -> R (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073633.
FT   VARIANT    1742   1742       D -> G (in GEFS+2; dbSNP:rs121918812).
FT                                {ECO:0000269|PubMed:15694566}.
FT                                /FTId=VAR_057998.
FT   VARIANT    1749   1749       G -> E (in EIEE6; dbSNP:rs121918798).
FT                                {ECO:0000269|PubMed:12754708}.
FT                                /FTId=VAR_029718.
FT   VARIANT    1756   1756       C -> G (in EIEE6; dbSNP:rs121918809).
FT                                {ECO:0000269|PubMed:19563458,
FT                                ECO:0000269|PubMed:20452746}.
FT                                /FTId=VAR_064273.
FT   VARIANT    1762   1762       G -> E (in EIEE6; dbSNP:rs121917950).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064328.
FT   VARIANT    1763   1763       I -> N (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073634.
FT   VARIANT    1765   1765       F -> L (in GEFS+2; disease phenotype
FT                                consists of partial epilepsy with
FT                                antecedent febrile seizures and seizure
FT                                aggravation by antiepileptic drugs; loss-
FT                                of-function mutation resulting in
FT                                complete absence of sodium current).
FT                                {ECO:0000269|PubMed:20550552}.
FT                                /FTId=VAR_073635.
FT   VARIANT    1766   1766       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029719.
FT   VARIANT    1770   1770       I -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073636.
FT   VARIANT    1770   1770       I -> N (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073637.
FT   VARIANT    1770   1770       I -> T (in EIEE6; borderline phenotype).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073638.
FT   VARIANT    1771   1771       I -> F (in EIEE6; borderline phenotype;
FT                                also found in a patient with focal
FT                                epilepsy). {ECO:0000269|PubMed:18330841,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073639.
FT   VARIANT    1771   1771       I -> N (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073640.
FT   VARIANT    1773   1773       S -> F (in EIEE6; dbSNP:rs121917951).
FT                                {ECO:0000269|PubMed:17054684}.
FT                                /FTId=VAR_064329.
FT   VARIANT    1780   1780       M -> T (in EIEE6; dbSNP:rs121917952).
FT                                {ECO:0000269|PubMed:12821740,
FT                                ECO:0000269|PubMed:17054684,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_029720.
FT   VARIANT    1781   1781       Y -> C (in EIEE6 and ICEGTC;
FT                                dbSNP:rs121918779).
FT                                {ECO:0000269|PubMed:14738421,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_029721.
FT   VARIANT    1781   1781       Y -> H (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073641.
FT   VARIANT    1782   1782       I -> M (in EIEE6; dbSNP:rs121918763).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:20522430}.
FT                                /FTId=VAR_064274.
FT   VARIANT    1782   1782       I -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073642.
FT   VARIANT    1783   1783       A -> T (in EIEE6; dbSNP:rs121917980).
FT                                {ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:19589774,
FT                                ECO:0000269|PubMed:20431604,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_064275.
FT   VARIANT    1783   1783       A -> V (in EIEE6; dbSNP:rs121917921).
FT                                {ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:18930999,
FT                                ECO:0000269|PubMed:21248271,
FT                                ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_064345.
FT   VARIANT    1787   1787       E -> K (in EIEE6; dbSNP:rs121917916).
FT                                {ECO:0000269|PubMed:17561957,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_064330.
FT   VARIANT    1788   1788       N -> K (in EIEE6; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073643.
FT   VARIANT    1792   1792       A -> T (in EIEE6).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073644.
FT   VARIANT    1795   1795       E -> K (in GEFS+2; dbSNP:rs121918813).
FT                                {ECO:0000269|PubMed:20600615}.
FT                                /FTId=VAR_064276.
FT   VARIANT    1807   1810       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029722.
FT   VARIANT    1808   1808       F -> I (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073645.
FT   VARIANT    1808   1808       F -> L (in ICEGTC; results in decreased
FT                                peak current density but significantly
FT                                greater levels of persistent non-
FT                                inactivating current compared to wild-
FT                                type channel; dbSNP:rs121918757).
FT                                {ECO:0000269|PubMed:12566275,
FT                                ECO:0000269|PubMed:16210358}.
FT                                /FTId=VAR_029723.
FT   VARIANT    1812   1815       WEKF -> C (in EIEE6).
FT                                /FTId=VAR_029725.
FT   VARIANT    1812   1812       W -> G (in EIEE6; dbSNP:rs121918751).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029724.
FT   VARIANT    1812   1812       W -> S (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073646.
FT   VARIANT    1813   1815       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073647.
FT   VARIANT    1831   1831       F -> S (in EIEE6; dbSNP:rs121918748).
FT                                {ECO:0000269|PubMed:12566275}.
FT                                /FTId=VAR_029726.
FT   VARIANT    1832   1832       A -> P (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073648.
FT   VARIANT    1835   1835       L -> F (in EIEE6).
FT                                {ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_073649.
FT   VARIANT    1852   1852       M -> K (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073650.
FT   VARIANT    1852   1852       M -> T (in GEFS+2; loss of function;
FT                                defective trafficking to cell membrane
FT                                and no inhibition of its interaction with
FT                                SCN1B; dbSNP:rs121918783).
FT                                {ECO:0000269|PubMed:12919402,
FT                                ECO:0000269|PubMed:17928445}.
FT                                /FTId=VAR_029727.
FT   VARIANT    1855   1855       P -> L (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073651.
FT   VARIANT    1857   1857       V -> L (in GEFS+2; dbSNP:rs121918814).
FT                                {ECO:0000269|PubMed:15715999}.
FT                                /FTId=VAR_057999.
FT   VARIANT    1861   1861       R -> W (in ICEGTC).
FT                                {ECO:0000269|PubMed:23195492}.
FT                                /FTId=VAR_073652.
FT   VARIANT    1866   1866       D -> Y (in GEFS+2; causes a positive
FT                                shift in the voltage dependence of sodium
FT                                channel fast inactivation; causes an
FT                                increase in the magnitude of the
FT                                persistent current; causes delay in the
FT                                kinetics of inactivation and
FT                                significantly reduces interaction with
FT                                SCN1B; dbSNP:rs121918815).
FT                                {ECO:0000269|PubMed:15525788}.
FT                                /FTId=VAR_058000.
FT   VARIANT    1867   1867       I -> T (in GEFS+2).
FT                                {ECO:0000269|PubMed:18251839,
FT                                ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073653.
FT   VARIANT    1880   1880       G -> E (in EIEE6; dbSNP:rs201905405).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073654.
FT   VARIANT    1881   1881       E -> D (in EIEE6; dbSNP:rs121918804).
FT                                {ECO:0000269|PubMed:14504318}.
FT                                /FTId=VAR_029728.
FT   VARIANT    1909   1909       T -> I (in EIEE6; functional channel
FT                                displaying decreased peak current
FT                                densities but increased persistent
FT                                current; dbSNP:rs121918793).
FT                                {ECO:0000269|PubMed:12083760,
FT                                ECO:0000269|PubMed:17054685}.
FT                                /FTId=VAR_029729.
FT   VARIANT    1909   1909       Missing (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073655.
FT   VARIANT    1922   1922       I -> T (in EIEE6; dbSNP:rs121917981).
FT                                {ECO:0000269|PubMed:17347258}.
FT                                /FTId=VAR_064351.
FT   VARIANT    1927   1927       R -> IIQ (in EIEE6).
FT                                {ECO:0000269|PubMed:21248271}.
FT                                /FTId=VAR_073656.
FT   VARIANT    1928   1928       R -> G (in dbSNP:rs121917956).
FT                                {ECO:0000269|PubMed:11254444,
FT                                ECO:0000269|PubMed:18413471,
FT                                ECO:0000269|PubMed:18930999}.
FT                                /FTId=VAR_043371.
FT   VARIANT    1955   1955       I -> T (in dbSNP:rs35735053).
FT                                {ECO:0000269|PubMed:12610651}.
FT                                /FTId=VAR_029730.
FT   VARIANT    1957   1957       E -> G (in infantile spasms;
FT                                dbSNP:rs121918802).
FT                                {ECO:0000269|PubMed:14504318}.
FT                                /FTId=VAR_029731.
FT   VARIANT    1977   1977       M -> L (found in a patient with febrile
FT                                seizures and non-specific acute
FT                                encephalopathy; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:22309220}.
FT                                /FTId=VAR_075571.
FT   CONFLICT    670    670       E -> G (in Ref. 2; AAK00217).
FT                                {ECO:0000305}.
FT   CONFLICT    746    746       L -> S (in Ref. 2; AAK00217).
FT                                {ECO:0000305}.
FT   CONFLICT    930    930       P -> PQ (in Ref. 2; AAK00217).
FT                                {ECO:0000305}.
FT   CONFLICT   1158   1161       DIGA -> GHRR (in Ref. 2; AAK00217).
FT                                {ECO:0000305}.
FT   CONFLICT   1537   1537       F -> L (in Ref. 7; CAA46439/M91803).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2009 AA;  228972 MW;  0593A6730F33C9A2 CRC64;
     MEQTVLVPPG PDSFNFFTRE SLAAIERRIA EEKAKNPKPD KKDDDENGPK PNSDLEAGKN
     LPFIYGDIPP EMVSEPLEDL DPYYINKKTF IVLNKGKAIF RFSATSALYI LTPFNPLRKI
     AIKILVHSLF SMLIMCTILT NCVFMTMSNP PDWTKNVEYT FTGIYTFESL IKIIARGFCL
     EDFTFLRDPW NWLDFTVITF AYVTEFVDLG NVSALRTFRV LRALKTISVI PGLKTIVGAL
     IQSVKKLSDV MILTVFCLSV FALIGLQLFM GNLRNKCIQW PPTNASLEEH SIEKNITVNY
     NGTLINETVF EFDWKSYIQD SRYHYFLEGF LDALLCGNSS DAGQCPEGYM CVKAGRNPNY
     GYTSFDTFSW AFLSLFRLMT QDFWENLYQL TLRAAGKTYM IFFVLVIFLG SFYLINLILA
     VVAMAYEEQN QATLEEAEQK EAEFQQMIEQ LKKQQEAAQQ AATATASEHS REPSAAGRLS
     DSSSEASKLS SKSAKERRNR RKKRKQKEQS GGEEKDEDEF QKSESEDSIR RKGFRFSIEG
     NRLTYEKRYS SPHQSLLSIR GSLFSPRRNS RTSLFSFRGR AKDVGSENDF ADDEHSTFED
     NESRRDSLFV PRRHGERRNS NLSQTSRSSR MLAVFPANGK MHSTVDCNGV VSLVGGPSVP
     TSPVGQLLPE VIIDKPATDD NGTTTETEMR KRRSSSFHVS MDFLEDPSQR QRAMSIASIL
     TNTVEELEES RQKCPPCWYK FSNIFLIWDC SPYWLKVKHV VNLVVMDPFV DLAITICIVL
     NTLFMAMEHY PMTDHFNNVL TVGNLVFTGI FTAEMFLKII AMDPYYYFQE GWNIFDGFIV
     TLSLVELGLA NVEGLSVLRS FRLLRVFKLA KSWPTLNMLI KIIGNSVGAL GNLTLVLAII
     VFIFAVVGMQ LFGKSYKDCV CKIASDCQLP RWHMNDFFHS FLIVFRVLCG EWIETMWDCM
     EVAGQAMCLT VFMMVMVIGN LVVLNLFLAL LLSSFSADNL AATDDDNEMN NLQIAVDRMH
     KGVAYVKRKI YEFIQQSFIR KQKILDEIKP LDDLNNKKDS CMSNHTAEIG KDLDYLKDVN
     GTTSGIGTGS SVEKYIIDES DYMSFINNPS LTVTVPIAVG ESDFENLNTE DFSSESDLEE
     SKEKLNESSS SSEGSTVDIG APVEEQPVVE PEETLEPEAC FTEGCVQRFK CCQINVEEGR
     GKQWWNLRRT CFRIVEHNWF ETFIVFMILL SSGALAFEDI YIDQRKTIKT MLEYADKVFT
     YIFILEMLLK WVAYGYQTYF TNAWCWLDFL IVDVSLVSLT ANALGYSELG AIKSLRTLRA
     LRPLRALSRF EGMRVVVNAL LGAIPSIMNV LLVCLIFWLI FSIMGVNLFA GKFYHCINTT
     TGDRFDIEDV NNHTDCLKLI ERNETARWKN VKVNFDNVGF GYLSLLQVAT FKGWMDIMYA
     AVDSRNVELQ PKYEESLYMY LYFVIFIIFG SFFTLNLFIG VIIDNFNQQK KKFGGQDIFM
     TEEQKKYYNA MKKLGSKKPQ KPIPRPGNKF QGMVFDFVTR QVFDISIMIL ICLNMVTMMV
     ETDDQSEYVT TILSRINLVF IVLFTGECVL KLISLRHYYF TIGWNIFDFV VVILSIVGMF
     LAELIEKYFV SPTLFRVIRL ARIGRILRLI KGAKGIRTLL FALMMSLPAL FNIGLLLFLV
     MFIYAIFGMS NFAYVKREVG IDDMFNFETF GNSMICLFQI TTSAGWDGLL APILNSKPPD
     CDPNKVNPGS SVKGDCGNPS VGIFFFVSYI IISFLVVVNM YIAVILENFS VATEESAEPL
     SEDDFEMFYE VWEKFDPDAT QFMEFEKLSQ FAAALEPPLN LPQPNKLQLI AMDLPMVSGD
     RIHCLDILFA FTKRVLGESG EMDALRIQME ERFMASNPSK VSYQPITTTL KRKQEEVSAV
     IIQRAYRRHL LKRTVKQASF TYNKNKIKGG ANLLIKEDMI IDRINENSIT EKTDLTMSTA
     ACPPSYDRVT KPIVEKHEQE GKDEKAKGK
//
ID   SCN2A_HUMAN             Reviewed;        2005 AA.
AC   Q99250; A6NC14; A6NIQ5; Q14472; Q53T77; Q9BZC9; Q9BZD0;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   08-NOV-2002, sequence version 3.
DT   15-FEB-2017, entry version 179.
DE   RecName: Full=Sodium channel protein type 2 subunit alpha;
DE   AltName: Full=HBSC II;
DE   AltName: Full=Sodium channel protein brain II subunit alpha;
DE   AltName: Full=Sodium channel protein type II subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.2;
GN   Name=SCN2A; Synonyms=NAC2, SCN2A1, SCN2A2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RC   TISSUE=Brain;
RX   PubMed=1325650; DOI=10.1073/pnas.89.17.8220;
RA   Ahmed C.M., Ware D.H., Lee S.C., Patten C.D., Ferrer-Montiel A.V.,
RA   Schinder A.F., McPherson J.D., Wagner-Mcpherson C.B., Wasmuth J.J.,
RA   Evans G.A., Montal M.;
RT   "Primary structure, chromosomal localization, and functional
RT   expression of a voltage-gated sodium channel from human brain.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:8220-8224(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2).
RX   PubMed=11245985; DOI=10.1016/S0378-1119(00)00594-1;
RA   Kasai N., Fukushima K., Ueki Y., Prasad S., Nosakowski J., Sugata K.,
RA   Sugata A., Nishizaki K., Meyer N.C., Smith R.J.H.;
RT   "Genomic structures of SCN2A and SCN3A -- candidate genes for deafness
RT   at the DFNA16 locus.";
RL   Gene 264:113-122(2001).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-89.
RA   Lu C.-M., Eichelberger J.S., Beckman M.L., Schade S.D., Brown G.B.;
RT   "Isolation of the 5'-flanking region for human brain sodium channel
RT   subtype II alpha-Subunit (SCN2A).";
RL   Submitted (APR-1998) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1709-1994.
RC   TISSUE=Brain;
RX   PubMed=1317301; DOI=10.1016/0014-5793(92)80476-W;
RA   Lu C.-M., Han J., Rado T.A., Brown G.B.;
RT   "Differential expression of two sodium channel subtypes in human
RT   brain.";
RL   FEBS Lett. 303:53-58(1992).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1702-1772.
RX   PubMed=1846440; DOI=10.1073/pnas.88.2.335;
RA   Han J., Lu C.-M., Brown G.B., Rado T.A.;
RT   "Direct amplification of a single dissected chromosomal segment by
RT   polymerase chain reaction: a human brain sodium channel gene is on
RT   chromosome 2q22-q23.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:335-339(1991).
RN   [7]
RP   INTERACTION WITH SCN4B.
RX   PubMed=24297919; DOI=10.1073/pnas.1314557110;
RA   Gilchrist J., Das S., Van Petegem F., Bosmans F.;
RT   "Crystallographic insights into sodium-channel modulation by the beta4
RT   subunit.";
RL   Proc. Natl. Acad. Sci. U.S.A. 110:E5016-E5024(2013).
RN   [8]
RP   INTERACTION WITH THE CONOTOXIN GVIIJ.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G.,
RA   Wickenden A.D., Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [9]
RP   VARIANT BFIS3 TRP-188, CHARACTERIZATION OF VARIANT BFIS3 TRP-188, AND
RP   VARIANTS LYS-19 AND GLN-524.
RX   PubMed=11371648; DOI=10.1073/pnas.111065098;
RA   Sugawara T., Tsurubuchi Y., Agarwala K.L., Ito M., Fukuma G.,
RA   Mazaki-Miyazaki E., Nagafuji H., Noda M., Imoto K., Wada K.,
RA   Mitsudome A., Kaneko S., Montal M., Nagata K., Hirose S., Yamakawa K.;
RT   "A missense mutation of the Na+ channel alpha II subunit gene Na(v)1.2
RT   in a patient with febrile and afebrile seizures causes channel
RT   dysfunction.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:6384-6389(2001).
RN   [10]
RP   ERRATUM.
RA   Sugawara T., Tsurubuchi Y., Agarwala K.L., Ito M., Fukuma G.,
RA   Mazaki-Miyazaki E., Nagafuji H., Noda M., Imoto K., Wada K.,
RA   Mitsudome A., Kaneko S., Montal M., Nagata K., Hirose S., Yamakawa K.;
RL   Proc. Natl. Acad. Sci. U.S.A. 98:10515-10515(2001).
RN   [11]
RP   VARIANTS BFIS3 PHE-1330 AND VAL-1563.
RX   PubMed=12243921; DOI=10.1016/S0140-6736(02)09968-3;
RA   Heron S.E., Crossland K.M., Andermann E., Phillips H.A., Hall A.J.,
RA   Bleasel A., Shevell M., Mercho S., Seni M.H., Guiot M.C., Mulley J.C.,
RA   Berkovic S.F., Scheffer I.E.;
RT   "Sodium-channel defects in benign familial neonatal-infantile
RT   seizures.";
RL   Lancet 360:851-852(2002).
RN   [12]
RP   ERRATUM.
RA   Heron S.E., Crossland K.M., Andermann E., Phillips H.A., Hall A.J.,
RA   Bleasel A., Shevell M., Mercho S., Seni M.H., Guiot M.C., Mulley J.C.,
RA   Berkovic S.F., Scheffer I.E.;
RL   Lancet 360:1520-1520(2002).
RN   [13]
RP   VARIANTS LYS-19 AND THR-1902.
RX   PubMed=12610651; DOI=10.1038/sj.mp.4001241;
RA   Weiss L.A., Escayg A., Kearney J.A., Trudeau M., MacDonald B.T.,
RA   Mori M., Reichert J., Buxbaum J.D., Meisler M.H.;
RT   "Sodium channels SCN1A, SCN2A and SCN3A in familial autism.";
RL   Mol. Psychiatry 8:186-194(2003).
RN   [14]
RP   VARIANTS BFIS3 GLN-223; ILE-892; ILE-1003 AND GLN-1319.
RX   PubMed=15048894; DOI=10.1002/ana.20029;
RA   Berkovic S.F., Heron S.E., Giordano L., Marini C., Guerrini R.,
RA   Kaplan R.E., Gambardella A., Steinlein O.K., Grinton B.E., Dean J.T.,
RA   Bordo L., Hodgson B.L., Yamamoto T., Mulley J.C., Zara F.,
RA   Scheffer I.E.;
RT   "Benign familial neonatal-infantile seizures: characterization of a
RT   new sodium channelopathy.";
RL   Ann. Neurol. 55:550-557(2004).
RN   [15]
RP   VARIANT VAL-328.
RX   PubMed=16122630; DOI=10.1016/j.braindev.2004.11.005;
RA   Kimura K., Sugawara T., Mazaki-Miyazaki E., Hoshino K., Nomura Y.,
RA   Tateno A., Hachimori K., Yamakawa K., Segawa M.;
RT   "A missense mutation in SCN1A in brothers with severe myoclonic
RT   epilepsy in infancy (SMEI) inherited from a father with febrile
RT   seizures.";
RL   Brain Dev. 27:424-430(2005).
RN   [16]
RP   VARIANTS ASN-322 AND VAL-328, AND VARIANT EIEE11 THR-1312.
RX   PubMed=19783390; DOI=10.1016/j.braindev.2009.08.009;
RA   Shi X., Yasumoto S., Nakagawa E., Fukasawa T., Uchiya S., Hirose S.;
RT   "Missense mutation of the sodium channel gene SCN2A causes Dravet
RT   syndrome.";
RL   Brain Dev. 31:758-762(2009).
RN   [17]
RP   VARIANTS EIEE11 LYS-1211 AND MET-1473, VARIANTS LYS-19; VAL-328;
RP   GLN-524 AND VAL-575, CHARACTERIZATION OF VARIANTS EIEE11 LYS-1211 AND
RP   MET-1473, AND CHARACTERIZATION OF VARIANT VAL-575.
RX   PubMed=19786696; DOI=10.1212/WNL.0b013e3181b9cebc;
RA   Ogiwara I., Ito K., Sawaishi Y., Osaka H., Mazaki E., Inoue I.,
RA   Montal M., Hashikawa T., Shike T., Fujiwara T., Inoue Y., Kaneda M.,
RA   Yamakawa K.;
RT   "De novo mutations of voltage-gated sodium channel alphaII gene SCN2A
RT   in intractable epilepsies.";
RL   Neurology 73:1046-1053(2009).
RN   [18]
RP   VARIANTS BFIS3 VAL-252 AND MET-261.
RX   PubMed=20371507; DOI=10.1093/brain/awq057;
RA   Liao Y., Deprez L., Maljevic S., Pitsch J., Claes L., Hristova D.,
RA   Jordanova A., Ala-Mello S., Bellan-Koch A., Blazevic D., Schubert S.,
RA   Thomas E.A., Petrou S., Becker A.J., De Jonghe P., Lerche H.;
RT   "Molecular correlates of age-dependent seizures in an inherited
RT   neonatal-infantile epilepsy.";
RL   Brain 133:1403-1414(2010).
RN   [19]
RP   VARIANT EIEE11 VAL-263.
RX   PubMed=20956790; DOI=10.1212/WNL.0b013e3181f8812e;
RA   Liao Y., Anttonen A.K., Liukkonen E., Gaily E., Maljevic S.,
RA   Schubert S., Bellan-Koch A., Petrou S., Ahonen V.E., Lerche H.,
RA   Lehesjoki A.E.;
RT   "SCN2A mutation associated with neonatal epilepsy, late-onset episodic
RT   ataxia, myoclonus, and pain.";
RL   Neurology 75:1454-1458(2010).
RN   [20]
RP   VARIANT BFIS3 GLU-208.
RX   PubMed=22612257; DOI=10.1111/j.1528-1167.2012.03516.x;
RA   Lemke J.R., Riesch E., Scheurenbrand T., Schubach M., Wilhelm C.,
RA   Steiner I., Hansen J., Courage C., Gallati S., Buerki S., Strozzi S.,
RA   Simonetti B.G., Grunt S., Steinlin M., Alber M., Wolff M.,
RA   Klopstock T., Prott E.C., Lorenz R., Spaich C., Rona S.,
RA   Lakshminarasimhan M., Kroell J., Dorn T., Kraemer G., Synofzik M.,
RA   Becker F., Weber Y.G., Lerche H., Boehm D., Biskup S.;
RT   "Targeted next generation sequencing as a diagnostic tool in epileptic
RT   disorders.";
RL   Epilepsia 53:1387-1398(2012).
RN   [21]
RP   VARIANT EIEE11 VAL-263.
RX   PubMed=23550958; DOI=10.1111/epi.12137;
RA   Touma M., Joshi M., Connolly M.C., Grant P.E., Hansen A.R., Khwaja O.,
RA   Berry G.T., Kinney H.C., Poduri A., Agrawal P.B.;
RT   "Whole genome sequencing identifies SCN2A mutation in monozygotic
RT   twins with Ohtahara syndrome and unique neuropathologic findings.";
RL   Epilepsia 54:E81-E85(2013).
RN   [22]
RP   VARIANTS EIEE11 GLY-169; ASP-212; ASP-213; SER-236; THR-263; GLN-853;
RP   THR-876; LYS-999; VAL-1323; LEU-1326; TYR-1336; THR-1338; ASN-1623 AND
RP   LEU-1629.
RX   PubMed=23935176; DOI=10.1212/WNL.0b013e3182a43e57;
RA   Nakamura K., Kato M., Osaka H., Yamashita S., Nakagawa E.,
RA   Haginoya K., Tohyama J., Okuda M., Wada T., Shimakawa S., Imai K.,
RA   Takeshita S., Ishiwata H., Lev D., Lerman-Sagie T.,
RA   Cervantes-Barragan D.E., Villarroel C.E., Ohfu M., Writzl K.,
RA   Gnidovec Strazisar B., Hirabayashi S., Chitayat D., Myles Reid D.,
RA   Nishiyama K., Kodera H., Nakashima M., Tsurusaki Y., Miyake N.,
RA   Hayasaka K., Matsumoto N., Saitsu H.;
RT   "Clinical spectrum of SCN2A mutations expanding to Ohtahara
RT   syndrome.";
RL   Neurology 81:992-998(2013).
RN   [23]
RP   VARIANT GLU-1422.
RX   PubMed=23827426; DOI=10.1016/j.pediatrneurol.2013.03.002;
RA   Sundaram S.K., Chugani H.T., Tiwari V.N., Huq A.H.;
RT   "SCN2A mutation is associated with infantile spasms and bitemporal
RT   glucose hypometabolism.";
RL   Pediatr. Neurol. 49:46-49(2013).
RN   [24]
RP   VARIANTS VAL-172 AND VAL-328.
RX   PubMed=26311622; DOI=10.1016/j.eplepsyres.2015.08.001;
RA   Saitoh M., Ishii A., Ihara Y., Hoshino A., Terashima H., Kubota M.,
RA   Kikuchi K., Yamanaka G., Amemiya K., Hirose S., Mizuguchi M.;
RT   "Missense mutations in sodium channel SCN1A and SCN2A predispose
RT   children to encephalopathy with severe febrile seizures.";
RL   Epilepsy Res. 117:1-6(2015).
CC   -!- FUNCTION: Mediates the voltage-dependent sodium ion permeability
CC       of excitable membranes. Assuming opened or closed conformations in
CC       response to the voltage difference across the membrane, the
CC       protein forms a sodium-selective channel through which Na(+) ions
CC       may pass in accordance with their electrochemical gradient.
CC       {ECO:0000269|PubMed:1325650}.
CC   -!- SUBUNIT: Heterooligomer of a large alpha subunit and a smaller
CC       beta subunit. Heterooligomer with SCN2B or SCN4B; disulfide-
CC       linked. Interacts with NEDD4L. Interacts with CALM. Interacts with
CC       the conotoxin GVIIJ (PubMed:24497506).
CC       {ECO:0000269|PubMed:24297919, ECO:0000269|PubMed:24497506}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1325650};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:1325650}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=Adult, 6A;
CC         IsoId=Q99250-1; Sequence=Displayed;
CC       Name=2; Synonyms=Neonatal, 6N;
CC         IsoId=Q99250-2; Sequence=VSP_001032;
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- PTM: May be ubiquitinated by NEDD4L; which would promote its
CC       endocytosis. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Ser-1506 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents. {ECO:0000250}.
CC   -!- DISEASE: Seizures, benign familial infantile, 3 (BFIS3)
CC       [MIM:607745]: A form of benign familial infantile epilepsy, a
CC       neurologic disorder characterized by afebrile seizures occurring
CC       in clusters during the first year of life, without neurologic
CC       sequelae. BFIS3 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:11371648, ECO:0000269|PubMed:12243921,
CC       ECO:0000269|PubMed:15048894, ECO:0000269|PubMed:20371507,
CC       ECO:0000269|PubMed:22612257}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 11 (EIEE11)
CC       [MIM:613721]: An autosomal dominant seizure disorder characterized
CC       by neonatal or infantile onset of refractory seizures with
CC       resultant delayed neurologic development and persistent neurologic
CC       abnormalities. Patients may progress to West syndrome, which is
CC       characterized by tonic spasms with clustering, arrest of
CC       psychomotor development, and hypsarrhythmia on EEG.
CC       {ECO:0000269|PubMed:19783390, ECO:0000269|PubMed:19786696,
CC       ECO:0000269|PubMed:20956790, ECO:0000269|PubMed:23550958,
CC       ECO:0000269|PubMed:23935176}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.2/SCN2A subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA46438.1; Type=Frameshift; Positions=1953; Evidence={ECO:0000305};
CC       Sequence=CAA46438.1; Type=Miscellaneous discrepancy; Note=Contaminating sequence. Sequence of unknown origin in the C-terminal part.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M94055; AAA18895.1; -; mRNA.
DR   EMBL; AF059683; AAC14574.1; -; Genomic_DNA.
DR   EMBL; AF327246; AAG53413.1; -; Genomic_DNA.
DR   EMBL; AF327226; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327227; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327228; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327229; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327230; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327231; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327232; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327233; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327234; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327235; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327236; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327237; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327238; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327239; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327240; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327241; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327242; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327243; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327244; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327245; AAG53413.1; JOINED; Genomic_DNA.
DR   EMBL; AF327246; AAG53412.1; -; Genomic_DNA.
DR   EMBL; AF327226; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327227; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327228; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327229; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327230; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327231; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327232; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327233; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327234; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327235; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327236; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327237; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327238; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327239; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327240; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327241; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327242; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327243; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327244; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AF327245; AAG53412.1; JOINED; Genomic_DNA.
DR   EMBL; AC011303; AAY14971.1; -; Genomic_DNA.
DR   EMBL; AC013438; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; X65361; CAA46438.1; ALT_SEQ; mRNA.
DR   EMBL; M91804; -; NOT_ANNOTATED_CDS; mRNA.
DR   EMBL; M55662; AAB65854.2; -; Genomic_DNA.
DR   CCDS; CCDS33313.1; -. [Q99250-2]
DR   CCDS; CCDS33314.1; -. [Q99250-1]
DR   PIR; A46269; A46269.
DR   PIR; I59194; I59194.
DR   RefSeq; NP_001035232.1; NM_001040142.1. [Q99250-1]
DR   RefSeq; NP_001035233.1; NM_001040143.1. [Q99250-2]
DR   RefSeq; NP_066287.2; NM_021007.2. [Q99250-1]
DR   RefSeq; XP_005246810.1; XM_005246753.3. [Q99250-2]
DR   RefSeq; XP_016860144.1; XM_017004655.1. [Q99250-1]
DR   RefSeq; XP_016860145.1; XM_017004656.1. [Q99250-1]
DR   RefSeq; XP_016860146.1; XM_017004657.1. [Q99250-2]
DR   UniGene; Hs.93485; -.
DR   PDB; 2KAV; NMR; -; A=1777-1882.
DR   PDB; 4JPZ; X-ray; 3.02 A; B/H=1777-1937.
DR   PDBsum; 2KAV; -.
DR   PDBsum; 4JPZ; -.
DR   ProteinModelPortal; Q99250; -.
DR   SMR; Q99250; -.
DR   IntAct; Q99250; 4.
DR   MINT; MINT-1388751; -.
DR   STRING; 9606.ENSP00000283256; -.
DR   BindingDB; Q99250; -.
DR   ChEMBL; CHEMBL4187; -.
DR   DrugBank; DB00555; Lamotrigine.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 579; -.
DR   TCDB; 1.A.1.10.12; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; Q99250; -.
DR   PhosphoSitePlus; Q99250; -.
DR   BioMuta; SCN2A; -.
DR   DMDM; 25014053; -.
DR   PaxDb; Q99250; -.
DR   PeptideAtlas; Q99250; -.
DR   PRIDE; Q99250; -.
DR   Ensembl; ENST00000283256; ENSP00000283256; ENSG00000136531. [Q99250-1]
DR   Ensembl; ENST00000375427; ENSP00000364576; ENSG00000136531. [Q99250-2]
DR   Ensembl; ENST00000375437; ENSP00000364586; ENSG00000136531. [Q99250-1]
DR   Ensembl; ENST00000631182; ENSP00000486885; ENSG00000136531. [Q99250-2]
DR   Ensembl; ENST00000636071; ENSP00000490107; ENSG00000136531. [Q99250-2]
DR   Ensembl; ENST00000637266; ENSP00000490866; ENSG00000136531. [Q99250-1]
DR   GeneID; 6326; -.
DR   KEGG; hsa:6326; -.
DR   UCSC; uc002udc.4; human. [Q99250-1]
DR   CTD; 6326; -.
DR   DisGeNET; 6326; -.
DR   GeneCards; SCN2A; -.
DR   H-InvDB; HIX0029932; -.
DR   HGNC; HGNC:10588; SCN2A.
DR   HPA; CAB022567; -.
DR   MalaCards; SCN2A; -.
DR   MIM; 182390; gene.
DR   MIM; 607745; phenotype.
DR   MIM; 613721; phenotype.
DR   neXtProt; NX_Q99250; -.
DR   OpenTargets; ENSG00000136531; -.
DR   Orphanet; 306; Benign familial infantile epilepsy.
DR   Orphanet; 140927; Benign familial neonatal-infantile seizures.
DR   Orphanet; 33069; Dravet syndrome.
DR   Orphanet; 1934; Early infantile epileptic encephalopathy.
DR   Orphanet; 36387; Generalized epilepsy with febrile seizures-plus.
DR   Orphanet; 3451; West syndrome.
DR   PharmGKB; PA35004; -.
DR   eggNOG; ENOG410INF8; Eukaryota.
DR   eggNOG; COG1226; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q99250; -.
DR   KO; K04834; -.
DR   OMA; DQTKEMD; -.
DR   OrthoDB; EOG0903014J; -.
DR   PhylomeDB; Q99250; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   SIGNOR; Q99250; -.
DR   ChiTaRS; SCN2A; human.
DR   EvolutionaryTrace; Q99250; -.
DR   GeneWiki; Nav1.2; -.
DR   GenomeRNAi; 6326; -.
DR   PRO; PR:Q99250; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000136531; -.
DR   CleanEx; HS_SCN2A; -.
DR   ExpressionAtlas; Q99250; baseline and differential.
DR   Genevisible; Q99250; HS.
DR   GO; GO:0030424; C:axon; TAS:BHF-UCL.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0014704; C:intercalated disc; IEA:Ensembl.
DR   GO; GO:0005622; C:intracellular; IEA:GOC.
DR   GO; GO:0031226; C:intrinsic component of plasma membrane; ISS:UniProtKB.
DR   GO; GO:0033268; C:node of Ranvier; ISS:BHF-UCL.
DR   GO; GO:0033270; C:paranode region of axon; IEA:Ensembl.
DR   GO; GO:0034706; C:sodium channel complex; ISS:UniProtKB.
DR   GO; GO:0030315; C:T-tubule; IEA:Ensembl.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; ISS:UniProtKB.
DR   GO; GO:0008627; P:intrinsic apoptotic signaling pathway in response to osmotic stress; IEA:Ensembl.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0042552; P:myelination; ISS:BHF-UCL.
DR   GO; GO:0051402; P:neuron apoptotic process; IEA:Ensembl.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; ISS:UniProtKB.
DR   GO; GO:0006814; P:sodium ion transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   SMART; SM00015; IQ; 1.
DR   PROSITE; PS50096; IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Disulfide bond; Epilepsy; Glycoprotein; Ion channel;
KW   Ion transport; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Sodium; Sodium channel; Sodium transport;
KW   Transmembrane; Transmembrane helix; Transport; Ubl conjugation;
KW   Voltage-gated channel.
FT   CHAIN         1   2005       Sodium channel protein type 2 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048491.
FT   TOPO_DOM      1    124       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    125    148       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    149    156       Extracellular. {ECO:0000255}.
FT   TRANSMEM    157    176       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    177    189       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    190    208       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    209    214       Extracellular. {ECO:0000255}.
FT   TRANSMEM    215    234       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000255}.
FT   TOPO_DOM    235    250       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    251    274       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    275    401       Extracellular. {ECO:0000255}.
FT   TRANSMEM    402    427       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    428    753       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    754    778       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    779    789       Extracellular. {ECO:0000255}.
FT   TRANSMEM    790    813       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    814    821       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    822    841       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    842    847       Extracellular. {ECO:0000255}.
FT   TRANSMEM    848    867       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000255}.
FT   TOPO_DOM    868    883       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    884    904       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    905    957       Extracellular. {ECO:0000255}.
FT   TRANSMEM    958    983       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    984   1203       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1204   1227       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1228   1240       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1241   1266       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1267   1272       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1273   1294       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1295   1298       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1299   1320       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000255}.
FT   TOPO_DOM   1321   1339       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1340   1367       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1368   1446       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1447   1473       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1474   1526       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1527   1550       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1551   1561       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1562   1585       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1586   1591       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1592   1615       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1616   1625       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1626   1647       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000255}.
FT   TOPO_DOM   1648   1662       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1663   1685       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1686   1751       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1752   1776       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1777   2005       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      111    456       I. {ECO:0000305}.
FT   REPEAT      741   1013       II. {ECO:0000305}.
FT   REPEAT     1190   1504       III. {ECO:0000305}.
FT   REPEAT     1513   1811       IV. {ECO:0000305}.
FT   DOMAIN     1905   1934       IQ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   SITE       1489   1489       Important for channel closure.
FT                                {ECO:0000250}.
FT   MOD_RES       4      4       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     468    468       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     471    471       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     484    484       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     526    526       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     528    528       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     531    531       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     553    553       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     554    554       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     558    558       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     573    573       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     576    576       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     589    589       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     610    610       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     623    623       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     686    686       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     687    687       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES     721    721       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES    1506   1506       Phosphoserine; by PKC. {ECO:0000250}.
FT   MOD_RES    1930   1930       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES    1943   1943       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES    1963   1963       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES    1966   1966       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   MOD_RES    1971   1971       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   CARBOHYD    212    212       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    285    285       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    291    291       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    297    297       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    303    303       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    308    308       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    340    340       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1368   1368       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1382   1382       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1393   1393       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    910    910       Interchain; with SCN2B or SCN4B.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   DISULFID    910    910       Interchain; with the conotoxin GVIIJ
FT                                (when the channel is not linked to SCN2B
FT                                or SCN4B; the bond to SCN2B or SCN4B
FT                                protects the channel from the inhibition
FT                                by toxin).
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   VAR_SEQ     209    209       D -> N (in isoform 2). {ECO:0000305}.
FT                                /FTId=VSP_001032.
FT   VARIANT      19     19       R -> K (in dbSNP:rs17183814).
FT                                {ECO:0000269|PubMed:11371648,
FT                                ECO:0000269|PubMed:12610651,
FT                                ECO:0000269|PubMed:19786696}.
FT                                /FTId=VAR_029732.
FT   VARIANT     169    169       E -> G (in EIEE11).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_069996.
FT   VARIANT     172    172       I -> V (found in a patient with non-
FT                                specific acute encephalopathy; unknown
FT                                pathological significance).
FT                                {ECO:0000269|PubMed:26311622}.
FT                                /FTId=VAR_075572.
FT   VARIANT     188    188       R -> W (in BFIS3; mutant channel
FT                                inactivates more slowly than wild-type
FT                                whereas the Na(+) channel conductance is
FT                                not affected; dbSNP:rs121917748).
FT                                {ECO:0000269|PubMed:11371648}.
FT                                /FTId=VAR_029733.
FT   VARIANT     208    208       V -> E (in BFIS3).
FT                                {ECO:0000269|PubMed:22612257}.
FT                                /FTId=VAR_072745.
FT   VARIANT     212    212       N -> D (in EIEE11; the disease progresses
FT                                to West syndrome).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_069997.
FT   VARIANT     213    213       V -> D (in EIEE11).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_069998.
FT   VARIANT     223    223       R -> Q (in BFIS3; dbSNP:rs121917752).
FT                                {ECO:0000269|PubMed:15048894}.
FT                                /FTId=VAR_029734.
FT   VARIANT     236    236       T -> S (in EIEE11).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_069999.
FT   VARIANT     252    252       M -> V (in BFIS3; dbSNP:rs387906687).
FT                                {ECO:0000269|PubMed:20371507}.
FT                                /FTId=VAR_065176.
FT   VARIANT     261    261       V -> M (in BFIS3).
FT                                {ECO:0000269|PubMed:20371507}.
FT                                /FTId=VAR_065177.
FT   VARIANT     263    263       A -> T (in EIEE11).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070000.
FT   VARIANT     263    263       A -> V (in EIEE11; dbSNP:rs387906686).
FT                                {ECO:0000269|PubMed:20956790,
FT                                ECO:0000269|PubMed:23550958}.
FT                                /FTId=VAR_065178.
FT   VARIANT     322    322       D -> N. {ECO:0000269|PubMed:19783390}.
FT                                /FTId=VAR_073428.
FT   VARIANT     328    328       F -> V (found in a patient with acute
FT                                encephalopathy with biphasic seizures and
FT                                late reduced diffusion; unknown
FT                                pathological significance;
FT                                dbSNP:rs781204054).
FT                                {ECO:0000269|PubMed:16122630,
FT                                ECO:0000269|PubMed:19783390,
FT                                ECO:0000269|PubMed:19786696,
FT                                ECO:0000269|PubMed:26311622}.
FT                                /FTId=VAR_064331.
FT   VARIANT     385    385       F -> Y (in dbSNP:rs2228988).
FT                                /FTId=VAR_029735.
FT   VARIANT     524    524       R -> Q (in dbSNP:rs186154973).
FT                                {ECO:0000269|PubMed:11371648,
FT                                ECO:0000269|PubMed:19786696}.
FT                                /FTId=VAR_029736.
FT   VARIANT     575    575       A -> V (there is no significant effetcs
FT                                on the voltage-dependence of the
FT                                channel). {ECO:0000269|PubMed:19786696}.
FT                                /FTId=VAR_065179.
FT   VARIANT     853    853       R -> Q (in EIEE11; phenotype consistent
FT                                with West syndrome; dbSNP:rs794727152).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070001.
FT   VARIANT     876    876       N -> T (in EIEE11; the disease progresses
FT                                to West syndrome).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070002.
FT   VARIANT     892    892       V -> I (in BFIS3; dbSNP:rs121917751).
FT                                {ECO:0000269|PubMed:15048894}.
FT                                /FTId=VAR_029737.
FT   VARIANT     999    999       E -> K (in EIEE11; the disease progresses
FT                                to West syndrome; dbSNP:rs796053126).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070003.
FT   VARIANT    1003   1003       L -> I (in BFIS3; dbSNP:rs121917754).
FT                                {ECO:0000269|PubMed:15048894}.
FT                                /FTId=VAR_029738.
FT   VARIANT    1211   1211       E -> K (in EIEE11; markedly altered the
FT                                voltage-dependence of the channel;
FT                                dbSNP:rs387906684).
FT                                {ECO:0000269|PubMed:19786696}.
FT                                /FTId=VAR_065180.
FT   VARIANT    1312   1312       R -> T (in EIEE11).
FT                                {ECO:0000269|PubMed:19783390}.
FT                                /FTId=VAR_073429.
FT   VARIANT    1319   1319       R -> Q (in BFIS3; dbSNP:rs121917753).
FT                                {ECO:0000269|PubMed:15048894}.
FT                                /FTId=VAR_029739.
FT   VARIANT    1323   1323       M -> V (in EIEE11; the disease progresses
FT                                to West syndrome).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070004.
FT   VARIANT    1326   1326       V -> L (in EIEE11; the disease progresses
FT                                to West syndrome).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070005.
FT   VARIANT    1330   1330       L -> F (in BFIS3; dbSNP:rs121917749).
FT                                {ECO:0000269|PubMed:12243921}.
FT                                /FTId=VAR_029740.
FT   VARIANT    1336   1336       S -> Y (in EIEE11; the disease progresses
FT                                to West syndrome).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070006.
FT   VARIANT    1338   1338       M -> T (in EIEE11).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070007.
FT   VARIANT    1422   1422       K -> E (probable disease-associated
FT                                mutation found in a boy with infantile
FT                                spasms and bitemporal glucose
FT                                hypometabolism; dbSNP:rs796053137).
FT                                {ECO:0000269|PubMed:23827426}.
FT                                /FTId=VAR_070008.
FT   VARIANT    1473   1473       I -> M (in EIEE11; markedly altered the
FT                                voltage-dependence of the channel;
FT                                dbSNP:rs387906685).
FT                                {ECO:0000269|PubMed:19786696}.
FT                                /FTId=VAR_065181.
FT   VARIANT    1563   1563       L -> V (in BFIS3; dbSNP:rs121917750).
FT                                {ECO:0000269|PubMed:12243921}.
FT                                /FTId=VAR_029741.
FT   VARIANT    1623   1623       T -> N (in EIEE11; the disease progresses
FT                                to West syndrome).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070009.
FT   VARIANT    1629   1629       R -> L (in EIEE11).
FT                                {ECO:0000269|PubMed:23935176}.
FT                                /FTId=VAR_070010.
FT   VARIANT    1902   1902       R -> T (associated with autism).
FT                                {ECO:0000269|PubMed:12610651}.
FT                                /FTId=VAR_029742.
FT   CONFLICT    524    524       R -> L (in Ref. 1; AAA18895).
FT                                {ECO:0000305}.
FT   CONFLICT   1325   1325       V -> A (in Ref. 1; AAA18895).
FT                                {ECO:0000305}.
FT   CONFLICT   1768   1768       V -> L (in Ref. 1; AAA18895).
FT                                {ECO:0000305}.
FT   CONFLICT   1990   1990       K -> R (in Ref. 5; CAA46438).
FT                                {ECO:0000305}.
FT   HELIX      1792   1805       {ECO:0000244|PDB:4JPZ}.
FT   STRAND     1811   1814       {ECO:0000244|PDB:4JPZ}.
FT   TURN       1815   1817       {ECO:0000244|PDB:4JPZ}.
FT   HELIX      1818   1823       {ECO:0000244|PDB:4JPZ}.
FT   TURN       1827   1829       {ECO:0000244|PDB:4JPZ}.
FT   HELIX      1836   1839       {ECO:0000244|PDB:4JPZ}.
FT   STRAND     1845   1847       {ECO:0000244|PDB:4JPZ}.
FT   TURN       1848   1850       {ECO:0000244|PDB:4JPZ}.
FT   STRAND     1851   1853       {ECO:0000244|PDB:4JPZ}.
FT   HELIX      1854   1866       {ECO:0000244|PDB:4JPZ}.
FT   HELIX      1870   1886       {ECO:0000244|PDB:4JPZ}.
FT   HELIX      1900   1926       {ECO:0000244|PDB:4JPZ}.
SQ   SEQUENCE   2005 AA;  227975 MW;  8A421AE6C7ED9A37 CRC64;
     MAQSVLVPPG PDSFRFFTRE SLAAIEQRIA EEKAKRPKQE RKDEDDENGP KPNSDLEAGK
     SLPFIYGDIP PEMVSVPLED LDPYYINKKT FIVLNKGKAI SRFSATPALY ILTPFNPIRK
     LAIKILVHSL FNMLIMCTIL TNCVFMTMSN PPDWTKNVEY TFTGIYTFES LIKILARGFC
     LEDFTFLRDP WNWLDFTVIT FAYVTEFVDL GNVSALRTFR VLRALKTISV IPGLKTIVGA
     LIQSVKKLSD VMILTVFCLS VFALIGLQLF MGNLRNKCLQ WPPDNSSFEI NITSFFNNSL
     DGNGTTFNRT VSIFNWDEYI EDKSHFYFLE GQNDALLCGN SSDAGQCPEG YICVKAGRNP
     NYGYTSFDTF SWAFLSLFRL MTQDFWENLY QLTLRAAGKT YMIFFVLVIF LGSFYLINLI
     LAVVAMAYEE QNQATLEEAE QKEAEFQQML EQLKKQQEEA QAAAAAASAE SRDFSGAGGI
     GVFSESSSVA SKLSSKSEKE LKNRRKKKKQ KEQSGEEEKN DRVRKSESED SIRRKGFRFS
     LEGSRLTYEK RFSSPHQSLL SIRGSLFSPR RNSRASLFSF RGRAKDIGSE NDFADDEHST
     FEDNDSRRDS LFVPHRHGER RHSNVSQASR ASRVLPILPM NGKMHSAVDC NGVVSLVGGP
     STLTSAGQLL PEGTTTETEI RKRRSSSYHV SMDLLEDPTS RQRAMSIASI LTNTMEELEE
     SRQKCPPCWY KFANMCLIWD CCKPWLKVKH LVNLVVMDPF VDLAITICIV LNTLFMAMEH
     YPMTEQFSSV LSVGNLVFTG IFTAEMFLKI IAMDPYYYFQ EGWNIFDGFI VSLSLMELGL
     ANVEGLSVLR SFRLLRVFKL AKSWPTLNML IKIIGNSVGA LGNLTLVLAI IVFIFAVVGM
     QLFGKSYKEC VCKISNDCEL PRWHMHDFFH SFLIVFRVLC GEWIETMWDC MEVAGQTMCL
     TVFMMVMVIG NLVVLNLFLA LLLSSFSSDN LAATDDDNEM NNLQIAVGRM QKGIDFVKRK
     IREFIQKAFV RKQKALDEIK PLEDLNNKKD SCISNHTTIE IGKDLNYLKD GNGTTSGIGS
     SVEKYVVDES DYMSFINNPS LTVTVPIAVG ESDFENLNTE EFSSESDMEE SKEKLNATSS
     SEGSTVDIGA PAEGEQPEVE PEESLEPEAC FTEDCVRKFK CCQISIEEGK GKLWWNLRKT
     CYKIVEHNWF ETFIVFMILL SSGALAFEDI YIEQRKTIKT MLEYADKVFT YIFILEMLLK
     WVAYGFQVYF TNAWCWLDFL IVDVSLVSLT ANALGYSELG AIKSLRTLRA LRPLRALSRF
     EGMRVVVNAL LGAIPSIMNV LLVCLIFWLI FSIMGVNLFA GKFYHCINYT TGEMFDVSVV
     NNYSECKALI ESNQTARWKN VKVNFDNVGL GYLSLLQVAT FKGWMDIMYA AVDSRNVELQ
     PKYEDNLYMY LYFVIFIIFG SFFTLNLFIG VIIDNFNQQK KKFGGQDIFM TEEQKKYYNA
     MKKLGSKKPQ KPIPRPANKF QGMVFDFVTK QVFDISIMIL ICLNMVTMMV ETDDQSQEMT
     NILYWINLVF IVLFTGECVL KLISLRYYYF TIGWNIFDFV VVILSIVGMF LAELIEKYFV
     SPTLFRVIRL ARIGRILRLI KGAKGIRTLL FALMMSLPAL FNIGLLLFLV MFIYAIFGMS
     NFAYVKREVG IDDMFNFETF GNSMICLFQI TTSAGWDGLL APILNSGPPD CDPDKDHPGS
     SVKGDCGNPS VGIFFFVSYI IISFLVVVNM YIAVILENFS VATEESAEPL SEDDFEMFYE
     VWEKFDPDAT QFIEFAKLSD FADALDPPLL IAKPNKVQLI AMDLPMVSGD RIHCLDILFA
     FTKRVLGESG EMDALRIQME ERFMASNPSK VSYEPITTTL KRKQEEVSAI IIQRAYRRYL
     LKQKVKKVSS IYKKDKGKEC DGTPIKEDTL IDKLNENSTP EKTDMTPSTT SPPSYDSVTK
     PEKEKFEKDK SEKEDKGKDI RESKK
//
ID   SCN3A_HUMAN             Reviewed;        2000 AA.
AC   Q9NY46; Q16142; Q53SX0; Q9BZB3; Q9C006; Q9NYK2; Q9P2J1; Q9UPD1;
AC   Q9Y6P4;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   08-NOV-2002, sequence version 2.
DT   15-FEB-2017, entry version 160.
DE   RecName: Full=Sodium channel protein type 3 subunit alpha;
DE   AltName: Full=Sodium channel protein brain III subunit alpha;
DE   AltName: Full=Sodium channel protein type III subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subtype III;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.3;
GN   Name=SCN3A; Synonyms=KIAA1356, NAC3;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2).
RC   TISSUE=Brain;
RA   Chen Y., Dale T.J., Romanos M.A., Whitaker W.R., Xie X., Clare J.J.;
RT   "Cloning, distribution and functional analysis of the human brain type
RT   III sodium channel from human brain.";
RL   Submitted (DEC-1999) to the EMBL/GenBank/DDBJ databases.
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3).
RA   Jeong S.-Y., Goto J., Kanazawa I.;
RT   "Cloning of cDNA for human voltage-gated sodium channel alpha subunit,
RT   SCN3A.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   INTERACTION WITH NEDD4L, POSSIBLE UBIQUITINATION, AND MUTAGENESIS OF
RP   TYR-1970.
RX   PubMed=15548568; DOI=10.1152/ajpcell.00460.2004;
RA   Rougier J.-S., van Bemmelen M.X., Bruce M.C., Jespersen T.,
RA   Gavillet B., Apotheloz F., Cordonier S., Staub O., Rotin D.,
RA   Abriel H.;
RT   "Molecular determinants of voltage-gated sodium channel regulation by
RT   the Nedd4/Nedd4-like proteins.";
RL   Am. J. Physiol. 288:C692-C701(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2; 3 AND 4), AND
RP   VARIANT THR-606.
RX   PubMed=11245985; DOI=10.1016/S0378-1119(00)00594-1;
RA   Kasai N., Fukushima K., Ueki Y., Prasad S., Nosakowski J., Sugata K.,
RA   Sugata A., Nishizaki K., Meyer N.C., Smith R.J.H.;
RT   "Genomic structures of SCN2A and SCN3A -- candidate genes for deafness
RT   at the DFNA16 locus.";
RL   Gene 264:113-122(2001).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1-1415 (ISOFORMS 2 AND 4).
RC   TISSUE=Brain;
RX   PubMed=9589372; DOI=10.1007/BF02737087;
RA   Lu C.M., Brown G.B.;
RT   "Isolation of a human-brain sodium-channel gene encoding two isoforms
RT   of the subtype III alpha-subunit.";
RL   J. Mol. Neurosci. 10:67-70(1998).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1324-1413.
RC   TISSUE=Placenta;
RX   PubMed=8159690; DOI=10.1073/pnas.91.8.2975;
RA   Malo M.S., Srivastava K., Andresen J.M., Chen X.N., Korenberg J.R.,
RA   Ingram V.M.;
RT   "Targeted gene walking by low stringency polymerase chain reaction:
RT   assignment of a putative human brain sodium channel gene (SCN3A) to
RT   chromosome 2q24-31.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:2975-2979(1994).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1482-2000.
RC   TISSUE=Brain;
RX   PubMed=10718198; DOI=10.1093/dnares/7.1.65;
RA   Nagase T., Kikuno R., Ishikawa K., Hirosawa M., Ohara O.;
RT   "Prediction of the coding sequences of unidentified human genes. XVI.
RT   The complete sequences of 150 new cDNA clones from brain which code
RT   for large proteins in vitro.";
RL   DNA Res. 7:65-73(2000).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1669-1750.
RC   TISSUE=Kidney;
RA   Tonkovich G.S., Kyle J.W.;
RT   "Endogenous sodium current in HEK293 cells: increase in cell surface
RT   expression of endogenous currents by stable transfection of the Beta 1
RT   subunit.";
RL   Submitted (FEB-2000) to the EMBL/GenBank/DDBJ databases.
RN   [10]
RP   INTERACTION WITH THE CONOTOXIN GVIIJ.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G.,
RA   Wickenden A.D., Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [11]
RP   VARIANTS ASN-43 DEL AND SER-1813.
RX   PubMed=12610651; DOI=10.1038/sj.mp.4001241;
RA   Weiss L.A., Escayg A., Kearney J.A., Trudeau M., MacDonald B.T.,
RA   Mori M., Reichert J., Buxbaum J.D., Meisler M.H.;
RT   "Sodium channels SCN1A, SCN2A and SCN3A in familial autism.";
RL   Mol. Psychiatry 8:186-194(2003).
RN   [12]
RP   VARIANT ILE-1084.
RX   PubMed=26566883; DOI=10.1136/jmedgenet-2015-103179;
RA   Rafiullah R., Aslamkhan M., Paramasivam N., Thiel C., Mustafa G.,
RA   Wiemann S., Schlesner M., Wade R.C., Rappold G.A., Berkel S.;
RT   "Homozygous missense mutation in the LMAN2L gene segregates with
RT   intellectual disability in a large consanguineous Pakistani family.";
RL   J. Med. Genet. 53:138-144(2016).
CC   -!- FUNCTION: Mediates the voltage-dependent sodium ion permeability
CC       of excitable membranes. Assuming opened or closed conformations in
CC       response to the voltage difference across the membrane, the
CC       protein forms a sodium-selective channel through which Na(+) ions
CC       may pass in accordance with their electrochemical gradient.
CC   -!- SUBUNIT: Heterooligomer of a large alpha subunit and 2-3 smaller
CC       beta subunits. Heterooligomer with SCN2B or SCN4B; disulfide-
CC       linked. Interacts with NEDD4L (PubMed:15548568). Interacts with
CC       the conotoxin GVIIJ (PubMed:24497506).
CC       {ECO:0000269|PubMed:15548568, ECO:0000269|PubMed:24497506}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000305}; Multi-pass
CC       membrane protein {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC         Comment=Exons 6A and 6N only differ by a single residue.;
CC       Name=1; Synonyms=6A-12+12b;
CC         IsoId=Q9NY46-1; Sequence=Displayed;
CC       Name=2; Synonyms=6A-12;
CC         IsoId=Q9NY46-2; Sequence=VSP_001034;
CC       Name=3; Synonyms=6N-12+12b;
CC         IsoId=Q9NY46-3; Sequence=VSP_001033;
CC       Name=4; Synonyms=6N-12;
CC         IsoId=Q9NY46-4; Sequence=VSP_001033, VSP_001034;
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- PTM: May be ubiquitinated by NEDD4L; which would promote its
CC       endocytosis.
CC   -!- PTM: Phosphorylation at Ser-1501 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents. {ECO:0000250}.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.3/SCN3A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AJ251507; CAB85895.1; -; mRNA.
DR   EMBL; AF225987; AAK00219.1; -; mRNA.
DR   EMBL; AF330135; AAG53414.1; -; Genomic_DNA.
DR   EMBL; AF330118; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330119; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330120; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330121; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330122; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330123; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330124; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330125; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330126; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330127; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330128; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330129; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330130; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330131; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330132; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330133; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330134; AAG53414.1; JOINED; Genomic_DNA.
DR   EMBL; AF330135; AAG53415.1; -; Genomic_DNA.
DR   EMBL; AF330118; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330119; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330120; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330121; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330122; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330123; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330124; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330125; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330126; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330127; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330128; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330129; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330130; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330131; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330132; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330133; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AF330134; AAG53415.1; JOINED; Genomic_DNA.
DR   EMBL; AC013463; AAY15072.1; -; Genomic_DNA.
DR   EMBL; AF035685; AAC29514.1; -; mRNA.
DR   EMBL; AF035686; AAC29515.1; -; mRNA.
DR   EMBL; S69887; AAB30530.1; -; Genomic_DNA.
DR   EMBL; AB037777; BAA92594.1; -; mRNA.
DR   EMBL; AF239921; AAF44690.1; -; mRNA.
DR   CCDS; CCDS33312.1; -. [Q9NY46-3]
DR   CCDS; CCDS46440.1; -. [Q9NY46-2]
DR   PIR; A54937; A54937.
DR   RefSeq; NP_001075145.1; NM_001081676.1. [Q9NY46-4]
DR   RefSeq; NP_001075146.1; NM_001081677.1. [Q9NY46-2]
DR   RefSeq; NP_008853.3; NM_006922.3. [Q9NY46-3]
DR   RefSeq; XP_011509912.1; XM_011511610.2. [Q9NY46-3]
DR   RefSeq; XP_016860149.1; XM_017004660.1. [Q9NY46-1]
DR   UniGene; Hs.435274; -.
DR   ProteinModelPortal; Q9NY46; -.
DR   BioGrid; 112233; 6.
DR   IntAct; Q9NY46; 2.
DR   MINT; MINT-8330038; -.
DR   STRING; 9606.ENSP00000283254; -.
DR   BindingDB; Q9NY46; -.
DR   ChEMBL; CHEMBL5163; -.
DR   DrugBank; DB06218; Lacosamide.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 580; -.
DR   iPTMnet; Q9NY46; -.
DR   PhosphoSitePlus; Q9NY46; -.
DR   BioMuta; SCN3A; -.
DR   DMDM; 25014054; -.
DR   PaxDb; Q9NY46; -.
DR   PeptideAtlas; Q9NY46; -.
DR   PRIDE; Q9NY46; -.
DR   Ensembl; ENST00000283254; ENSP00000283254; ENSG00000153253. [Q9NY46-3]
DR   Ensembl; ENST00000360093; ENSP00000353206; ENSG00000153253. [Q9NY46-1]
DR   Ensembl; ENST00000409101; ENSP00000386726; ENSG00000153253. [Q9NY46-2]
DR   GeneID; 6328; -.
DR   KEGG; hsa:6328; -.
DR   UCSC; uc002ucx.4; human. [Q9NY46-1]
DR   CTD; 6328; -.
DR   DisGeNET; 6328; -.
DR   GeneCards; SCN3A; -.
DR   HGNC; HGNC:10590; SCN3A.
DR   HPA; HPA035396; -.
DR   MIM; 182391; gene.
DR   neXtProt; NX_Q9NY46; -.
DR   OpenTargets; ENSG00000153253; -.
DR   PharmGKB; PA35005; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q9NY46; -.
DR   KO; K04836; -.
DR   OMA; YFNGTMD; -.
DR   OrthoDB; EOG0903014J; -.
DR   PhylomeDB; Q9NY46; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   ChiTaRS; SCN3A; human.
DR   GeneWiki; SCN3A; -.
DR   GenomeRNAi; 6328; -.
DR   PRO; PR:Q9NY46; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000153253; -.
DR   CleanEx; HS_SCN3A; -.
DR   ExpressionAtlas; Q9NY46; baseline and differential.
DR   Genevisible; Q9NY46; HS.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; NAS:UniProtKB.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0006814; P:sodium ion transport; NAS:UniProtKB.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PROSITE; PS50096; IQ; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disulfide bond; Glycoprotein; Ion channel; Ion transport; Membrane;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Sodium;
KW   Sodium channel; Sodium transport; Transmembrane; Transmembrane helix;
KW   Transport; Ubl conjugation; Voltage-gated channel.
FT   CHAIN         1   2000       Sodium channel protein type 3 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048493.
FT   TOPO_DOM      1    123       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    124    147       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    148    155       Extracellular. {ECO:0000255}.
FT   TRANSMEM    156    175       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    176    188       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    189    207       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    208    213       Extracellular. {ECO:0000255}.
FT   TRANSMEM    214    233       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000255}.
FT   TOPO_DOM    234    248       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    249    273       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    274    400       Extracellular. {ECO:0000255}.
FT   TRANSMEM    401    426       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    427    754       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    755    779       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    780    790       Extracellular. {ECO:0000255}.
FT   TRANSMEM    791    814       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    815    822       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    823    842       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    843    848       Extracellular. {ECO:0000255}.
FT   TRANSMEM    849    869       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000255}.
FT   TOPO_DOM    870    884       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    885    905       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    906    958       Extracellular. {ECO:0000255}.
FT   TRANSMEM    959    984       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    985   1201       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1202   1225       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1226   1238       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1239   1264       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1265   1270       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1271   1292       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1293   1296       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1297   1318       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000255}.
FT   TOPO_DOM   1319   1337       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1338   1359       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1360   1441       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1442   1468       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1469   1521       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1522   1545       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1546   1556       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1557   1580       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1581   1586       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1587   1610       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1611   1620       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1621   1642       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000255}.
FT   TOPO_DOM   1643   1657       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1658   1680       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1681   1746       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1747   1771       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1772   2000       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      110    455       I. {ECO:0000305}.
FT   REPEAT      742   1014       II. {ECO:0000305}.
FT   REPEAT     1188   1499       III. {ECO:0000305}.
FT   REPEAT     1508   1806       IV. {ECO:0000305}.
FT   DOMAIN     1900   1929       IQ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   MOD_RES     484    484       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08104}.
FT   MOD_RES     485    485       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08104}.
FT   MOD_RES     486    486       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P08104}.
FT   MOD_RES    1501   1501       Phosphoserine; by PKC. {ECO:0000250}.
FT   CARBOHYD    211    211       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    290    290       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    296    296       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    302    302       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    307    307       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    339    339       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1366   1366       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1380   1380       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    911    911       Interchain; with SCN2B or SCN4B.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   DISULFID    911    911       Interchain; with the conotoxin GVIIJ
FT                                (when the channel is not linked to SCN2B
FT                                or SCN4B; the bond to SCN2B or SCN4B
FT                                protects the channel from the inhibition
FT                                by toxin).
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   VAR_SEQ     208    208       S -> D (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:9589372,
FT                                ECO:0000303|Ref.2}.
FT                                /FTId=VSP_001033.
FT   VAR_SEQ     625    673       Missing (in isoform 2 and isoform 4).
FT                                {ECO:0000303|PubMed:9589372,
FT                                ECO:0000303|Ref.1}.
FT                                /FTId=VSP_001034.
FT   VARIANT      43     43       Missing. {ECO:0000269|PubMed:12610651}.
FT                                /FTId=VAR_029743.
FT   VARIANT     606    606       S -> T. {ECO:0000269|PubMed:11245985}.
FT                                /FTId=VAR_014275.
FT   VARIANT    1084   1084       V -> I (in dbSNP:rs140990288).
FT                                {ECO:0000269|PubMed:26566883}.
FT                                /FTId=VAR_076435.
FT   VARIANT    1107   1107       V -> A (in dbSNP:rs12474273).
FT                                /FTId=VAR_029744.
FT   VARIANT    1803   1803       D -> N (in dbSNP:rs3731762).
FT                                /FTId=VAR_055640.
FT   VARIANT    1813   1813       L -> S. {ECO:0000269|PubMed:12610651}.
FT                                /FTId=VAR_029745.
FT   MUTAGEN    1970   1970       Y->A: Abolishes interaction with NEDD4L.
FT                                {ECO:0000269|PubMed:15548568}.
FT   CONFLICT    175    175       A -> V (in Ref. 4; AAC29514/AAC29515).
FT                                {ECO:0000305}.
FT   CONFLICT    318    318       Y -> N (in Ref. 4; AAC29514/AAC29515).
FT                                {ECO:0000305}.
FT   CONFLICT    401    401       M -> T (in Ref. 4; AAC29514/AAC29515).
FT                                {ECO:0000305}.
FT   CONFLICT    475    475       I -> V (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
FT   CONFLICT    495    495       S -> G (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
FT   CONFLICT    604    604       S -> G (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
FT   CONFLICT    613    613       V -> E (in Ref. 4; AAC29514/AAC29515).
FT                                {ECO:0000305}.
FT   CONFLICT   1060   1060       E -> A (in Ref. 4; AAC29514/AAC29515).
FT                                {ECO:0000305}.
FT   CONFLICT   1163   1163       L -> F (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
FT   CONFLICT   1274   1274       W -> R (in Ref. 4; AAC29514/AAC29515).
FT                                {ECO:0000305}.
FT   CONFLICT   1329   1329       V -> L (in Ref. 6; AAB30530).
FT                                {ECO:0000305}.
FT   CONFLICT   1414   1415       AT -> VS (in Ref. 4; AAC29514/AAC29515).
FT                                {ECO:0000305}.
FT   CONFLICT   1614   1614       F -> S (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
FT   CONFLICT   1741   1743       CGN -> RGD (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
FT   CONFLICT   1862   1862       G -> C (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
FT   CONFLICT   1966   1966       S -> P (in Ref. 2; AAK00219).
FT                                {ECO:0000305}.
SQ   SEQUENCE   2000 AA;  226294 MW;  F754A1C7D49ECB58 CRC64;
     MAQALLVPPG PESFRLFTRE SLAAIEKRAA EEKAKKPKKE QDNDDENKPK PNSDLEAGKN
     LPFIYGDIPP EMVSEPLEDL DPYYINKKTF IVMNKGKAIF RFSATSALYI LTPLNPVRKI
     AIKILVHSLF SMLIMCTILT NCVFMTLSNP PDWTKNVEYT FTGIYTFESL IKILARGFCL
     EDFTFLRDPW NWLDFSVIVM AYVTEFVSLG NVSALRTFRV LRALKTISVI PGLKTIVGAL
     IQSVKKLSDV MILTVFCLSV FALIGLQLFM GNLRNKCLQW PPSDSAFETN TTSYFNGTMD
     SNGTFVNVTM STFNWKDYIG DDSHFYVLDG QKDPLLCGNG SDAGQCPEGY ICVKAGRNPN
     YGYTSFDTFS WAFLSLFRLM TQDYWENLYQ LTLRAAGKTY MIFFVLVIFL GSFYLVNLIL
     AVVAMAYEEQ NQATLEEAEQ KEAEFQQMLE QLKKQQEEAQ AVAAASAASR DFSGIGGLGE
     LLESSSEASK LSSKSAKEWR NRRKKRRQRE HLEGNNKGER DSFPKSESED SVKRSSFLFS
     MDGNRLTSDK KFCSPHQSLL SIRGSLFSPR RNSKTSIFSF RGRAKDVGSE NDFADDEHST
     FEDSESRRDS LFVPHRHGER RNSNVSQASM SSRMVPGLPA NGKMHSTVDC NGVVSLVGGP
     SALTSPTGQL PPEGTTTETE VRKRRLSSYQ ISMEMLEDSS GRQRAVSIAS ILTNTMEELE
     ESRQKCPPCW YRFANVFLIW DCCDAWLKVK HLVNLIVMDP FVDLAITICI VLNTLFMAME
     HYPMTEQFSS VLTVGNLVFT GIFTAEMVLK IIAMDPYYYF QEGWNIFDGI IVSLSLMELG
     LSNVEGLSVL RSFRLLRVFK LAKSWPTLNM LIKIIGNSVG ALGNLTLVLA IIVFIFAVVG
     MQLFGKSYKE CVCKINDDCT LPRWHMNDFF HSFLIVFRVL CGEWIETMWD CMEVAGQTMC
     LIVFMLVMVI GNLVVLNLFL ALLLSSFSSD NLAATDDDNE MNNLQIAVGR MQKGIDYVKN
     KMRECFQKAF FRKPKVIEIH EGNKIDSCMS NNTGIEISKE LNYLRDGNGT TSGVGTGSSV
     EKYVIDENDY MSFINNPSLT VTVPIAVGES DFENLNTEEF SSESELEESK EKLNATSSSE
     GSTVDVVLPR EGEQAETEPE EDLKPEACFT EGCIKKFPFC QVSTEEGKGK IWWNLRKTCY
     SIVEHNWFET FIVFMILLSS GALAFEDIYI EQRKTIKTML EYADKVFTYI FILEMLLKWV
     AYGFQTYFTN AWCWLDFLIV DVSLVSLVAN ALGYSELGAI KSLRTLRALR PLRALSRFEG
     MRVVVNALVG AIPSIMNVLL VCLIFWLIFS IMGVNLFAGK FYHCVNMTTG NMFDISDVNN
     LSDCQALGKQ ARWKNVKVNF DNVGAGYLAL LQVATFKGWM DIMYAAVDSR DVKLQPVYEE
     NLYMYLYFVI FIIFGSFFTL NLFIGVIIDN FNQQKKKFGG QDIFMTEEQK KYYNAMKKLG
     SKKPQKPIPR PANKFQGMVF DFVTRQVFDI SIMILICLNM VTMMVETDDQ GKYMTLVLSR
     INLVFIVLFT GEFVLKLVSL RHYYFTIGWN IFDFVVVILS IVGMFLAEMI EKYFVSPTLF
     RVIRLARIGR ILRLIKGAKG IRTLLFALMM SLPALFNIGL LLFLVMFIYA IFGMSNFAYV
     KKEAGIDDMF NFETFGNSMI CLFQITTSAG WDGLLAPILN SAPPDCDPDT IHPGSSVKGD
     CGNPSVGIFF FVSYIIISFL VVVNMYIAVI LENFSVATEE SAEPLSEDDF EMFYEVWEKF
     DPDATQFIEF SKLSDFAAAL DPPLLIAKPN KVQLIAMDLP MVSGDRIHCL DILFAFTKRV
     LGESGEMDAL RIQMEDRFMA SNPSKVSYEP ITTTLKRKQE EVSAAIIQRN FRCYLLKQRL
     KNISSNYNKE AIKGRIDLPI KQDMIIDKLN GNSTPEKTDG SSSTTSPPSY DSVTKPDKEK
     FEKDKPEKES KGKEVRENQK
//
ID   SCN4A_HUMAN             Reviewed;        1836 AA.
AC   P35499; Q15478; Q16447; Q7Z6B1;
DT   01-JUN-1994, integrated into UniProtKB/Swiss-Prot.
DT   23-MAR-2010, sequence version 4.
DT   15-FEB-2017, entry version 176.
DE   RecName: Full=Sodium channel protein type 4 subunit alpha;
DE   AltName: Full=SkM1;
DE   AltName: Full=Sodium channel protein skeletal muscle subunit alpha;
DE   AltName: Full=Sodium channel protein type IV subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.4;
GN   Name=SCN4A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA / MRNA], AND VARIANTS GLY-524;
RP   ASP-559 AND ASP-1376.
RC   TISSUE=Skeletal muscle;
RX   PubMed=1315496; DOI=10.1002/ana.410310203;
RA   George A.L. Jr., Komisarof J., Kallen R.G., Barchi R.L.;
RT   "Primary structure of the adult human skeletal muscle voltage-
RT   dependent sodium channel.";
RL   Ann. Neurol. 31:131-137(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=1310396; DOI=10.1016/0006-291X(92)91802-W;
RA   Wang J., Rojas C.V., Zhou J., Schwartz L.S., Nicholas H.,
RA   Hoffmann E.P.;
RT   "Sequence and genomic structure of the human adult skeletal muscle
RT   sodium channel alpha subunit gene on 17q.";
RL   Biochem. Biophys. Res. Commun. 182:794-801(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], VARIANT CMS16 GLU-1442, AND VARIANTS
RP   LEU-246; GLY-524 AND ASP-559.
RX   PubMed=12766226; DOI=10.1073/pnas.1230273100;
RA   Tsujino A., Maertens C., Ohno K., Shen X.-M., Fukuda T., Harper C.M.,
RA   Cannon S.C., Engel A.G.;
RT   "Myasthenic syndrome caused by mutation of the SCN4A sodium channel.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:7377-7382(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANT GLY-524.
RX   PubMed=1339144; DOI=10.1093/hmg/1.7.521;
RA   McClatchey A.I., Lin C.S., Wang J., Hoffman E.P., Rojas C.V.,
RA   Gusella J.F.;
RT   "The genomic structure of the human skeletal muscle sodium channel
RT   gene.";
RL   Hum. Mol. Genet. 1:521-527(1992).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R.,
RA   Gnerre S., Goldstein S., Grafham D.V., Grocock R., Hafez N.,
RA   Hagopian D.S., Hart E., Norman C.H., Humphray S., Jaffe D.B.,
RA   Jones M., Kamal M., Khodiyar V.K., LaButti K., Laird G., Lehoczky J.,
RA   Liu X., Lokyitsang T., Loveland J., Lui A., Macdonald P., Major J.E.,
RA   Matthews L., Mauceli E., McCarroll S.A., Mihalev A.H., Mudge J.,
RA   Nguyen C., Nicol R., O'Leary S.B., Osoegawa K., Schwartz D.C.,
RA   Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in
RT   the human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1305-1339, AND VARIANTS PMC
RP   VAL-1306 AND MET-1313.
RX   PubMed=1310898; DOI=10.1016/0092-8674(92)90151-2;
RA   McClatchey A.I., van den Bergh P., Pericak-Vance M.A., Raskind W.,
RA   Verellen C., McKenna-Yasek D., Rao K., Haines J.L., Bird T.,
RA   Brown R.H. Jr., Gusella J.F.;
RT   "Temperature-sensitive mutations in the III-IV cytoplasmic loop region
RT   of the skeletal muscle sodium channel gene in paramyotonia
RT   congenita.";
RL   Cell 68:769-774(1992).
RN   [7]
RP   INTERACTION WITH THE CONOTOXIN GVIIJ.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G.,
RA   Wickenden A.D., Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [8]
RP   VARIANT HYPP MET-704.
RX   PubMed=1659948; DOI=10.1016/0092-8674(91)90374-8;
RA   Ptacek L.J., George A.L. Jr., Griggs R.C., Tawil R., Kallen R.G.,
RA   Barchi R.L., Robertson M., Leppert M.F.;
RT   "Identification of a mutation in the gene causing hyperkalemic
RT   periodic paralysis.";
RL   Cell 67:1021-1027(1991).
RN   [9]
RP   VARIANT HYPP VAL-1592.
RX   PubMed=1659668; DOI=10.1038/354387a0;
RA   Rojas C.V., Wang J., Schwartz L.S., Hoffman E.P., Powell B.R.,
RA   Brown R.H. Jr.;
RT   "A Met-to-Val mutation in the skeletal muscle Na+ channel alpha-
RT   subunit in hyperkalaemic periodic paralysis.";
RL   Nature 354:387-389(1991).
RN   [10]
RP   VARIANTS PMC PHE-804 AND THR-1156.
RX   PubMed=1338909; DOI=10.1038/ng1092-148;
RA   McClatchey A.I., McKenna-Yasek D., Cros D., Worthen H.G., Kuncl R.W.,
RA   Desilva S.M., Cornblath D.R., Gusella J.F., Brown R.H. Jr.;
RT   "Novel mutations in families with unusual and variable disorders of
RT   the skeletal muscle sodium channel.";
RL   Nat. Genet. 2:148-152(1992).
RN   [11]
RP   VARIANTS PMC CYS-1448 AND HIS-1448.
RX   PubMed=1316765; DOI=10.1016/0896-6273(92)90203-P;
RA   Ptacek L.J., George A.L. Jr., Barchi R.L., Griggs R.C., Riggs J.E.,
RA   Robertson M., Leppert M.F.;
RT   "Mutations in an S4 segment of the adult skeletal muscle sodium
RT   channel cause paramyotonia congenita.";
RL   Neuron 8:891-897(1992).
RN   [12]
RP   VARIANT PMC/HYPP ARG-1433.
RX   PubMed=8388676; DOI=10.1002/ana.410330312;
RA   Ptacek L.J., Gouw L., Kwiecinski H., McManis P., Mendell J.R.,
RA   Barohn R.J., George A.L. Jr., Barchi R.L., Robertson M., Leppert M.F.;
RT   "Sodium channel mutations in paramyotonia congenita and hyperkalemic
RT   periodic paralysis.";
RL   Ann. Neurol. 33:300-307(1993).
RN   [13]
RP   VARIANTS PMC ALA-1306; GLU-1306 AND VAL-1306.
RX   PubMed=8308722; DOI=10.1113/jphysiol.1993.sp019843;
RA   Lerche H., Heine R., Pika U., George A.L. Jr., Mitrovic N.,
RA   Browatzki M., Weiss T., Rivet-Bastide M., Franke C., Lomonaco M.,
RA   Ricker K., Lehmann-Horn F.;
RT   "Human sodium channel myotonia: slowed channel inactivation due to
RT   substitutions for a glycine within the III-IV linker.";
RL   J. Physiol. (Lond.) 470:13-22(1993).
RN   [14]
RP   VARIANT PMC MET-1589.
RX   PubMed=8242056; DOI=10.1093/hmg/2.9.1349;
RA   Heine R., Pika U., Lehmann-Horn F.;
RT   "A novel SCN4A mutation causing myotonia aggravated by cold and
RT   potassium.";
RL   Hum. Mol. Genet. 2:1349-1353(1993).
RN   [15]
RP   VARIANT MYOSCN4A VAL-1160.
RX   PubMed=8058156; DOI=10.1212/WNL.44.8.1500;
RA   Ptacek L.J., Tawil R., Griggs R.C., Meola G., McManis P., Barohn R.J.,
RA   Mendell J.R., Harris C., Spitzer R., Santiago F., Leppert M.F.;
RT   "Sodium channel mutations in acetazolamide-responsive myotonia
RT   congenita, paramyotonia congenita, and hyperkalemic periodic
RT   paralysis.";
RL   Neurology 44:1500-1503(1994).
RN   [16]
RP   VARIANT ILE-781.
RX   PubMed=7695243; DOI=10.1002/ana.410370320;
RA   Baquero J.L., Ayala R.A., Wang J., Curless R.G., Feero W.G.,
RA   Hoffman E.P., Ebeid M.R.;
RT   "Hyperkalemic periodic paralysis with cardiac dysrhythmia: a novel
RT   sodium channel mutation?";
RL   Ann. Neurol. 37:408-411(1995).
RN   [17]
RP   VARIANT PMC ILE-1293.
RX   PubMed=8580427;
RA   Koch M.C., Baumbach K., George A.L. Jr., Ricker K.;
RT   "Paramyotonia congenita without paralysis on exposure to cold: a novel
RT   mutation in the SCN4A gene (Val1293Ile).";
RL   NeuroReport 6:2001-2004(1995).
RN   [18]
RP   VARIANT ILE-781.
RX   PubMed=9266738; DOI=10.1002/ana.410420219;
RA   Green D.S., Hayward L.J., George A.L. Jr., Cannon S.C.;
RT   "A proposed mutation, Val781Ile, associated with hyperkalemic periodic
RT   paralysis and cardiac dysrhythmia is a benign polymorphism.";
RL   Ann. Neurol. 42:253-256(1997).
RN   [19]
RP   VARIANT MYOSCN4A MET-445.
RX   PubMed=9392583; DOI=10.1002/ana.410420520;
RA   Rosenfeld J., Sloan-Brown K., George A.L. Jr.;
RT   "A novel muscle sodium channel mutation causes painful congenital
RT   myotonia.";
RL   Ann. Neurol. 42:811-814(1997).
RN   [20]
RP   VARIANT PMC GLU-1456.
RX   PubMed=10369308; DOI=10.1001/archneur.56.6.692;
RA   Sasaki R., Takano H., Kamakura K., Kaida K., Hirata A., Saito M.,
RA   Tanaka H., Kuzuhara S., Tsuji S.;
RT   "A novel mutation in the gene for the adult skeletal muscle sodium
RT   channel alpha-subunit (SCN4A) that causes paramyotonia congenita of
RT   von Eulenburg.";
RL   Arch. Neurol. 56:692-696(1999).
RN   [21]
RP   VARIANT MYOSCN4A MET-445.
RX   PubMed=10218481; DOI=10.1016/S0014-5793(99)00338-5;
RA   Wang D.W., VanDeCarr D., Ruben P.C., George A.L. Jr., Bennett P.B.;
RT   "Functional consequences of a domain 1/S6 segment sodium channel
RT   mutation associated with painful congenital myotonia.";
RL   FEBS Lett. 448:231-234(1999).
RN   [22]
RP   VARIANT HOKPP2 HIS-669.
RX   PubMed=10599760; DOI=10.1212/WNL.53.9.1932;
RA   Bulman D.E., Scoggan K.A., van Oene M.D., Nicolle M.W., Hahn A.F.,
RA   Tollar L.L., Ebers G.C.;
RT   "A novel sodium channel mutation in a family with hypokalemic periodic
RT   paralysis.";
RL   Neurology 53:1932-1936(1999).
RN   [23]
RP   VARIANT PMC GLU-1456.
RX   PubMed=10727489; DOI=10.1136/jnnp.68.4.504;
RA   Davies N.P., Eunson L.H., Gregory R.P., Mills K.R., Morrison P.J.,
RA   Hanna M.G.;
RT   "Clinical, electrophysiological, and molecular genetic studies in a
RT   new family with paramyotonia congenita.";
RL   J. Neurol. Neurosurg. Psych. 68:504-507(2000).
RN   [24]
RP   VARIANT HOKPP2 SER-1158.
RX   PubMed=10851391; DOI=10.1212/WNL.54.11.2179;
RA   Sugiura Y., Aoki T., Sugiyama Y., Hida C., Ogata M., Yamamoto T.;
RT   "Temperature-sensitive sodium channelopathy with heat-induced myotonia
RT   and cold-induced paralysis.";
RL   Neurology 54:2179-2181(2000).
RN   [25]
RP   VARIANTS HOKPP2 GLY-672 AND HIS-672.
RX   PubMed=10944223; DOI=10.1073/pnas.97.17.9549;
RA   Jurkat-Rott K., Mitrovic N., Hang C., Kouzmekine A., Iaizzo P.,
RA   Herzog J., Lerche H., Nicole S., Vale-Santos J., Chauveau D.,
RA   Fontaine B., Lehmann-Horn F.;
RT   "Voltage-sensor sodium channel mutations cause hypokalemic periodic
RT   paralysis type 2 by enhanced inactivation and reduced current.";
RL   Proc. Natl. Acad. Sci. U.S.A. 97:9549-9554(2000).
RN   [26]
RP   VARIANT HOKPP2 SER-672.
RX   PubMed=11558801; DOI=10.1002/ana.1144;
RA   Bendahhou S., Cummins T.R., Griggs R.C., Fu Y.H., Ptacek L.J.;
RT   "Sodium channel inactivation defects are associated with
RT   acetazolamide-exacerbated hypokalemic periodic paralysis.";
RL   Ann. Neurol. 50:417-420(2001).
RN   [27]
RP   VARIANT HOKPP2 SER-672.
RX   PubMed=11591859; DOI=10.1212/WNL.57.7.1323;
RA   Davies N.P., Eunson L.H., Samuel M., Hanna M.G.;
RT   "Sodium channel gene mutations in hypokalemic periodic paralysis: an
RT   uncommon cause in the UK.";
RL   Neurology 57:1323-1325(2001).
RN   [28]
RP   VARIANTS PMC MET-1313 AND CYS-1448, CHARACTERIZATION OF VARIANTS PMC
RP   MET-1313 AND CYS-1448, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=15318338; DOI=10.1002/mus.20080;
RA   Dice M.S., Abbruzzese J.L., Wheeler J.T., Groome J.R., Fujimoto E.,
RA   Ruben P.C.;
RT   "Temperature-sensitive defects in paramyotonia congenita mutants
RT   R1448C and T1313M.";
RL   Muscle Nerve 30:277-288(2004).
RN   [29]
RP   VARIANTS NKPP GLY-675; GLN-675 AND TRP-675.
RX   PubMed=15596759; DOI=10.1212/01.WNL.0000145768.09934.EC;
RA   Vicart S., Sternberg D., Fournier E., Ochsner F., Laforet P.,
RA   Kuntzer T., Eymard B., Hainque B., Fontaine B.;
RT   "New mutations of SCN4A cause a potassium-sensitive normokalemic
RT   periodic paralysis.";
RL   Neurology 63:2120-2127(2004).
RN   [30]
RP   VARIANT PMC ASP-1152.
RX   PubMed=15790667; DOI=10.1113/jphysiol.2004.081018;
RA   Bouhours M., Luce S., Sternberg D., Willer J.-C., Fontaine B.,
RA   Tabti N.;
RT   "A1152D mutation of the Na+ channel causes paramyotonia congenita and
RT   emphasizes the role of DIII/S4-S5 linker in fast inactivation.";
RL   J. Physiol. (Lond.) 565:415-427(2005).
RN   [31]
RP   VARIANT PMC LYS-270, AND VARIANTS MYOSCN4A THR-715; ASN-804 AND
RP   ASN-1310.
RX   PubMed=16786525; DOI=10.1002/ana.20905;
RA   Fournier E., Viala K., Gervais H., Sternberg D., Arzel-Hezode M.,
RA   Laforet P., Eymard B., Tabti N., Willer J.-C., Vial C., Fontaine B.;
RT   "Cold extends electromyography distinction between ion channel
RT   mutations causing myotonia.";
RL   Ann. Neurol. 60:356-365(2006).
RN   [32]
RP   VARIANT HOKPP2 GLN-1132, CHARACTERIZATION OF VARIANT HOKPP2 GLN-1132,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=16890191; DOI=10.1016/j.bbrc.2006.07.101;
RA   Carle T., Lhuillier L., Luce S., Sternberg D., Devuyst O.,
RA   Fontaine B., Tabti N.;
RT   "Gating defects of a novel Na+ channel mutant causing hypokalemic
RT   periodic paralysis.";
RL   Biochem. Biophys. Res. Commun. 348:653-661(2006).
RN   [33]
RP   VARIANT MYOSCN4A GLU-1306.
RX   PubMed=16832098; DOI=10.1212/01.wnl.0000223838.88872.da;
RA   Colding-Joergensen E., Duno M., Vissing J.;
RT   "Autosomal dominant monosymptomatic myotonia permanens.";
RL   Neurology 67:153-155(2006).
RN   [34]
RP   VARIANTS HOKPP2 HIS-669; CYS-672 AND GLY-672.
RX   PubMed=18162704; DOI=10.3346/jkms.2007.22.6.946;
RA   Kim J.-B., Kim M.-H., Lee S.J., Kim D.-J., Lee B.C.;
RT   "The genotype and clinical phenotype of Korean patients with familial
RT   hypokalemic periodic paralysis.";
RL   J. Korean Med. Sci. 22:946-951(2007).
RN   [35]
RP   VARIANT MYOSCN4A ASP-1481.
RX   PubMed=17212350; DOI=10.1002/mus.20733;
RA   Schoser B.G.H., Schroeder J.M., Grimm T., Sternberg D., Kress W.;
RT   "A large German kindred with cold-aggravated myotonia and a
RT   heterozygous A1481D mutation in the SCN4A gene.";
RL   Muscle Nerve 35:599-606(2007).
RN   [36]
RP   VARIANT MYOSCN4A ILE-1476.
RX   PubMed=17998485; DOI=10.1212/01.wnl.0000290831.08585.2c;
RA   Rossignol E., Mathieu J., Thiffault I., Tetreault M., Dicaire M.J.,
RA   Chrestian N., Dupre N., Puymirat J., Brais B.;
RT   "A novel founder SCN4A mutation causes painful cold-induced myotonia
RT   in French-Canadians.";
RL   Neurology 69:1937-1941(2007).
RN   [37]
RP   VARIANT MYOSCN4A LYS-1297.
RX   PubMed=18203179; DOI=10.1002/ajmg.a.32141;
RA   Gay S., Dupuis D., Faivre L., Masurel-Paulet A., Labenne M.,
RA   Colombani M., Soichot P., Huet F., Hainque B., Sternberg D.,
RA   Fontaine B., Gouyon J.B., Thauvin-Robinet C.;
RT   "Severe neonatal non-dystrophic myotonia secondary to a novel mutation
RT   of the voltage-gated sodium channel (SCN4A) gene.";
RL   Am. J. Med. Genet. A 146:380-383(2008).
RN   [38]
RP   VARIANTS NKPP GLN-675 AND VAL-1592, AND VARIANT ILE-781.
RX   PubMed=18046642; DOI=10.1007/s10571-007-9231-4;
RA   Xiuhai G., Weiping W., Ke Z., Hongbin W., Yiling S., Yanling M.;
RT   "Mutations of sodium channel alpha-subunit genes in Chinese patients
RT   with normokalemic periodic paralysis.";
RL   Cell. Mol. Neurobiol. 28:653-661(2008).
RN   [39]
RP   CHARACTERIZATION OF VARIANTS PMC SER-1473 AND ILE-1705.
RX   PubMed=18690054; DOI=10.4161/chan.2.1.6051;
RA   Groome J.R., Larsen M.F., Coonts A.;
RT   "Differential effects of paramyotonia congenita mutations F1473S and
RT   F1705I on sodium channel gating.";
RL   Channels 2:39-50(2008).
RN   [40]
RP   VARIANTS PMC LYS-270; MET-704; ALA-1306; GLU-1306; MET-1313; PRO-1436;
RP   CYS-1448; HIS-1448; LEU-1448; GLU-1456; SER-1473 AND MET-1589.
RX   PubMed=18166706; DOI=10.1212/01.wnl.0000287069.21162.94;
RA   Matthews E., Tan S.V., Fialho D., Sweeney M.G., Sud R., Haworth A.,
RA   Stanley E., Cea G., Davis M.B., Hanna M.G.;
RT   "What causes paramyotonia in the United Kingdom? Common and new SCN4A
RT   mutations revealed.";
RL   Neurology 70:50-53(2008).
RN   [41]
RP   VARIANT HOKPP2 SER-1158, AND CHARACTERIZATION OF VARIANT HOKPP2
RP   SER-1158.
RX   PubMed=17898326; DOI=10.1212/01.wnl.0000265397.70057.d8;
RA   Webb J., Cannon S.C.;
RT   "Cold-induced defects of sodium channel gating in atypical periodic
RT   paralysis plus myotonia.";
RL   Neurology 70:755-761(2008).
RN   [42]
RP   VARIANT MYOSCN4A VAL-141, AND CHARACTERIZATION OF VARIANT MYOSCN4A
RP   VAL-141.
RX   PubMed=19015483; DOI=10.1212/01.wnl.0000335168.86248.55;
RA   Petitprez S., Tiab L., Chen L., Kappeler L., Rosler K.M.,
RA   Schorderet D., Abriel H., Burgunder J.M.;
RT   "A novel dominant mutation of the Nav1.4 alpha-subunit domain I
RT   leading to sodium channel myotonia.";
RL   Neurology 71:1669-1675(2008).
RN   [43]
RP   VARIANTS MYOSCN4A TRP-225; THR-1156 AND GLU-1306, VARIANT PMC THR-693,
RP   AND VARIANT HYPP THR-1156.
RX   PubMed=20076800; DOI=10.3988/jcn.2009.5.4.186;
RA   Lee S.C., Kim H.S., Park Y.E., Choi Y.C., Park K.H., Kim D.S.;
RT   "Clinical diversity of SCN4A-mutation-associated skeletal muscle
RT   sodium channelopathy.";
RL   J. Clin. Neurol. 5:186-191(2009).
RN   [44]
RP   VARIANT MYOSCN4A GLU-1633, AND CHARACTERIZATION OF VARIANT MYOSCN4A
RP   GLU-1633.
RX   PubMed=19347921; DOI=10.1002/mus.21155;
RA   Kubota T., Kinoshita M., Sasaki R., Aoike F., Takahashi M.P.,
RA   Sakoda S., Hirose K.;
RT   "New mutation of the Na channel in the severe form of potassium-
RT   aggravated myotonia.";
RL   Muscle Nerve 39:666-673(2009).
RN   [45]
RP   VARIANTS MYOSCN4A MET-445; LYS-452; SER-671; VAL-1306 AND ILE-1476.
RX   PubMed=18337100; DOI=10.1016/j.nmd.2008.01.007;
RA   Dupre N., Chrestian N., Bouchard J.-P., Rossignol E., Brunet D.,
RA   Sternberg D., Brais B., Mathieu J., Puymirat J.;
RT   "Clinical, electrophysiologic, and genetic study of non-dystrophic
RT   myotonia in French-Canadians.";
RL   Neuromuscul. Disord. 19:330-334(2009).
RN   [46]
RP   VARIANTS HOKPP2 TRP-222; CYS-672; GLY-672; HIS-672; SER-672; GLN-1132
RP   AND HIS-1135.
RX   PubMed=19118277; DOI=10.1212/01.wnl.0000342387.65477.46;
RA   Matthews E., Labrum R., Sweeney M.G., Sud R., Haworth A.,
RA   Chinnery P.F., Meola G., Schorge S., Kullmann D.M., Davis M.B.,
RA   Hanna M.G.;
RT   "Voltage sensor charge loss accounts for most cases of hypokalemic
RT   periodic paralysis.";
RL   Neurology 72:1544-1547(2009).
RN   [47]
RP   VARIANT PMC MET-704.
RX   PubMed=19077043; DOI=10.1111/j.1440-1789.2008.00985.x;
RA   Luan X., Chen B., Liu Y., Zheng R., Zhang W., Yuan Y.;
RT   "Tubular aggregates in paralysis periodica paramyotonica with T704M
RT   mutation of SCN4A.";
RL   Neuropathology 29:579-584(2009).
RN   [48]
RP   VARIANT NKPP GLN-1129, AND VARIANT HOKPP2 GLN-1129.
RX   PubMed=20522878; DOI=10.1136/jnnp.2009.177451;
RA   Hong D., Luan X., Chen B., Zheng R., Zhang W., Wang Z., Yuan Y.;
RT   "Both hypokalaemic and normokalaemic periodic paralysis in different
RT   members of a single family with novel R1129Q mutation in SCN4A gene.";
RL   J. Neurol. Neurosurg. Psych. 81:703-704(2010).
RN   [49]
RP   VARIANT HOKPP2 HIS-672.
RX   PubMed=21043388;
RA   Incecik F., Herguner M.O., Altunbasak S., Lehman-Horn F.;
RT   "Hypokalemic periodic paralysis due to the SCN4A R672H mutation in a
RT   Turkish family.";
RL   Turk. J. Pediatr. 52:409-410(2010).
RN   [50]
RP   VARIANTS HOKPP2 CYS-1135 AND HIS-1135, AND CHARACTERIZATION OF
RP   VARIANTS HOKPP2 CYS-1135 AND HIS-1135.
RX   PubMed=24549961; DOI=10.1093/brain/awu015;
RA   Groome J.R., Lehmann-Horn F., Fan C., Wolf M., Winston V., Merlini L.,
RA   Jurkat-Rott K.;
RT   "NaV1.4 mutations cause hypokalaemic periodic paralysis by disrupting
RT   IIIS4 movement during recovery.";
RL   Brain 137:998-1008(2014).
RN   [51]
RP   VARIANT CMS16 HIS-1457, AND CHARACTERIZATION OF VARIANT CMS16
RP   HIS-1457.
RX   PubMed=25707578; DOI=10.1002/ana.24389;
RA   Arnold W.D., Feldman D.H., Ramirez S., He L., Kassar D., Quick A.,
RA   Klassen T.L., Lara M., Nguyen J., Kissel J.T., Lossin C.,
RA   Maselli R.A.;
RT   "Defective fast inactivation recovery of Nav 1.4 in congenital
RT   myasthenic syndrome.";
RL   Ann. Neurol. 77:840-850(2015).
RN   [52]
RP   INVOLVEMENT IN FETAL HYPOKINESIA AND CONGENITAL MYOPATHY, VARIANTS
RP   HIS-104; LYS-203; TRP-225; THR-382; ASN-1069; CYS-1135 AND PHE-1209,
RP   AND CHARACTERIZATION OF VARIANTS HIS-104; LYS-203; TRP-225; THR-382;
RP   ASN-1069 AND PHE-1209.
RX   PubMed=26700687; DOI=10.1093/brain/awv352;
RA   Zaharieva I.T., Thor M.G., Oates E.C., van Karnebeek C., Hendson G.,
RA   Blom E., Witting N., Rasmussen M., Gabbett M.T., Ravenscroft G.,
RA   Sframeli M., Suetterlin K., Sarkozy A., D'Argenzio L., Hartley L.,
RA   Matthews E., Pitt M., Vissing J., Ballegaard M., Krarup C.,
RA   Sloerdahl A., Halvorsen H., Ye X.C., Zhang L.H., Loekken N.,
RA   Werlauff U., Abdelsayed M., Davis M.R., Feng L., Phadke R.,
RA   Sewry C.A., Morgan J.E., Laing N.G., Vallance H., Ruben P.,
RA   Hanna M.G., Lewis S., Kamsteeg E.J., Maennikkoe R., Muntoni F.;
RT   "Loss-of-function mutations in SCN4A cause severe foetal hypokinesia
RT   or 'classical' congenital myopathy.";
RL   Brain 139:674-691(2016).
RN   [53]
RP   VARIANT LEU-72, CHARACTERIZATION OF VARIANT LEU-72, AND INVOLVEMENT IN
RP   DM2.
RX   PubMed=25660391; DOI=10.1016/j.nmd.2015.01.006;
RA   Bugiardini E., Rivolta I., Binda A., Soriano Caminero A., Cirillo F.,
RA   Cinti A., Giovannoni R., Botta A., Cardani R., Wicklund M.P.,
RA   Meola G.;
RT   "SCN4A mutation as modifying factor of myotonic dystrophy type 2
RT   phenotype.";
RL   Neuromuscul. Disord. 25:301-307(2015).
RN   [54]
RP   VARIANT ILE-781.
RX   PubMed=27535533; DOI=10.1038/nature19057;
RG   Exome Aggregation Consortium;
RA   Lek M., Karczewski K.J., Minikel E.V., Samocha K.E., Banks E.,
RA   Fennell T., O'Donnell-Luria A.H., Ware J.S., Hill A.J., Cummings B.B.,
RA   Tukiainen T., Birnbaum D.P., Kosmicki J.A., Duncan L.E., Estrada K.,
RA   Zhao F., Zou J., Pierce-Hoffman E., Berghout J., Cooper D.N.,
RA   Deflaux N., DePristo M., Do R., Flannick J., Fromer M., Gauthier L.,
RA   Goldstein J., Gupta N., Howrigan D., Kiezun A., Kurki M.I.,
RA   Moonshine A.L., Natarajan P., Orozco L., Peloso G.M., Poplin R.,
RA   Rivas M.A., Ruano-Rubio V., Rose S.A., Ruderfer D.M., Shakir K.,
RA   Stenson P.D., Stevens C., Thomas B.P., Tiao G., Tusie-Luna M.T.,
RA   Weisburd B., Won H.H., Yu D., Altshuler D.M., Ardissino D.,
RA   Boehnke M., Danesh J., Donnelly S., Elosua R., Florez J.C.,
RA   Gabriel S.B., Getz G., Glatt S.J., Hultman C.M., Kathiresan S.,
RA   Laakso M., McCarroll S., McCarthy M.I., McGovern D., McPherson R.,
RA   Neale B.M., Palotie A., Purcell S.M., Saleheen D., Scharf J.M.,
RA   Sklar P., Sullivan P.F., Tuomilehto J., Tsuang M.T., Watkins H.C.,
RA   Wilson J.G., Daly M.J., MacArthur D.G.;
RT   "Analysis of protein-coding genetic variation in 60,706 humans.";
RL   Nature 536:285-291(2016).
RN   [55]
RP   VARIANT CMS16 TRP-1454, AND CHARACTERIZATION OF VARIANT CMS16
RP   TRP-1454.
RX   PubMed=26659129; DOI=10.1212/WNL.0000000000002264;
RA   Habbout K., Poulin H., Rivier F., Giuliano S., Sternberg D.,
RA   Fontaine B., Eymard B., Morales R.J., Echenne B., King L., Hanna M.G.,
RA   Maennikkoe R., Chahine M., Nicole S., Bendahhou S.;
RT   "A recessive Nav1.4 mutation underlies congenital myasthenic syndrome
RT   with periodic paralysis.";
RL   Neurology 86:161-169(2016).
CC   -!- FUNCTION: This protein mediates the voltage-dependent sodium ion
CC       permeability of excitable membranes. Assuming opened or closed
CC       conformations in response to the voltage difference across the
CC       membrane, the protein forms a sodium-selective channel through
CC       which Na(+) ions may pass in accordance with their electrochemical
CC       gradient. This sodium channel may be present in both denervated
CC       and innervated skeletal muscle. {ECO:0000269|PubMed:15318338,
CC       ECO:0000269|PubMed:16890191}.
CC   -!- SUBUNIT: Muscle sodium channels contain an alpha subunit and a
CC       smaller beta subunit. Heterooligomer with SCN2B or SCN4B;
CC       disulfide-linked. Interacts with the PDZ domain of the syntrophin
CC       SNTA1, SNTB1 and SNTB2. Interacts with the conotoxin GVIIJ
CC       (PubMed:24497506). {ECO:0000250|UniProtKB:P04775,
CC       ECO:0000250|UniProtKB:Q9JJV9, ECO:0000269|PubMed:24497506}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15318338,
CC       ECO:0000269|PubMed:16890191}; Multi-pass membrane protein
CC       {ECO:0000305}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- PTM: Phosphorylation at Ser-1328 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents. {ECO:0000250}.
CC   -!- DISEASE: Paramyotonia congenita of von Eulenburg (PMC)
CC       [MIM:168300]: An autosomal dominant channelopathy characterized by
CC       myotonia, increased by exposure to cold, intermittent flaccid
CC       paresis, not necessarily dependent on cold or myotonia, lability
CC       of serum potassium, non-progressive nature and lack of atrophy or
CC       hypertrophy of muscles. In some patients, myotonia is not
CC       increased by cold exposure (paramyotonia without cold paralysis).
CC       Patients may have a combination phenotype of PMC and HYPP.
CC       {ECO:0000269|PubMed:10369308, ECO:0000269|PubMed:10727489,
CC       ECO:0000269|PubMed:1310898, ECO:0000269|PubMed:1316765,
CC       ECO:0000269|PubMed:1338909, ECO:0000269|PubMed:15318338,
CC       ECO:0000269|PubMed:15790667, ECO:0000269|PubMed:16786525,
CC       ECO:0000269|PubMed:18166706, ECO:0000269|PubMed:18690054,
CC       ECO:0000269|PubMed:19077043, ECO:0000269|PubMed:20076800,
CC       ECO:0000269|PubMed:8242056, ECO:0000269|PubMed:8308722,
CC       ECO:0000269|PubMed:8388676, ECO:0000269|PubMed:8580427}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Periodic paralysis hypokalemic 2 (HOKPP2) [MIM:613345]:
CC       An autosomal dominant disorder manifested by episodic flaccid
CC       generalized muscle weakness associated with falls of serum
CC       potassium levels. {ECO:0000269|PubMed:10599760,
CC       ECO:0000269|PubMed:10851391, ECO:0000269|PubMed:10944223,
CC       ECO:0000269|PubMed:11558801, ECO:0000269|PubMed:11591859,
CC       ECO:0000269|PubMed:16890191, ECO:0000269|PubMed:17898326,
CC       ECO:0000269|PubMed:18162704, ECO:0000269|PubMed:19118277,
CC       ECO:0000269|PubMed:20522878, ECO:0000269|PubMed:21043388,
CC       ECO:0000269|PubMed:24549961}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Periodic paralysis hyperkalemic (HYPP) [MIM:170500]: An
CC       autosomal dominant channelopathy characterized by episodic flaccid
CC       generalized muscle weakness associated with high levels of serum
CC       potassium. Concurrence of myotonia is found in HYPP patients.
CC       {ECO:0000269|PubMed:1659668, ECO:0000269|PubMed:1659948,
CC       ECO:0000269|PubMed:20076800}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Periodic paralysis normokalemic (NKPP) [MIM:170500]: A
CC       disorder closely related to hyperkalemic periodic paralysis, but
CC       marked by a lack of alterations in potassium levels during attacks
CC       of muscle weakness. {ECO:0000269|PubMed:15596759,
CC       ECO:0000269|PubMed:18046642, ECO:0000269|PubMed:20522878}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Myotonia SCN4A-related (MYOSCN4A) [MIM:608390]: A
CC       phenotypically highly variable myotonia aggravated by potassium
CC       loading, and sometimes by cold. Myotonia is characterized by
CC       sustained muscle tensing that prevents muscles from relaxing
CC       normally. It causes muscle stiffness that can interfere with
CC       movement. In some people the stiffness is very mild, while in
CC       other cases it may be severe enough to interfere with walking,
CC       running, and other activities of daily life. Myotonia SCN4A-
CC       related includes myotonia permanens and myotonia fluctuans. In
CC       myotonia permanens, the myotonia is generalized and there is a
CC       hypertrophy of the muscle, particularly in the neck and the
CC       shoulder. Attacks of severe muscle stiffness of the thoracic
CC       muscles may be life threatening due to impaired ventilation. In
CC       myotonia fluctuans, the muscle stiffness may fluctuate from day to
CC       day, provoked by exercise. {ECO:0000269|PubMed:10218481,
CC       ECO:0000269|PubMed:16786525, ECO:0000269|PubMed:16832098,
CC       ECO:0000269|PubMed:17212350, ECO:0000269|PubMed:17998485,
CC       ECO:0000269|PubMed:18203179, ECO:0000269|PubMed:18337100,
CC       ECO:0000269|PubMed:19015483, ECO:0000269|PubMed:19347921,
CC       ECO:0000269|PubMed:20076800, ECO:0000269|PubMed:8058156,
CC       ECO:0000269|PubMed:9392583}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Myasthenic syndrome, congenital, 16 (CMS16) [MIM:614198]:
CC       A form of congenital myasthenic syndrome, a group of disorders
CC       characterized by failure of neuromuscular transmission, including
CC       pre-synaptic, synaptic, and post-synaptic disorders that are not
CC       of autoimmune origin. Clinical features are easy fatigability and
CC       muscle weakness. CMS16 is characterized by fatigable generalized
CC       weakness and recurrent attacks of respiratory and bulbar paralysis
CC       since birth. The fatigable weakness involves lid-elevator,
CC       external ocular, facial, limb and truncal muscles and an
CC       decremental response of the compound muscle action potential on
CC       repetitive stimulation. {ECO:0000269|PubMed:12766226,
CC       ECO:0000269|PubMed:25707578, ECO:0000269|PubMed:26659129}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Note=SCN4A mutations are the cause of an autosomal
CC       recessive neuromuscular disorder characterized by severe fetal
CC       hypokinesia, neonatal hypotonia and congenital myopathy of
CC       variable severity. The most severe clinical features include
CC       reduced or absent fetal movements, in-utero upper and lower limb
CC       contractures, talipes and hydrops, and intrauterine or early
CC       postnatal death. Mildly affected patients present with generalized
CC       hypotonia and weakness at birth or within the first few days of
CC       life, mild-to-moderate facial muscle weakness without ptosis,
CC       significant early respiratory and feeding difficulties, and
CC       skeletal abnormalities of the spine and palate. Symptoms improve
CC       over time in patients who survive infancy, resulting in gain of
CC       muscle strength and motor skills and concomitant resolution of
CC       early respiratory and feeding difficulties. In contrast to other
CC       SCN4A-related channelopathies, affected individuals manifest in-
CC       utero or neonatal onset of permanent muscle weakness, rather than
CC       later-onset episodic muscle weakness.
CC       {ECO:0000269|PubMed:26700687}.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.4/SCN4A subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=SCN4A entry;
CC       URL="https://en.wikipedia.org/wiki/SCN4A";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M81758; AAA60554.1; -; mRNA.
DR   EMBL; L04236; AAB59624.1; -; Genomic_DNA.
DR   EMBL; L04216; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04217; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04218; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04219; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04220; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04221; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04222; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04223; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04224; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04225; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04226; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04227; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04228; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04229; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04230; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04231; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04232; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04233; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04234; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; L04235; AAB59624.1; JOINED; Genomic_DNA.
DR   EMBL; AY212253; AAO83647.1; -; mRNA.
DR   EMBL; L01983; AAA75557.1; ALT_SEQ; Genomic_DNA.
DR   EMBL; L01962; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01963; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01964; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01965; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01966; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01967; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01968; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01969; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01970; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01971; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01972; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01973; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01974; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01975; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01976; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01977; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01978; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01979; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01980; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01981; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; L01982; AAA75557.1; JOINED; Genomic_DNA.
DR   EMBL; AC127029; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; S82622; AAB21450.2; -; Genomic_DNA.
DR   CCDS; CCDS45761.1; -.
DR   PIR; I51964; I51964.
DR   PIR; I54323; I54323.
DR   PIR; I64893; I64893.
DR   PIR; JS0648; JS0648.
DR   RefSeq; NP_000325.4; NM_000334.4.
DR   UniGene; Hs.46038; -.
DR   ProteinModelPortal; P35499; -.
DR   BioGrid; 112234; 4.
DR   STRING; 9606.ENSP00000396320; -.
DR   BindingDB; P35499; -.
DR   ChEMBL; CHEMBL2072; -.
DR   DrugBank; DB00586; Diclofenac.
DR   DrugBank; DB01195; Flecainide.
DR   DrugBank; DB00818; Propofol.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 581; -.
DR   TCDB; 1.A.1.10.4; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; P35499; -.
DR   PhosphoSitePlus; P35499; -.
DR   BioMuta; SCN4A; -.
DR   DMDM; 292495096; -.
DR   PaxDb; P35499; -.
DR   PeptideAtlas; P35499; -.
DR   PRIDE; P35499; -.
DR   DNASU; 6329; -.
DR   Ensembl; ENST00000435607; ENSP00000396320; ENSG00000007314.
DR   GeneID; 6329; -.
DR   KEGG; hsa:6329; -.
DR   UCSC; uc002jds.1; human.
DR   CTD; 6329; -.
DR   DisGeNET; 6329; -.
DR   GeneCards; SCN4A; -.
DR   GeneReviews; SCN4A; -.
DR   H-InvDB; HIX0039131; -.
DR   HGNC; HGNC:10591; SCN4A.
DR   HPA; HPA053992; -.
DR   MalaCards; SCN4A; -.
DR   MIM; 168300; phenotype.
DR   MIM; 170500; phenotype.
DR   MIM; 603967; gene.
DR   MIM; 608390; phenotype.
DR   MIM; 613345; phenotype.
DR   MIM; 614198; phenotype.
DR   neXtProt; NX_P35499; -.
DR   OpenTargets; ENSG00000007314; -.
DR   Orphanet; 99736; Acetazolamide-responsive myotonia.
DR   Orphanet; 682; Hyperkalemic periodic paralysis.
DR   Orphanet; 681; Hypokalemic periodic paralysis.
DR   Orphanet; 99734; Myotonia fluctuans.
DR   Orphanet; 99735; Myotonia permanens.
DR   Orphanet; 684; Paramyotonia congenita of Von Eulenburg.
DR   Orphanet; 98913; Postsynaptic congenital myasthenic syndromes.
DR   PharmGKB; PA35006; -.
DR   eggNOG; ENOG410INF8; Eukaryota.
DR   eggNOG; COG1226; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOGENOM; HOG000231755; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; P35499; -.
DR   KO; K04837; -.
DR   OrthoDB; EOG090301DH; -.
DR   PhylomeDB; P35499; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   ChiTaRS; SCN4A; human.
DR   GeneWiki; Nav1.4; -.
DR   GenomeRNAi; 6329; -.
DR   PRO; PR:P35499; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000007314; -.
DR   CleanEx; HS_SCN4A; -.
DR   ExpressionAtlas; P35499; baseline and differential.
DR   Genevisible; P35499; HS.
DR   GO; GO:0005887; C:integral component of plasma membrane; TAS:ProtInc.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; TAS:ProtInc.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0006936; P:muscle contraction; TAS:ProtInc.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0006814; P:sodium ion transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR008052; Na_channel_a4su_mammal.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PRINTS; PR01665; NACHANNEL4.
DR   PROSITE; PS50096; IQ; 1.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Congenital myasthenic syndrome;
KW   Disease mutation; Disulfide bond; Glycoprotein; Ion channel;
KW   Ion transport; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Sodium; Sodium channel; Sodium transport;
KW   Transmembrane; Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN         1   1836       Sodium channel protein type 4 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048495.
FT   TOPO_DOM      1    128       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    129    150       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    151    158       Extracellular. {ECO:0000255}.
FT   TRANSMEM    159    178       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    179    190       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    191    210       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    211    216       Extracellular. {ECO:0000255}.
FT   TRANSMEM    217    236       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000255}.
FT   TOPO_DOM    237    252       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    253    266       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    267    423       Extracellular. {ECO:0000255}.
FT   TRANSMEM    424    449       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    450    573       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    574    597       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    598    608       Extracellular. {ECO:0000255}.
FT   TRANSMEM    609    632       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    633    640       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    641    660       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    661    666       Extracellular. {ECO:0000255}.
FT   TRANSMEM    667    686       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000255}.
FT   TOPO_DOM    687    701       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    702    724       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    725    776       Extracellular. {ECO:0000255}.
FT   TRANSMEM    777    802       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    803   1026       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1027   1049       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1050   1063       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1064   1089       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1090   1095       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1096   1116       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1117   1121       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1122   1143       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000255}.
FT   TOPO_DOM   1144   1162       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1163   1184       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1185   1268       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1269   1295       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1296   1348       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1349   1372       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1373   1383       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1384   1407       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1408   1413       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1414   1437       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1438   1446       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1447   1469       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000255}.
FT   TOPO_DOM   1470   1484       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1485   1507       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1508   1573       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1574   1598       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1599   1836       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      113    454       I. {ECO:0000305}.
FT   REPEAT      560    832       II. {ECO:0000305}.
FT   REPEAT     1013   1326       III. {ECO:0000305}.
FT   REPEAT     1335   1633       IV. {ECO:0000305}.
FT   DOMAIN     1727   1756       IQ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116}.
FT   MOD_RES    1328   1328       Phosphoserine; by PKC. {ECO:0000250}.
FT   CARBOHYD    214    214       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    288    288       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    291    291       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    297    297       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    303    303       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    315    315       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    321    321       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    333    333       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    362    362       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1191   1191       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1205   1205       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    729    729       Interchain; with SCN2B or SCN4B.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   DISULFID    729    729       Interchain; with the conotoxin GVIIJ
FT                                (when the channel is not linked to SCN2B
FT                                or SCN4B; the bond to SCN2B or SCN4B
FT                                protects the channel from the inhibition
FT                                by toxin).
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   VARIANT      72     72       P -> L (found in a patient with severe
FT                                dystrophia myotonica 2 (DM2) carrying a
FT                                pathogenic CCTG repeat expansion in CNBP;
FT                                unknown pathological significance; may
FT                                act as a disease modifier; changes the
FT                                voltage-gated sodium channel activity;
FT                                increases membrane hyperexcitability;
FT                                decreases channel fast inactivation).
FT                                {ECO:0000269|PubMed:25660391}.
FT                                /FTId=VAR_074598.
FT   VARIANT     104    104       R -> H (probable disease-associated
FT                                mutation found in patients with severe
FT                                fetal hypokinesia or congenital myopathy;
FT                                complete loss of sodium channel
FT                                function). {ECO:0000269|PubMed:26700687}.
FT                                /FTId=VAR_075430.
FT   VARIANT     135    135       M -> V.
FT                                /FTId=VAR_001560.
FT   VARIANT     141    141       I -> V (in MYOSCN4A; causes a
FT                                hyperpolarizing shift of the activation
FT                                curve; enhances channel slow
FT                                inactivation; dbSNP:rs121908561).
FT                                {ECO:0000269|PubMed:19015483}.
FT                                /FTId=VAR_054934.
FT   VARIANT     203    203       M -> K (probable disease-associated
FT                                mutation found in patients with severe
FT                                fetal hypokinesia or congenital myopathy;
FT                                impaired sodium channel function).
FT                                {ECO:0000269|PubMed:26700687}.
FT                                /FTId=VAR_075431.
FT   VARIANT     222    222       R -> W (in HOKPP2; dbSNP:rs527236148).
FT                                {ECO:0000269|PubMed:19118277}.
FT                                /FTId=VAR_054935.
FT   VARIANT     225    225       R -> W (in MYOSCN4A; also found in
FT                                patients with severe fetal hypokinesia or
FT                                congenital myopathy; impaired sodium
FT                                channel function; dbSNP:rs764718003).
FT                                {ECO:0000269|PubMed:20076800,
FT                                ECO:0000269|PubMed:26700687}.
FT                                /FTId=VAR_065230.
FT   VARIANT     246    246       S -> L (in dbSNP:rs80338951).
FT                                {ECO:0000269|PubMed:12766226}.
FT                                /FTId=VAR_017785.
FT   VARIANT     270    270       Q -> K (in PMC).
FT                                {ECO:0000269|PubMed:16786525,
FT                                ECO:0000269|PubMed:18166706}.
FT                                /FTId=VAR_054936.
FT   VARIANT     382    382       P -> T (probable disease-associated
FT                                mutation found in patients with severe
FT                                fetal hypokinesia or congenital myopathy;
FT                                complete loss of sodium channel
FT                                function). {ECO:0000269|PubMed:26700687}.
FT                                /FTId=VAR_075432.
FT   VARIANT     445    445       V -> M (in MYOSCN4A; dbSNP:rs121908552).
FT                                {ECO:0000269|PubMed:10218481,
FT                                ECO:0000269|PubMed:18337100,
FT                                ECO:0000269|PubMed:9392583}.
FT                                /FTId=VAR_017786.
FT   VARIANT     452    452       E -> K (in MYOSCN4A; variable phenotype
FT                                ranging from mild to severe myotonia;
FT                                dbSNP:rs372631097).
FT                                {ECO:0000269|PubMed:18337100}.
FT                                /FTId=VAR_054937.
FT   VARIANT     524    524       S -> G (in dbSNP:rs6504191).
FT                                {ECO:0000269|PubMed:12766226,
FT                                ECO:0000269|PubMed:1315496,
FT                                ECO:0000269|PubMed:1339144}.
FT                                /FTId=VAR_001561.
FT   VARIANT     559    559       N -> D (in dbSNP:rs1047705).
FT                                {ECO:0000269|PubMed:12766226,
FT                                ECO:0000269|PubMed:1315496}.
FT                                /FTId=VAR_017787.
FT   VARIANT     669    669       R -> H (in HOKPP2; dbSNP:rs80338784).
FT                                {ECO:0000269|PubMed:10599760,
FT                                ECO:0000269|PubMed:18162704}.
FT                                /FTId=VAR_017788.
FT   VARIANT     671    671       F -> S (in MYOSCN4A).
FT                                {ECO:0000269|PubMed:18337100}.
FT                                /FTId=VAR_054938.
FT   VARIANT     672    672       R -> C (in HOKPP2; dbSNP:rs80338785).
FT                                {ECO:0000269|PubMed:18162704,
FT                                ECO:0000269|PubMed:19118277}.
FT                                /FTId=VAR_054939.
FT   VARIANT     672    672       R -> G (in HOKPP2; dbSNP:rs80338785).
FT                                {ECO:0000269|PubMed:10944223,
FT                                ECO:0000269|PubMed:18162704,
FT                                ECO:0000269|PubMed:19118277}.
FT                                /FTId=VAR_017789.
FT   VARIANT     672    672       R -> H (in HOKPP2; dbSNP:rs80338788).
FT                                {ECO:0000269|PubMed:10944223,
FT                                ECO:0000269|PubMed:19118277,
FT                                ECO:0000269|PubMed:21043388}.
FT                                /FTId=VAR_017790.
FT   VARIANT     672    672       R -> S (in HOKPP2; dbSNP:rs80338785).
FT                                {ECO:0000269|PubMed:11558801,
FT                                ECO:0000269|PubMed:11591859,
FT                                ECO:0000269|PubMed:19118277}.
FT                                /FTId=VAR_017791.
FT   VARIANT     675    675       R -> G (in NKPP; dbSNP:rs121908556).
FT                                {ECO:0000269|PubMed:15596759}.
FT                                /FTId=VAR_037104.
FT   VARIANT     675    675       R -> Q (in NKPP; dbSNP:rs121908557).
FT                                {ECO:0000269|PubMed:15596759,
FT                                ECO:0000269|PubMed:18046642}.
FT                                /FTId=VAR_037105.
FT   VARIANT     675    675       R -> W (in NKPP; dbSNP:rs121908556).
FT                                {ECO:0000269|PubMed:15596759}.
FT                                /FTId=VAR_037106.
FT   VARIANT     693    693       I -> T (in PMC; dbSNP:rs80338956).
FT                                {ECO:0000269|PubMed:20076800}.
FT                                /FTId=VAR_065231.
FT   VARIANT     704    704       T -> M (in HYPP and PMC;
FT                                dbSNP:rs80338957).
FT                                {ECO:0000269|PubMed:1659948,
FT                                ECO:0000269|PubMed:18166706,
FT                                ECO:0000269|PubMed:19077043}.
FT                                /FTId=VAR_001562.
FT   VARIANT     715    715       A -> T (in MYOSCN4A; dbSNP:rs749400108).
FT                                {ECO:0000269|PubMed:16786525}.
FT                                /FTId=VAR_054940.
FT   VARIANT     781    781       V -> I (polymorphism; voltage-gated
FT                                sodium channel activity is not affected
FT                                and channel activation as well as fast
FT                                and slow inactivation curves are normal;
FT                                dbSNP:rs62070884).
FT                                {ECO:0000269|PubMed:18046642,
FT                                ECO:0000269|PubMed:27535533,
FT                                ECO:0000269|PubMed:7695243,
FT                                ECO:0000269|PubMed:9266738}.
FT                                /FTId=VAR_054941.
FT   VARIANT     804    804       S -> F (in PMC; dbSNP:rs121908546).
FT                                {ECO:0000269|PubMed:1338909}.
FT                                /FTId=VAR_001563.
FT   VARIANT     804    804       S -> N (in MYOSCN4A).
FT                                {ECO:0000269|PubMed:16786525}.
FT                                /FTId=VAR_054942.
FT   VARIANT     861    861       A -> D.
FT                                /FTId=VAR_001564.
FT   VARIANT    1069   1069       D -> N (probable disease-associated
FT                                mutation found in patients with severe
FT                                fetal hypokinesia or congenital myopathy;
FT                                impaired sodium channel function;
FT                                dbSNP:rs373150395).
FT                                {ECO:0000269|PubMed:26700687}.
FT                                /FTId=VAR_075433.
FT   VARIANT    1129   1129       R -> Q (in NKPP and HOKPP2; detected in a
FT                                family where three affected members
FT                                manifested hypokalemic periodic paralysis
FT                                whereas five other patients had
FT                                normokalemic periodic paralysis;
FT                                dbSNP:rs527236149).
FT                                {ECO:0000269|PubMed:20522878}.
FT                                /FTId=VAR_064987.
FT   VARIANT    1132   1132       R -> Q (in HOKPP2; changes the voltage-
FT                                gated sodium channel activity; increases
FT                                membrane hypoexcitability; increases
FT                                channel activation and both fast and slow
FT                                channel inactivation; dbSNP:rs80338789).
FT                                {ECO:0000269|PubMed:16890191,
FT                                ECO:0000269|PubMed:19118277}.
FT                                /FTId=VAR_054943.
FT   VARIANT    1135   1135       R -> C (in HOKPP2; also found in patients
FT                                with severe fetal hypokinesia or
FT                                congenital myopathy; increased
FT                                depolarization tendency at normal and
FT                                reduced extracellular potassium and
FT                                reduced amplitude and rise time of action
FT                                potentials).
FT                                {ECO:0000269|PubMed:24549961,
FT                                ECO:0000269|PubMed:26700687}.
FT                                /FTId=VAR_075434.
FT   VARIANT    1135   1135       R -> H (in HOKPP2; increased
FT                                depolarization tendency at normal and
FT                                reduced extracellular potassium and
FT                                reduced amplitude and rise time of action
FT                                potentials; dbSNP:rs527236150).
FT                                {ECO:0000269|PubMed:19118277,
FT                                ECO:0000269|PubMed:24549961}.
FT                                /FTId=VAR_054944.
FT   VARIANT    1152   1152       A -> D (in PMC).
FT                                {ECO:0000269|PubMed:15790667}.
FT                                /FTId=VAR_022341.
FT   VARIANT    1156   1156       A -> T (in PMC, MYOSCN4A and HYPP;
FT                                dbSNP:rs80338958).
FT                                {ECO:0000269|PubMed:1338909,
FT                                ECO:0000269|PubMed:20076800}.
FT                                /FTId=VAR_001565.
FT   VARIANT    1158   1158       P -> S (in HOKPP2; atypical phenotype
FT                                with heat-induced myotonia and cold-
FT                                induced paralysis with hypokalemia;
FT                                changes the voltage-gated sodium channel
FT                                activity; increases channel activation
FT                                and slow inactivation at low temperature;
FT                                dbSNP:rs121908555).
FT                                {ECO:0000269|PubMed:10851391,
FT                                ECO:0000269|PubMed:17898326}.
FT                                /FTId=VAR_017792.
FT   VARIANT    1160   1160       I -> V (in MYOSCN4A; acetazolamide-
FT                                responsive myotonia; dbSNP:rs121908549).
FT                                {ECO:0000269|PubMed:8058156}.
FT                                /FTId=VAR_017793.
FT   VARIANT    1209   1209       C -> F (probable disease-associated
FT                                mutation found in patients with severe
FT                                fetal hypokinesia or congenital myopathy;
FT                                complete loss of sodium channel
FT                                function). {ECO:0000269|PubMed:26700687}.
FT                                /FTId=VAR_075435.
FT   VARIANT    1293   1293       V -> I (in PMC; without cold paralysis;
FT                                dbSNP:rs121908551).
FT                                {ECO:0000269|PubMed:8580427}.
FT                                /FTId=VAR_001566.
FT   VARIANT    1297   1297       N -> K (in MYOSCN4A; unusually severe and
FT                                lethal phenotype with neonatal onset;
FT                                dbSNP:rs121908560).
FT                                {ECO:0000269|PubMed:18203179}.
FT                                /FTId=VAR_054945.
FT   VARIANT    1306   1306       G -> A (in PMC; dbSNP:rs80338792).
FT                                {ECO:0000269|PubMed:18166706,
FT                                ECO:0000269|PubMed:8308722}.
FT                                /FTId=VAR_001567.
FT   VARIANT    1306   1306       G -> E (in MYOSCN4A and PMC; severe;
FT                                dbSNP:rs80338792).
FT                                {ECO:0000269|PubMed:16832098,
FT                                ECO:0000269|PubMed:18166706,
FT                                ECO:0000269|PubMed:20076800,
FT                                ECO:0000269|PubMed:8308722}.
FT                                /FTId=VAR_001568.
FT   VARIANT    1306   1306       G -> V (in MYOSCN4A and PMC;
FT                                dbSNP:rs80338792).
FT                                {ECO:0000269|PubMed:1310898,
FT                                ECO:0000269|PubMed:18337100,
FT                                ECO:0000269|PubMed:8308722}.
FT                                /FTId=VAR_001569.
FT   VARIANT    1310   1310       I -> N (in MYOSCN4A).
FT                                {ECO:0000269|PubMed:16786525}.
FT                                /FTId=VAR_054946.
FT   VARIANT    1313   1313       T -> M (in PMC; changes the voltage-gated
FT                                sodium channel activity; increases
FT                                membrane hyperexcitability at low
FT                                temperature; decreases channel
FT                                activation, deactivation, fast
FT                                inactivation and recovery delay from fast
FT                                inactivation; dbSNP:rs121908547).
FT                                {ECO:0000269|PubMed:1310898,
FT                                ECO:0000269|PubMed:15318338,
FT                                ECO:0000269|PubMed:18166706}.
FT                                /FTId=VAR_001570.
FT   VARIANT    1376   1376       N -> D (in dbSNP:rs2058194).
FT                                {ECO:0000269|PubMed:1315496}.
FT                                /FTId=VAR_017794.
FT   VARIANT    1433   1433       L -> R (in PMC and HYPP;
FT                                dbSNP:rs121908550).
FT                                {ECO:0000269|PubMed:8388676}.
FT                                /FTId=VAR_001571.
FT   VARIANT    1436   1436       L -> P (in PMC).
FT                                {ECO:0000269|PubMed:18166706}.
FT                                /FTId=VAR_054947.
FT   VARIANT    1442   1442       V -> E (in CMS16; dbSNP:rs121908553).
FT                                {ECO:0000269|PubMed:12766226}.
FT                                /FTId=VAR_017795.
FT   VARIANT    1448   1448       R -> C (in PMC; changes the voltage-gated
FT                                sodium channel activity; increases
FT                                membrane hyperexcitability at low
FT                                temperature; decreases channel
FT                                activation, deactivation, fast
FT                                inactivation and recovery delay from fast
FT                                inactivation; dbSNP:rs121908544).
FT                                {ECO:0000269|PubMed:1316765,
FT                                ECO:0000269|PubMed:15318338,
FT                                ECO:0000269|PubMed:18166706}.
FT                                /FTId=VAR_001572.
FT   VARIANT    1448   1448       R -> H (in PMC; dbSNP:rs121908545).
FT                                {ECO:0000269|PubMed:1316765,
FT                                ECO:0000269|PubMed:18166706}.
FT                                /FTId=VAR_001573.
FT   VARIANT    1448   1448       R -> L (in PMC).
FT                                {ECO:0000269|PubMed:18166706}.
FT                                /FTId=VAR_054948.
FT   VARIANT    1454   1454       R -> W (in CMS16; leads to
FT                                hyperpolarization of the steady-state
FT                                fast inactivation, slow recovery from
FT                                inactivation and reduces the channel
FT                                ability to activate in response to
FT                                repetitive stimulating pulses).
FT                                {ECO:0000269|PubMed:26659129}.
FT                                /FTId=VAR_075436.
FT   VARIANT    1456   1456       G -> E (in PMC; dbSNP:rs121908554).
FT                                {ECO:0000269|PubMed:10369308,
FT                                ECO:0000269|PubMed:10727489,
FT                                ECO:0000269|PubMed:18166706}.
FT                                /FTId=VAR_037107.
FT   VARIANT    1457   1457       R -> H (in CMS16; enhanced fast
FT                                inactivation and slowed recovery from
FT                                fast inactivation; dbSNP:rs863225046).
FT                                {ECO:0000269|PubMed:25707578}.
FT                                /FTId=VAR_075437.
FT   VARIANT    1473   1473       F -> S (in PMC; accelerates deactivation
FT                                from the inactivated state and enhances
FT                                the remobilization of gating charge).
FT                                {ECO:0000269|PubMed:18166706,
FT                                ECO:0000269|PubMed:18690054}.
FT                                /FTId=VAR_054949.
FT   VARIANT    1476   1476       M -> I (in MYOSCN4A; highly variable
FT                                severity; dbSNP:rs121908559).
FT                                {ECO:0000269|PubMed:17998485,
FT                                ECO:0000269|PubMed:18337100}.
FT                                /FTId=VAR_054950.
FT   VARIANT    1481   1481       A -> D (in MYOSCN4A; fluctuating cold-
FT                                induced and exercise-induced stiffness).
FT                                {ECO:0000269|PubMed:17212350}.
FT                                /FTId=VAR_054951.
FT   VARIANT    1589   1589       V -> M (in PMC; dbSNP:rs121908548).
FT                                {ECO:0000269|PubMed:18166706,
FT                                ECO:0000269|PubMed:8242056}.
FT                                /FTId=VAR_001574.
FT   VARIANT    1592   1592       M -> V (in HYPP and NKPP;
FT                                dbSNP:rs80338962).
FT                                {ECO:0000269|PubMed:1659668,
FT                                ECO:0000269|PubMed:18046642}.
FT                                /FTId=VAR_001575.
FT   VARIANT    1633   1633       Q -> E (in MYOSCN4A; changes the voltage-
FT                                gated sodium channel activity; increases
FT                                membrane hyperexcitability; decreases
FT                                channel fast inactivation).
FT                                {ECO:0000269|PubMed:19347921}.
FT                                /FTId=VAR_074581.
FT   VARIANT    1705   1705       F -> I (in PMC; increases the extent of
FT                                charge immobilization in response to
FT                                strong depolarization).
FT                                {ECO:0000269|PubMed:18690054}.
FT                                /FTId=VAR_054952.
FT   CONFLICT     10     11       VP -> AR (in Ref. 1; AAA60554).
FT                                {ECO:0000305}.
FT   CONFLICT    371    371       E -> K (in Ref. 1; AAA60554).
FT                                {ECO:0000305}.
FT   CONFLICT    371    371       E -> Q (in Ref. 1; AAB59624).
FT                                {ECO:0000305}.
FT   CONFLICT    870    870       A -> G (in Ref. 1; AAB59624).
FT                                {ECO:0000305}.
FT   CONFLICT   1151   1152       NA -> KP (in Ref. 1; AAB59624).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1836 AA;  208061 MW;  FA9A6B81B7C2D50F CRC64;
     MARPSLCTLV PLGPECLRPF TRESLAAIEQ RAVEEEARLQ RNKQMEIEEP ERKPRSDLEA
     GKNLPMIYGD PPPEVIGIPL EDLDPYYSNK KTFIVLNKGK AIFRFSATPA LYLLSPFSVV
     RRGAIKVLIH ALFSMFIMIT ILTNCVFMTM SDPPPWSKNV EYTFTGIYTF ESLIKILARG
     FCVDDFTFLR DPWNWLDFSV IMMAYLTEFV DLGNISALRT FRVLRALKTI TVIPGLKTIV
     GALIQSVKKL SDVMILTVFC LSVFALVGLQ LFMGNLRQKC VRWPPPFNDT NTTWYSNDTW
     YGNDTWYGNE MWYGNDSWYA NDTWNSHASW ATNDTFDWDA YISDEGNFYF LEGSNDALLC
     GNSSDAGHCP EGYECIKTGR NPNYGYTSYD TFSWAFLALF RLMTQDYWEN LFQLTLRAAG
     KTYMIFFVVI IFLGSFYLIN LILAVVAMAY AEQNEATLAE DKEKEEEFQQ MLEKFKKHQE
     ELEKAKAAQA LEGGEADGDP AHGKDCNGSL DTSQGEKGAP RQSSSGDSGI SDAMEELEEA
     HQKCPPWWYK CAHKVLIWNC CAPWLKFKNI IHLIVMDPFV DLGITICIVL NTLFMAMEHY
     PMTEHFDNVL TVGNLVFTGI FTAEMVLKLI AMDPYEYFQQ GWNIFDSIIV TLSLVELGLA
     NVQGLSVLRS FRLLRVFKLA KSWPTLNMLI KIIGNSVGAL GNLTLVLAII VFIFAVVGMQ
     LFGKSYKECV CKIALDCNLP RWHMHDFFHS FLIVFRILCG EWIETMWDCM EVAGQAMCLT
     VFLMVMVIGN LVVLNLFLAL LLSSFSADSL AASDEDGEMN NLQIAIGRIK LGIGFAKAFL
     LGLLHGKILS PKDIMLSLGE ADGAGEAGEA GETAPEDEKK EPPEEDLKKD NHILNHMGLA
     DGPPSSLELD HLNFINNPYL TIQVPIASEE SDLEMPTEEE TDTFSEPEDS KKPPQPLYDG
     NSSVCSTADY KPPEEDPEEQ AEENPEGEQP EECFTEACVQ RWPCLYVDIS QGRGKKWWTL
     RRACFKIVEH NWFETFIVFM ILLSSGALAF EDIYIEQRRV IRTILEYADK VFTYIFIMEM
     LLKWVAYGFK VYFTNAWCWL DFLIVDVSII SLVANWLGYS ELGPIKSLRT LRALRPLRAL
     SRFEGMRVVV NALLGAIPSI MNVLLVCLIF WLIFSIMGVN LFAGKFYYCI NTTTSERFDI
     SEVNNKSECE SLMHTGQVRW LNVKVNYDNV GLGYLSLLQV ATFKGWMDIM YAAVDSREKE
     EQPQYEVNLY MYLYFVIFII FGSFFTLNLF IGVIIDNFNQ QKKKLGGKDI FMTEEQKKYY
     NAMKKLGSKK PQKPIPRPQN KIQGMVYDLV TKQAFDITIM ILICLNMVTM MVETDNQSQL
     KVDILYNINM IFIIIFTGEC VLKMLALRQY YFTVGWNIFD FVVVILSIVG LALSDLIQKY
     FVSPTLFRVI RLARIGRVLR LIRGAKGIRT LLFALMMSLP ALFNIGLLLF LVMFIYSIFG
     MSNFAYVKKE SGIDDMFNFE TFGNSIICLF EITTSAGWDG LLNPILNSGP PDCDPNLENP
     GTSVKGDCGN PSIGICFFCS YIIISFLIVV NMYIAIILEN FNVATEESSE PLGEDDFEMF
     YETWEKFDPD ATQFIAYSRL SDFVDTLQEP LRIAKPNKIK LITLDLPMVP GDKIHCLDIL
     FALTKEVLGD SGEMDALKQT MEEKFMAANP SKVSYEPITT TLKRKHEEVC AIKIQRAYRR
     HLLQRSMKQA SYMYRHSHDG SGDDAPEKEG LLANTMSKMY GHENGNSSSP SPEEKGEAGD
     AGPTMGLMPI SPSDTAWPPA PPPGQTVRPG VKESLV
//
ID   SCN5A_HUMAN             Reviewed;        2016 AA.
AC   Q14524; A5H1P8; A6N922; A6N923; B2RTU0; E7ET19; E9PEF3; E9PEK2;
AC   E9PFW7; Q59H93; Q75RX9; Q75RY0; Q86UR3; Q8IZC9; Q96J69;
DT   15-DEC-1998, integrated into UniProtKB/Swiss-Prot.
DT   25-NOV-2008, sequence version 2.
DT   15-FEB-2017, entry version 188.
DE   RecName: Full=Sodium channel protein type 5 subunit alpha;
DE   AltName: Full=HH1;
DE   AltName: Full=Sodium channel protein cardiac muscle subunit alpha;
DE   AltName: Full=Sodium channel protein type V subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.5;
GN   Name=SCN5A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, SUBCELLULAR
RP   LOCATION, AND VARIANTS ARG-552 AND GLN-1027.
RC   TISSUE=Heart;
RX   PubMed=1309946; DOI=10.1073/pnas.89.2.554;
RA   Gellens M.E., George A.L. Jr., Chen L.Q., Chahine M., Horn R.,
RA   Barchi R.L., Kallen R.G.;
RT   "Primary structure and functional expression of the human cardiac
RT   tetrodotoxin-insensitive voltage-dependent sodium channel.";
RL   Proc. Natl. Acad. Sci. U.S.A. 89:554-558(1992).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), TISSUE SPECIFICITY, AND
RP   VARIANT ARG-552.
RC   TISSUE=Jejunal smooth muscle;
RX   PubMed=12358675; DOI=10.1046/j.1365-2982.2002.00348.x;
RA   Ou Y., Gibbons S.J., Miller S.M., Strege P.R., Rich A., Distad M.A.,
RA   Ackerman M.J., Rae J.L., Szurszewski J.H., Farrugia G.;
RT   "SCN5A is expressed in human jejunal circular smooth muscle cells.";
RL   Neurogastroenterol. Motil. 14:477-486(2002).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), AND VARIANTS ARG-558 AND
RP   TYR-1103.
RX   PubMed=14500339; DOI=10.1161/01.RES.0000096652.14509.96;
RA   Makielski J.C., Ye B., Valdivia C.R., Pagel M.D., Pu J., Tester D.J.,
RA   Ackerman M.J.;
RT   "A ubiquitous splice variant and a common polymorphism affect
RT   heterologous expression of recombinant human SCN5A heart sodium
RT   channels.";
RL   Circ. Res. 93:821-828(2003).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT ARG-558, AND
RP   CHARACTERIZATION OF VARIANT LQT3 LEU-1766.
RX   PubMed=12454206; DOI=10.1152/physiolgenomics.00117.2002;
RA   Ye B., Valdivia C.R., Ackerman M.J., Makielski J.C.;
RT   "A common human SCN5A polymorphism modifies expression of an
RT   arrhythmia causing mutation.";
RL   Physiol. Genomics 12:187-193(2003).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 5), AND VARIANT THR-1498.
RX   PubMed=16115203; DOI=10.1111/j.1460-9568.2005.04280.x;
RA   Ou S.-W., Kameyama A., Hao L.-Y., Horiuchi M., Minobe E., Wang W.-Y.,
RA   Makita N., Kameyama M.;
RT   "Tetrodotoxin-resistant Na+ channels in human neuroblastoma cells are
RT   encoded by new variants of Nav1.5/SCN5A.";
RL   Eur. J. Neurosci. 22:793-801(2005).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 4 AND 6), AND VARIANTS LEU-336
RP   AND GLN-1027.
RA   Wang J., Ou S.-W., Wang Y.-J., Zong Z.-H.;
RT   "Cloning, distribution and analysis of the new exon encoding Nav1.5
RT   channel in brain tissues.";
RL   Sheng Wu Hua Xue Yu Sheng Wu Wu Li Jin Zhan 34:255-259(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (JUN-2006) to the EMBL/GenBank/DDBJ databases.
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3), AND VARIANT
RP   ARG-558.
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 422-2016 (ISOFORMS 3/6).
RC   TISSUE=Brain;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [11]
RP   INTERACTION WITH NEDD4L, UBIQUITINATION, AND MUTAGENESIS OF TYR-1977
RP   AND VAL-1980.
RX   PubMed=15217910; DOI=10.1161/01.RES.0000136816.05109.89;
RA   van Bemmelen M.X., Rougier J.-S., Gavillet B., Apotheloz F.,
RA   Daidie D., Tateyama M., Rivolta I., Thomas M.A., Kass R.S., Staub O.,
RA   Abriel H.;
RT   "Cardiac voltage-gated sodium channel Nav1.5 is regulated by Nedd4-2
RT   mediated ubiquitination.";
RL   Circ. Res. 95:284-291(2004).
RN   [12]
RP   INTERACTION WITH NEDD4; NEDD4L AND WWP2, UBIQUITINATION, AND
RP   MUTAGENESIS OF PRO-1974; PRO-1975; SER-1976; TYR-1977; ASP-1978;
RP   SER-1979 AND VAL-1980.
RX   PubMed=15548568; DOI=10.1152/ajpcell.00460.2004;
RA   Rougier J.-S., van Bemmelen M.X., Bruce M.C., Jespersen T.,
RA   Gavillet B., Apotheloz F., Cordonier S., Staub O., Rotin D.,
RA   Abriel H.;
RT   "Molecular determinants of voltage-gated sodium channel regulation by
RT   the Nedd4/Nedd4-like proteins.";
RL   Am. J. Physiol. 288:C692-C701(2005).
RN   [13]
RP   MUTAGENESIS OF GLN-1476.
RX   PubMed=16054936; DOI=10.1016/S0140-6736(05)66786-4;
RA   Dichgans M., Freilinger T., Eckstein G., Babini E.,
RA   Lorenz-Depiereux B., Biskup S., Ferrari M.D., Herzog J.,
RA   van den Maagdenberg A.M.J.M., Pusch M., Strom T.M.;
RT   "Mutation in the neuronal voltage-gated sodium channel SCN1A in
RT   familial hemiplegic migraine.";
RL   Lancet 366:371-377(2005).
RN   [14]
RP   INTERACTION WITH GPD1L, AND PHOSPHORYLATION AT SER-1503 BY PKC.
RX   PubMed=19666841; DOI=10.1152/ajpheart.00513.2009;
RA   Valdivia C.R., Ueda K., Ackerman M.J., Makielski J.C.;
RT   "GPD1L links redox state to cardiac excitability by PKC-dependent
RT   phosphorylation of the sodium channel SCN5A.";
RL   Am. J. Physiol. 297:H1446-H1452(2009).
RN   [15]
RP   ALTERNATIVE SPLICING, AND TISSUE SPECIFICITY (ISOFORM 4).
RX   PubMed=19376164; DOI=10.1016/j.neures.2009.04.003;
RA   Wang J., Ou S.-W., Wang Y.-J., Kameyama M., Kameyama A., Zong Z.-H.;
RT   "Analysis of four novel variants of Nav1.5/SCN5A cloned from the
RT   brain.";
RL   Neurosci. Res. 64:339-347(2009).
RN   [16]
RP   REVIEW ON VARIANTS.
RX   PubMed=19027780; DOI=10.1016/j.pbiomolbio.2008.10.005;
RA   Zimmer T., Surber R.;
RT   "SCN5A channelopathies - An update on mutations and mechanisms.";
RL   Prog. Biophys. Mol. Biol. 98:120-136(2008).
RN   [17]
RP   ALTERNATIVE SPLICING.
RX   PubMed=20398673; DOI=10.1016/j.yjmcc.2010.04.004;
RA   Schroeter A., Walzik S., Blechschmidt S., Haufe V., Benndorf K.,
RA   Zimmer T.;
RT   "Structure and function of splice variants of the cardiac voltage-
RT   gated sodium channel Na(v)1.5.";
RL   J. Mol. Cell. Cardiol. 49:16-24(2010).
RN   [18]
RP   INTERACTION WITH FGF13.
RX   PubMed=21817159; DOI=10.1161/CIRCRESAHA.111.247957;
RA   Wang C., Hennessey J.A., Kirkton R.D., Wang C., Graham V.,
RA   Puranam R.S., Rosenberg P.B., Bursac N., Pitt G.S.;
RT   "Fibroblast growth factor homologous factor 13 regulates Na+ channels
RT   and conduction velocity in murine hearts.";
RL   Circ. Res. 109:775-782(2011).
RN   [19]
RP   METHYLATION AT ARG-513; ARG-526 AND ARG-680.
RX   PubMed=21726068; DOI=10.1021/pr200339n;
RA   Beltran-Alvarez P., Pagans S., Brugada R.;
RT   "The cardiac sodium channel is post-translationally modified by
RT   arginine methylation.";
RL   J. Proteome Res. 10:3712-3719(2011).
RN   [20]
RP   PHOSPHORYLATION AT SER-36; THR-38; SER-457; SER-460; SER-483; SER-484;
RP   SER-497; SER-510; SER-571; SER-664 AND SER-667.
RX   PubMed=23092124; DOI=10.1021/pr300702c;
RA   Marionneau C., Lichti C.F., Lindenbaum P., Charpentier F.,
RA   Nerbonne J.M., Townsend R.R., Merot J.;
RT   "Mass spectrometry-based identification of native cardiac Nav1.5
RT   channel alpha subunit phosphorylation sites.";
RL   J. Proteome Res. 11:5994-6007(2012).
RN   [21]
RP   MUTAGENESIS OF ASP-1610.
RX   PubMed=24898004; DOI=10.1124/mol.114.092338;
RA   Xiao Y., Blumenthal K., Cummins T.R.;
RT   "Gating-pore currents demonstrate selective and specific modulation of
RT   individual sodium channel voltage-sensors by biological toxins.";
RL   Mol. Pharmacol. 86:159-167(2014).
RN   [22]
RP   STRUCTURE BY NMR OF 1773-1865, FUNCTION, SUBCELLULAR LOCATION,
RP   RESPONSE TO CALCIUM, AND MUTAGENESIS OF 1802-ASP--GLU-1804.
RX   PubMed=19074138; DOI=10.1074/jbc.M807747200;
RA   Chagot B., Potet F., Balser J.R., Chazin W.J.;
RT   "Solution NMR structure of the C-terminal EF-hand domain of human
RT   cardiac sodium channel NaV1.5.";
RL   J. Biol. Chem. 284:6436-6445(2009).
RN   [23]
RP   STRUCTURE BY NMR OF 1901-1927 IN COMPLEX WITH CALM, AND INTERACTION
RP   WITH CALM.
RX   PubMed=21167176; DOI=10.1016/j.jmb.2010.11.046;
RA   Chagot B., Chazin W.J.;
RT   "Solution NMR structure of Apo-calmodulin in complex with the IQ motif
RT   of human cardiac sodium channel NaV1.5.";
RL   J. Mol. Biol. 406:106-119(2011).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1773-1940 IN COMPLEX WITH
RP   FGF13 AND CALMODULIN.
RX   PubMed=22705208; DOI=10.1016/j.str.2012.05.001;
RA   Wang C., Chung B.C., Yan H., Lee S.Y., Pitt G.S.;
RT   "Crystal structure of the ternary complex of a NaV C-terminal domain,
RT   a fibroblast growth factor homologous factor, and calmodulin.";
RL   Structure 20:1167-1176(2012).
RN   [25]
RP   VARIANTS LQT3.
RX   PubMed=7889574; DOI=10.1016/0092-8674(95)90359-3;
RA   Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J.L.,
RA   Moss A.J., Towbin J.A., Keating M.T.;
RT   "SCN5A mutations associated with an inherited cardiac arrhythmia, long
RT   QT syndrome.";
RL   Cell 80:805-811(1995).
RN   [26]
RP   VARIANTS LQT3.
RX   PubMed=8541846; DOI=10.1093/hmg/4.9.1603;
RA   Wang Q., Shen J., Li Z., Timothy K.W., Vincent G.M., Priori S.G.,
RA   Schwartz P.J., Keating M.T.;
RT   "Cardiac sodium channel mutations in patients with long QT syndrome,
RT   an inherited cardiac arrhythmia.";
RL   Hum. Mol. Genet. 4:1603-1607(1995).
RN   [27]
RP   VARIANT LQT3 1505-LYS--GLN-1507 DEL.
RX   PubMed=7651517; DOI=10.1038/376683a0;
RA   Bennett P.B., Yazawa K., Makita N., George A.L. Jr.;
RT   "Molecular mechanism for an inherited cardiac arrhythmia.";
RL   Nature 376:683-685(1995).
RN   [28]
RP   VARIANT LQT3 GLY-1790.
RX   PubMed=9686753; DOI=10.1161/01.RES.83.2.141;
RA   An R.H., Wang X.L., Kerem B., Benhorin J., Medina A., Goldmit M.,
RA   Kass R.S.;
RT   "Novel LQT-3 mutation affects Na+ channel activity through
RT   interactions between alpha- and beta1-subunits.";
RL   Circ. Res. 83:141-146(1998).
RN   [29]
RP   VARIANT LQT3 GLN-1623.
RX   PubMed=9506831; DOI=10.1016/S0014-5793(98)00033-7;
RA   Makita N., Shirai N., Nagashima M., Matsuoka R., Yamada Y., Tohse N.,
RA   Kitabatake A.;
RT   "A de novo missense mutation of human cardiac Na(+) channel exhibiting
RT   novel molecular mechanisms of long QT syndrome.";
RL   FEBS Lett. 423:5-9(1998).
RN   [30]
RP   VARIANT LQT3 GLY-1839.
RX   PubMed=10627139;
RX   DOI=10.1002/(SICI)1098-1004(1998)12:1<72::AID-HUMU17>3.0.CO;2-Z;
RA   Benhorin J., Goldmit M., Maccluer J.W., Blangero J., Goffen R.,
RA   Leibovitch A., Rahat A., Wang Q., Medina A., Towbin J.A., Kerem B.;
RT   "Identification of a new SCN5A mutation, D1840G, associated with the
RT   long QT syndrome.";
RL   Hum. Mutat. 12:72-72(1998).
RN   [31]
RP   VARIANT LQT3 GLN-1623.
RA   Yamagishi H., Furutani M., Kamisago M., Morikawa Y., Kojima Y.,
RA   Hino Y., Furutani Y., Kimura M., Imamura S., Takao A., Momma K.,
RA   Matsuoka R.;
RT   "A De Novo missense mutation (R1623Q) of the SCN5A gene in a Japanese
RT   girl with sporadic long QT syndrome.";
RL   Hum. Mutat. 12:481-481(1998).
RN   [32]
RP   VARIANTS BRGDA1 TRP-1232 AND MET-1620.
RX   PubMed=9521325; DOI=10.1038/32675;
RA   Chen Q., Kirsch G.E., Zhang D., Brugada R., Brugada J., Brugada P.,
RA   Potenza D., Moya A., Borggrefe M., Breithardt G., Ortiz-Lopez R.,
RA   Wang Z., Antzelevitch C., O'Brien R.E., Schulze-Bahr E., Keating M.T.,
RA   Towbin J.A., Wang Q.;
RT   "Genetic basis and molecular mechanism for idiopathic ventricular
RT   fibrillation.";
RL   Nature 392:293-296(1998).
RN   [33]
RP   VARIANTS LQT3 MET-1304 AND MET-1645, AND VARIANT ASN-1500.
RX   PubMed=10508990;
RX   DOI=10.1002/(SICI)1096-8628(19991029)86:5<470::AID-AJMG13>3.0.CO;2-Y;
RA   Wattanasirichaigoon D., Vesely M.R., Duggal P., Levine J.C.,
RA   Blume E.D., Wolff G.S., Edwards S.B., Beggs A.H.;
RT   "Sodium channel abnormalities are infrequent in patients with long QT
RT   syndrome: identification of two novel SCN5A mutations.";
RL   Am. J. Med. Genet. 86:470-476(1999).
RN   [34]
RP   CHARACTERIZATION OF VARIANTS BRGDA1 TRP-1512 AND THR-1924.
RX   PubMed=10690282; DOI=10.1016/S0008-6363(99)00350-8;
RA   Rook M.B., Bezzina Alshinawi C., Groenewegen W.A., van Gelder I.C.,
RA   van Ginneken A.C.G., Jongsma H.J., Mannens M.M.A.M., Wilde A.A.M.;
RT   "Human SCN5A gene mutations alter cardiac sodium channel kinetics and
RT   are associated with the Brugada syndrome.";
RL   Cardiovasc. Res. 44:507-517(1999).
RN   [35]
RP   VARIANT LQT3 LYS-1784.
RX   PubMed=10377081; DOI=10.1161/01.CIR.99.24.3165;
RA   Wei J., Wang D.W., Alings M., Fish F., Wathen M., Roden D.M.,
RA   George A.L. Jr.;
RT   "Congenital long-QT syndrome caused by a novel mutation in a conserved
RT   acidic domain of the cardiac Na+ channel.";
RL   Circulation 99:3165-3171(1999).
RN   [36]
RP   CHARACTERIZATION OF VARIANT BRGDA1 MET-1620.
RX   PubMed=10532948; DOI=10.1161/01.RES.85.9.803;
RA   Dumaine R., Towbin J.A., Brugada P., Vatta M., Nesterenko D.V.,
RA   Nesterenko V.V., Brugada J., Brugada R., Antzelevitch C.;
RT   "Ionic mechanisms responsible for the electrocardiographic phenotype
RT   of the Brugada syndrome are temperature dependent.";
RL   Circ. Res. 85:803-809(1999).
RN   [37]
RP   CHARACTERIZATION OF VARIANT LQT3/BRGDA1 ASP-1795 INS.
RX   PubMed=10590249; DOI=10.1161/01.RES.85.12.1206;
RA   Bezzina C.R., Veldkamp M.W., van Den Berg M.P., Postma A.V.,
RA   Rook M.B., Viersma J.-W., van Langen I.M., Tan-Sindhunata G.,
RA   Bink-Boelkens M.T.E., van Der Hout A.H., Mannens M.M.A.M.,
RA   Wilde A.A.M.;
RT   "A single Na(+) channel mutation causing both long-QT and Brugada
RT   syndromes.";
RL   Circ. Res. 85:1206-1213(1999).
RN   [38]
RP   DISEASE.
RX   PubMed=10471492; DOI=10.1038/12618;
RA   Schott J.-J., Alshinawi C., Kyndt F., Probst V., Hoorntje T.M.,
RA   Hulsbeek M., Wilde A.A.M., Escande D., Mannens M.M.A.M., Le Marec H.;
RT   "Cardiac conduction defects associate with mutations in SCN5A.";
RL   Nat. Genet. 23:20-21(1999).
RN   [39]
RP   CHARACTERIZATION OF VARIANT BRGDA1 MET-1620.
RX   PubMed=10618304; DOI=10.1161/01.CIR.101.1.54;
RA   Makita N., Shirai N., Wang D.W., Sasaki K., George A.L. Jr., Kanno M.,
RA   Kitabatake A.;
RT   "Cardiac Na(+) channel dysfunction in Brugada syndrome is aggravated
RT   by beta(1)-subunit.";
RL   Circulation 101:54-60(2000).
RN   [40]
RP   VARIANTS LQT3 ASN-1114; VAL-1501; LEU-1623 AND HIS-1644, AND VARIANT
RP   ASN-1787.
RX   PubMed=10973849; DOI=10.1161/01.CIR.102.10.1178;
RA   Splawski I., Shen J., Timothy K.W., Lehmann M.H., Priori S.G.,
RA   Robinson J.L., Moss A.J., Schwartz P.J., Towbin J.A., Vincent G.M.,
RA   Keating M.T.;
RT   "Spectrum of mutations in long-QT syndrome genes. KVLQT1, HERG, SCN5A,
RT   KCNE1, and KCNE2.";
RL   Circulation 102:1178-1185(2000).
RN   [41]
RP   VARIANT VF1 LEU-1710.
RX   PubMed=10940383; DOI=10.1016/S0014-5793(00)01875-5;
RA   Akai J., Makita N., Sakurada H., Shirai N., Ueda K., Kitabatake A.,
RA   Nakazawa K., Kimura A., Hiraoka M.;
RT   "A novel SCN5A mutation associated with idiopathic ventricular
RT   fibrillation without typical ECG findings of Brugada syndrome.";
RL   FEBS Lett. 479:29-34(2000).
RN   [42]
RP   VARIANT LQT3 ASN-941.
RX   PubMed=10911008; DOI=10.1056/NEJM200007273430405;
RA   Schwartz P.J., Priori S.G., Dumaine R., Napolitano C.,
RA   Antzelevitch C., Stramba-Badiale M., Richard T.A., Berti M.R.,
RA   Bloise R.;
RT   "A molecular link between the sudden infant death syndrome and the
RT   long-QT syndrome.";
RL   N. Engl. J. Med. 343:262-267(2000).
RN   [43]
RP   VARIANT LQT3 LYS-1295, AND CHARACTERIZATION OF VARIANT LQT3 LYS-1295.
RX   PubMed=11304498; DOI=10.1161/hh0701.089668;
RA   Abriel H., Cabo C., Wehrens X.H., Rivolta I., Motoike H.K., Memmi M.,
RA   Napolitano C., Priori S.G., Kass R.S.;
RT   "Novel arrhythmogenic mechanism revealed by a long-QT syndrome
RT   mutation in the cardiac Na(+) channel.";
RL   Circ. Res. 88:740-745(2001).
RN   [44]
RP   CHARACTERIZATION OF VARIANT LQT3 CYS-1795, AND CHARACTERIZATION OF
RP   VARIANT BRGDA1 HIS-1795.
RX   PubMed=11410597; DOI=10.1074/jbc.M104471200;
RA   Rivolta I., Abriel H., Tateyama M., Liu H., Memmi M., Vardas P.,
RA   Napolitano C., Priori S.G., Kass R.S.;
RT   "Inherited Brugada and long QT-3 syndrome mutations of a single
RT   residue of the cardiac sodium channel confer distinct channel and
RT   clinical phenotypes.";
RL   J. Biol. Chem. 276:30623-30630(2001).
RN   [45]
RP   VARIANT SSS1/BRGDA1 ARG-1408.
RX   PubMed=11748104; DOI=10.1161/hc5001.100834;
RA   Kyndt F., Probst V., Potet F., Demolombe S., Chevallier J.-C.,
RA   Baro I., Moisan J.-P., Boisseau P., Schott J.-J., Escande D.,
RA   Le Marec H.;
RT   "Novel SCN5A mutation leading either to isolated cardiac conduction
RT   defect or Brugada syndrome in a large French family.";
RL   Circulation 104:3081-3086(2001).
RN   [46]
RP   CHARACTERIZATION OF VARIANTS LQT3 SER-997 AND HIS-1826.
RX   PubMed=11710892; DOI=10.1001/jama.286.18.2264;
RA   Ackerman M.J., Siu B.L., Sturner W.Q., Tester D.J., Valdivia C.R.,
RA   Makielski J.C., Towbin J.A.;
RT   "Postmortem molecular analysis of SCN5A defects in sudden infant death
RT   syndrome.";
RL   JAMA 286:2264-2269(2001).
RN   [47]
RP   CHARACTERIZATION OF VARIANT PFHB1A CYS-514.
RX   PubMed=11234013; DOI=10.1038/35059090;
RA   Tan H.L., Bink-Boelkens M.T.E., Bezzina C.R., Viswanathan P.C.,
RA   Beaufort-Krol G.C.M., van Tintelen P.J., van den Berg M.P.,
RA   Wilde A.A.M., Balser J.R.;
RT   "A sodium-channel mutation causes isolated cardiac conduction
RT   disease.";
RL   Nature 409:1043-1047(2001).
RN   [48]
RP   VARIANTS BRGDA1 LYS-161; CYS-367; LYS-369; ARG-752; LYS-1225;
RP   VAL-1319; ILE-1382; LEU-1405; ARG-1406; LYS-1479 DEL; SER-1502;
RP   TRP-1512; GLU-1743 AND THR-1924.
RX   PubMed=12106943; DOI=10.1016/S0735-1097(02)01962-9;
RA   Smits J.P.P., Eckardt L., Probst V., Bezzina C.R., Schott J.-J.,
RA   Remme C.A., Haverkamp W., Breithardt G., Escande D., Schulze-Bahr E.,
RA   LeMarec H., Wilde A.A.M.;
RT   "Genotype-phenotype relationship in Brugada syndrome:
RT   electrocardiographic features differentiate SCN5A-related patients
RT   from non-SCN5A-related patients.";
RL   J. Am. Coll. Cardiol. 40:350-356(2002).
RN   [49]
RP   CHARACTERIZATION OF VARIANTS PFHB1A SER-298 AND ASN-1595.
RX   PubMed=11804990; DOI=10.1161/hc0302.102592;
RA   Wang D.W., Viswanathan P.C., Balser J.R., George A.L. Jr.,
RA   Benson D.W.;
RT   "Clinical, genetic and biophysical characterisation of SCN5A mutations
RT   associated with atrioventricular conduction block.";
RL   Circulation 105:341-346(2002).
RN   [50]
RP   MODELING OF VARIANT LQT3/BRGDA1 ASP-1795 INS.
RX   PubMed=11889015; DOI=10.1161/hc1002.105183;
RA   Clancy C.E., Rudy Y.;
RT   "Na(+) channel mutation that causes both Brugada and long-QT syndrome
RT   phenotypes: a simulation study of mechanism.";
RL   Circulation 105:1208-1213(2002).
RN   [51]
RP   VARIANTS BRGDA1 HIS-27; VAL-226; VAL-230; HIS-282; MET-294; SER-319;
RP   PHE-393 DEL; GLN-567; PRO-681; GLU-735; LEU-851; ILE-892; SER-896;
RP   LEU-910; CYS-965; LYS-1053; ASN-1236; GLN-1240; SER-1293; LYS-1500
RP   DEL; ARG-1740; LYS-1784; HIS-1795 AND LEU-1951.
RX   PubMed=11901046; DOI=10.1161/hc1102.105288;
RA   Priori S.G., Napolitano C., Gasparini M., Pappone C., Della Bella P.,
RA   Giordano U., Bloise R., Giustetto C., De Nardis R., Grillo M.,
RA   Ronchetti E., Faggiano G., Nastoli J.;
RT   "Natural history of Brugada syndrome: insights for risk stratification
RT   and management.";
RL   Circulation 105:1342-1347(2002).
RN   [52]
RP   VARIANTS LQT3 GLU-615; PHE-619 AND LEU-1250, AND VARIANTS CYS-34 AND
RP   ARG-558.
RX   PubMed=11997281; DOI=10.1161/01.CIR.0000014448.19052.4C;
RA   Yang P., Kanki H., Drolet B., Yang T., Wei J., Viswanathan P.C.,
RA   Hohnloser S.H., Shimizu W., Schwartz P.J., Stanton M., Murray K.T.,
RA   Norris K., George A.L. Jr., Roden D.M.;
RT   "Allelic variants in long-QT disease genes in patients with drug-
RT   associated torsades de pointes.";
RL   Circulation 105:1943-1948(2002).
RN   [53]
RP   CHARACTERIZATION OF VARIANTS BRGDA1 HIS-367; VAL-735 AND GLN-1193.
RX   PubMed=11823453; DOI=10.1093/hmg/11.3.337;
RA   Vatta M., Dumaine R., Varghese G., Richard T.A., Shimizu W.,
RA   Aihara N., Nademanee K., Brugada R., Brugada J., Veerakul G., Li H.,
RA   Bowles N.E., Brugada P., Antzelevitch C., Towbin J.A.;
RT   "Genetic and biophysical basis of sudden unexplained nocturnal death
RT   syndrome (SUNDS), a disease allelic to Brugada syndrome.";
RL   Hum. Mol. Genet. 11:337-345(2002).
RN   [54]
RP   VARIANT TYR-1103.
RX   PubMed=12471205; DOI=10.1136/jmg.39.12.913;
RA   Chen S., Chung M.K., Martin D., Rozich R., Tchou P.J., Wang Q.;
RT   "SNP S1103Y in the cardiac sodium channel gene SCN5A is associated
RT   with cardiac arrhythmias and sudden death in a white family.";
RL   J. Med. Genet. 39:913-915(2002).
RN   [55]
RP   VARIANTS BRGDA1 GLU-126 AND VAL-351, CHARACTERIZATION OF VARIANT
RP   BRGDA1 VAL-351, AND VARIANT ARG-558.
RX   PubMed=12051963; DOI=10.1016/S1096-7192(02)00006-9;
RA   Vatta M., Dumaine R., Antzelevitch C., Brugada R., Li H., Bowles N.E.,
RA   Nademanee K., Brugada J., Brugada P., Towbin J.A.;
RT   "Novel mutations in domain I of SCN5A cause Brugada syndrome.";
RL   Mol. Genet. Metab. 75:317-324(2002).
RN   [56]
RP   VARIANT LQT3 VAL-1768, AND CHARACTERIZATION OF VARIANT LQT3 VAL-1768.
RX   PubMed=12209021; DOI=10.1152/physiolgenomics.00039.2002;
RA   Rivolta I., Clancy C.E., Tateyama M., Liu H., Priori S.G., Kass R.S.;
RT   "A novel SCN5A mutation associated with long QT-3: altered
RT   inactivation kinetics and channel dysfunction.";
RL   Physiol. Genomics 10:191-197(2002).
RN   [57]
RP   VARIANT TYR-1103.
RX   PubMed=12193783; DOI=10.1126/science.1073569;
RA   Splawski I., Timothy K.W., Tateyama M., Clancy C.E., Malhotra A.,
RA   Beggs A.H., Cappuccio F.P., Sagnella G.A., Kass R.S., Keating M.T.;
RT   "Variant of SCN5A sodium channel implicated in risk of cardiac
RT   arrhythmia.";
RL   Science 297:1333-1336(2002).
RN   [58]
RP   VARIANT ATRST1 ASN-1275.
RX   PubMed=12522116; DOI=10.1161/01.RES.0000050585.07097.D7;
RA   Groenewegen W.A., Firouzi M., Bezzina C.R., Vliex S., van Langen I.M.,
RA   Sandkuijl L., Smits J.P., Hulsbeek M., Rook M.B., Jongsma H.J.,
RA   Wilde A.A.M.;
RT   "A cardiac sodium channel mutation cosegregates with a rare connexin40
RT   genotype in familial atrial standstill.";
RL   Circ. Res. 92:14-22(2003).
RN   [59]
RP   VARIANT PFHB1A TRP-225.
RX   PubMed=12574143; DOI=10.1161/01.RES.0000052672.97759.36;
RA   Bezzina C.R., Rook M.B., Groenewegen W.A., Herfst L.J.,
RA   van der Wal A.C., Lam J., Jongsma H.J., Wilde A.A.M., Mannens M.M.;
RT   "Compound heterozygosity for mutations (W156X and R225W) in SCN5A
RT   associated with severe cardiac conduction disturbances and
RT   degenerative changes in the conduction system.";
RL   Circ. Res. 92:159-168(2003).
RN   [60]
RP   VARIANT LQT3 PHE-619.
RX   PubMed=12673799; DOI=10.1002/humu.9136;
RA   Wehrens X.H., Rossenbacker T., Jongbloed R.J., Gewillig M.,
RA   Heidbuchel H., Doevendans P.A., Vos M.A., Wellens H.J., Kass R.S.;
RT   "A novel mutation L619F in the cardiac Na+ channel SCN5A associated
RT   with long-QT syndrome (LQT3): a role for the I-II linker in
RT   inactivation gating.";
RL   Hum. Mutat. 21:552-552(2003).
RN   [61]
RP   VARIANT PFHB1A ILE-512, CHARACTERIZATION OF VARIANT PFHB1A ILE-512,
RP   VARIANT ARG-558, AND CHARACTERIZATION OF VARIANT ARG-558.
RX   PubMed=12569159; DOI=10.1172/JCI200316879;
RA   Viswanathan P.C., Benson D.W., Balser J.R.;
RT   "A common SCN5A polymorphism modulates the biophysical effects of an
RT   SCN5A mutation.";
RL   J. Clin. Invest. 111:341-346(2003).
RN   [62]
RP   VARIANTS SSS1 ILE-220; LEU-1298 AND ARG-1408.
RX   PubMed=14523039; DOI=10.1172/JCI200318062;
RA   Benson D.W., Wang D.W., Dyment M., Knilans T.K., Fish F.A.,
RA   Strieper M.J., Rhodes T.H., George A.L. Jr.;
RT   "Congenital sick sinus syndrome caused by recessive mutations in the
RT   cardiac sodium channel gene (SCN5A).";
RL   J. Clin. Invest. 112:1019-1028(2003).
RN   [63]
RP   VARIANT BRGDA1 ARG-1743, AND CHARACTERIZATION OF VARIANT BRGDA1
RP   ARG-1743.
RX   PubMed=15023552; DOI=10.1016/j.cardiores.2004.01.022;
RA   Valdivia C.R., Tester D.J., Rok B.A., Porter C.B., Munger T.M.,
RA   Jahangir A., Makielski J.C., Ackerman M.J.;
RT   "A trafficking defective, Brugada syndrome-causing SCN5A mutation
RT   rescued by drugs.";
RL   Cardiovasc. Res. 62:53-62(2004).
RN   [64]
RP   VARIANT CMD1E ASN-1275.
RX   PubMed=15466643; DOI=10.1161/01.CIR.0000144458.58660.BB;
RG   The familial cardiomyopathy registry research group;
RA   McNair W.P., Ku L., Taylor M.R.G., Fain P.R., Dao D., Wolfel E.,
RA   Mestroni L.;
RT   "SCN5A mutation associated with dilated cardiomyopathy, conduction
RT   disorder, and arrhythmia.";
RL   Circulation 110:2163-2167(2004).
RN   [65]
RP   VARIANT BRGDA1 SER-1262.
RX   PubMed=15338453; DOI=10.1007/s10038-004-0182-z;
RA   Shin D.-J., Jang Y., Park H.-Y., Lee J.E., Yang K., Kim E., Bae Y.,
RA   Kim J., Kim J., Kim S.S., Lee M.H., Chahine M., Yoon S.K.;
RT   "Genetic analysis of the cardiac sodium channel gene SCN5A in Koreans
RT   with Brugada syndrome.";
RL   J. Hum. Genet. 49:573-578(2004).
RN   [66]
RP   VARIANT BRGDA1 LYS-1053, AND CHARACTERIZATION OF VARIANT BRGDA1
RP   LYS-1053.
RX   PubMed=15579534; DOI=10.1073/pnas.0403711101;
RA   Mohler P.J., Rivolta I., Napolitano C., LeMaillet G., Lambert S.,
RA   Priori S.G., Bennett V.;
RT   "Nav1.5 E1053K mutation causing Brugada syndrome blocks binding to
RT   ankyrin-G and expression of Nav1.5 on the surface of cardiomyocytes.";
RL   Proc. Natl. Acad. Sci. U.S.A. 101:17533-17538(2004).
RN   [67]
RP   VARIANT BRGDA1 GLY-1714, AND CHARACTERIZATION OF VARIANT BRGDA1
RP   GLY-1714.
RX   PubMed=16266370; DOI=10.1111/j.1365-201X.2005.01496.x;
RA   Amin A.S., Verkerk A.O., Bhuiyan Z.A., Wilde A.A.M., Tan H.L.;
RT   "Novel Brugada syndrome-causing mutation in ion-conducting pore of
RT   cardiac Na+ channel does not affect ion selectivity properties.";
RL   Acta Physiol. Scand. 185:291-301(2005).
RN   [68]
RP   VARIANTS BRGDA1 ARG-1527 AND PRO-1569.
RX   PubMed=15851320; DOI=10.1016/j.hrthm.2004.11.022;
RA   Yokoi H., Makita N., Sasaki K., Takagi Y., Okumura Y., Nishino T.,
RA   Makiyama T., Kitabatake A., Horie M., Watanabe I., Tsutsui H.;
RT   "Double SCN5A mutation underlying asymptomatic Brugada syndrome.";
RL   Heart Rhythm 2:285-292(2005).
RN   [69]
RP   VARIANTS LQT3 GLU-413; THR-413; GLU-573; ARG-579; HIS-689; PRO-1626;
RP   CYS-1644; VAL-1660; CYS-1767; GLY-1790 AND HIS-1913, AND VARIANTS
RP   THR-1498 AND ASN-1787.
RX   PubMed=16414944; DOI=10.1001/jama.294.23.2975;
RA   Napolitano C., Priori S.G., Schwartz P.J., Bloise R., Ronchetti E.,
RA   Nastoli J., Bottelli G., Cerrone M., Leonardi S.;
RT   "Genetic testing in the long QT syndrome: development and validation
RT   of an efficient approach to genotyping in clinical practice.";
RL   JAMA 294:2975-2980(2005).
RN   [70]
RP   VARIANTS LQT3 LEU-125; LYS-245; GLN-404; LYS-406; MET-411; LYS-462;
RP   ASP-572; GLU-615; LEU-637; LEU-648; CYS-971; MET-1069; LYS-1225;
RP   LYS-1231; SER-1325; TYR-1458; GLU-1481; 1505-LYS--GLN-1507 DEL;
RP   LEU-1623; HIS-1644; ILE-1667; MET-1763; LEU-1766; MET-1777; MET-1779;
RP   LYS-1784; CYS-1795; ARG-1909 AND SER-1949, AND VARIANTS TRP-18;
RP   PHE-618 AND GLN-1958.
RX   PubMed=15840476; DOI=10.1016/j.hrthm.2005.01.020;
RA   Tester D.J., Will M.L., Haglund C.M., Ackerman M.J.;
RT   "Compendium of cardiac channel mutations in 541 consecutive unrelated
RT   patients referred for long QT syndrome genetic testing.";
RL   Heart Rhythm 2:507-517(2005).
RN   [71]
RP   VARIANTS BRGDA1 ILE-187 AND ASN-356, AND CHARACTERIZATION OF VARIANTS
RP   BRGDA1 ILE-187 AND ASN-356.
RX   PubMed=16325048; DOI=10.1016/j.jacc.2005.08.043;
RA   Makiyama T., Akao M., Tsuji K., Doi T., Ohno S., Takenaka K.,
RA   Kobori A., Ninomiya T., Yoshida H., Takano M., Makita N.,
RA   Yanagisawa F., Higashi Y., Takeyama Y., Kita T., Horie M.;
RT   "High risk for bradyarrhythmic complications in patients with Brugada
RT   syndrome caused by SCN5A gene mutations.";
RL   J. Am. Coll. Cardiol. 46:2100-2106(2005).
RN   [72]
RP   VARIANT BRGDA1 SER-1344, AND VARIANTS ARG-552 AND GLN-1027.
RX   PubMed=16616735; DOI=10.1016/j.cardiores.2006.02.030;
RA   Keller D.I., Huang H., Zhao J., Frank R., Suarez V., Delacretaz E.,
RA   Brink M., Osswald S., Schwick N., Chahine M.;
RT   "A novel SCN5A mutation, F1344S, identified in a patient with Brugada
RT   syndrome and fever-induced ventricular fibrillation.";
RL   Cardiovasc. Res. 70:521-529(2006).
RN   [73]
RP   VARIANTS BRGDA1 LEU-336 AND VAL-1660, AND CHARACTERIZATION OF VARIANTS
RP   BRGDA1 LEU-336 AND VAL-1660.
RX   PubMed=17075016; DOI=10.1161/CIRCULATIONAHA.106.627489;
RA   Cordeiro J.M., Barajas-Martinez H., Hong K., Burashnikov E.,
RA   Pfeiffer R., Orsino A.M., Wu Y.S., Hu D., Brugada J., Brugada P.,
RA   Antzelevitch C., Dumaine R., Brugada R.;
RT   "Compound heterozygous mutations P336L and I1660V in the human cardiac
RT   sodium channel associated with the Brugada syndrome.";
RL   Circulation 114:2026-2033(2006).
RN   [74]
RP   VARIANTS LQT3 VAL-9; GLN-225; ARG-639; TYR-1333; TRP-1609 AND
RP   ASN-1819.
RX   PubMed=16922724; DOI=10.1111/j.1399-0004.2006.00671.x;
RA   Millat G., Chevalier P., Restier-Miron L., Da Costa A., Bouvagnet P.,
RA   Kugener B., Fayol L., Gonzalez Armengod C., Oddou B., Chanavat V.,
RA   Froidefond E., Perraudin R., Rousson R., Rodriguez-Lafrasse C.;
RT   "Spectrum of pathogenic mutations and associated polymorphisms in a
RT   cohort of 44 unrelated patients with long QT syndrome.";
RL   Clin. Genet. 70:214-227(2006).
RN   [75]
RP   VARIANTS BRGDA1 ILE-95; PHE-1617 DEL AND VAL-1649.
RX   PubMed=17081365;
RA   Liang P., Liu W.L., Hu D.Y., Li C.L., Tao W.H., Li L.;
RT   "Novel SCN5A gene mutations associated with Brugada syndrome: V95I,
RT   A1649V and delF1617.";
RL   Zhonghua Xin Xue Guan Bing Za Zhi 34:616-619(2006).
RN   [76]
RP   VARIANT LQT3 LEU-1904, AND CHARACTERIZATION OF VARIANT LQT3 LEU-1904.
RX   PubMed=18708744; DOI=10.4161/chan.4956;
RA   Bankston J.R., Sampson K.J., Kateriya S., Glaaser I.W., Malito D.L.,
RA   Chung W.K., Kass R.S.;
RT   "A novel LQT-3 mutation disrupts an inactivation gate complex with
RT   distinct rate-dependent phenotypic consequences.";
RL   Channels 1:273-280(2007).
RN   [77]
RP   VARIANT BRGDA1 ILE-353.
RX   PubMed=17198989; DOI=10.1016/j.hrthm.2006.09.031;
RA   Pfahnl A.E., Viswanathan P.C., Weiss R., Shang L.L., Sanyal S.,
RA   Shusterman V., Kornblit C., London B., Dudley S.C. Jr.;
RT   "A sodium channel pore mutation causing Brugada syndrome.";
RL   Heart Rhythm 4:46-53(2007).
RN   [78]
RP   VARIANT LQT3 CYS-1473.
RX   PubMed=18060054; DOI=10.1371/journal.pone.0001258;
RA   Bankston J.R., Yue M., Chung W., Spyres M., Pass R.H., Silver E.,
RA   Sampson K.J., Kass R.S.;
RT   "A novel and lethal de novo LQT-3 mutation in a newborn with distinct
RT   molecular pharmacology and therapeutic response.";
RL   PLoS ONE 2:E1258-E1258(2007).
RN   [79]
RP   VARIANT BRGDA1 ASN-1494.
RX   PubMed=18341814;
RA   Tian L., Zhu J.F., Yang J.G.;
RT   "Gene (SCN5A) mutation analysis of a Chinese family with Brugada
RT   syndrome.";
RL   Zhonghua Xin Xue Guan Bing Za Zhi 35:1122-1125(2007).
RN   [80]
RP   VARIANT BRGDA1 CYS-878.
RX   PubMed=18616619; DOI=10.1111/j.1748-1716.2008.01883.x;
RA   Zhang Y., Wang T., Ma A., Zhou X., Gui J., Wan H., Shi R., Huang C.,
RA   Grace A.A., Huang C.L., Trump D., Zhang H., Zimmer T., Lei M.;
RT   "Correlations between clinical and physiological consequences of the
RT   novel mutation R878C in a highly conserved pore residue in the cardiac
RT   Na+ channel.";
RL   Acta Physiol. 194:311-323(2008).
RN   [81]
RP   VARIANT BRGDA1 LEU-2004, AND CHARACTERIZATION OF VARIANT BRGDA1
RP   LEU-2004.
RX   PubMed=18456723; DOI=10.1152/ajpheart.91495.2007;
RA   Bebarova M., O'Hara T., Geelen J.L.M.C., Jongbloed R.J.,
RA   Timmermans C., Arens Y.H., Rodriguez L.-M., Rudy Y., Volders P.G.A.;
RT   "Subepicardial phase 0 block and discontinuous transmural conduction
RT   underlie right precordial ST-segment elevation by a SCN5A loss-of-
RT   function mutation.";
RL   Am. J. Physiol. 295:H48-H58(2008).
RN   [82]
RP   VARIANT BRGDA1 SER-1850, AND CHARACTERIZATION OF VARIANT BRGDA1
RP   SER-1850.
RX   PubMed=18252757; DOI=10.1093/cvr/cvn023;
RA   Petitprez S., Jespersen T., Pruvot E., Keller D.I., Corbaz C.,
RA   Schlapfer J., Abriel H., Kucera J.P.;
RT   "Analyses of a novel SCN5A mutation (C1850S): conduction vs.
RT   repolarization disorder hypotheses in the Brugada syndrome.";
RL   Cardiovasc. Res. 78:494-504(2008).
RN   [83]
RP   VARIANTS ILE-232 AND PHE-1308.
RX   PubMed=18599870; DOI=10.1161/CIRCRESAHA.108.172619;
RA   Barajas-Martinez H.M., Hu D., Cordeiro J.M., Wu Y., Kovacs R.J.,
RA   Meltser H., Kui H., Elena B., Brugada R., Antzelevitch C., Dumaine R.;
RT   "Lidocaine-induced Brugada syndrome phenotype linked to a novel double
RT   mutation in the cardiac sodium channel.";
RL   Circ. Res. 103:396-404(2008).
RN   [84]
RP   VARIANTS ATFB10 ILE-138; LYS-428; ASP-445; LYS-470; ASP-572; LYS-655;
RP   LYS-1053; ILE-1131; CYS-1826 AND MET-1951, AND VARIANTS CYS-34;
RP   LEU-216; HIS-376; VAL-461; TRP-481; TYR-524; ARG-558; PHE-618;
RP   SER-997; TYR-1103; GLN-1193; LEU-1951 AND LEU-2004.
RX   PubMed=18378609; DOI=10.1161/CIRCULATIONAHA.107.757955;
RA   Darbar D., Kannankeril P.J., Donahue B.S., Kucera G., Stubblefield T.,
RA   Haines J.L., George A.L. Jr., Roden D.M.;
RT   "Cardiac sodium channel (SCN5A) variants associated with atrial
RT   fibrillation.";
RL   Circulation 117:1927-1935(2008).
RN   [85]
RP   VARIANT ATFB10 LYS-1987.
RX   PubMed=18088563; DOI=10.1016/j.hrthm.2007.09.015;
RA   Ellinor P.T., Nam E.G., Shea M.A., Milan D.J., Ruskin J.N.,
RA   MacRae C.A.;
RT   "Cardiac sodium channel mutation in atrial fibrillation.";
RL   Heart Rhythm 5:99-105(2008).
RN   [86]
RP   VARIANT LQT3 CYS-1795.
RX   PubMed=18929331; DOI=10.1016/j.hrthm.2008.07.013;
RA   Benito B., Brugada R., Perich R.M., Lizotte E., Cinca J., Mont L.,
RA   Berruezo A., Tolosana J.M., Freixa X., Brugada P., Brugada J.;
RT   "A mutation in the sodium channel is responsible for the association
RT   of long QT syndrome and familial atrial fibrillation.";
RL   Heart Rhythm 5:1434-1440(2008).
RN   [87]
RP   VARIANT LQT3 GLN-43, AND CHARACTERIZATION OF VARIANT LQT3 GLN-43.
RX   PubMed=18848812; DOI=10.1016/j.hrthm.2008.08.010;
RA   Lin M.-T., Wu M.-H., Chang C.-C., Chiu S.-N., Theriault O., Huang H.,
RA   Christe G., Ficker E., Chahine M.;
RT   "In utero onset of long QT syndrome with atrioventricular block and
RT   spontaneous or lidocaine-induced ventricular tachycardia: compound
RT   effects of hERG pore region mutation and SCN5A N-terminus variant.";
RL   Heart Rhythm 5:1567-1574(2008).
RN   [88]
RP   VARIANT ATRIAL FIBRILLATION THR-1875, AND CHARACTERIZATION OF VARIANT
RP   ATRIAL FIBRILLATION THR-1875.
RX   PubMed=18929244; DOI=10.1016/j.jacc.2008.07.013;
RA   Makiyama T., Akao M., Shizuta S., Doi T., Nishiyama K., Oka Y.,
RA   Ohno S., Nishio Y., Tsuji K., Itoh H., Kimura T., Kita T., Horie M.;
RT   "A novel SCN5A gain-of-function mutation M1875T associated with
RT   familial atrial fibrillation.";
RL   J. Am. Coll. Cardiol. 52:1326-1334(2008).
RN   [89]
RP   VARIANT LQT3/BRGDA1/SSS1 LYS-1784.
RX   PubMed=18451998; DOI=10.1172/JCI34057;
RA   Makita N., Behr E., Shimizu W., Horie M., Sunami A., Crotti L.,
RA   Schulze-Bahr E., Fukuhara S., Mochizuki N., Makiyama T., Itoh H.,
RA   Christiansen M., McKeown P., Miyamoto K., Kamakura S., Tsutsui H.,
RA   Schwartz P.J., George A.L. Jr., Roden D.M.;
RT   "The E1784K mutation in SCN5A is associated with mixed clinical
RT   phenotype of type 3 long QT syndrome.";
RL   J. Clin. Invest. 118:2219-2229(2008).
RN   [90]
RP   VARIANTS ARG-558 AND LEU-1090.
RX   PubMed=18368697; DOI=10.1016/j.ymgme.2007.10.009;
RA   Shan L., Makita N., Xing Y., Watanabe S., Futatani T., Ye F.,
RA   Saito K., Ibuki K., Watanabe K., Hirono K., Uese K., Ichida F.,
RA   Miyawaki T., Origasa H., Bowles N.E., Towbin J.A.;
RT   "SCN5A variants in Japanese patients with left ventricular
RT   noncompaction and arrhythmia.";
RL   Mol. Genet. Metab. 93:468-474(2008).
RN   [91]
RP   VARIANTS SIDS CYS-532; SER-1084 AND SER-1705, AND CHARACTERIZATION OF
RP   VARIANT SIDS SER-1705.
RX   PubMed=18596570; DOI=10.1203/PDR.0b013e3181841eca;
RA   Otagiri T., Kijima K., Osawa M., Ishii K., Makita N., Matoba R.,
RA   Umetsu K., Hayasaka K.;
RT   "Cardiac ion channel gene mutations in sudden infant death syndrome.";
RL   Pediatr. Res. 64:482-487(2008).
RN   [92]
RP   VARIANT IRRITABLE BOWEL SYNDROME SER-298, AND CHARACTERIZATION OF
RP   VARIANT IRRITABLE BOWEL SYNDROME SER-298.
RX   PubMed=19056759; DOI=10.1152/ajpgi.90571.2008;
RA   Saito Y.A., Strege P.R., Tester D.J., Locke G.R. III, Talley N.J.,
RA   Bernard C.E., Rae J.L., Makielski J.C., Ackerman M.J., Farrugia G.;
RT   "Sodium channel mutation in irritable bowel syndrome: evidence for an
RT   ion channelopathy.";
RL   Am. J. Physiol. 296:G211-G218(2009).
RN   [93]
RP   VARIANT SIDS TYR-1333.
RX   PubMed=19302788; DOI=10.1016/j.febslet.2009.02.007;
RA   Huang H., Millat G., Rodriguez-Lafrasse C., Rousson R., Kugener B.,
RA   Chevalier P., Chahine M.;
RT   "Biophysical characterization of a new SCN5A mutation S1333Y in a SIDS
RT   infant linked to long QT syndrome.";
RL   FEBS Lett. 583:890-896(2009).
RN   [94]
RP   VARIANTS BRGDA1 LYS-161; CYS-367; HIS-367; CYS-514; ARG-752; TRP-1232;
RP   ASN-1275; VAL-1319; ARG-1408; TRP-1512; GLY-1714; ARG-1740; GLU-1743
RP   AND THR-1924, AND VARIANTS PFHB1A LYS-161; CYS-367; HIS-367; CYS-514;
RP   ARG-752; TRP-1232; ASN-1275; VAL-1319; ARG-1408; TRP-1512; GLY-1714;
RP   ARG-1740; GLU-1743 AND THR-1924.
RX   PubMed=19251209; DOI=10.1016/j.hrthm.2008.11.009;
RA   Meregalli P.G., Tan H.L., Probst V., Koopmann T.T., Tanck M.W.,
RA   Bhuiyan Z.A., Sacher F., Kyndt F., Schott J.-J., Albuisson J.,
RA   Mabo P., Bezzina C.R., Le Marec H., Wilde A.A.M.;
RT   "Type of SCN5A mutation determines clinical severity and degree of
RT   conduction slowing in loss-of-function sodium channelopathies.";
RL   Heart Rhythm 6:341-348(2009).
RN   [95]
RP   VARIANTS LQT3 GLN-18; HIS-27; GLY-30; GLN-43; LYS-48; SER-52; GLN-53;
RP   GLY-104; GLY-115; LEU-125; PRO-212; GLN-222; TRP-225; MET-240;
RP   LEU-247; LYS-275; SER-289; TRP-340; CYS-367; MET-370; THR-397;
RP   LYS-406; VAL-409; MET-411; GLU-429 DEL; ALA-462; VAL-530; GLN-535;
RP   TRP-569; ILE-571; SER-572; VAL-572; 586-ALA-LEU-587 DEL; GLU-615;
RP   ARG-639; LYS-654; PRO-673; CYS-689; LEU-701; ILE-731; ARG-750;
RP   ASN-772; TYR-816; PHE-848; LYS-960; LEU-965; PHE-981; SER-997;
RP   ARG-1004; LYS-1053; MET-1069; VAL-1100; ASN-1114; ASN-1166; SER-1199;
RP   ILE-1212 DEL; MET-1283; MET-1304; SER-1325; SER-1326; VAL-1334;
RP   VAL-1338; SER-1432; SER-1472; CYS-1473; GLU-1481; LEU-1487; ARG-1488;
RP   ASP-1489; ARG-1493; SER-1495; VAL-1498; VAL-1501; ASN-1505; ILE-1532;
RP   PHE-1560; MET-1593; SER-1594; ILE-1596; PHE-1617 DEL; GLN-1623;
RP   LEU-1623; HIS-1626; CYS-1644; PHE-1650; THR-1652; ASN-1723; TRP-1739;
RP   HIS-1761; PHE-1761; MET-1763; MET-1777; MET-1779; LYS-1784; CYS-1795;
RP   HIS-1826; GLY-1839; TRP-1897; GLN-1901; ASN-1977; VAL-2004 AND
RP   CYS-2012.
RX   PubMed=19716085; DOI=10.1016/j.hrthm.2009.05.021;
RA   Kapplinger J.D., Tester D.J., Salisbury B.A., Carr J.L.,
RA   Harris-Kerr C., Pollevick G.D., Wilde A.A., Ackerman M.J.;
RT   "Spectrum and prevalence of mutations from the first 2,500 consecutive
RT   unrelated patients referred for the FAMILION long QT syndrome genetic
RT   test.";
RL   Heart Rhythm 6:1297-1303(2009).
RN   [96]
RP   VARIANT BRGDA1 CYS-965, AND CHARACTERIZATION OF VARIANT BRGDA1
RP   CYS-965.
RX   PubMed=19272188; DOI=10.1186/1423-0127-16-23;
RA   Hsueh C.H., Chen W.P., Lin J.L., Tsai C.T., Liu Y.B., Juang J.M.,
RA   Tsao H.M., Su M.J., Lai L.P.;
RT   "Distinct functional defect of three novel Brugada syndrome related
RT   cardiac sodium channel mutations.";
RL   J. Biomed. Sci. 16:23-23(2009).
RN   [97]
RP   VARIANTS TRP-18; CYS-34; HIS-34; LEU-216; SER-286; SER-291; MET-299;
RP   CYS-376; GLY-447; ALA-449; VAL-461; SER-475; TRP-481; TYR-524;
RP   ARG-558; HIS-568; ARG-579; LYS-592; GLY-596; ALA-601; PHE-618;
RP   ASP-638; LEU-656; THR-672; HIS-689; LYS-692; PHE-705; ILE-924;
RP   GLN-986; MET-1016; ARG-1040; ALA-1082; LEU-1090; LEU-1098; TYR-1103;
RP   LYS-1107; TRP-1116; GLN-1193; MET-1251; SER-1293; PHE-1308; TRP-1512;
RP   ASN-1787; THR-1836; LYS-1901; CYS-1919; LEU-1951; GLN-1958; LEU-1962;
RP   MET-1968; GLN-1991; LEU-2004 AND ALA-2006, AND VARIANTS BRGDA1 GLN-18;
RP   LYS-70; ASN-84; SER-93; SER-94; GLN-104; TRP-104; LYS-109; GLN-121;
RP   TRP-121; GLU-126; PRO-136; MET-146; GLN-161; LYS-161; ASN-175;
RP   GLY-178; ARG-182; VAL-185; VAL-204; GLN-212; ILE-220; GLN-222;
RP   LEU-223; TRP-225; VAL-226; ILE-232; MET-240; LYS-270; GLN-276;
RP   ASP-278; CYS-282; ILE-300; PRO-315; ASN-320; ARG-325; LEU-336;
RP   ASP-351; VAL-351; ASN-356; CYS-367; HIS-367; LEU-367; LYS-369;
RP   GLY-374; HIS-376; ARG-386; GLU-386; ALA-396; LEU-396; LYS-439;
RP   GLY-501; HIS-526; CYS-532; LEU-543; ARG-552; GLU-615; PHE-619;
RP   CYS-620; MET-632; ALA-640; ASP-647; LEU-648; TRP-661; GLY-683;
RP   LEU-701; LEU-717; VAL-735; LYS-746; ARG-752; GLU-758; ARG-764;
RP   ASN-772; SER-773; ILE-789; PRO-808; PRO-839; LEU-851; GLN-867;
RP   CYS-878; HIS-878; PRO-886; CYS-893; HIS-893; LYS-901; LEU-910;
RP   ARG-915; ARG-917; SER-927; PRO-928; PRO-935; CYS-965; HIS-965;
RP   THR-997; LYS-1053; GLY-1055; TYR-1079; VAL-1113; THR-1140; ASN-1219;
RP   LYS-1225; HIS-1228; GLN-1232; TRP-1232; PRO-1239; ASN-1243; ASP-1249;
RP   GLY-1253; SER-1262; CYS-1271; ASN-1275; GLY-1288; PRO-1311; VAL-1319;
RP   GLY-1323; LEU-1332; LEU-1344; ILE-1346; PRO-1346; ARG-1351; MET-1353;
RP   TRP-1358; ASN-1359; CYS-1360; TYR-1363; ILE-1382; LEU-1405; MET-1405;
RP   ARG-1406; GLU-1406; ARG-1408; CYS-1409; PHE-1412; GLU-1419; ARG-1420;
RP   SER-1427; VAL-1428; GLY-1432; SER-1432; VAL-1433; LEU-1438; GLN-1441;
RP   LEU-1448; THR-1448; CYS-1449; ASP-1451; TYR-1463; PHE-1468; VAL-1501;
RP   LYS-1521; MET-1525; LYS-1548; CYS-1571; LYS-1574; PRO-1582; CYS-1583;
RP   HIS-1583; MET-1604; LEU-1613; MET-1620; GLN-1623; GLN-1629; GLU-1642;
RP   VAL-1660; ARG-1661; ILE-1667; TYR-1672; THR-1680; THR-1698; ARG-1709;
RP   MET-1709; SER-1712; GLY-1714; ASP-1722; ARG-1728; TRP-1728; ARG-1740;
RP   ARG-1743; GLU-1743; PHE-1764; MET-1779; LYS-1784; GLU-1832; ILE-1861;
RP   ASN-1872; LEU-1903; THR-1924; SER-1935; LYS-1938 AND VAL-2004.
RX   PubMed=20129283; DOI=10.1016/j.hrthm.2009.09.069;
RA   Kapplinger J.D., Tester D.J., Alders M., Benito B., Berthet M.,
RA   Brugada J., Brugada P., Fressart V., Guerchicoff A., Harris-Kerr C.,
RA   Kamakura S., Kyndt F., Koopmann T.T., Miyamoto Y., Pfeiffer R.,
RA   Pollevick G.D., Probst V., Zumhagen S., Vatta M., Towbin J.A.,
RA   Shimizu W., Schulze-Bahr E., Antzelevitch C., Salisbury B.A.,
RA   Guicheney P., Wilde A.A., Brugada R., Schott J.J., Ackerman M.J.;
RT   "An international compendium of mutations in the SCN5A-encoded cardiac
RT   sodium channel in patients referred for Brugada syndrome genetic
RT   testing.";
RL   Heart Rhythm 7:33-46(2010).
RN   [98]
RP   CHARACTERIZATION OF VARIANTS ARG-558 AND ALA-2006.
RX   PubMed=21109022; DOI=10.1016/j.hrthm.2010.11.034;
RA   Shinlapawittayatorn K., Du X.X., Liu H., Ficker E., Kaufman E.S.,
RA   Deschenes I.;
RT   "A common SCN5A polymorphism modulates the biophysical defects of
RT   SCN5A mutations.";
RL   Heart Rhythm 8:455-462(2011).
RN   [99]
RP   VARIANTS SSS1 VAL-735 AND ASN-1792.
RX   PubMed=22795782; DOI=10.1016/j.arcped.2012.04.017;
RA   Selly J.B., Boumahni B., Edmar A., Jamal Bey K., Randrianaivo H.,
RA   Clerici G., Millat G., Caillet D.;
RT   "Cardiac sinus node dysfunction due to a new mutation of the SCN5A
RT   gene.";
RL   Arch. Pediatr. 19:837-841(2012).
RN   [100]
RP   VARIANT ARG-558, VARIANTS BRGDA1 ASN-1690 AND ASP-1748,
RP   CHARACTERIZATION OF VARIANTS BRGDA1 ASN-1690 AND ASP-1748, FUNCTION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=23085483; DOI=10.1016/j.hrthm.2012.10.025;
RA   Nunez L., Barana A., Amoros I., de la Fuente M.G., Dolz-Gaiton P.,
RA   Gomez R., Rodriguez-Garcia I., Mosquera I., Monserrat L., Delpon E.,
RA   Caballero R., Castro-Beiras A., Tamargo J.;
RT   "p.D1690N Nav1.5 rescues p.G1748D mutation gating defects in a
RT   compound heterozygous Brugada syndrome patient.";
RL   Heart Rhythm 10:264-272(2013).
RN   [101]
RP   VARIANT BRGDA1 GLN-1629, CHARACTERIZATION OF VARIANT BRGDA1 GLN-1629,
RP   AND FUNCTION.
RX   PubMed=24167619; DOI=10.1371/journal.pone.0078382;
RA   Zeng Z., Zhou J., Hou Y., Liang X., Zhang Z., Xu X., Xie Q., Li W.,
RA   Huang Z.;
RT   "Electrophysiological characteristics of a SCN5A voltage sensors
RT   mutation R1629Q associated with Brugada syndrome.";
RL   PLoS ONE 8:E78382-E78382(2013).
RN   [102]
RP   VARIANT BRGDA1 GLN-812, CHARACTERIZATION OF VARIANT BRGDA1 GLN-812,
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=26279430; DOI=10.1159/000430189;
RA   Wang L., Meng X., Yuchi Z., Zhao Z., Xu D., Fedida D., Wang Z.,
RA   Huang C.;
RT   "De novo mutation in the SCN5A gene associated with brugada
RT   syndrome.";
RL   Cell. Physiol. Biochem. 36:2250-2262(2015).
RN   [103]
RP   VARIANT LQT3 ARG-1849, CHARACTERIZATION OF VARIANT LQT3 ARG-1849,
RP   FUNCTION, AND INTERACTION WITH FGF12; FGF13 AND FGF14.
RX   PubMed=26392562; DOI=10.1073/pnas.1516430112;
RA   Musa H., Kline C.F., Sturm A.C., Murphy N., Adelman S., Wang C.,
RA   Yan H., Johnson B.L., Csepe T.A., Kilic A., Higgins R.S.,
RA   Janssen P.M., Fedorov V.V., Weiss R., Salazar C., Hund T.J.,
RA   Pitt G.S., Mohler P.J.;
RT   "SCN5A variant that blocks fibroblast growth factor homologous factor
RT   regulation causes human arrhythmia.";
RL   Proc. Natl. Acad. Sci. U.S.A. 112:12528-12533(2015).
RN   [104]
RP   VARIANT BRGDA1 GLU-817, CHARACTERIZATION OF VARIANT BRGDA1 GLU-817,
RP   AND FUNCTION.
RX   PubMed=26776555; DOI=10.1016/j.hrthm.2016.01.008;
RA   Kinoshita K., Takahashi H., Hata Y., Nishide K., Kato M., Fujita H.,
RA   Yoshida S., Murai K., Mizumaki K., Nishida K., Yamaguchi Y., Kano M.,
RA   Tabata T., Nishida N.;
RT   "SCN5A(K817E), a novel Brugada syndrome-associated mutation that
RT   alters the activation gating of NaV1.5 channel.";
RL   Heart Rhythm 13:1113-1120(2016).
CC   -!- FUNCTION: This protein mediates the voltage-dependent sodium ion
CC       permeability of excitable membranes. Assuming opened or closed
CC       conformations in response to the voltage difference across the
CC       membrane, the protein forms a sodium-selective channel through
CC       which Na(+) ions may pass in accordance with their electrochemical
CC       gradient. It is a tetrodotoxin-resistant Na(+) channel isoform.
CC       This channel is responsible for the initial upstroke of the action
CC       potential. Channel inactivation is regulated by intracellular
CC       calcium levels. {ECO:0000269|PubMed:1309946,
CC       ECO:0000269|PubMed:19074138, ECO:0000269|PubMed:23085483,
CC       ECO:0000269|PubMed:24167619, ECO:0000269|PubMed:26279430,
CC       ECO:0000269|PubMed:26392562, ECO:0000269|PubMed:26776555}.
CC   -!- SUBUNIT: Interacts with the PDZ domain of the syntrophin SNTA1,
CC       SNTB1 and SNTB2 (By similarity). Interacts with NEDD4, NEDD4L,
CC       WWP2 and GPD1L (PubMed:15217910, PubMed:15548568,
CC       PubMed:19666841). Interacts with CALM (PubMed:21167176,
CC       PubMed:22705208). Interacts with FGF13; the interaction is direct
CC       and FGF13 may regulate SNC5A density at membranes and function
CC       (PubMed:21817159, PubMed:22705208, PubMed:26392562). May also
CC       interact with FGF12 and FGF14 (PubMed:26392562).
CC       {ECO:0000250|UniProtKB:Q9JJV9, ECO:0000269|PubMed:15217910,
CC       ECO:0000269|PubMed:15548568, ECO:0000269|PubMed:19666841,
CC       ECO:0000269|PubMed:21167176, ECO:0000269|PubMed:21817159,
CC       ECO:0000269|PubMed:22705208, ECO:0000269|PubMed:26392562}.
CC   -!- INTERACTION:
CC       P62158:CALM3; NbExp=2; IntAct=EBI-726858, EBI-397435;
CC       Q13557:CAMK2D; NbExp=16; IntAct=EBI-726858, EBI-351018;
CC       Q99873:PRMT1; NbExp=2; IntAct=EBI-726858, EBI-78738;
CC       O60678:PRMT3; NbExp=2; IntAct=EBI-726858, EBI-2809009;
CC       P26045:PTPN3; NbExp=2; IntAct=EBI-726858, EBI-1047946;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:1309946,
CC       ECO:0000269|PubMed:19074138, ECO:0000269|PubMed:23085483,
CC       ECO:0000269|PubMed:26279430}; Multi-pass membrane protein
CC       {ECO:0000305}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=6;
CC       Name=1; Synonyms=CAG-inclusive variant, Nav1.5c;
CC         IsoId=Q14524-1; Sequence=Displayed;
CC         Note=Most abundant isoform in heart.;
CC       Name=2; Synonyms=Nav1.5b;
CC         IsoId=Q14524-2; Sequence=VSP_037478;
CC         Note=Very abundant isoform.;
CC       Name=3;
CC         IsoId=Q14524-3; Sequence=VSP_037477, VSP_037478, VSP_037481;
CC       Name=4; Synonyms=Nav1.5e, neonatal;
CC         IsoId=Q14524-4; Sequence=VSP_037477;
CC         Note=Abundantly expressed in neonatal brain and heart, slower
CC         kinetics of activation and inactivation.;
CC       Name=5; Synonyms=Ex18del, Nav1.5a;
CC         IsoId=Q14524-5; Sequence=VSP_037477, VSP_037479;
CC         Note=Only detected in neuroblastoma in humans.;
CC       Name=6; Synonyms=Ex24del, Nav1.5f;
CC         IsoId=Q14524-6; Sequence=VSP_037477, VSP_037480;
CC         Note=High expression in brain where it accounts for nearly 50%
CC         of the total transcripts. Non-functional channel, may exist to
CC         limit the number of undesired functional Nav1.5 channels.;
CC   -!- TISSUE SPECIFICITY: Found in jejunal circular smooth muscle cells
CC       (at protein level). Expressed in human atrial and ventricular
CC       cardiac muscle but not in adult skeletal muscle, brain,
CC       myometrium, liver, or spleen. Isoform 4 is expressed in brain.
CC       {ECO:0000269|PubMed:12358675}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- DOMAIN: The IQ domain mediates association with calmodulin.
CC       {ECO:0000269|PubMed:21167176, ECO:0000269|PubMed:22705208}.
CC   -!- PTM: Ubiquitinated by NEDD4L; which promotes its endocytosis. Does
CC       not seem to be ubiquitinated by NEDD4 or WWP2.
CC       {ECO:0000269|PubMed:15217910, ECO:0000269|PubMed:15548568}.
CC   -!- PTM: Phosphorylation at Ser-1503 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents (Probable). Regulated through
CC       phosphorylation by CaMK2D (By similarity).
CC       {ECO:0000250|UniProtKB:Q9JJV9, ECO:0000305|PubMed:19666841}.
CC   -!- PTM: Lacks the cysteine which covalently binds the conotoxin
CC       GVIIJ. This cysteine (position 868) is speculated in other sodium
CC       channel subunits alpha to be implied in covalent binding with the
CC       sodium channel subunit beta-2 or beta-4.
CC       {ECO:0000250|UniProtKB:P15389}.
CC   -!- DISEASE: Progressive familial heart block 1A (PFHB1A)
CC       [MIM:113900]: A cardiac bundle branch disorder characterized by
CC       progressive alteration of cardiac conduction through the His-
CC       Purkinje system, with a pattern of a right bundle-branch block
CC       and/or left anterior hemiblock occurring individually or together.
CC       It leads to complete atrio-ventricular block causing syncope and
CC       sudden death. {ECO:0000269|PubMed:11234013,
CC       ECO:0000269|PubMed:11804990, ECO:0000269|PubMed:12569159,
CC       ECO:0000269|PubMed:12574143, ECO:0000269|PubMed:19251209}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Long QT syndrome 3 (LQT3) [MIM:603830]: A heart disorder
CC       characterized by a prolonged QT interval on the ECG and
CC       polymorphic ventricular arrhythmias. They cause syncope and sudden
CC       death in response to exercise or emotional stress, and can present
CC       with a sentinel event of sudden cardiac death in infancy.
CC       {ECO:0000269|PubMed:10377081, ECO:0000269|PubMed:10508990,
CC       ECO:0000269|PubMed:10590249, ECO:0000269|PubMed:10627139,
CC       ECO:0000269|PubMed:10911008, ECO:0000269|PubMed:10973849,
CC       ECO:0000269|PubMed:11304498, ECO:0000269|PubMed:11410597,
CC       ECO:0000269|PubMed:11710892, ECO:0000269|PubMed:11889015,
CC       ECO:0000269|PubMed:11997281, ECO:0000269|PubMed:12209021,
CC       ECO:0000269|PubMed:12454206, ECO:0000269|PubMed:12673799,
CC       ECO:0000269|PubMed:15840476, ECO:0000269|PubMed:16414944,
CC       ECO:0000269|PubMed:16922724, ECO:0000269|PubMed:18060054,
CC       ECO:0000269|PubMed:18451998, ECO:0000269|PubMed:18708744,
CC       ECO:0000269|PubMed:18848812, ECO:0000269|PubMed:18929331,
CC       ECO:0000269|PubMed:19716085, ECO:0000269|PubMed:26392562,
CC       ECO:0000269|PubMed:7651517, ECO:0000269|PubMed:7889574,
CC       ECO:0000269|PubMed:8541846, ECO:0000269|PubMed:9506831,
CC       ECO:0000269|PubMed:9686753, ECO:0000269|Ref.31}. Note=The disease
CC       is caused by mutations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Brugada syndrome 1 (BRGDA1) [MIM:601144]: A
CC       tachyarrhythmia characterized by right bundle branch block and ST
CC       segment elevation on an electrocardiogram (ECG). It can cause the
CC       ventricles to beat so fast that the blood is prevented from
CC       circulating efficiently in the body. When this situation occurs,
CC       the individual will faint and may die in a few minutes if the
CC       heart is not reset. {ECO:0000269|PubMed:10532948,
CC       ECO:0000269|PubMed:10618304, ECO:0000269|PubMed:10690282,
CC       ECO:0000269|PubMed:11410597, ECO:0000269|PubMed:11748104,
CC       ECO:0000269|PubMed:11823453, ECO:0000269|PubMed:11901046,
CC       ECO:0000269|PubMed:12051963, ECO:0000269|PubMed:12106943,
CC       ECO:0000269|PubMed:15023552, ECO:0000269|PubMed:15338453,
CC       ECO:0000269|PubMed:15579534, ECO:0000269|PubMed:15851320,
CC       ECO:0000269|PubMed:16266370, ECO:0000269|PubMed:16325048,
CC       ECO:0000269|PubMed:16616735, ECO:0000269|PubMed:17075016,
CC       ECO:0000269|PubMed:17081365, ECO:0000269|PubMed:17198989,
CC       ECO:0000269|PubMed:18252757, ECO:0000269|PubMed:18341814,
CC       ECO:0000269|PubMed:18451998, ECO:0000269|PubMed:18456723,
CC       ECO:0000269|PubMed:18616619, ECO:0000269|PubMed:19251209,
CC       ECO:0000269|PubMed:19272188, ECO:0000269|PubMed:20129283,
CC       ECO:0000269|PubMed:23085483, ECO:0000269|PubMed:24167619,
CC       ECO:0000269|PubMed:26279430, ECO:0000269|PubMed:26776555,
CC       ECO:0000269|PubMed:9521325}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Sick sinus syndrome 1 (SSS1) [MIM:608567]: The term 'sick
CC       sinus syndrome' encompasses a variety of conditions caused by
CC       sinus node dysfunction. The most common clinical manifestations
CC       are syncope, presyncope, dizziness, and fatigue. Electrocardiogram
CC       typically shows sinus bradycardia, sinus arrest, and/or sinoatrial
CC       block. Episodes of atrial tachycardias coexisting with sinus
CC       bradycardia ('tachycardia-bradycardia syndrome') are also common
CC       in this disorder. SSS occurs most often in the elderly associated
CC       with underlying heart disease or previous cardiac surgery, but can
CC       also occur in the fetus, infant, or child without heart disease or
CC       other contributing factors. SSS1 onset is in utero, infancy, or
CC       early childhood. {ECO:0000269|PubMed:11748104,
CC       ECO:0000269|PubMed:14523039, ECO:0000269|PubMed:22795782}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Familial paroxysmal ventricular fibrillation 1 (VF1)
CC       [MIM:603829]: A cardiac arrhythmia marked by fibrillary
CC       contractions of the ventricular muscle due to rapid repetitive
CC       excitation of myocardial fibers without coordinated contraction of
CC       the ventricle and by absence of atrial activity.
CC       {ECO:0000269|PubMed:10940383}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Sudden infant death syndrome (SIDS) [MIM:272120]: SIDS is
CC       the sudden death of an infant younger than 1 year that remains
CC       unexplained after a thorough case investigation, including
CC       performance of a complete autopsy, examination of the death scene,
CC       and review of clinical history. Pathophysiologic mechanisms for
CC       SIDS may include respiratory dysfunction, cardiac dysrhythmias,
CC       cardiorespiratory instability, and inborn errors of metabolism,
CC       but definitive pathogenic mechanisms precipitating an infant
CC       sudden death remain elusive. {ECO:0000269|PubMed:18596570,
CC       ECO:0000269|PubMed:19302788}. Note=Disease susceptibility is
CC       associated with variations affecting the gene represented in this
CC       entry.
CC   -!- DISEASE: Atrial standstill 1 (ATRST1) [MIM:108770]: A rare
CC       arrhythmia characterized by the absence of electrical and
CC       mechanical activity in the atria. Electrocardiographically, it is
CC       characterized by bradycardia, the absence of P waves, and a
CC       junctional narrow complex escape rhythm.
CC       {ECO:0000269|PubMed:12522116}. Note=The disease may be caused by
CC       mutations affecting distinct genetic loci, including the gene
CC       represented in this entry. A mutation in SCN5A has been detected
CC       in combination with a rare GJA5 genotype in a large family with
CC       atrial standstill.
CC   -!- DISEASE: Cardiomyopathy, dilated 1E (CMD1E) [MIM:601154]: A
CC       disorder characterized by ventricular dilation and impaired
CC       systolic function, resulting in congestive heart failure and
CC       arrhythmia. Patients are at risk of premature death.
CC       {ECO:0000269|PubMed:15466643}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Atrial fibrillation, familial, 10 (ATFB10) [MIM:614022]:
CC       A familial form of atrial fibrillation, a common sustained cardiac
CC       rhythm disturbance. Atrial fibrillation is characterized by
CC       disorganized atrial electrical activity and ineffective atrial
CC       contraction promoting blood stasis in the atria and reduces
CC       ventricular filling. It can result in palpitations, syncope,
CC       thromboembolic stroke, and congestive heart failure.
CC       {ECO:0000269|PubMed:18088563, ECO:0000269|PubMed:18378609}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- MISCELLANEOUS: Na(+) channels in mammalian cardiac membrane have
CC       functional properties quite distinct from Na(+) channels in nerve
CC       and skeletal muscle.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.5/SCN5A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; M77235; AAA58644.1; -; mRNA.
DR   EMBL; AY038064; AAK74065.1; -; mRNA.
DR   EMBL; AY148488; AAN61120.1; -; mRNA.
DR   EMBL; AF482988; AAO91669.1; -; mRNA.
DR   EMBL; AB158469; BAD12084.1; -; mRNA.
DR   EMBL; AB158470; BAD12085.1; -; mRNA.
DR   EMBL; EF629346; ABR15763.1; -; mRNA.
DR   EMBL; EF629347; ABR15764.1; -; mRNA.
DR   EMBL; DQ784809; ABQ01244.1; -; Genomic_DNA.
DR   EMBL; EF179185; ABN05288.1; -; Genomic_DNA.
DR   EMBL; AP006241; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC140813; AAI40814.1; -; mRNA.
DR   EMBL; BC144621; AAI44622.1; -; mRNA.
DR   EMBL; AB208866; BAD92103.1; -; mRNA.
DR   CCDS; CCDS46796.1; -. [Q14524-1]
DR   CCDS; CCDS46797.1; -. [Q14524-2]
DR   CCDS; CCDS46798.1; -. [Q14524-6]
DR   CCDS; CCDS46799.1; -. [Q14524-4]
DR   CCDS; CCDS54569.1; -. [Q14524-5]
DR   CCDS; CCDS54570.1; -. [Q14524-3]
DR   PIR; A38195; A38195.
DR   RefSeq; NP_000326.2; NM_000335.4. [Q14524-2]
DR   RefSeq; NP_001092874.1; NM_001099404.1.
DR   RefSeq; NP_001092875.1; NM_001099405.1.
DR   RefSeq; NP_001153632.1; NM_001160160.1.
DR   RefSeq; NP_001153633.1; NM_001160161.1.
DR   RefSeq; NP_932173.1; NM_198056.2. [Q14524-1]
DR   UniGene; Hs.517898; -.
DR   PDB; 2KBI; NMR; -; A=1773-1865.
DR   PDB; 2L53; NMR; -; B=1901-1927.
DR   PDB; 4DCK; X-ray; 2.20 A; A=1773-1940.
DR   PDB; 4DJC; X-ray; 1.35 A; B=1491-1522.
DR   PDB; 4JQ0; X-ray; 3.84 A; D=1773-1940.
DR   PDB; 4OVN; X-ray; 2.80 A; F/G/H/I/J=1773-1929.
DR   PDBsum; 2KBI; -.
DR   PDBsum; 2L53; -.
DR   PDBsum; 4DCK; -.
DR   PDBsum; 4DJC; -.
DR   PDBsum; 4JQ0; -.
DR   PDBsum; 4OVN; -.
DR   ProteinModelPortal; Q14524; -.
DR   SMR; Q14524; -.
DR   BioGrid; 112236; 12.
DR   DIP; DIP-38416N; -.
DR   DIP; DIP-46144N; -.
DR   IntAct; Q14524; 10.
DR   MINT; MINT-249922; -.
DR   STRING; 9606.ENSP00000328968; -.
DR   BindingDB; Q14524; -.
DR   ChEMBL; CHEMBL1980; -.
DR   DrugBank; DB01426; Ajmaline.
DR   DrugBank; DB01429; Aprindine.
DR   DrugBank; DB00868; Benzonatate.
DR   DrugBank; DB00564; Carbamazepine.
DR   DrugBank; DB00527; Cinchocaine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB00280; Disopyramide.
DR   DrugBank; DB01228; Encainide.
DR   DrugBank; DB00754; Ethotoin.
DR   DrugBank; DB01195; Flecainide.
DR   DrugBank; DB01320; Fosphenytoin.
DR   DrugBank; DB00473; Hexylcaine.
DR   DrugBank; DB00192; Indecainide.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB00379; Mexiletine.
DR   DrugBank; DB00680; Moricizine.
DR   DrugBank; DB00776; Oxcarbazepine.
DR   DrugBank; DB00252; Phenytoin.
DR   DrugBank; DB00750; Prilocaine.
DR   DrugBank; DB01035; Procainamide.
DR   DrugBank; DB01182; Propafenone.
DR   DrugBank; DB00908; Quinidine.
DR   DrugBank; DB01346; Quinidine barbiturate.
DR   DrugBank; DB00243; Ranolazine.
DR   DrugBank; DB00740; Riluzole.
DR   DrugBank; DB01056; Tocainide.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00661; Verapamil.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 582; -.
DR   TCDB; 1.A.1.10.3; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; Q14524; -.
DR   PhosphoSitePlus; Q14524; -.
DR   BioMuta; SCN5A; -.
DR   DMDM; 215273881; -.
DR   PaxDb; Q14524; -.
DR   PeptideAtlas; Q14524; -.
DR   PRIDE; Q14524; -.
DR   Ensembl; ENST00000333535; ENSP00000328968; ENSG00000183873. [Q14524-1]
DR   Ensembl; ENST00000423572; ENSP00000398266; ENSG00000183873. [Q14524-2]
DR   GeneID; 6331; -.
DR   KEGG; hsa:6331; -.
DR   UCSC; uc062ihe.1; human. [Q14524-1]
DR   CTD; 6331; -.
DR   DisGeNET; 6331; -.
DR   GeneCards; SCN5A; -.
DR   GeneReviews; SCN5A; -.
DR   HGNC; HGNC:10593; SCN5A.
DR   MalaCards; SCN5A; -.
DR   MIM; 108770; phenotype.
DR   MIM; 113900; phenotype.
DR   MIM; 272120; phenotype.
DR   MIM; 600163; gene.
DR   MIM; 601144; phenotype.
DR   MIM; 601154; phenotype.
DR   MIM; 603829; phenotype.
DR   MIM; 603830; phenotype.
DR   MIM; 608567; phenotype.
DR   MIM; 614022; phenotype.
DR   neXtProt; NX_Q14524; -.
DR   OpenTargets; ENSG00000183873; -.
DR   Orphanet; 1344; Atrial stand still.
DR   Orphanet; 130; Brugada syndrome.
DR   Orphanet; 334; Familial atrial fibrillation.
DR   Orphanet; 154; Familial isolated dilated cardiomyopathy.
DR   Orphanet; 871; Familial progressive cardiac conduction defect.
DR   Orphanet; 166282; Familial sick sinus syndrome.
DR   Orphanet; 228140; Idiopathic ventricular fibrillation, not Brugada type.
DR   Orphanet; 101016; Romano-Ward syndrome.
DR   PharmGKB; PA304; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q14524; -.
DR   KO; K04838; -.
DR   OrthoDB; EOG0903010X; -.
DR   PhylomeDB; Q14524; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   SIGNOR; Q14524; -.
DR   EvolutionaryTrace; Q14524; -.
DR   GeneWiki; Nav1.5; -.
DR   GenomeRNAi; 6331; -.
DR   PRO; PR:Q14524; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000183873; -.
DR   CleanEx; HS_SCN5A; -.
DR   ExpressionAtlas; Q14524; baseline and differential.
DR   Genevisible; Q14524; HS.
DR   GO; GO:0005901; C:caveola; IDA:BHF-UCL.
DR   GO; GO:0009986; C:cell surface; IDA:UniProtKB.
DR   GO; GO:0005783; C:endoplasmic reticulum; IDA:BHF-UCL.
DR   GO; GO:0016021; C:integral component of membrane; IDA:UniProtKB.
DR   GO; GO:0014704; C:intercalated disc; IDA:BHF-UCL.
DR   GO; GO:0005622; C:intracellular; IDA:UniProtKB.
DR   GO; GO:0016328; C:lateral plasma membrane; TAS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IMP:UniProtKB.
DR   GO; GO:0042383; C:sarcolemma; IDA:BHF-UCL.
DR   GO; GO:0030315; C:T-tubule; IDA:BHF-UCL.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IDA:BHF-UCL.
DR   GO; GO:0030018; C:Z disc; IDA:UniProtKB.
DR   GO; GO:0030506; F:ankyrin binding; IDA:BHF-UCL.
DR   GO; GO:0005516; F:calmodulin binding; IPI:BHF-UCL.
DR   GO; GO:0019899; F:enzyme binding; IPI:BHF-UCL.
DR   GO; GO:0017134; F:fibroblast growth factor binding; IPI:BHF-UCL.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0050998; F:nitric-oxide synthase binding; IPI:BHF-UCL.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IPI:BHF-UCL.
DR   GO; GO:0097110; F:scaffold protein binding; IPI:BHF-UCL.
DR   GO; GO:0017080; F:sodium channel regulator activity; IDA:BHF-UCL.
DR   GO; GO:0031625; F:ubiquitin protein ligase binding; IPI:BHF-UCL.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IDA:UniProtKB.
DR   GO; GO:0086060; F:voltage-gated sodium channel activity involved in AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086061; F:voltage-gated sodium channel activity involved in bundle of His cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086006; F:voltage-gated sodium channel activity involved in cardiac muscle cell action potential; IDA:BHF-UCL.
DR   GO; GO:0086062; F:voltage-gated sodium channel activity involved in Purkinje myocyte action potential; IMP:BHF-UCL.
DR   GO; GO:0086063; F:voltage-gated sodium channel activity involved in SA node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086014; P:atrial cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086016; P:AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086067; P:AV node cell to bundle of His cell communication; IMP:BHF-UCL.
DR   GO; GO:0003360; P:brainstem development; ISS:BHF-UCL.
DR   GO; GO:0086043; P:bundle of His cell action potential; IMP:BHF-UCL.
DR   GO; GO:0061337; P:cardiac conduction; TAS:Reactome.
DR   GO; GO:0086002; P:cardiac muscle cell action potential involved in contraction; IMP:BHF-UCL.
DR   GO; GO:0060048; P:cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0003231; P:cardiac ventricle development; ISS:BHF-UCL.
DR   GO; GO:0071277; P:cellular response to calcium ion; IDA:UniProtKB.
DR   GO; GO:0021549; P:cerebellum development; ISS:BHF-UCL.
DR   GO; GO:0051899; P:membrane depolarization; IDA:BHF-UCL.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IDA:BHF-UCL.
DR   GO; GO:0098912; P:membrane depolarization during atrial cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086045; P:membrane depolarization during AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086048; P:membrane depolarization during bundle of His cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086012; P:membrane depolarization during cardiac muscle cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086047; P:membrane depolarization during Purkinje myocyte cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086046; P:membrane depolarization during SA node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; ISS:BHF-UCL.
DR   GO; GO:0045760; P:positive regulation of action potential; ISS:BHF-UCL.
DR   GO; GO:0050679; P:positive regulation of epithelial cell proliferation; ISS:BHF-UCL.
DR   GO; GO:0010765; P:positive regulation of sodium ion transport; IDA:BHF-UCL.
DR   GO; GO:0060371; P:regulation of atrial cardiac muscle cell membrane depolarization; IMP:BHF-UCL.
DR   GO; GO:0060372; P:regulation of atrial cardiac muscle cell membrane repolarization; IMP:BHF-UCL.
DR   GO; GO:0086004; P:regulation of cardiac muscle cell contraction; IMP:BHF-UCL.
DR   GO; GO:0002027; P:regulation of heart rate; IMP:UniProtKB.
DR   GO; GO:0086091; P:regulation of heart rate by cardiac conduction; IMP:BHF-UCL.
DR   GO; GO:1902305; P:regulation of sodium ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:0060373; P:regulation of ventricular cardiac muscle cell membrane depolarization; IMP:BHF-UCL.
DR   GO; GO:0060307; P:regulation of ventricular cardiac muscle cell membrane repolarization; IMP:BHF-UCL.
DR   GO; GO:0014894; P:response to denervation involved in regulation of muscle adaptation; ISS:BHF-UCL.
DR   GO; GO:0086015; P:SA node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006814; P:sodium ion transport; IDA:UniProtKB.
DR   GO; GO:0021537; P:telencephalon development; ISS:BHF-UCL.
DR   GO; GO:0086005; P:ventricular cardiac muscle cell action potential; IMP:BHF-UCL.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR008053; Na_channel_a5su.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PRINTS; PR01666; NACHANNEL5.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Atrial fibrillation;
KW   Brugada syndrome; Calmodulin-binding; Cardiomyopathy; Cell membrane;
KW   Complete proteome; Disease mutation; Glycoprotein; Ion channel;
KW   Ion transport; Long QT syndrome; Membrane; Methylation;
KW   Phosphoprotein; Polymorphism; Reference proteome; Repeat; Sodium;
KW   Sodium channel; Sodium transport; Transmembrane; Transmembrane helix;
KW   Transport; Ubl conjugation; Voltage-gated channel.
FT   CHAIN         1   2016       Sodium channel protein type 5 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048497.
FT   TOPO_DOM      1    126       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    127    150       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    151    158       Extracellular. {ECO:0000255}.
FT   TRANSMEM    159    178       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    179    191       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    192    210       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    211    216       Extracellular. {ECO:0000255}.
FT   TRANSMEM    217    236       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000255}.
FT   TOPO_DOM    237    252       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    253    276       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    277    389       Extracellular. {ECO:0000255}.
FT   TRANSMEM    390    415       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    416    711       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    712    736       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    737    747       Extracellular. {ECO:0000255}.
FT   TRANSMEM    748    771       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    772    779       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    780    799       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    800    805       Extracellular. {ECO:0000255}.
FT   TRANSMEM    806    825       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000255}.
FT   TOPO_DOM    826    841       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    842    862       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    863    913       Extracellular. {ECO:0000255}.
FT   TRANSMEM    914    939       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    940   1200       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1201   1224       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1225   1237       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1238   1263       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1264   1269       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1270   1291       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1292   1295       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1296   1317       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000255}.
FT   TOPO_DOM   1318   1336       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1337   1359       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1360   1443       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1444   1470       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1471   1523       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1524   1547       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1548   1558       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1559   1582       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1583   1588       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1589   1612       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1613   1622       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1623   1644       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000255}.
FT   TOPO_DOM   1645   1659       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1660   1682       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1683   1747       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1748   1772       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1773   2016       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      113    420       I. {ECO:0000305}.
FT   REPEAT      699    969       II. {ECO:0000305}.
FT   REPEAT     1187   1501       III. {ECO:0000305}.
FT   REPEAT     1510   1807       IV. {ECO:0000305}.
FT   DOMAIN     1901   1930       IQ.
FT   REGION     1839   1901       Interaction with FGF13.
FT                                {ECO:0000269|PubMed:22705208}.
FT   REGION     1974   1977       Interaction with NEDD4, NEDD4L and WWP2.
FT                                {ECO:0000269|PubMed:15548568}.
FT   MOD_RES      36     36       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES      38     38       Phosphothreonine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     457    457       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     460    460       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     483    483       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     484    484       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     486    486       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P15389}.
FT   MOD_RES     497    497       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     510    510       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     513    513       Dimethylated arginine; alternate.
FT                                {ECO:0000269|PubMed:21726068}.
FT   MOD_RES     513    513       Omega-N-methylarginine; alternate.
FT                                {ECO:0000269|PubMed:21726068}.
FT   MOD_RES     526    526       Dimethylated arginine; alternate.
FT                                {ECO:0000269|PubMed:21726068}.
FT   MOD_RES     526    526       Omega-N-methylarginine; alternate.
FT                                {ECO:0000269|PubMed:21726068}.
FT   MOD_RES     539    539       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9JJV9}.
FT   MOD_RES     571    571       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     664    664       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     667    667       Phosphoserine.
FT                                {ECO:0000269|PubMed:23092124}.
FT   MOD_RES     680    680       Dimethylated arginine; alternate.
FT                                {ECO:0000269|PubMed:21726068}.
FT   MOD_RES     680    680       Omega-N-methylarginine; alternate.
FT                                {ECO:0000269|PubMed:21726068}.
FT   MOD_RES    1503   1503       Phosphoserine; by PKC.
FT                                {ECO:0000305|PubMed:19666841}.
FT   CARBOHYD    214    214       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    283    283       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    288    288       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    291    291       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    318    318       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    328    328       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    740    740       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    803    803       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    864    864       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1365   1365       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1374   1374       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1380   1380       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1388   1388       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1736   1736       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     206    211       TTEFVD -> VSENIK (in isoform 3, isoform
FT                                4, isoform 5 and isoform 6).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:16115203,
FT                                ECO:0000303|Ref.6}.
FT                                /FTId=VSP_037477.
FT   VAR_SEQ    1076   1076       Missing (in isoform 2 and isoform 3).
FT                                {ECO:0000303|PubMed:12358675,
FT                                ECO:0000303|PubMed:12454206,
FT                                ECO:0000303|PubMed:14500339,
FT                                ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037478.
FT   VAR_SEQ    1077   1130       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:16115203}.
FT                                /FTId=VSP_037479.
FT   VAR_SEQ    1416   1433       Missing (in isoform 6).
FT                                {ECO:0000303|Ref.6}.
FT                                /FTId=VSP_037480.
FT   VAR_SEQ    1573   1604       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15489334}.
FT                                /FTId=VSP_037481.
FT   VARIANT       9      9       G -> V (in LQT3; dbSNP:rs199473043).
FT                                {ECO:0000269|PubMed:16922724}.
FT                                /FTId=VAR_036660.
FT   VARIANT      18     18       R -> Q (in BRGDA1 and LQT3; unknown
FT                                pathological significance;
FT                                dbSNP:rs41311087).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074312.
FT   VARIANT      18     18       R -> W (rare variant; found in a patient
FT                                with long QT syndrome; unknown
FT                                pathological significance;
FT                                dbSNP:rs199473044).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_068325.
FT   VARIANT      27     27       R -> H (in BRGDA1 and LQT3;
FT                                dbSNP:rs199473045).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_026341.
FT   VARIANT      30     30       E -> G (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473551).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074695.
FT   VARIANT      34     34       R -> C (in dbSNP:rs6791924).
FT                                {ECO:0000269|PubMed:11997281,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026342.
FT   VARIANT      34     34       R -> H (in dbSNP:rs199473046).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074313.
FT   VARIANT      43     43       R -> Q (in LQT3; does not affect baseline
FT                                kinetics of sodium currents; causes an
FT                                unusual hyperpolarizing shift of the
FT                                activation kinetics after lidocaine
FT                                treatment; dbSNP:rs199473047).
FT                                {ECO:0000269|PubMed:18848812,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055159.
FT   VARIANT      48     48       E -> K (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473048).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074696.
FT   VARIANT      52     52       P -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473553).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074697.
FT   VARIANT      53     53       R -> Q (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473049).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074698.
FT   VARIANT      70     70       N -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473050).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074314.
FT   VARIANT      84     84       D -> N (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473051).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074315.
FT   VARIANT      93     93       F -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473052).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074316.
FT   VARIANT      94     94       I -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473053).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074317.
FT   VARIANT      95     95       V -> I (in BRGDA1; dbSNP:rs199473054).
FT                                {ECO:0000269|PubMed:17081365}.
FT                                /FTId=VAR_055160.
FT   VARIANT     104    104       R -> G (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473055).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074699.
FT   VARIANT     104    104       R -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473554).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074318.
FT   VARIANT     104    104       R -> W (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473055).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074319.
FT   VARIANT     109    109       N -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473056).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074320.
FT   VARIANT     115    115       S -> G (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473057).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074700.
FT   VARIANT     121    121       R -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473058).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074321.
FT   VARIANT     121    121       R -> W (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473556).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074322.
FT   VARIANT     125    125       V -> L (in LQT3; dbSNP:rs199473059).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_068326.
FT   VARIANT     126    126       K -> E (in BRGDA1; dbSNP:rs185492581).
FT                                {ECO:0000269|PubMed:12051963,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026343.
FT   VARIANT     136    136       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473557).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074323.
FT   VARIANT     138    138       M -> I (in ATFB10; dbSNP:rs199473060).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055161.
FT   VARIANT     146    146       V -> M (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473061).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074324.
FT   VARIANT     161    161       E -> K (in BRGDA1 and PFHB1A;
FT                                dbSNP:rs199473062).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026344.
FT   VARIANT     161    161       E -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473062).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074325.
FT   VARIANT     175    175       K -> N (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473063).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074326.
FT   VARIANT     178    178       A -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473065).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074327.
FT   VARIANT     182    182       C -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473066).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074328.
FT   VARIANT     185    185       A -> V (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473067).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074329.
FT   VARIANT     187    187       T -> I (in BRGDA1; loss of function;
FT                                dbSNP:rs199473558).
FT                                {ECO:0000269|PubMed:16325048}.
FT                                /FTId=VAR_026345.
FT   VARIANT     204    204       A -> V (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473559).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074330.
FT   VARIANT     212    212       L -> P (in LQT3; dbSNP:rs199473070).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055162.
FT   VARIANT     212    212       L -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473070).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074331.
FT   VARIANT     216    216       S -> L (rare variant found in patients
FT                                with atrial fibrillation; unknown
FT                                pathological significance;
FT                                dbSNP:rs41276525).
FT                                {ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055163.
FT   VARIANT     220    220       T -> I (in SSS1 and BRGDA1;
FT                                dbSNP:rs45620037).
FT                                {ECO:0000269|PubMed:14523039,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_017670.
FT   VARIANT     222    222       R -> Q (in BRGDA1 and LQT3;
FT                                dbSNP:rs45546039).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074332.
FT   VARIANT     223    223       V -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473560).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074333.
FT   VARIANT     225    225       R -> Q (in LQT3; dbSNP:rs199473071).
FT                                {ECO:0000269|PubMed:16922724}.
FT                                /FTId=VAR_036661.
FT   VARIANT     225    225       R -> W (in PFHB1A, BRGDA1 and LQT3;
FT                                dbSNP:rs199473072).
FT                                {ECO:0000269|PubMed:12574143,
FT                                ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055164.
FT   VARIANT     226    226       A -> V (in BRGDA1; dbSNP:rs199473561).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026346.
FT   VARIANT     230    230       I -> V (in BRGDA1; dbSNP:rs199473074).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026347.
FT   VARIANT     232    232       V -> I (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs45471994).
FT                                {ECO:0000269|PubMed:18599870,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055165.
FT   VARIANT     240    240       V -> M (in BRGDA1 and LQT3;
FT                                dbSNP:rs199473076).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074334.
FT   VARIANT     245    245       Q -> K (in LQT3; dbSNP:rs199473077).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068327.
FT   VARIANT     247    247       V -> L (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473078).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074701.
FT   VARIANT     270    270       Q -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473079).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074335.
FT   VARIANT     275    275       N -> K (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473080).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074702.
FT   VARIANT     276    276       L -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473081).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074336.
FT   VARIANT     278    278       H -> D (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473562).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074337.
FT   VARIANT     282    282       R -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473082).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074338.
FT   VARIANT     282    282       R -> H (in BRGDA1; dbSNP:rs199473083).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026348.
FT   VARIANT     286    286       A -> S (in dbSNP:rs61746118).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074339.
FT   VARIANT     289    289       G -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473084).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074703.
FT   VARIANT     291    291       N -> S (in dbSNP:rs199473563).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074340.
FT   VARIANT     294    294       V -> M (in BRGDA1; dbSNP:rs199473086).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026349.
FT   VARIANT     298    298       G -> S (in PFHB1A; also in irritable
FT                                bowel syndrome; results in reduction of
FT                                whole cell current density and a delay in
FT                                channel activation kinetics without a
FT                                change in single-channel conductance;
FT                                dbSNP:rs137854608).
FT                                {ECO:0000269|PubMed:11804990,
FT                                ECO:0000269|PubMed:19056759}.
FT                                /FTId=VAR_017671.
FT   VARIANT     299    299       L -> M (in dbSNP:rs199473087).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074341.
FT   VARIANT     300    300       V -> I (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473088).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074342.
FT   VARIANT     315    315       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473564).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074343.
FT   VARIANT     319    319       G -> S (in BRGDA1; dbSNP:rs199473090).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026350.
FT   VARIANT     320    320       T -> N (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473091).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074344.
FT   VARIANT     325    325       L -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473092).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055166.
FT   VARIANT     336    336       P -> L (in BRGDA1; detected in a compound
FT                                heterozygote also carrying V-1660; the
FT                                presence of both mutations is necessary
FT                                for the phenotypic expression of the
FT                                disease; severe reduction of sodium
FT                                currents; dbSNP:rs199473093).
FT                                {ECO:0000269|PubMed:17075016,
FT                                ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_055167.
FT   VARIANT     340    340       R -> W (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473094).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074704.
FT   VARIANT     351    351       G -> D (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473095).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074345.
FT   VARIANT     351    351       G -> V (in BRGDA1; 7-fold current
FT                                reduction; dbSNP:rs199473095).
FT                                {ECO:0000269|PubMed:12051963,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026351.
FT   VARIANT     353    353       T -> I (in BRGDA1; dbSNP:rs199473096).
FT                                {ECO:0000269|PubMed:17198989}.
FT                                /FTId=VAR_055168.
FT   VARIANT     356    356       D -> N (in BRGDA1; loss of function;
FT                                dbSNP:rs199473565).
FT                                {ECO:0000269|PubMed:16325048,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026352.
FT   VARIANT     367    367       R -> C (in BRGDA1 and LQT3; express no
FT                                current; dbSNP:rs28937318).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026353.
FT   VARIANT     367    367       R -> H (in BRGDA1; express no current;
FT                                dbSNP:rs28937318).
FT                                {ECO:0000269|PubMed:11823453,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_017672.
FT   VARIANT     367    367       R -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs28937318).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074346.
FT   VARIANT     369    369       M -> K (in BRGDA1; dbSNP:rs199473098).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026354.
FT   VARIANT     370    370       T -> M (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473099).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074705.
FT   VARIANT     374    374       W -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473566).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074347.
FT   VARIANT     376    376       R -> C (in dbSNP:rs199473100).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074348.
FT   VARIANT     376    376       R -> H (in BRGDA1; unknown pathological
FT                                significance; also found in patients with
FT                                atrial fibrillation; dbSNP:rs199473101).
FT                                {ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055169.
FT   VARIANT     386    386       G -> E (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473567).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074349.
FT   VARIANT     386    386       G -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473102).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074350.
FT   VARIANT     393    393       Missing (in BRGDA1).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026355.
FT   VARIANT     396    396       V -> A (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473103).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074351.
FT   VARIANT     396    396       V -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473104).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074352.
FT   VARIANT     397    397       I -> T (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473105).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074706.
FT   VARIANT     404    404       L -> Q (in LQT3; dbSNP:rs199473107).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068328.
FT   VARIANT     406    406       N -> K (in LQT3; dbSNP:rs199473108).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055170.
FT   VARIANT     406    406       N -> S (in BRGDA1; dbSNP:rs199473568).
FT                                /FTId=VAR_055171.
FT   VARIANT     409    409       L -> V (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473109).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074707.
FT   VARIANT     411    411       V -> M (in LQT3; dbSNP:rs72549410).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_068329.
FT   VARIANT     413    413       A -> E (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473569).
FT                                {ECO:0000269|PubMed:16414944}.
FT                                /FTId=VAR_074708.
FT   VARIANT     413    413       A -> T (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473110).
FT                                {ECO:0000269|PubMed:16414944}.
FT                                /FTId=VAR_074709.
FT   VARIANT     428    428       E -> K (in ATFB10; dbSNP:rs199473111).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055172.
FT   VARIANT     429    429       Missing (in LQT3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074710.
FT   VARIANT     439    439       E -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473570).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074353.
FT   VARIANT     445    445       H -> D (in ATFB10; dbSNP:rs199473112).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055173.
FT   VARIANT     447    447       A -> G (in dbSNP:rs199473113).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074354.
FT   VARIANT     449    449       T -> A (in dbSNP:rs199473571).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074355.
FT   VARIANT     461    461       L -> V (in dbSNP:rs41313697).
FT                                {ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055174.
FT   VARIANT     462    462       E -> A (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473114).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074711.
FT   VARIANT     462    462       E -> K (in LQT3; dbSNP:rs199473572).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068330.
FT   VARIANT     470    470       N -> K (in ATFB10; dbSNP:rs199473115).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055175.
FT   VARIANT     475    475       R -> S (in dbSNP:rs199473116).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074356.
FT   VARIANT     481    481       R -> W (in dbSNP:rs144511230).
FT                                {ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055176.
FT   VARIANT     501    501       D -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473117).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074357.
FT   VARIANT     512    512       T -> I (in PFHB1A; voltage-dependent
FT                                activation and inactivation of the I-512
FT                                channel is shifted negatively by 8 to 9
FT                                mV and had enhanced slow activation and
FT                                slower recovery from inactivation
FT                                commpared to the wild-type channel; the
FT                                double mutant R-558/I-512 channel shows
FT                                that R-558 eliminates the negative shift
FT                                induced by I-512 but only partially
FT                                restores the kinetic abnormalities;
FT                                dbSNP:rs199473118).
FT                                {ECO:0000269|PubMed:12569159}.
FT                                /FTId=VAR_036662.
FT   VARIANT     514    514       G -> C (in BRGDA1 and PFHB1A;
FT                                dbSNP:rs137854606).
FT                                {ECO:0000269|PubMed:11234013,
FT                                ECO:0000269|PubMed:19251209}.
FT                                /FTId=VAR_017673.
FT   VARIANT     524    524       S -> Y (in dbSNP:rs41313691).
FT                                {ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_036663.
FT   VARIANT     526    526       R -> H (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs45627438).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074358.
FT   VARIANT     530    530       F -> V (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473120).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074712.
FT   VARIANT     532    532       F -> C (in SIDS and BRGDA1;
FT                                dbSNP:rs199473573).
FT                                {ECO:0000269|PubMed:18596570,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055177.
FT   VARIANT     535    535       R -> Q (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473121).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074713.
FT   VARIANT     543    543       F -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473122).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074359.
FT   VARIANT     552    552       G -> R (in BRGDA1; dbSNP:rs3918389).
FT                                {ECO:0000269|PubMed:12358675,
FT                                ECO:0000269|PubMed:1309946,
FT                                ECO:0000269|PubMed:16616735,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026356.
FT   VARIANT     558    558       H -> R (polymorphism; channels properties
FT                                are similar to wild-type; the double
FT                                mutant R-558/I-512 channel shows that R-
FT                                558 eliminates the negative shift induced
FT                                by Ile-512 but only partially restores
FT                                the kinetic abnormalities; can modulate
FT                                the gating defects caused by Ala-2006 and
FT                                other mutations; dbSNP:rs1805124).
FT                                {ECO:0000269|PubMed:11997281,
FT                                ECO:0000269|PubMed:12051963,
FT                                ECO:0000269|PubMed:12454206,
FT                                ECO:0000269|PubMed:12569159,
FT                                ECO:0000269|PubMed:14500339,
FT                                ECO:0000269|PubMed:15489334,
FT                                ECO:0000269|PubMed:18368697,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|PubMed:21109022,
FT                                ECO:0000269|PubMed:23085483}.
FT                                /FTId=VAR_008955.
FT   VARIANT     567    567       L -> Q (in BRGDA1; dbSNP:rs199473124).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026357.
FT   VARIANT     568    568       R -> H (in dbSNP:rs199473125).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074360.
FT   VARIANT     569    569       R -> W (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473576).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074714.
FT   VARIANT     571    571       S -> I (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473126).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074715.
FT   VARIANT     572    572       A -> D (in LQT3 and ATFB10;
FT                                dbSNP:rs36210423).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055178.
FT   VARIANT     572    572       A -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs184442491).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074716.
FT   VARIANT     572    572       A -> V (in LQT3; unknown pathological
FT                                significance; dbSNP:rs36210423).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074717.
FT   VARIANT     573    573       Q -> E (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473127).
FT                                {ECO:0000269|PubMed:16414944}.
FT                                /FTId=VAR_074718.
FT   VARIANT     579    579       G -> R (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473128).
FT                                {ECO:0000269|PubMed:16414944,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074361.
FT   VARIANT     586    587       Missing (in LQT3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055179.
FT   VARIANT     592    592       N -> K (in dbSNP:rs199473130).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074362.
FT   VARIANT     596    596       D -> G (in dbSNP:rs199473131).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074363.
FT   VARIANT     601    601       V -> A (in dbSNP:rs199473132).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074364.
FT   VARIANT     615    615       G -> E (in LQT3 and BRGDA1; drug-induced
FT                                LQT syndrome; dbSNP:rs12720452).
FT                                {ECO:0000269|PubMed:11997281,
FT                                ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026358.
FT   VARIANT     618    618       L -> F (found in patients with drug-
FT                                induced LQT syndrome; also found in
FT                                patients with atrial fibrillation;
FT                                unknown pathological significance;
FT                                dbSNP:rs45488304).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_047360.
FT   VARIANT     619    619       L -> F (in LQT3 and BRGDA1;
FT                                dbSNP:rs199473133).
FT                                {ECO:0000269|PubMed:11997281,
FT                                ECO:0000269|PubMed:12673799,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_015682.
FT   VARIANT     620    620       R -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473577).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074365.
FT   VARIANT     632    632       T -> M (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473134).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074366.
FT   VARIANT     637    637       P -> L (in LQT3; dbSNP:rs199473135).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068331.
FT   VARIANT     638    638       G -> D (in dbSNP:rs199473578).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074367.
FT   VARIANT     639    639       G -> R (in LQT3; dbSNP:rs199473136).
FT                                {ECO:0000269|PubMed:16922724,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_036664.
FT   VARIANT     640    640       P -> A (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473137).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074368.
FT   VARIANT     647    647       A -> D (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs185638763).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074369.
FT   VARIANT     648    648       P -> L (in LQT3 and BRGDA1;
FT                                dbSNP:rs45609733).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_068332.
FT   VARIANT     654    654       E -> K (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473138).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074719.
FT   VARIANT     655    655       E -> K (in ATFB10; dbSNP:rs199473579).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055180.
FT   VARIANT     656    656       P -> L (in dbSNP:rs41313681).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074370.
FT   VARIANT     661    661       R -> W (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473139).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074371.
FT   VARIANT     672    672       A -> T (in dbSNP:rs199473140).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074372.
FT   VARIANT     673    673       L -> P (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473141).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074720.
FT   VARIANT     680    680       R -> H (in LQT3; dbSNP:rs199473142).
FT                                /FTId=VAR_055181.
FT   VARIANT     681    681       H -> P (in BRGDA1; dbSNP:rs199473143).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026359.
FT   VARIANT     683    683       C -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473144).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074373.
FT   VARIANT     689    689       R -> C (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473580).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074721.
FT   VARIANT     689    689       R -> H (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473145).
FT                                {ECO:0000269|PubMed:16414944,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074374.
FT   VARIANT     692    692       Q -> K (in dbSNP:rs45553235).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074375.
FT   VARIANT     701    701       P -> L (in BRGDA1 and LQT3;
FT                                dbSNP:rs199473147).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074376.
FT   VARIANT     705    705       S -> F (in dbSNP:rs199473148).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074377.
FT   VARIANT     717    717       P -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473149).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074378.
FT   VARIANT     731    731       T -> I (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473150).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074722.
FT   VARIANT     735    735       A -> E (in BRGDA1; dbSNP:rs137854611).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026360.
FT   VARIANT     735    735       A -> V (in BRGDA1 and SSS1; expresses
FT                                currents with steady state activation
FT                                voltage shifted to more positive
FT                                potentials and exhibit reduced sodium
FT                                channel current at the end of phase I of
FT                                the action potential; dbSNP:rs137854611).
FT                                {ECO:0000269|PubMed:11823453,
FT                                ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|PubMed:22795782}.
FT                                /FTId=VAR_017674.
FT   VARIANT     746    746       E -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473582).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074379.
FT   VARIANT     750    750       Q -> R (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473152).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074723.
FT   VARIANT     752    752       G -> R (in BRGDA1 and PFHB1A;
FT                                dbSNP:rs199473153).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026361.
FT   VARIANT     758    758       G -> E (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473154).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074380.
FT   VARIANT     764    764       M -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473156).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074381.
FT   VARIANT     772    772       D -> N (in BRGDA1 and LQT3;
FT                                dbSNP:rs199473157).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074382.
FT   VARIANT     773    773       P -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473158).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074383.
FT   VARIANT     789    789       V -> I (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473159).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074384.
FT   VARIANT     808    808       R -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473160).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074385.
FT   VARIANT     812    812       L -> Q (in BRGDA1; decreased protein
FT                                abundance; retained intracellularly;
FT                                decreased voltage-gated sodium channel
FT                                activity; hyperpolarizing shift of the
FT                                voltage dependence of inactivation
FT                                leading to reduced sodium window current;
FT                                no dominant negative effect).
FT                                {ECO:0000269|PubMed:26279430}.
FT                                /FTId=VAR_076555.
FT   VARIANT     814    814       R -> Q (in BRGDA1; dbSNP:rs199473584).
FT                                /FTId=VAR_055182.
FT   VARIANT     816    816       F -> Y (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473162).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074724.
FT   VARIANT     817    817       K -> E (in BRGDA1; no effect on
FT                                localization to the plasma membrane;
FT                                decreased voltage-gated sodium channel
FT                                activity; shift in the voltage dependence
FT                                of activation and changed recovery from
FT                                inactivation).
FT                                {ECO:0000269|PubMed:26776555}.
FT                                /FTId=VAR_076556.
FT   VARIANT     839    839       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473164).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074386.
FT   VARIANT     848    848       I -> F (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473166).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074725.
FT   VARIANT     851    851       F -> L (in BRGDA1; dbSNP:rs199473586).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026362.
FT   VARIANT     867    867       E -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473167).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074387.
FT   VARIANT     878    878       R -> C (in BRGDA1; dbSNP:rs199473168).
FT                                {ECO:0000269|PubMed:18616619,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055183.
FT   VARIANT     878    878       R -> H (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473587).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074388.
FT   VARIANT     886    886       H -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473169).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074389.
FT   VARIANT     892    892       F -> I (in BRGDA1; dbSNP:rs199473170).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026363.
FT   VARIANT     893    893       R -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473171).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074390.
FT   VARIANT     893    893       R -> H (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473172).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074391.
FT   VARIANT     896    896       C -> S (in BRGDA1; dbSNP:rs199473173).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026364.
FT   VARIANT     901    901       E -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473174).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074392.
FT   VARIANT     910    910       S -> L (in BRGDA1; dbSNP:rs199473175).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026365.
FT   VARIANT     915    915       C -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473588).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074393.
FT   VARIANT     917    917       L -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473176).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074394.
FT   VARIANT     924    924       V -> I (in dbSNP:rs199473177).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074395.
FT   VARIANT     927    927       N -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473589).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074396.
FT   VARIANT     928    928       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473178).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074397.
FT   VARIANT     935    935       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473179).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074398.
FT   VARIANT     941    941       S -> N (in LQT3; also in SIDS;
FT                                dbSNP:rs137854605).
FT                                {ECO:0000269|PubMed:10911008}.
FT                                /FTId=VAR_017675.
FT   VARIANT     960    960       Q -> K (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473590).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074726.
FT   VARIANT     965    965       R -> C (in BRGDA1; steady state
FT                                inactivation shifted to a more negative
FT                                potential; slower recovery from
FT                                inactivation; dbSNP:rs199473180).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:19272188,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026366.
FT   VARIANT     965    965       R -> H (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473181).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074399.
FT   VARIANT     965    965       R -> L (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473181).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074727.
FT   VARIANT     971    971       R -> C (in LQT3; dbSNP:rs61737825).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068333.
FT   VARIANT     981    981       C -> F (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473591).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074728.
FT   VARIANT     986    986       R -> Q (in dbSNP:rs41313667).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074400.
FT   VARIANT     997    997       A -> S (in LQT3; also found in patients
FT                                with atrial fibrillation; sodium current
FT                                characterized by slower decay and a 2- to
FT                                3-fold increase in late sodium current;
FT                                dbSNP:rs137854609).
FT                                {ECO:0000269|PubMed:11710892,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_017676.
FT   VARIANT     997    997       A -> T (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs137854609).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074401.
FT   VARIANT    1004   1004       C -> R (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473183).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074729.
FT   VARIANT    1016   1016       T -> M (in dbSNP:rs199473185).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074402.
FT   VARIANT    1023   1023       R -> H (in BRGDA1; dbSNP:rs199473592).
FT                                /FTId=VAR_055184.
FT   VARIANT    1027   1027       R -> Q (in dbSNP:rs763891399).
FT                                {ECO:0000269|PubMed:1309946,
FT                                ECO:0000269|PubMed:16616735,
FT                                ECO:0000269|Ref.6}.
FT                                /FTId=VAR_026367.
FT   VARIANT    1040   1040       G -> R (in dbSNP:rs199473186).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074403.
FT   VARIANT    1041   1041       D -> N (in dbSNP:rs45491996).
FT                                /FTId=VAR_047361.
FT   VARIANT    1053   1053       E -> K (in BRGDA1, ATFB10 and LQT3;
FT                                abolishes binding to ANK3 and also
FT                                prevents accumulation of SCN5A at cell
FT                                surface sites in ventricular
FT                                cardiomyocytes; dbSNP:rs137854617).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:15579534,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026368.
FT   VARIANT    1055   1055       D -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473593).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074404.
FT   VARIANT    1069   1069       T -> M (in LQT3; dbSNP:rs199473187).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_068334.
FT   VARIANT    1079   1079       S -> Y (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473188).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074405.
FT   VARIANT    1082   1082       V -> A (in dbSNP:rs199473189).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074406.
FT   VARIANT    1084   1084       G -> S (in SIDS; may be a rare
FT                                polymorphism; dbSNP:rs199473190).
FT                                {ECO:0000269|PubMed:18596570}.
FT                                /FTId=VAR_055185.
FT   VARIANT    1090   1090       P -> L (in dbSNP:rs1805125).
FT                                {ECO:0000269|PubMed:18368697,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_014464.
FT   VARIANT    1098   1098       V -> L (in dbSNP:rs199473191).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074407.
FT   VARIANT    1100   1100       A -> V (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473192).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074730.
FT   VARIANT    1103   1103       S -> Y (polymorphism; may confer
FT                                susceptibility to acquired arrhythmia;
FT                                dbSNP:rs7626962).
FT                                {ECO:0000269|PubMed:12193783,
FT                                ECO:0000269|PubMed:12471205,
FT                                ECO:0000269|PubMed:14500339,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_017677.
FT   VARIANT    1107   1107       E -> K (in dbSNP:rs199473193).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074408.
FT   VARIANT    1113   1113       A -> V (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473194).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074409.
FT   VARIANT    1114   1114       D -> N (in LQT3; dbSNP:rs199473195).
FT                                {ECO:0000269|PubMed:10973849,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_009935.
FT   VARIANT    1116   1116       R -> W (in dbSNP:rs199473196).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074410.
FT   VARIANT    1131   1131       T -> I (in ATFB10; dbSNP:rs199473197).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055186.
FT   VARIANT    1140   1140       S -> T (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473199).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074411.
FT   VARIANT    1166   1166       D -> N (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473594).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074731.
FT   VARIANT    1180   1180       A -> V (in dbSNP:rs41310765).
FT                                /FTId=VAR_047362.
FT   VARIANT    1193   1193       R -> Q (in BRGDA1 and LQT3; also found in
FT                                patients with atrial fibrillation;
FT                                accelerates the inactivation of the
FT                                sodium channel current and exhibit
FT                                reduced sodium channel current at the end
FT                                of phase I of the action potential;
FT                                dbSNP:rs41261344).
FT                                {ECO:0000269|PubMed:11823453,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_017678.
FT   VARIANT    1199   1199       Y -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473202).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074732.
FT   VARIANT    1212   1212       Missing (in LQT3; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074733.
FT   VARIANT    1219   1219       S -> N (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473597).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074412.
FT   VARIANT    1225   1225       E -> K (in BRGDA1 and LQT3;
FT                                dbSNP:rs199473204).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026369.
FT   VARIANT    1228   1228       Y -> H (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473205).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074413.
FT   VARIANT    1231   1231       E -> K (in LQT3; dbSNP:rs199473598).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068335.
FT   VARIANT    1232   1232       R -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473206).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074414.
FT   VARIANT    1232   1232       R -> W (in BRGDA1 and PFHB1A;
FT                                dbSNP:rs199473207).
FT                                {ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|PubMed:9521325}.
FT                                /FTId=VAR_017679.
FT   VARIANT    1236   1236       K -> N (in BRGDA1; dbSNP:rs199473208).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026370.
FT   VARIANT    1239   1239       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473210).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074415.
FT   VARIANT    1240   1240       E -> Q (in BRGDA1; dbSNP:rs199473211).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026371.
FT   VARIANT    1243   1243       D -> N (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473599).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074416.
FT   VARIANT    1249   1249       V -> D (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473213).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074417.
FT   VARIANT    1250   1250       F -> L (in LQT3; drug-induced LQT
FT                                syndrome; dbSNP:rs45589741).
FT                                {ECO:0000269|PubMed:11997281}.
FT                                /FTId=VAR_026372.
FT   VARIANT    1251   1251       V -> M (in dbSNP:rs199473600).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074418.
FT   VARIANT    1253   1253       E -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473214).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074419.
FT   VARIANT    1262   1262       G -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs137854616).
FT                                {ECO:0000269|PubMed:15338453,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_036665.
FT   VARIANT    1271   1271       W -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473601).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074420.
FT   VARIANT    1275   1275       D -> N (in CMD1E, BRGDA1, PFHB1A and
FT                                ATRST1; in familial atrial standstill is
FT                                found in association with polymorphisms
FT                                in the regulatory region of GJA5;
FT                                dbSNP:rs137854618).
FT                                {ECO:0000269|PubMed:12522116,
FT                                ECO:0000269|PubMed:15466643,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026373.
FT   VARIANT    1283   1283       L -> M (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473216).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074734.
FT   VARIANT    1288   1288       A -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473217).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074421.
FT   VARIANT    1293   1293       F -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs41311127).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026374.
FT   VARIANT    1295   1295       E -> K (in LQT3; causes significant
FT                                positive shifts in the half-maximal
FT                                voltage of steady-state inactivation and
FT                                activation; dbSNP:rs199473218).
FT                                {ECO:0000269|PubMed:11304498}.
FT                                /FTId=VAR_055187.
FT   VARIANT    1298   1298       P -> L (in SSS1; dbSNP:rs28937319).
FT                                {ECO:0000269|PubMed:14523039}.
FT                                /FTId=VAR_017680.
FT   VARIANT    1304   1304       T -> M (in LQT3; dbSNP:rs199473603).
FT                                {ECO:0000269|PubMed:10508990,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_008956.
FT   VARIANT    1308   1308       L -> F (polymorphism; associated with I-
FT                                232 in a case of lidocaine-induced
FT                                Brugada syndrome; dbSNP:rs41313031).
FT                                {ECO:0000269|PubMed:18599870,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055188.
FT   VARIANT    1311   1311       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473219).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074422.
FT   VARIANT    1319   1319       G -> V (in BRGDA1; dbSNP:rs199473220).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026375.
FT   VARIANT    1323   1323       V -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473221).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074423.
FT   VARIANT    1325   1325       N -> S (in LQT3; dbSNP:rs28937317).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_001577.
FT   VARIANT    1326   1326       A -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473222).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074735.
FT   VARIANT    1330   1330       A -> P (in LQT3; dbSNP:rs199473224).
FT                                /FTId=VAR_055189.
FT   VARIANT    1330   1330       A -> T (in LQT3; dbSNP:rs199473224).
FT                                /FTId=VAR_055190.
FT   VARIANT    1332   1332       P -> L (in LQT3 and BRGDA1; unknown
FT                                pathological significance;
FT                                dbSNP:rs199473225).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055191.
FT   VARIANT    1333   1333       S -> Y (in LQT3 and SIDS;
FT                                dbSNP:rs199473604).
FT                                {ECO:0000269|PubMed:16922724,
FT                                ECO:0000269|PubMed:19302788}.
FT                                /FTId=VAR_036666.
FT   VARIANT    1334   1334       I -> V (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473226).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074736.
FT   VARIANT    1338   1338       L -> V (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473227).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074737.
FT   VARIANT    1344   1344       F -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473228).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074424.
FT   VARIANT    1344   1344       F -> S (in BRGDA1; dbSNP:rs199473229).
FT                                {ECO:0000269|PubMed:16616735}.
FT                                /FTId=VAR_026376.
FT   VARIANT    1346   1346       L -> I (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473230).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074425.
FT   VARIANT    1346   1346       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473231).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074426.
FT   VARIANT    1351   1351       M -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473232).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074427.
FT   VARIANT    1353   1353       V -> M (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473233).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074428.
FT   VARIANT    1358   1358       G -> W (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473234).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074429.
FT   VARIANT    1359   1359       K -> N (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473235).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074430.
FT   VARIANT    1360   1360       F -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473236).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074431.
FT   VARIANT    1363   1363       C -> Y (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473237).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074432.
FT   VARIANT    1382   1382       S -> I (in BRGDA1; dbSNP:rs199473608).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026377.
FT   VARIANT    1405   1405       V -> L (in BRGDA1; dbSNP:rs199473239).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026378.
FT   VARIANT    1405   1405       V -> M (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473239).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074433.
FT   VARIANT    1406   1406       G -> E (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473609).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074434.
FT   VARIANT    1406   1406       G -> R (in BRGDA1; dbSNP:rs199473240).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026379.
FT   VARIANT    1408   1408       G -> R (in SSS1 and BRGDA1;
FT                                dbSNP:rs28936971).
FT                                {ECO:0000269|PubMed:11748104,
FT                                ECO:0000269|PubMed:14523039,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_017681.
FT   VARIANT    1409   1409       Y -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473610).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074435.
FT   VARIANT    1412   1412       L -> F (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473241).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074436.
FT   VARIANT    1419   1419       K -> E (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473242).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074437.
FT   VARIANT    1420   1420       G -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473611).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074438.
FT   VARIANT    1427   1427       A -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473244).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074439.
FT   VARIANT    1428   1428       A -> V (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473612).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074440.
FT   VARIANT    1432   1432       R -> G (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473245).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055192.
FT   VARIANT    1432   1432       R -> S (in BRGDA1 and LQT3;
FT                                dbSNP:rs199473246).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074441.
FT   VARIANT    1433   1433       G -> V (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473247).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074442.
FT   VARIANT    1438   1438       P -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473248).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055193.
FT   VARIANT    1441   1441       E -> Q (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473249).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074443.
FT   VARIANT    1448   1448       I -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473250).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074444.
FT   VARIANT    1448   1448       I -> T (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473251).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074445.
FT   VARIANT    1449   1449       Y -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473613).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074446.
FT   VARIANT    1451   1451       V -> D (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473252).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074447.
FT   VARIANT    1458   1458       S -> Y (in LQT3; dbSNP:rs199473253).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068336.
FT   VARIANT    1463   1463       N -> Y (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473614).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074448.
FT   VARIANT    1468   1468       V -> F (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473254).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074449.
FT   VARIANT    1472   1472       N -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473255).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074738.
FT   VARIANT    1473   1473       F -> C (in LQT3; dbSNP:rs199473256).
FT                                {ECO:0000269|PubMed:18060054,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055194.
FT   VARIANT    1479   1479       Missing (in BRGDA1).
FT                                {ECO:0000269|PubMed:12106943}.
FT                                /FTId=VAR_026380.
FT   VARIANT    1481   1481       G -> E (in LQT3; dbSNP:rs199473257).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_068337.
FT   VARIANT    1486   1486       F -> L (in LQT3; dbSNP:rs199473615).
FT                                /FTId=VAR_055195.
FT   VARIANT    1487   1487       M -> L (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473258).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074739.
FT   VARIANT    1488   1488       T -> R (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473259).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074740.
FT   VARIANT    1489   1489       E -> D (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473616).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074741.
FT   VARIANT    1493   1493       K -> R (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473260).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074742.
FT   VARIANT    1494   1494       Y -> N (in BRGDA1; dbSNP:rs199473261).
FT                                {ECO:0000269|PubMed:18341814}.
FT                                /FTId=VAR_055196.
FT   VARIANT    1495   1495       Y -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473262).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074743.
FT   VARIANT    1498   1498       M -> T (found in a patient with long QT
FT                                syndrome; unknown pathological
FT                                significance; dbSNP:rs199473263).
FT                                {ECO:0000269|PubMed:16115203,
FT                                ECO:0000269|PubMed:16414944}.
FT                                /FTId=VAR_074744.
FT   VARIANT    1498   1498       M -> V (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473264).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074745.
FT   VARIANT    1500   1500       K -> N (in dbSNP:rs199473265).
FT                                {ECO:0000269|PubMed:10508990}.
FT                                /FTId=VAR_008957.
FT   VARIANT    1500   1500       Missing (in BRGDA1).
FT                                {ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_026381.
FT   VARIANT    1501   1501       L -> V (in LQT3 and BRGDA1;
FT                                dbSNP:rs199473266).
FT                                {ECO:0000269|PubMed:10973849,
FT                                ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_009936.
FT   VARIANT    1502   1502       G -> S (in BRGDA1; dbSNP:rs199473267).
FT                                {ECO:0000269|PubMed:12106943}.
FT                                /FTId=VAR_026382.
FT   VARIANT    1505   1507       Missing (in LQT3).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:7651517}.
FT                                /FTId=VAR_001576.
FT   VARIANT    1505   1505       K -> N (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473268).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074746.
FT   VARIANT    1507   1509       Missing (in LQT3).
FT                                /FTId=VAR_055197.
FT   VARIANT    1512   1512       R -> W (in BRGDA1; significantly affects
FT                                cardiac sodium channel characteristics;
FT                                associated with an increase in inward
FT                                sodium current during the action
FT                                potential upstroke; dbSNP:rs137854602).
FT                                {ECO:0000269|PubMed:10690282,
FT                                ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_017682.
FT   VARIANT    1521   1521       I -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473617).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074450.
FT   VARIANT    1525   1525       V -> M (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473269).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074451.
FT   VARIANT    1527   1527       K -> R (in BRGDA1; asymptomatic patient;
FT                                associated with P-1569;
FT                                dbSNP:rs199473270).
FT                                {ECO:0000269|PubMed:15851320}.
FT                                /FTId=VAR_055198.
FT   VARIANT    1532   1532       V -> I (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473618).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074747.
FT   VARIANT    1548   1548       E -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473271).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074452.
FT   VARIANT    1560   1560       L -> F (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473619).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074748.
FT   VARIANT    1569   1569       A -> P (in BRGDA1; asymptomatic patient;
FT                                associated with R-1527;
FT                                dbSNP:rs199473273).
FT                                {ECO:0000269|PubMed:15851320}.
FT                                /FTId=VAR_055199.
FT   VARIANT    1571   1571       F -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473274).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074453.
FT   VARIANT    1574   1574       E -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473620).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074454.
FT   VARIANT    1582   1582       L -> P (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473275).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074455.
FT   VARIANT    1583   1583       R -> C (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs45514691).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074456.
FT   VARIANT    1583   1583       R -> H (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473621).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074457.
FT   VARIANT    1593   1593       I -> M (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473276).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074749.
FT   VARIANT    1594   1594       F -> S (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473277).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074750.
FT   VARIANT    1595   1595       D -> N (in PFHB1A; significant defect in
FT                                the kinetics of fast-channel inactivation
FT                                distinct from mutations reported in LQT3;
FT                                dbSNP:rs137854607).
FT                                {ECO:0000269|PubMed:11804990}.
FT                                /FTId=VAR_017683.
FT   VARIANT    1596   1596       F -> I (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473278).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074751.
FT   VARIANT    1604   1604       V -> M (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473280).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074458.
FT   VARIANT    1609   1609       S -> W (in LQT3; dbSNP:rs199473622).
FT                                {ECO:0000269|PubMed:16922724}.
FT                                /FTId=VAR_036667.
FT   VARIANT    1613   1613       Q -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473281).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074459.
FT   VARIANT    1617   1617       Missing (in LQT3 and BRGDA1).
FT                                {ECO:0000269|PubMed:17081365,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055200.
FT   VARIANT    1620   1620       T -> K (in LQT3 and PFHB1A;
FT                                dbSNP:rs199473282).
FT                                /FTId=VAR_055201.
FT   VARIANT    1620   1620       T -> M (in BRGDA1; arrhythmogenicity
FT                                revealed only at temperatures approaching
FT                                the physiologic range;
FT                                dbSNP:rs199473282).
FT                                {ECO:0000269|PubMed:10532948,
FT                                ECO:0000269|PubMed:10618304,
FT                                ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|PubMed:9521325}.
FT                                /FTId=VAR_017684.
FT   VARIANT    1623   1623       R -> L (in LQT3; dbSNP:rs137854600).
FT                                {ECO:0000269|PubMed:10973849,
FT                                ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_009937.
FT   VARIANT    1623   1623       R -> Q (in LQT3 and BRGDA1;
FT                                dbSNP:rs137854600).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|PubMed:9506831,
FT                                ECO:0000269|Ref.31}.
FT                                /FTId=VAR_001578.
FT   VARIANT    1626   1626       R -> H (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473283).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074752.
FT   VARIANT    1626   1626       R -> P (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473283).
FT                                {ECO:0000269|PubMed:16414944}.
FT                                /FTId=VAR_055202.
FT   VARIANT    1629   1629       R -> Q (in BRGDA1; changed voltage-gated
FT                                sodium channel activity; no difference in
FT                                current density but changed inactivation
FT                                kinetics and prolonged recovery from
FT                                inactivation; dbSNP:rs199473623).
FT                                {ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|PubMed:24167619}.
FT                                /FTId=VAR_074460.
FT   VARIANT    1642   1642       G -> E (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473624).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074461.
FT   VARIANT    1644   1644       R -> C (in LQT3 and BRGDA1;
FT                                dbSNP:rs199473287).
FT                                {ECO:0000269|PubMed:16414944,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055203.
FT   VARIANT    1644   1644       R -> H (in LQT3; dbSNP:rs28937316).
FT                                {ECO:0000269|PubMed:10973849,
FT                                ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_001579.
FT   VARIANT    1645   1645       T -> M (in LQT3; dbSNP:rs199473288).
FT                                {ECO:0000269|PubMed:10508990}.
FT                                /FTId=VAR_008958.
FT   VARIANT    1649   1649       A -> V (in BRGDA1; dbSNP:rs199473289).
FT                                {ECO:0000269|PubMed:17081365}.
FT                                /FTId=VAR_055204.
FT   VARIANT    1650   1650       L -> F (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473290).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074753.
FT   VARIANT    1652   1652       M -> R (in LQT3; dbSNP:rs199473291).
FT                                /FTId=VAR_055205.
FT   VARIANT    1652   1652       M -> T (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473291).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074754.
FT   VARIANT    1660   1660       I -> V (in BRGDA1 and LQT3; the BRGDA1
FT                                patient is a compound heterozygote also
FT                                carrying L-336; the presence of both
FT                                mutations is necessary for phenotypic
FT                                expression of the disease in this
FT                                patient; complete loss of sodium currents
FT                                due to defective channel trafficking to
FT                                the plasma membrane; dbSNP:rs199473625).
FT                                {ECO:0000269|PubMed:16414944,
FT                                ECO:0000269|PubMed:17075016,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055206.
FT   VARIANT    1661   1661       G -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473292).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074462.
FT   VARIANT    1667   1667       V -> I (in LQT3 and BRGDA1;
FT                                dbSNP:rs199473293).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_068338.
FT   VARIANT    1672   1672       S -> Y (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473626).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074463.
FT   VARIANT    1680   1680       A -> T (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473294).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074464.
FT   VARIANT    1690   1690       D -> N (in BRGDA1; decreased localization
FT                                to the plasma membrane; decreased
FT                                voltage-gated sodium channel activity;
FT                                dominant negative effect; no effect on
FT                                voltage dependence for activation and
FT                                inactivation).
FT                                {ECO:0000269|PubMed:23085483}.
FT                                /FTId=VAR_076557.
FT   VARIANT    1698   1698       A -> T (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473295).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074465.
FT   VARIANT    1705   1705       F -> S (in SIDS; causes a hyperpolarizing
FT                                shift of steady-state inactivation and
FT                                delayed recovery from inactivation;
FT                                dbSNP:rs199473627).
FT                                {ECO:0000269|PubMed:18596570}.
FT                                /FTId=VAR_055207.
FT   VARIANT    1709   1709       T -> M (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473297).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074466.
FT   VARIANT    1709   1709       T -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473297).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074467.
FT   VARIANT    1710   1710       S -> L (in VF1; dbSNP:rs137854604).
FT                                {ECO:0000269|PubMed:10940383}.
FT                                /FTId=VAR_017685.
FT   VARIANT    1712   1712       G -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473298).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074468.
FT   VARIANT    1714   1714       D -> G (in BRGDA1; strong decrease of
FT                                current density; does not affect ion
FT                                selectivity properties;
FT                                dbSNP:rs199473628).
FT                                {ECO:0000269|PubMed:16266370,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026383.
FT   VARIANT    1722   1722       N -> D (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473299).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074469.
FT   VARIANT    1723   1723       T -> N (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473300).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074755.
FT   VARIANT    1728   1728       C -> R (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473302).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074470.
FT   VARIANT    1728   1728       C -> W (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs193922726).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074471.
FT   VARIANT    1739   1739       R -> W (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473303).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074756.
FT   VARIANT    1740   1740       G -> R (in BRGDA1; dbSNP:rs199473304).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026384.
FT   VARIANT    1743   1743       G -> E (in BRGDA1; dbSNP:rs199473629).
FT                                {ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026385.
FT   VARIANT    1743   1743       G -> R (in BRGDA1; yields nearly
FT                                undetectable currents in transfected
FT                                cells; dbSNP:rs199473305).
FT                                {ECO:0000269|PubMed:15023552,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055208.
FT   VARIANT    1748   1748       G -> D (in BRGDA1; decreased localization
FT                                to the plasma membrane; decreased
FT                                voltage-gated sodium channel activity;
FT                                dominant negative effect; changed voltage
FT                                dependence for activation and
FT                                inactivation).
FT                                {ECO:0000269|PubMed:23085483}.
FT                                /FTId=VAR_076558.
FT   VARIANT    1761   1761       L -> F (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473307).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074757.
FT   VARIANT    1761   1761       L -> H (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473308).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074758.
FT   VARIANT    1763   1763       V -> M (in LQT3; dbSNP:rs199473631).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055209.
FT   VARIANT    1764   1764       V -> F (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473309).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074472.
FT   VARIANT    1766   1766       M -> L (in LQT3; affects protein
FT                                trafficking; dbSNP:rs199473310).
FT                                {ECO:0000269|PubMed:12454206,
FT                                ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_055210.
FT   VARIANT    1767   1767       Y -> C (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473632).
FT                                {ECO:0000269|PubMed:16414944}.
FT                                /FTId=VAR_074759.
FT   VARIANT    1768   1768       I -> V (in LQT3; increases the rate of
FT                                recovery from inactivation and the
FT                                channel availability, observed as a
FT                                positive shift of the steady-state
FT                                inactivation curve; dbSNP:rs199473311).
FT                                {ECO:0000269|PubMed:12209021}.
FT                                /FTId=VAR_055211.
FT   VARIANT    1777   1777       V -> M (in LQT3; dbSNP:rs199473314).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_055212.
FT   VARIANT    1779   1779       T -> M (in LQT3 and BRGDA1;
FT                                dbSNP:rs199473634).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_068339.
FT   VARIANT    1784   1784       E -> K (in LQT3 and BRGDA1;
FT                                dbSNP:rs137854601).
FT                                {ECO:0000269|PubMed:10377081,
FT                                ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:18451998,
FT                                ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_008959.
FT   VARIANT    1787   1787       S -> N (in dbSNP:rs199473316).
FT                                {ECO:0000269|PubMed:10973849,
FT                                ECO:0000269|PubMed:16414944,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_009938.
FT   VARIANT    1790   1790       D -> G (in LQT3; dbSNP:rs199473317).
FT                                {ECO:0000269|PubMed:16414944,
FT                                ECO:0000269|PubMed:9686753}.
FT                                /FTId=VAR_001580.
FT   VARIANT    1792   1792       D -> N (in SSS1; dbSNP:rs727504495).
FT                                {ECO:0000269|PubMed:22795782}.
FT                                /FTId=VAR_068475.
FT   VARIANT    1795   1795       Y -> C (in LQT3; also in a family
FT                                associating LQT syndrome and atrial
FT                                fibrillation; slows the onset of
FT                                activation, but does not cause a marked
FT                                negative shift in the voltage dependence
FT                                of inactivation or affect the kinetics of
FT                                the recovery from inactivation; increases
FT                                the expression of sustained Na(+) channel
FT                                activity and promotes entrance into an
FT                                intermediate or slowly developing
FT                                inactivated state; dbSNP:rs137854614).
FT                                {ECO:0000269|PubMed:11410597,
FT                                ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:18929331,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_019123.
FT   VARIANT    1795   1795       Y -> H (in BRGDA1; accelerates the onset
FT                                of activation and causes a marked
FT                                negative shift in the voltage dependence
FT                                of inactivation; does not affect the
FT                                kinetics of the recovery from
FT                                inactivation; increases the expression of
FT                                sustained Na(+) channel activity and
FT                                promotes entrance into an intermediate or
FT                                slowly developing inactivated state;
FT                                dbSNP:rs137854615).
FT                                {ECO:0000269|PubMed:11410597,
FT                                ECO:0000269|PubMed:11901046}.
FT                                /FTId=VAR_019124.
FT   VARIANT    1795   1795       Y -> YD (in LQT3 and BRGDA1; 7.3-mV
FT                                negative shift of the steady-state
FT                                inactivation curve and 8.1-mV positive
FT                                shift of the steady-state activation
FT                                curve; may reduced sodium current during
FT                                the upstroke of the action potential).
FT                                {ECO:0000269|PubMed:10590249,
FT                                ECO:0000269|PubMed:11889015}.
FT                                /FTId=VAR_017686.
FT   VARIANT    1819   1819       D -> N (in LQT3; digenic; the patient
FT                                also carries mutation G-100 on KCNH2;
FT                                dbSNP:rs137854619).
FT                                {ECO:0000269|PubMed:16922724}.
FT                                /FTId=VAR_036668.
FT   VARIANT    1825   1825       L -> P (in LQT3; drug-induced LQT
FT                                syndrome; dbSNP:rs79299226).
FT                                /FTId=VAR_055213.
FT   VARIANT    1826   1826       R -> C (in ATFB10; dbSNP:rs199473635).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055214.
FT   VARIANT    1826   1826       R -> H (in LQT3; sodium current
FT                                characterized by slower decay and a 2- to
FT                                3-fold increase in late sodium current;
FT                                dbSNP:rs137854610).
FT                                {ECO:0000269|PubMed:11710892,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_017687.
FT   VARIANT    1832   1832       Q -> E (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473320).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074473.
FT   VARIANT    1836   1836       I -> T (in dbSNP:rs45563942).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074474.
FT   VARIANT    1839   1839       D -> G (in LQT3; dbSNP:rs199473321).
FT                                {ECO:0000269|PubMed:10627139,
FT                                ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_001581.
FT   VARIANT    1849   1849       H -> R (in LQT3; decreased interaction
FT                                with FGF12, FGF13 and FGF14; increased
FT                                voltage-gated sodium channel activity;
FT                                altered inactivation; dbSNP:rs794728898).
FT                                {ECO:0000269|PubMed:26392562}.
FT                                /FTId=VAR_076559.
FT   VARIANT    1850   1850       C -> S (in BRGDA1; decreased I(Na)
FT                                density; shift of the steady-state
FT                                inactivation towards negative potentials;
FT                                dbSNP:rs199473322).
FT                                {ECO:0000269|PubMed:18252757}.
FT                                /FTId=VAR_055215.
FT   VARIANT    1861   1861       V -> I (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473636).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074475.
FT   VARIANT    1872   1872       K -> N (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473323).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074476.
FT   VARIANT    1875   1875       M -> T (in atrial fibrillation;
FT                                pronounced depolarized shift of the
FT                                voltage dependence of steady-state
FT                                inactivation; no persistent sodium
FT                                current; dbSNP:rs199473324).
FT                                {ECO:0000269|PubMed:18929244}.
FT                                /FTId=VAR_055216.
FT   VARIANT    1897   1897       R -> W (in LQT3; unknown pathological
FT                                significance; dbSNP:rs45465995).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074760.
FT   VARIANT    1901   1901       E -> K (in dbSNP:rs199473325).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074477.
FT   VARIANT    1901   1901       E -> Q (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473325).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074761.
FT   VARIANT    1903   1903       V -> L (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs864622270).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074478.
FT   VARIANT    1904   1904       S -> L (in LQT3; promotes late sodium
FT                                currents by increasing the propensity of
FT                                the channel to reopen during prolonged
FT                                depolarization; dbSNP:rs150264233).
FT                                {ECO:0000269|PubMed:18708744}.
FT                                /FTId=VAR_055217.
FT   VARIANT    1909   1909       Q -> R (in LQT3; dbSNP:rs199473326).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068340.
FT   VARIANT    1913   1913       R -> H (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473327).
FT                                {ECO:0000269|PubMed:16414944}.
FT                                /FTId=VAR_074762.
FT   VARIANT    1919   1919       R -> C (in dbSNP:rs199473328).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074479.
FT   VARIANT    1924   1924       A -> T (in BRGDA1; significantly affect
FT                                cardiac sodium channel characteristics;
FT                                associated with an increase in inward
FT                                sodium current during the action
FT                                potential upstroke; dbSNP:rs137854603).
FT                                {ECO:0000269|PubMed:10690282,
FT                                ECO:0000269|PubMed:12106943,
FT                                ECO:0000269|PubMed:19251209,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_017688.
FT   VARIANT    1935   1935       G -> S (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473637).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055218.
FT   VARIANT    1938   1938       E -> K (in BRGDA1; unknown pathological
FT                                significance; dbSNP:rs199473329).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074480.
FT   VARIANT    1949   1949       A -> S (in LQT3; dbSNP:rs199473330).
FT                                {ECO:0000269|PubMed:15840476}.
FT                                /FTId=VAR_068341.
FT   VARIANT    1951   1951       V -> L (in BRGDA1 and LQT3; also found in
FT                                patients with atrial fibrillation;
FT                                unknown pathological significance;
FT                                dbSNP:rs41315493).
FT                                {ECO:0000269|PubMed:11901046,
FT                                ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_026386.
FT   VARIANT    1951   1951       V -> M (in ATFB10; dbSNP:rs41315493).
FT                                {ECO:0000269|PubMed:18378609}.
FT                                /FTId=VAR_055219.
FT   VARIANT    1958   1958       R -> Q (found in a patient with long QT
FT                                syndrome; unknown pathological
FT                                significance; dbSNP:rs199473331).
FT                                {ECO:0000269|PubMed:15840476,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_068342.
FT   VARIANT    1962   1962       P -> L (in dbSNP:rs199473638).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074481.
FT   VARIANT    1968   1968       I -> M (in dbSNP:rs199473333).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074482.
FT   VARIANT    1968   1968       I -> S (in BRGDA1; dbSNP:rs199473639).
FT                                /FTId=VAR_055220.
FT   VARIANT    1977   1977       Y -> N (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473334).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074763.
FT   VARIANT    1987   1987       N -> K (in ATFB10; dbSNP:rs199473335).
FT                                {ECO:0000269|PubMed:18088563}.
FT                                /FTId=VAR_065865.
FT   VARIANT    1991   1991       R -> Q (in dbSNP:rs199473336).
FT                                {ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074483.
FT   VARIANT    2004   2004       F -> L (in LQT3 and BRGDA1; also found in
FT                                patients with atrial fibrillation;
FT                                results in channels with decreased peak
FT                                and persistent current amplitudes;
FT                                increased closed-state and slow
FT                                inactivation; decelerated recovery from
FT                                inactivation; dbSNP:rs41311117).
FT                                {ECO:0000269|PubMed:18378609,
FT                                ECO:0000269|PubMed:18456723,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_055221.
FT   VARIANT    2004   2004       F -> V (in BRGDA1 and LQT3;
FT                                dbSNP:rs41311117).
FT                                {ECO:0000269|PubMed:19716085,
FT                                ECO:0000269|PubMed:20129283}.
FT                                /FTId=VAR_074484.
FT   VARIANT    2006   2006       P -> A (found in a patient with long QT
FT                                syndrome; unknown pathological
FT                                significance; causes an increase of
FT                                persistent sodium current and produces a
FT                                depolarizing shift in voltage dependence
FT                                of inactivation; dbSNP:rs45489199).
FT                                {ECO:0000269|PubMed:20129283,
FT                                ECO:0000269|PubMed:21109022}.
FT                                /FTId=VAR_055222.
FT   VARIANT    2012   2012       R -> C (in LQT3; unknown pathological
FT                                significance; dbSNP:rs199473640).
FT                                {ECO:0000269|PubMed:19716085}.
FT                                /FTId=VAR_074764.
FT   MUTAGEN    1476   1476       Q->K: Induces accelerated recovery from
FT                                channel fast inactivation.
FT                                {ECO:0000269|PubMed:16054936}.
FT   MUTAGEN    1610   1610       D->R: High decrease in affinity to the
FT                                sea anemone toxin anthopleurin-B.
FT                                {ECO:0000269|PubMed:24898004}.
FT   MUTAGEN    1802   1804       DPE->APA: Abolishes calcium response on
FT                                channel inactivation.
FT                                {ECO:0000269|PubMed:19074138}.
FT   MUTAGEN    1974   1974       P->A: Strongly reduces interaction with
FT                                NEDD4, NEDD4L or WWP2.
FT                                {ECO:0000269|PubMed:15548568}.
FT   MUTAGEN    1975   1975       P->A: Strongly reduces interaction with
FT                                NEDD4, NEDD4L or WWP2.
FT                                {ECO:0000269|PubMed:15548568}.
FT   MUTAGEN    1976   1976       S->A: Strongly reduces interaction with
FT                                NEDD4, NEDD4L or WWP2.
FT                                {ECO:0000269|PubMed:15548568}.
FT   MUTAGEN    1977   1977       Y->A: Strongly reduces interaction with
FT                                NEDD4, NEDD4L or WWP2.
FT                                {ECO:0000269|PubMed:15217910,
FT                                ECO:0000269|PubMed:15548568}.
FT   MUTAGEN    1978   1978       D->A: No effect on interaction with
FT                                NEDD4, NEDD4L or WWP2.
FT                                {ECO:0000269|PubMed:15548568}.
FT   MUTAGEN    1979   1979       S->A: No effect on interaction with
FT                                NEDD4, NEDD4L or WWP2.
FT                                {ECO:0000269|PubMed:15548568}.
FT   MUTAGEN    1980   1980       V->A: No effect on interaction with
FT                                NEDD4, NEDD4L or WWP2.
FT                                {ECO:0000269|PubMed:15217910,
FT                                ECO:0000269|PubMed:15548568}.
FT   MUTAGEN    1980   1980       V->D,R: Strongly reduces interaction with
FT                                NEDD4L. {ECO:0000269|PubMed:15217910,
FT                                ECO:0000269|PubMed:15548568}.
FT   CONFLICT     91     91       K -> R (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT     96     96       L -> P (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    120    120       I -> V (in Ref. 1; AAA58644).
FT                                {ECO:0000305}.
FT   CONFLICT    162    162       Y -> H (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    180    180       G -> A (in Ref. 1; AAA58644).
FT                                {ECO:0000305}.
FT   CONFLICT    181    181       F -> S (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    191    191       D -> G (in Ref. 5; BAD12084/BAD12085 and
FT                                6; ABR15763/ABR15764). {ECO:0000305}.
FT   CONFLICT    196    196       L -> P (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    215    215       V -> L (in Ref. 5; BAD12084/BAD12085, 6;
FT                                ABR15763/ABR15764 and 9; AAI44622/
FT                                AAI40814). {ECO:0000305}.
FT   CONFLICT    234    234       S -> P (in Ref. 5; BAD12084/BAD12085, 6;
FT                                ABR15763/ABR15764 and 9; AAI44622/
FT                                AAI40814). {ECO:0000305}.
FT   CONFLICT    280    280       C -> R (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    290    290       T -> I (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    516    516       S -> N (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    608    608       D -> N (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    618    618       L -> I (in Ref. 4; AAO91669).
FT                                {ECO:0000305}.
FT   CONFLICT    653    653       F -> V (in Ref. 5; BAD12084/BAD12085).
FT                                {ECO:0000305}.
FT   CONFLICT    918    918       V -> G (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT    987    987       Q -> H (in Ref. 1; AAA58644, 5; BAD12084/
FT                                BAD12085 and 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT   1085   1085       G -> W (in Ref. 1; AAA58644 and 5;
FT                                BAD12084). {ECO:0000305}.
FT   CONFLICT   1087   1087       E -> R (in Ref. 1; AAA58644 and 5;
FT                                BAD12084). {ECO:0000305}.
FT   CONFLICT   1088   1088       A -> G (in Ref. 1; AAA58644 and 5;
FT                                BAD12084). {ECO:0000305}.
FT   CONFLICT   1342   1342       L -> H (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT   1479   1479       K -> T (in Ref. 5; BAD12084/BAD12085).
FT                                {ECO:0000305}.
FT   CONFLICT   1480   1481       LG -> IR (in Ref. 7; ABQ01244).
FT                                {ECO:0000305}.
FT   CONFLICT   1616   1616       F -> S (in Ref. 10; BAD92103).
FT                                {ECO:0000305}.
FT   CONFLICT   1657   1657       L -> P (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   CONFLICT   1850   1850       C -> R (in Ref. 6; ABR15763/ABR15764).
FT                                {ECO:0000305}.
FT   HELIX      1491   1500       {ECO:0000244|PDB:4DJC}.
FT   HELIX      1788   1801       {ECO:0000244|PDB:4DCK}.
FT   STRAND     1807   1810       {ECO:0000244|PDB:4DCK}.
FT   HELIX      1811   1813       {ECO:0000244|PDB:4DCK}.
FT   HELIX      1814   1820       {ECO:0000244|PDB:4DCK}.
FT   TURN       1823   1825       {ECO:0000244|PDB:4DCK}.
FT   HELIX      1832   1837       {ECO:0000244|PDB:4DCK}.
FT   STRAND     1841   1843       {ECO:0000244|PDB:4DCK}.
FT   TURN       1844   1846       {ECO:0000244|PDB:4DCK}.
FT   STRAND     1847   1849       {ECO:0000244|PDB:4DCK}.
FT   HELIX      1850   1862       {ECO:0000244|PDB:4DCK}.
FT   HELIX      1866   1882       {ECO:0000244|PDB:4DCK}.
FT   HELIX      1886   1888       {ECO:0000244|PDB:4DCK}.
FT   STRAND     1891   1894       {ECO:0000244|PDB:4OVN}.
FT   HELIX      1896   1926       {ECO:0000244|PDB:4DCK}.
SQ   SEQUENCE   2016 AA;  226940 MW;  841E3A365931190B CRC64;
     MANFLLPRGT SSFRRFTRES LAAIEKRMAE KQARGSTTLQ ESREGLPEEE APRPQLDLQA
     SKKLPDLYGN PPQELIGEPL EDLDPFYSTQ KTFIVLNKGK TIFRFSATNA LYVLSPFHPI
     RRAAVKILVH SLFNMLIMCT ILTNCVFMAQ HDPPPWTKYV EYTFTAIYTF ESLVKILARG
     FCLHAFTFLR DPWNWLDFSV IIMAYTTEFV DLGNVSALRT FRVLRALKTI SVISGLKTIV
     GALIQSVKKL ADVMVLTVFC LSVFALIGLQ LFMGNLRHKC VRNFTALNGT NGSVEADGLV
     WESLDLYLSD PENYLLKNGT SDVLLCGNSS DAGTCPEGYR CLKAGENPDH GYTSFDSFAW
     AFLALFRLMT QDCWERLYQQ TLRSAGKIYM IFFMLVIFLG SFYLVNLILA VVAMAYEEQN
     QATIAETEEK EKRFQEAMEM LKKEHEALTI RGVDTVSRSS LEMSPLAPVN SHERRSKRRK
     RMSSGTEECG EDRLPKSDSE DGPRAMNHLS LTRGLSRTSM KPRSSRGSIF TFRRRDLGSE
     ADFADDENST AGESESHHTS LLVPWPLRRT SAQGQPSPGT SAPGHALHGK KNSTVDCNGV
     VSLLGAGDPE ATSPGSHLLR PVMLEHPPDT TTPSEEPGGP QMLTSQAPCV DGFEEPGARQ
     RALSAVSVLT SALEELEESR HKCPPCWNRL AQRYLIWECC PLWMSIKQGV KLVVMDPFTD
     LTITMCIVLN TLFMALEHYN MTSEFEEMLQ VGNLVFTGIF TAEMTFKIIA LDPYYYFQQG
     WNIFDSIIVI LSLMELGLSR MSNLSVLRSF RLLRVFKLAK SWPTLNTLIK IIGNSVGALG
     NLTLVLAIIV FIFAVVGMQL FGKNYSELRD SDSGLLPRWH MMDFFHAFLI IFRILCGEWI
     ETMWDCMEVS GQSLCLLVFL LVMVIGNLVV LNLFLALLLS SFSADNLTAP DEDREMNNLQ
     LALARIQRGL RFVKRTTWDF CCGLLRQRPQ KPAALAAQGQ LPSCIATPYS PPPPETEKVP
     PTRKETRFEE GEQPGQGTPG DPEPVCVPIA VAESDTDDQE EDEENSLGTE EESSKQQESQ
     PVSGGPEAPP DSRTWSQVSA TASSEAEASA SQADWRQQWK AEPQAPGCGE TPEDSCSEGS
     TADMTNTAEL LEQIPDLGQD VKDPEDCFTE GCVRRCPCCA VDTTQAPGKV WWRLRKTCYH
     IVEHSWFETF IIFMILLSSG ALAFEDIYLE ERKTIKVLLE YADKMFTYVF VLEMLLKWVA
     YGFKKYFTNA WCWLDFLIVD VSLVSLVANT LGFAEMGPIK SLRTLRALRP LRALSRFEGM
     RVVVNALVGA IPSIMNVLLV CLIFWLIFSI MGVNLFAGKF GRCINQTEGD LPLNYTIVNN
     KSQCESLNLT GELYWTKVKV NFDNVGAGYL ALLQVATFKG WMDIMYAAVD SRGYEEQPQW
     EYNLYMYIYF VIFIIFGSFF TLNLFIGVII DNFNQQKKKL GGQDIFMTEE QKKYYNAMKK
     LGSKKPQKPI PRPLNKYQGF IFDIVTKQAF DVTIMFLICL NMVTMMVETD DQSPEKINIL
     AKINLLFVAI FTGECIVKLA ALRHYYFTNS WNIFDFVVVI LSIVGTVLSD IIQKYFFSPT
     LFRVIRLARI GRILRLIRGA KGIRTLLFAL MMSLPALFNI GLLLFLVMFI YSIFGMANFA
     YVKWEAGIDD MFNFQTFANS MLCLFQITTS AGWDGLLSPI LNTGPPYCDP TLPNSNGSRG
     DCGSPAVGIL FFTTYIIISF LIVVNMYIAI ILENFSVATE ESTEPLSEDD FDMFYEIWEK
     FDPEATQFIE YSVLSDFADA LSEPLRIAKP NQISLINMDL PMVSGDRIHC MDILFAFTKR
     VLGESGEMDA LKIQMEEKFM AANPSKISYE PITTTLRRKH EEVSAMVIQR AFRRHLLQRS
     LKHASFLFRQ QAGSGLSEED APEREGLIAY VMSENFSRPL GPPSSSSISS TSFPPSYDSV
     TRATSDNLQV RGSDYSHSED LADFPPSPDR DRESIV
//
ID   SCN8A_HUMAN             Reviewed;        1980 AA.
AC   Q9UQD0; B9VWG8; O95788; Q9NYX2; Q9UPB2;
DT   15-AUG-2003, integrated into UniProtKB/Swiss-Prot.
DT   01-MAY-2000, sequence version 1.
DT   15-FEB-2017, entry version 153.
DE   RecName: Full=Sodium channel protein type 8 subunit alpha;
DE   AltName: Full=Sodium channel protein type VIII subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.6;
GN   Name=SCN8A; Synonyms=MED;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606 {ECO:0000312|EMBL:BAA78033.1};
RN   [1] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE (ISOFORM 4).
RC   TISSUE=Brain {ECO:0000269|PubMed:9295353}, and
RC   Fetal brain {ECO:0000269|PubMed:9295353};
RX   PubMed=9295353; DOI=10.1074/jbc.272.38.24008;
RA   Plummer N.W., McBurney M.W., Meisler M.H.;
RT   "Alternative splicing of the sodium channel SCN8A predicts a truncated
RT   two-domain protein in fetal brain and non-neuronal cells.";
RL   J. Biol. Chem. 272:24008-24015(1997).
RN   [2] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1; 2 AND 3).
RX   PubMed=9828131; DOI=10.1006/geno.1998.5550;
RA   Plummer N.W., Galt J., Jones J.M., Burgess D.L., Sprunger L.K.,
RA   Kohrman D.C., Meisler M.H.;
RT   "Exon organization, coding sequence, physical mapping, and polymorphic
RT   intragenic markers for the human neuronal sodium channel gene SCN8A.";
RL   Genomics 54:287-296(1998).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 5), FUNCTION, SUBCELLULAR
RP   LOCATION, AND TISSUE SPECIFICITY.
RC   TISSUE=Monocytic leukemia;
RX   PubMed=19136557; DOI=10.1074/jbc.M801892200;
RA   Carrithers M.D., Chatterjee G., Carrithers L.M., Offoha R.,
RA   Iheagwara U., Rahner C., Graham M., Waxman S.G.;
RT   "Regulation of podosome formation in macrophages by a splice variant
RT   of the sodium channel SCN8A.";
RL   J. Biol. Chem. 284:8114-8126(2009).
RN   [4] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Lin C., Numakura C., Kiyoshi H.;
RT   "cDNA sequence of human sodium channel, SCN8A.";
RL   Submitted (JUN-1999) to the EMBL/GenBank/DDBJ databases.
RN   [5] {ECO:0000305}
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Jeong S.-Y., Goto J., Kanazawa I.;
RT   "Cloning of cDNA for human voltage-gated sodium channel alpha subunit,
RT   SCN8A.";
RL   Submitted (JAN-2000) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16541075; DOI=10.1038/nature04569;
RA   Scherer S.E., Muzny D.M., Buhay C.J., Chen R., Cree A., Ding Y.,
RA   Dugan-Rocha S., Gill R., Gunaratne P., Harris R.A., Hawes A.C.,
RA   Hernandez J., Hodgson A.V., Hume J., Jackson A., Khan Z.M.,
RA   Kovar-Smith C., Lewis L.R., Lozado R.J., Metzker M.L.,
RA   Milosavljevic A., Miner G.R., Montgomery K.T., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D.,
RA   Lovering R.C., Wheeler D.A., Worley K.C., Yuan Y., Zhang Z.,
RA   Adams C.Q., Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clerc-Blankenburg K.P., Davis C., Delgado O., Dinh H.H., Draper H.,
RA   Gonzalez-Garay M.L., Havlak P., Jackson L.R., Jacob L.S., Kelly S.H.,
RA   Li L., Li Z., Liu J., Liu W., Lu J., Maheshwari M., Nguyen B.-V.,
RA   Okwuonu G.O., Pasternak S., Perez L.M., Plopper F.J.H., Santibanez J.,
RA   Shen H., Tabor P.E., Verduzco D., Waldron L., Wang Q., Williams G.A.,
RA   Zhang J., Zhou J., Allen C.C., Amin A.G., Anyalebechi V., Bailey M.,
RA   Barbaria J.A., Bimage K.E., Bryant N.P., Burch P.E., Burkett C.E.,
RA   Burrell K.L., Calderon E., Cardenas V., Carter K., Casias K.,
RA   Cavazos I., Cavazos S.R., Ceasar H., Chacko J., Chan S.N., Chavez D.,
RA   Christopoulos C., Chu J., Cockrell R., Cox C.D., Dang M.,
RA   Dathorne S.R., David R., Davis C.M., Davy-Carroll L., Deshazo D.R.,
RA   Donlin J.E., D'Souza L., Eaves K.A., Egan A., Emery-Cohen A.J.,
RA   Escotto M., Flagg N., Forbes L.D., Gabisi A.M., Garza M., Hamilton C.,
RA   Henderson N., Hernandez O., Hines S., Hogues M.E., Huang M.,
RA   Idlebird D.G., Johnson R., Jolivet A., Jones S., Kagan R., King L.M.,
RA   Leal B., Lebow H., Lee S., LeVan J.M., Lewis L.C., London P.,
RA   Lorensuhewa L.M., Loulseged H., Lovett D.A., Lucier A., Lucier R.L.,
RA   Ma J., Madu R.C., Mapua P., Martindale A.D., Martinez E., Massey E.,
RA   Mawhiney S., Meador M.G., Mendez S., Mercado C., Mercado I.C.,
RA   Merritt C.E., Miner Z.L., Minja E., Mitchell T., Mohabbat F.,
RA   Mohabbat K., Montgomery B., Moore N., Morris S., Munidasa M.,
RA   Ngo R.N., Nguyen N.B., Nickerson E., Nwaokelemeh O.O., Nwokenkwo S.,
RA   Obregon M., Oguh M., Oragunye N., Oviedo R.J., Parish B.J.,
RA   Parker D.N., Parrish J., Parks K.L., Paul H.A., Payton B.A., Perez A.,
RA   Perrin W., Pickens A., Primus E.L., Pu L.-L., Puazo M., Quiles M.M.,
RA   Quiroz J.B., Rabata D., Reeves K., Ruiz S.J., Shao H., Sisson I.,
RA   Sonaike T., Sorelle R.P., Sutton A.E., Svatek A.F., Svetz L.A.,
RA   Tamerisa K.S., Taylor T.R., Teague B., Thomas N., Thorn R.D.,
RA   Trejos Z.Y., Trevino B.K., Ukegbu O.N., Urban J.B., Vasquez L.I.,
RA   Vera V.A., Villasana D.M., Wang L., Ward-Moore S., Warren J.T.,
RA   Wei X., White F., Williamson A.L., Wleczyk R., Wooden H.S.,
RA   Wooden S.H., Yen J., Yoon L., Yoon V., Zorrilla S.E., Nelson D.,
RA   Kucherlapati R., Weinstock G., Gibbs R.A.;
RT   "The finished DNA sequence of human chromosome 12.";
RL   Nature 440:346-351(2006).
RN   [7]
RP   INTERACTION WITH FGF13.
RX   PubMed=15282281; DOI=10.1523/JNEUROSCI.1628-04.2004;
RA   Wittmack E.K., Rush A.M., Craner M.J., Goldfarb M., Waxman S.G.,
RA   Dib-Hajj S.D.;
RT   "Fibroblast growth factor homologous factor 2B: association with
RT   Nav1.6 and selective colocalization at nodes of Ranvier of dorsal root
RT   axons.";
RL   J. Neurosci. 24:6765-6775(2004).
RN   [8]
RP   INVOLVEMENT IN CIAT.
RX   PubMed=16236810; DOI=10.1136/jmg.2005.035667;
RA   Trudeau M.M., Dalton J.C., Day J.W., Ranum L.P., Meisler M.H.;
RT   "Heterozygosity for a protein truncation mutation of sodium channel
RT   SCN8A in a patient with cerebellar atrophy, ataxia, and mental
RT   retardation.";
RL   J. Med. Genet. 43:527-530(2006).
RN   [9]
RP   INTERACTION WITH THE CONOTOXIN GVIIJ.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G.,
RA   Wickenden A.D., Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [10]
RP   VARIANT EIEE13 ASP-1768, AND CHARACTERIZATION OF VARIANT EIEE13
RP   ASP-1768.
RX   PubMed=22365152; DOI=10.1016/j.ajhg.2012.01.006;
RA   Veeramah K.R., O'Brien J.E., Meisler M.H., Cheng X., Dib-Hajj S.D.,
RA   Waxman S.G., Talwar D., Girirajan S., Eichler E.E., Restifo L.L.,
RA   Erickson R.P., Hammer M.F.;
RT   "de novo pathogenic SCN8A mutation identified by whole-genome
RT   sequencing of a family quartet affected by infantile epileptic
RT   encephalopathy and SUDEP.";
RL   Am. J. Hum. Genet. 90:502-510(2012).
RN   [11]
RP   VARIANT EIEE13 VAL-1327.
RX   PubMed=24352161; DOI=10.1177/0883073813511300;
RA   Vaher U., Noukas M., Nikopensius T., Kals M., Annilo T., Nelis M.,
RA   Ounap K., Reimand T., Talvik I., Ilves P., Piirsoo A., Seppet E.,
RA   Metspalu A., Talvik T.;
RT   "De novo SCN8A mutation identified by whole-exome sequencing in a boy
RT   with neonatal epileptic encephalopathy, multiple congenital anomalies,
RT   and movement disorders.";
RL   J. Child Neurol. 0:0-0(2013).
RN   [12]
RP   VARIANTS EIEE13 ASP-216; SER-846; LYS-1466; THR-1466; GLN-1617;
RP   THR-1650 AND TRP-1872.
RX   PubMed=24888894; DOI=10.1111/epi.12668;
RA   Ohba C., Kato M., Takahashi S., Lerman-Sagie T., Lev D., Terashima H.,
RA   Kubota M., Kawawaki H., Matsufuji M., Kojima Y., Tateno A.,
RA   Goldberg-Stern H., Straussberg R., Marom D., Leshinsky-Silver E.,
RA   Nakashima M., Nishiyama K., Tsurusaki Y., Miyake N., Tanaka F.,
RA   Matsumoto N., Saitsu H.;
RT   "Early onset epileptic encephalopathy caused by de novo SCN8A
RT   mutations.";
RL   Epilepsia 55:994-1000(2014).
RN   [13]
RP   VARIANT EIEE13 GLY-223, AND CHARACTERIZATION OF VARIANT EIEE13
RP   GLY-223.
RX   PubMed=25239001; DOI=10.1016/j.eplepsyres.2014.08.020;
RA   de Kovel C.G., Meisler M.H., Brilstra E.H., van Berkestijn F.M.,
RA   Slot R.V., van Lieshout S., Nijman I.J., O'Brien J.E., Hammer M.F.,
RA   Estacion M., Waxman S.G., Dib-Hajj S.D., Koeleman B.P.;
RT   "Characterization of a de novo SCN8A mutation in a patient with
RT   epileptic encephalopathy.";
RL   Epilepsy Res. 108:1511-1518(2014).
RN   [14]
RP   VARIANT EIEE13 ILE-767, AND CHARACTERIZATION OF VARIANT EIEE13
RP   ILE-767.
RX   PubMed=24874546; DOI=10.1016/j.nbd.2014.05.017;
RA   Estacion M., O'Brien J.E., Conravey A., Hammer M.F., Waxman S.G.,
RA   Dib-Hajj S.D., Meisler M.H.;
RT   "A novel de novo mutation of SCN8A (Nav1.6) with enhanced channel
RT   activation in a child with epileptic encephalopathy.";
RL   Neurobiol. Dis. 69:117-123(2014).
RN   [15]
RP   VARIANTS EIEE13 PHE-407; GLN-850; THR-890; CYS-1596 AND GLN-1617.
RX   PubMed=25785782; DOI=10.1111/epi.12925;
RA   Kong W., Zhang Y., Gao Y., Liu X., Gao K., Xie H., Wang J., Wu Y.,
RA   Zhang Y., Wu X., Jiang Y.;
RT   "SCN8A mutations in Chinese children with early onset epilepsy and
RT   intellectual disability.";
RL   Epilepsia 56:431-438(2015).
RN   [16]
RP   VARIANTS EIEE13 ASN-58; LYS-984 AND SER-1451, AND CHARACTERIZATION OF
RP   VARIANTS EIEE13 ASN-58; LYS-984 AND SER-1451.
RX   PubMed=25725044; DOI=10.1136/jmedgenet-2014-102813;
RA   Blanchard M.G., Willemsen M.H., Walker J.B., Dib-Hajj S.D.,
RA   Waxman S.G., Jongmans M.C., Kleefstra T., van de Warrenburg B.P.,
RA   Praamstra P., Nicolai J., Yntema H.G., Bindels R.J., Meisler M.H.,
RA   Kamsteeg E.J.;
RT   "De novo gain-of-function and loss-of-function mutations of SCN8A in
RT   patients with intellectual disabilities and epilepsy.";
RL   J. Med. Genet. 52:330-337(2015).
RN   [17]
RP   VARIANTS EIEE13 ARG-215; SER-260; LEU-410; VAL-479; THR-890; ASP-960;
RP   VAL-1331; VAL-1479; LEU-1592; ARG-1605; GLN-1617; THR-1650; GLU-1801;
RP   GLN-1872 AND TRP-1872.
RX   PubMed=25568300; DOI=10.1212/WNL.0000000000001211;
RG   EuroEPINOMICS RES Consortium CRP;
RA   Larsen J., Carvill G.L., Gardella E., Kluger G., Schmiedel G.,
RA   Barisic N., Depienne C., Brilstra E., Mang Y., Nielsen J.E.,
RA   Kirkpatrick M., Goudie D., Goldman R., Jaehn J.A., Jepsen B., Gill D.,
RA   Doecker M., Biskup S., McMahon J.M., Koeleman B., Harris M., Braun K.,
RA   de Kovel C.G., Marini C., Specchio N., Djemie T., Weckhuysen S.,
RA   Tommerup N., Troncoso M., Troncoso L., Bevot A., Wolff M.,
RA   Hjalgrim H., Guerrini R., Scheffer I.E., Mefford H.C., Moeller R.S.;
RT   "The phenotypic spectrum of SCN8A encephalopathy.";
RL   Neurology 84:480-489(2015).
RN   [18]
RP   VARIANT EIEE13 SER-1877, AND VARIANT BFIS5 SER-1877.
RX   PubMed=27210545; DOI=10.1016/j.ejpn.2016.04.015;
RA   Anand G., Collett-White F., Orsini A., Thomas S., Jayapal S.,
RA   Trump N., Zaiwalla Z., Jayawant S.;
RT   "Autosomal dominant SCN8A mutation with an unusually mild phenotype.";
RL   Eur. J. Paediatr. Neurol. 20:761-765(2016).
RN   [19]
RP   VARIANTS EIEE13 GLN-1617; GLN-1872; LEU-1872 AND TRP-1872,
RP   CHARACTERIZATION OF VARIANTS EIEE13 GLN-1617; GLN-1872; LEU-1872 AND
RP   TRP-1872, AND INTERACTION WITH FGF14; GBG3; GBB2 AND SCN1B.
RX   PubMed=26900580; DOI=10.1002/acn3.276;
RA   Wagnon J.L., Barker B.S., Hounshell J.A., Haaxma C.A., Shealy A.,
RA   Moss T., Parikh S., Messer R.D., Patel M.K., Meisler M.H.;
RT   "Pathogenic mechanism of recurrent mutations of SCN8A in epileptic
RT   encephalopathy.";
RL   Ann. Clin. Transl. Neurol. 3:114-123(2016).
RN   [20]
RP   VARIANT BFIS5 LYS-1483, AND INVOLVEMENT IN BFIS5.
RX   PubMed=26677014; DOI=10.1002/ana.24580;
RA   Gardella E., Becker F., Moeller R.S., Schubert J., Lemke J.R.,
RA   Larsen L.H., Eiberg H., Nothnagel M., Thiele H., Altmueller J.,
RA   Syrbe S., Merkenschlager A., Bast T., Steinhoff B., Nuernberg P.,
RA   Mang Y., Bakke Moeller L., Gellert P., Heron S.E., Dibbens L.M.,
RA   Weckhuysen S., Dahl H.A., Biskup S., Tommerup N., Hjalgrim H.,
RA   Lerche H., Beniczky S., Weber Y.G.;
RT   "Benign infantile seizures and paroxysmal dyskinesia caused by an
RT   SCN8A mutation.";
RL   Ann. Neurol. 79:428-436(2016).
CC   -!- FUNCTION: Mediates the voltage-dependent sodium ion permeability
CC       of excitable membranes. Assuming opened or closed conformations in
CC       response to the voltage difference across the membrane, the
CC       protein forms a sodium-selective channel through which Na(+) ions
CC       may pass in accordance with their electrochemical gradient. In
CC       macrophages and melanoma cells, isoform 5 may participate in the
CC       control of podosome and invadopodia formation.
CC       {ECO:0000269|PubMed:19136557}.
CC   -!- SUBUNIT: The voltage-sensitive sodium channel consists of an ion
CC       conducting pore forming alpha-subunit regulated by one or more
CC       beta-1 (SCN1B), beta-2 (SCN2B), beta-3 (SCN3B) and/or beta-4
CC       (SCN4B). Beta-1 (SCN1B) and beta-3 (SCN3B) are non-covalently
CC       associated with alpha, while beta-2 (SCN2B) and beta-4 (SCN4B) are
CC       covalently linked by disulfide bonds. Interacts with NEDD4 and
CC       NEDD4L (By similarity). Interacts with FGF13. Interacts with
CC       FGF14, GBG3, GBB2 and SCN1B (PubMed:26900580). Interacts with the
CC       conotoxin GVIIJ (PubMed:24497506). {ECO:0000250|UniProtKB:Q9WTU3,
CC       ECO:0000269|PubMed:15282281, ECO:0000269|PubMed:24497506,
CC       ECO:0000269|PubMed:26900580}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:19136557};
CC       Multi-pass membrane protein {ECO:0000269|PubMed:19136557}.
CC   -!- SUBCELLULAR LOCATION: Isoform 5: Cytoplasmic vesicle. Note=Some
CC       vesicles are localized adjacent to melanoma invadopodia and
CC       macrophage podosomes. Does not localize to the plasma membrane.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=5;
CC       Name=1 {ECO:0000269|PubMed:9828131};
CC         IsoId=Q9UQD0-1; Sequence=Displayed;
CC       Name=2 {ECO:0000269|PubMed:9828131}; Synonyms=5A
CC       {ECO:0000269|PubMed:9828131};
CC         IsoId=Q9UQD0-2; Sequence=VSP_050589, VSP_050590;
CC       Name=3 {ECO:0000269|PubMed:9828131};
CC         IsoId=Q9UQD0-3; Sequence=VSP_050591;
CC       Name=4 {ECO:0000269|PubMed:9295353}; Synonyms=18N
CC       {ECO:0000269|PubMed:9295353};
CC         IsoId=Q9UQD0-4; Sequence=VSP_050592, VSP_050593;
CC       Name=5;
CC         IsoId=Q9UQD0-5; Sequence=VSP_038651;
CC   -!- TISSUE SPECIFICITY: Isoform 5 is expressed in non-neuronal
CC       tissues, such as monocytes/macrophages.
CC       {ECO:0000269|PubMed:19136557}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position. {ECO:0000305}.
CC   -!- PTM: May be ubiquitinated by NEDD4L; which would promote its
CC       endocytosis. {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Ser-1497 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents. {ECO:0000250}.
CC   -!- DISEASE: Cognitive impairment with or without cerebellar ataxia
CC       (CIAT) [MIM:614306]: A disorder characterized by markedly delayed
CC       cognitive and motor development, attention deficit disorder, and
CC       cerebellar ataxia. Features include bilateral esophoria,
CC       strabismatic amblyopia, unsustained gaze evoked nystagmus on
CC       horizontal gaze, ataxic gait, dysmetria in the upper limbs and
CC       dysarthria, with normal strength, tone, and reflexes.
CC       {ECO:0000269|PubMed:16236810}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Epileptic encephalopathy, early infantile, 13 (EIEE13)
CC       [MIM:614558]: A form of epilepsy characterized by frequent tonic
CC       seizures or spasms beginning in infancy with a specific EEG
CC       finding of suppression-burst patterns, characterized by high-
CC       voltage bursts alternating with almost flat suppression phases.
CC       Patients may progress to West syndrome, which is characterized by
CC       tonic spasms with clustering, arrest of psychomotor development,
CC       and hypsarrhythmia on EEG. EIEE13 is a severe form consisting of
CC       early-onset seizures, features of autism, intellectual disability,
CC       ataxia, and sudden unexplained death in epilepsy.
CC       {ECO:0000269|PubMed:22365152, ECO:0000269|PubMed:24352161,
CC       ECO:0000269|PubMed:24874546, ECO:0000269|PubMed:24888894,
CC       ECO:0000269|PubMed:25239001, ECO:0000269|PubMed:25568300,
CC       ECO:0000269|PubMed:25725044, ECO:0000269|PubMed:25785782,
CC       ECO:0000269|PubMed:26900580, ECO:0000269|PubMed:27210545}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- DISEASE: Seizures, benign familial infantile, 5 (BFIS5)
CC       [MIM:617080]: A form of benign familial infantile epilepsy, a
CC       neurologic disorder characterized by afebrile seizures occurring
CC       in clusters during the first year of life, without neurologic
CC       sequelae. BFIS5 inheritance is autosomal dominant.
CC       {ECO:0000269|PubMed:26677014, ECO:0000269|PubMed:27210545}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.6/SCN8A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF050736; AAD15789.1; -; Genomic_DNA.
DR   EMBL; AF050711; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050712; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050713; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050714; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050715; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050716; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050717; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050718; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050719; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050720; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050721; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050722; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050723; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050724; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050725; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050726; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050727; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050728; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050729; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050730; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050731; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050732; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050733; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050734; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF050735; AAD15789.1; JOINED; Genomic_DNA.
DR   EMBL; AF049618; AAD20439.1; -; Genomic_DNA.
DR   EMBL; FJ611941; ACM63162.1; -; mRNA.
DR   EMBL; AB027567; BAA78033.1; -; mRNA.
DR   EMBL; AF225988; AAF35390.1; -; mRNA.
DR   EMBL; AC013421; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025097; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC068987; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC140060; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS44891.1; -. [Q9UQD0-1]
DR   CCDS; CCDS53794.1; -. [Q9UQD0-5]
DR   CCDS; CCDS81692.1; -. [Q9UQD0-2]
DR   RefSeq; NP_001171455.1; NM_001177984.2. [Q9UQD0-5]
DR   RefSeq; NP_001317189.1; NM_001330260.1. [Q9UQD0-2]
DR   RefSeq; NP_055006.1; NM_014191.3. [Q9UQD0-1]
DR   RefSeq; XP_006719619.1; XM_006719556.3. [Q9UQD0-2]
DR   RefSeq; XP_011536953.1; XM_011538651.2. [Q9UQD0-2]
DR   RefSeq; XP_016875283.1; XM_017019794.1. [Q9UQD0-1]
DR   UniGene; Hs.436550; -.
DR   UniGene; Hs.710638; -.
DR   ProteinModelPortal; Q9UQD0; -.
DR   BioGrid; 112238; 1.
DR   IntAct; Q9UQD0; 1.
DR   STRING; 9606.ENSP00000346534; -.
DR   BindingDB; Q9UQD0; -.
DR   ChEMBL; CHEMBL5202; -.
DR   DrugBank; DB00313; Valproic Acid.
DR   GuidetoPHARMACOLOGY; 583; -.
DR   TCDB; 1.A.1.10.8; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; Q9UQD0; -.
DR   PhosphoSitePlus; Q9UQD0; -.
DR   BioMuta; SCN8A; -.
DR   DMDM; 34098756; -.
DR   PaxDb; Q9UQD0; -.
DR   PeptideAtlas; Q9UQD0; -.
DR   PRIDE; Q9UQD0; -.
DR   Ensembl; ENST00000354534; ENSP00000346534; ENSG00000196876. [Q9UQD0-1]
DR   Ensembl; ENST00000355133; ENSP00000347255; ENSG00000196876. [Q9UQD0-5]
DR   Ensembl; ENST00000545061; ENSP00000440360; ENSG00000196876. [Q9UQD0-5]
DR   Ensembl; ENST00000599343; ENSP00000476447; ENSG00000196876. [Q9UQD0-3]
DR   Ensembl; ENST00000627620; ENSP00000487583; ENSG00000196876. [Q9UQD0-2]
DR   GeneID; 6334; -.
DR   KEGG; hsa:6334; -.
DR   UCSC; uc001ryw.4; human. [Q9UQD0-1]
DR   CTD; 6334; -.
DR   DisGeNET; 6334; -.
DR   GeneCards; SCN8A; -.
DR   HGNC; HGNC:10596; SCN8A.
DR   HPA; CAB022169; -.
DR   MalaCards; SCN8A; -.
DR   MIM; 600702; gene.
DR   MIM; 614306; phenotype.
DR   MIM; 614558; phenotype.
DR   MIM; 617080; phenotype.
DR   neXtProt; NX_Q9UQD0; -.
DR   OpenTargets; ENSG00000196876; -.
DR   Orphanet; 1934; Early infantile epileptic encephalopathy.
DR   PharmGKB; PA35009; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOGENOM; HOG000231755; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q9UQD0; -.
DR   KO; K04840; -.
DR   OMA; GFICKKT; -.
DR   OrthoDB; EOG09030140; -.
DR   PhylomeDB; Q9UQD0; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   ChiTaRS; SCN8A; human.
DR   GeneWiki; SCN8A; -.
DR   GenomeRNAi; 6334; -.
DR   PRO; PR:Q9UQD0; -.
DR   Proteomes; UP000005640; Chromosome 12.
DR   Bgee; ENSG00000196876; -.
DR   CleanEx; HS_SCN8A; -.
DR   ExpressionAtlas; Q9UQD0; baseline and differential.
DR   Genevisible; Q9UQD0; HS.
DR   GO; GO:0043194; C:axon initial segment; ISS:BHF-UCL.
DR   GO; GO:0031410; C:cytoplasmic vesicle; IEA:UniProtKB-KW.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0033268; C:node of Ranvier; ISS:BHF-UCL.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IC:UniProtKB.
DR   GO; GO:0030018; C:Z disc; ISS:BHF-UCL.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IDA:UniProtKB.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0042552; P:myelination; ISS:BHF-UCL.
DR   GO; GO:0007399; P:nervous system development; TAS:ProtInc.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0007422; P:peripheral nervous system development; ISS:BHF-UCL.
DR   GO; GO:0006814; P:sodium ion transport; NAS:UniProtKB.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR008054; Na_channel_a8su.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF00612; IQ; 1.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   PRINTS; PR01667; NACHANNEL8.
DR   SMART; SM00015; IQ; 1.
DR   PROSITE; PS50096; IQ; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell membrane; Complete proteome;
KW   Cytoplasmic vesicle; Disease mutation; Disulfide bond; Epilepsy;
KW   Glycoprotein; Ion channel; Ion transport; Membrane;
KW   Mental retardation; Nucleotide-binding; Phosphoprotein;
KW   Reference proteome; Repeat; Sodium; Sodium channel; Sodium transport;
KW   Transmembrane; Transmembrane helix; Transport; Ubl conjugation;
KW   Voltage-gated channel.
FT   CHAIN         1   1980       Sodium channel protein type 8 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048500.
FT   TOPO_DOM      1    127       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    128    151       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    152    159       Extracellular. {ECO:0000255}.
FT   TRANSMEM    160    179       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    180    192       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    193    211       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    212    217       Extracellular. {ECO:0000255}.
FT   TRANSMEM    218    237       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000255}.
FT   TOPO_DOM    238    252       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    253    277       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    278    387       Extracellular. {ECO:0000255}.
FT   TRANSMEM    388    413       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    414    747       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    748    772       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    773    783       Extracellular. {ECO:0000255}.
FT   TRANSMEM    784    807       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    808    815       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    816    835       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    836    841       Extracellular. {ECO:0000255}.
FT   TRANSMEM    842    862       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000255}.
FT   TOPO_DOM    863    877       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    878    898       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    899    951       Extracellular. {ECO:0000255}.
FT   TRANSMEM    952    977       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    978   1193       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1194   1217       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1218   1230       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1231   1256       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1257   1262       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1263   1284       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1285   1288       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1289   1310       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000255}.
FT   TOPO_DOM   1311   1329       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1330   1351       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1352   1437       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1438   1464       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1465   1517       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1518   1541       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1542   1552       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1553   1576       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1577   1582       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1583   1606       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1607   1616       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1617   1638       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000255}.
FT   TOPO_DOM   1639   1653       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1654   1676       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1677   1741       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1742   1766       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1767   1980       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      114    442       I. {ECO:0000305}.
FT   REPEAT      735   1007       II. {ECO:0000305}.
FT   REPEAT     1180   1495       III. {ECO:0000305}.
FT   REPEAT     1504   1801       IV. {ECO:0000305}.
FT   DOMAIN     1895   1924       IQ. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00116, ECO:0000305}.
FT   NP_BIND     893    900       ATP. {ECO:0000255}.
FT   MOD_RES     477    477       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     504    504       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     518    518       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88420}.
FT   MOD_RES     520    520       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:O88420}.
FT   MOD_RES     546    546       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     579    579       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q9JJV9}.
FT   MOD_RES     613    613       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     699    699       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     702    702       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES    1497   1497       Phosphoserine; by PKC. {ECO:0000250}.
FT   CARBOHYD    215    215       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    289    289       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    295    295       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    308    308       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    326    326       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1358   1358       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1372   1372       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1383   1383       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    904    904       Interchain; with SCN2B or SCN4B.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   DISULFID    904    904       Interchain; with the conotoxin GVIIJ
FT                                (when the channel is not linked to SCN2B
FT                                or SCN4B; the bond to SCN2B or SCN4B
FT                                protects the channel from the inhibition
FT                                by toxin).
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   VAR_SEQ     207    207       I -> V (in isoform 2).
FT                                {ECO:0000303|PubMed:9828131}.
FT                                /FTId=VSP_050589.
FT   VAR_SEQ     212    212       N -> D (in isoform 2).
FT                                {ECO:0000303|PubMed:9828131}.
FT                                /FTId=VSP_050590.
FT   VAR_SEQ     666    666       E -> EVKIDKAATDDS (in isoform 3).
FT                                {ECO:0000303|PubMed:9828131}.
FT                                /FTId=VSP_050591.
FT   VAR_SEQ    1275   1315       Missing (in isoform 5).
FT                                {ECO:0000303|PubMed:19136557}.
FT                                /FTId=VSP_038651.
FT   VAR_SEQ    1275   1283       SLVSLIANA -> PLNLSGLI (in isoform 4).
FT                                {ECO:0000303|PubMed:9295353}.
FT                                /FTId=VSP_050592.
FT   VAR_SEQ    1284   1980       Missing (in isoform 4).
FT                                {ECO:0000303|PubMed:9295353}.
FT                                /FTId=VSP_050593.
FT   VARIANT      58     58       D -> N (in EIEE13; unknown pathological
FT                                significance; no effect on channel
FT                                activity). {ECO:0000269|PubMed:25725044}.
FT                                /FTId=VAR_076598.
FT   VARIANT     215    215       N -> R (in EIEE13; unknown pathological
FT                                significance; requires 2 nucleotide
FT                                substitutions).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076599.
FT   VARIANT     216    216       V -> D (in EIEE13).
FT                                {ECO:0000269|PubMed:24888894}.
FT                                /FTId=VAR_071674.
FT   VARIANT     223    223       R -> G (in EIEE13; loss of function
FT                                mutation; reduces channel activity;
FT                                dbSNP:rs672601319).
FT                                {ECO:0000269|PubMed:25239001}.
FT                                /FTId=VAR_072182.
FT   VARIANT     260    260       F -> S (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076600.
FT   VARIANT     407    407       L -> F (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25785782}.
FT                                /FTId=VAR_076601.
FT   VARIANT     410    410       V -> L (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076602.
FT   VARIANT     479    479       E -> V (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076603.
FT   VARIANT     767    767       T -> I (in EIEE13; gain-of-function
FT                                mutation; increases channel activity;
FT                                dbSNP:rs797045013).
FT                                {ECO:0000269|PubMed:24874546}.
FT                                /FTId=VAR_072183.
FT   VARIANT     846    846       F -> S (in EIEE13).
FT                                {ECO:0000269|PubMed:24888894}.
FT                                /FTId=VAR_071675.
FT   VARIANT     850    850       R -> Q (in EIEE13; unknown pathological
FT                                significance; dbSNP:rs587780586).
FT                                {ECO:0000269|PubMed:25785782}.
FT                                /FTId=VAR_076604.
FT   VARIANT     890    890       A -> T (in EIEE13).
FT                                {ECO:0000269|PubMed:25568300,
FT                                ECO:0000269|PubMed:25785782}.
FT                                /FTId=VAR_076605.
FT   VARIANT     960    960       V -> D (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076606.
FT   VARIANT     984    984       N -> K (in EIEE13; gain-of-function
FT                                mutation; increased channel activity).
FT                                {ECO:0000269|PubMed:25725044}.
FT                                /FTId=VAR_076607.
FT   VARIANT    1327   1327       I -> V (in EIEE13).
FT                                {ECO:0000269|PubMed:24352161}.
FT                                /FTId=VAR_071676.
FT   VARIANT    1331   1331       L -> V (in EIEE13; unknown pathological
FT                                significance; dbSNP:rs397514738).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076608.
FT   VARIANT    1451   1451       G -> S (in EIEE13; loss of channel
FT                                activity; dbSNP:rs863223345).
FT                                {ECO:0000269|PubMed:25725044}.
FT                                /FTId=VAR_076609.
FT   VARIANT    1466   1466       N -> K (in EIEE13; dbSNP:rs587777722).
FT                                {ECO:0000269|PubMed:24888894}.
FT                                /FTId=VAR_071677.
FT   VARIANT    1466   1466       N -> T (in EIEE13; dbSNP:rs587777723).
FT                                {ECO:0000269|PubMed:24888894}.
FT                                /FTId=VAR_071678.
FT   VARIANT    1479   1479       I -> V (in EIEE13; unknown pathological
FT                                significance; dbSNP:rs796053217).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076610.
FT   VARIANT    1483   1483       E -> K (in BFIS5).
FT                                {ECO:0000269|PubMed:26677014}.
FT                                /FTId=VAR_076927.
FT   VARIANT    1592   1592       V -> L (in EIEE13; unknown pathological
FT                                significance; dbSNP:rs587780454).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076611.
FT   VARIANT    1596   1596       S -> C (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25785782}.
FT                                /FTId=VAR_076612.
FT   VARIANT    1605   1605       I -> R (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076613.
FT   VARIANT    1617   1617       R -> Q (in EIEE13; gain-of-function
FT                                mutation; increased channel activity;
FT                                impaired channel inactivation;
FT                                dbSNP:rs587777721).
FT                                {ECO:0000269|PubMed:24888894,
FT                                ECO:0000269|PubMed:25568300,
FT                                ECO:0000269|PubMed:25785782,
FT                                ECO:0000269|PubMed:26900580}.
FT                                /FTId=VAR_071679.
FT   VARIANT    1650   1650       A -> T (in EIEE13).
FT                                {ECO:0000269|PubMed:24888894,
FT                                ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_071680.
FT   VARIANT    1768   1768       N -> D (in EIEE13; gain-of-function
FT                                mutation; results in increased persistent
FT                                sodium currents and incomplete channel
FT                                inactivation; dbSNP:rs202151337).
FT                                {ECO:0000269|PubMed:22365152}.
FT                                /FTId=VAR_067539.
FT   VARIANT    1801   1801       Q -> E (in EIEE13; unknown pathological
FT                                significance).
FT                                {ECO:0000269|PubMed:25568300}.
FT                                /FTId=VAR_076614.
FT   VARIANT    1872   1872       R -> L (in EIEE13; gain-of-function
FT                                mutation; increased channel activity;
FT                                impaired channel inactivation;
FT                                dbSNP:rs796053229).
FT                                {ECO:0000269|PubMed:26900580}.
FT                                /FTId=VAR_076615.
FT   VARIANT    1872   1872       R -> Q (in EIEE13; gain-of-function
FT                                mutation; increased channel activity;
FT                                impaired channel inactivation).
FT                                {ECO:0000269|PubMed:25568300,
FT                                ECO:0000269|PubMed:26900580}.
FT                                /FTId=VAR_076616.
FT   VARIANT    1872   1872       R -> W (in EIEE13; gain-of-function
FT                                mutation; increased channel activity;
FT                                impaired channel inactivation; no effect
FT                                on interactions with FGF14, SCN1B, GNB2
FT                                and GNG3; dbSNP:rs796053228).
FT                                {ECO:0000269|PubMed:24888894,
FT                                ECO:0000269|PubMed:25568300,
FT                                ECO:0000269|PubMed:26900580}.
FT                                /FTId=VAR_071681.
FT   VARIANT    1877   1877       N -> S (in EIEE13 and BFIS5;
FT                                dbSNP:rs587780455).
FT                                {ECO:0000269|PubMed:27210545}.
FT                                /FTId=VAR_076617.
FT   CONFLICT      5      5       L -> V (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    133    133       V -> L (in Ref. 1; AAD15789).
FT                                {ECO:0000305}.
FT   CONFLICT    257    257       L -> M (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    273    273       F -> I (in Ref. 3; ACM63162).
FT                                {ECO:0000305}.
FT   CONFLICT    274    278       MGNLR -> HGEPS (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    453    453       T -> N (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    477    477       S -> F (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    483    483       L -> I (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    492    492       R -> S (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    504    504       S -> F (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT    547    548       LL -> MF (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
FT   CONFLICT   1416   1416       M -> V (in Ref. 3; ACM63162).
FT                                {ECO:0000305}.
FT   CONFLICT   1445   1445       V -> I (in Ref. 1; AAD15789).
FT                                {ECO:0000305}.
FT   CONFLICT   1519   1519       V -> I (in Ref. 1; AAD15789).
FT                                {ECO:0000305}.
FT   CONFLICT   1702   1702       T -> A (in Ref. 5; AAF35390).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1980 AA;  225280 MW;  0EFC7BFB137FD4F0 CRC64;
     MAARLLAPPG PDSFKPFTPE SLANIERRIA ESKLKKPPKA DGSHREDDED SKPKPNSDLE
     AGKSLPFIYG DIPQGLVAVP LEDFDPYYLT QKTFVVLNRG KTLFRFSATP ALYILSPFNL
     IRRIAIKILI HSVFSMIIMC TILTNCVFMT FSNPPDWSKN VEYTFTGIYT FESLVKIIAR
     GFCIDGFTFL RDPWNWLDFS VIMMAYITEF VNLGNVSALR TFRVLRALKT ISVIPGLKTI
     VGALIQSVKK LSDVMILTVF CLSVFALIGL QLFMGNLRNK CVVWPINFNE SYLENGTKGF
     DWEEYINNKT NFYTVPGMLE PLLCGNSSDA GQCPEGYQCM KAGRNPNYGY TSFDTFSWAF
     LALFRLMTQD YWENLYQLTL RAAGKTYMIF FVLVIFVGSF YLVNLILAVV AMAYEEQNQA
     TLEEAEQKEA EFKAMLEQLK KQQEEAQAAA MATSAGTVSE DAIEEEGEEG GGSPRSSSEI
     SKLSSKSAKE RRNRRKKRKQ KELSEGEEKG DPEKVFKSES EDGMRRKAFR LPDNRIGRKF
     SIMNQSLLSI PGSPFLSRHN SKSSIFSFRG PGRFRDPGSE NEFADDEHST VEESEGRRDS
     LFIPIRARER RSSYSGYSGY SQGSRSSRIF PSLRRSVKRN STVDCNGVVS LIGGPGSHIG
     GRLLPEATTE VEIKKKGPGS LLVSMDQLAS YGRKDRINSI MSVVTNTLVE ELEESQRKCP
     PCWYKFANTF LIWECHPYWI KLKEIVNLIV MDPFVDLAIT ICIVLNTLFM AMEHHPMTPQ
     FEHVLAVGNL VFTGIFTAEM FLKLIAMDPY YYFQEGWNIF DGFIVSLSLM ELSLADVEGL
     SVLRSFRLLR VFKLAKSWPT LNMLIKIIGN SVGALGNLTL VLAIIVFIFA VVGMQLFGKS
     YKECVCKINQ DCELPRWHMH DFFHSFLIVF RVLCGEWIET MWDCMEVAGQ AMCLIVFMMV
     MVIGNLVVLN LFLALLLSSF SADNLAATDD DGEMNNLQIS VIRIKKGVAW TKLKVHAFMQ
     AHFKQREADE VKPLDELYEK KANCIANHTG ADIHRNGDFQ KNGNGTTSGI GSSVEKYIID
     EDHMSFINNP NLTVRVPIAV GESDFENLNT EDVSSESDPE GSKDKLDDTS SSEGSTIDIK
     PEVEEVPVEQ PEEYLDPDAC FTEGCVQRFK CCQVNIEEGL GKSWWILRKT CFLIVEHNWF
     ETFIIFMILL SSGALAFEDI YIEQRKTIRT ILEYADKVFT YIFILEMLLK WTAYGFVKFF
     TNAWCWLDFL IVAVSLVSLI ANALGYSELG AIKSLRTLRA LRPLRALSRF EGMRVVVNAL
     VGAIPSIMNV LLVCLIFWLI FSIMGVNLFA GKYHYCFNET SEIRFEIEDV NNKTECEKLM
     EGNNTEIRWK NVKINFDNVG AGYLALLQVA TFKGWMDIMY AAVDSRKPDE QPKYEDNIYM
     YIYFVIFIIF GSFFTLNLFI GVIIDNFNQQ KKKFGGQDIF MTEEQKKYYN AMKKLGSKKP
     QKPIPRPLNK IQGIVFDFVT QQAFDIVIMM LICLNMVTMM VETDTQSKQM ENILYWINLV
     FVIFFTCECV LKMFALRHYY FTIGWNIFDF VVVILSIVGM FLADIIEKYF VSPTLFRVIR
     LARIGRILRL IKGAKGIRTL LFALMMSLPA LFNIGLLLFL VMFIFSIFGM SNFAYVKHEA
     GIDDMFNFET FGNSMICLFQ ITTSAGWDGL LLPILNRPPD CSLDKEHPGS GFKGDCGNPS
     VGIFFFVSYI IISFLIVVNM YIAIILENFS VATEESADPL SEDDFETFYE IWEKFDPDAT
     QFIEYCKLAD FADALEHPLR VPKPNTIELI AMDLPMVSGD RIHCLDILFA FTKRVLGDSG
     ELDILRQQME ERFVASNPSK VSYEPITTTL RRKQEEVSAV VLQRAYRGHL ARRGFICKKT
     TSNKLENGGT HREKKESTPS TASLPSYDSV TKPEKEKQQR AEEGRRERAK RQKEVRESKC
//
ID   SCN9A_HUMAN             Reviewed;        1988 AA.
AC   Q15858; A1BUH5; Q6B4R9; Q6B4S0; Q6B4S1; Q70HX1; Q70HX2; Q8WTU1;
AC   Q8WWN4;
DT   23-NOV-2004, integrated into UniProtKB/Swiss-Prot.
DT   05-APR-2011, sequence version 3.
DT   15-FEB-2017, entry version 158.
DE   RecName: Full=Sodium channel protein type 9 subunit alpha {ECO:0000305};
DE   AltName: Full=Neuroendocrine sodium channel {ECO:0000303|PubMed:7720699};
DE            Short=hNE-Na {ECO:0000303|PubMed:7720699};
DE   AltName: Full=Peripheral sodium channel 1;
DE            Short=PN1 {ECO:0000250|UniProtKB:O08562};
DE   AltName: Full=Sodium channel protein type IX subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.7;
GN   Name=SCN9A {ECO:0000312|HGNC:HGNC:10597}; Synonyms=NENA;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), FUNCTION IN VOLTAGE-EVOKED
RP   DEPOLARIZATION, SUBCELLULAR LOCATION, SUBUNIT, TISSUE SPECIFICITY, AND
RP   VARIANT ARG-1161.
RC   TISSUE=Thyroid;
RX   PubMed=7720699;
RA   Klugbauer N., Lacinova L., Flockerzi V., Hofmann F.;
RT   "Structure and functional expression of a new member of the
RT   tetrodotoxin-sensitive voltage-activated sodium channel family from
RT   human neuroendocrine cells.";
RL   EMBO J. 14:1084-1090(1995).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 3), INVOLVEMENT IN CONGENITAL
RP   INSENSITIVITY TO PAIN, FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, AND
RP   VARIANT ARG-1161.
RX   PubMed=17167479; DOI=10.1038/nature05413;
RA   Cox J.J., Reimann F., Nicholas A.K., Thornton G., Roberts E.,
RA   Springell K., Karbani G., Jafri H., Mannan J., Raashid Y.,
RA   Al-Gazali L., Hamamy H., Valente E.M., Gorman S., Williams R.,
RA   McHale D.P., Wood J.N., Gribble F.M., Woods C.G.;
RT   "An SCN9A channelopathy causes congenital inability to experience
RT   pain.";
RL   Nature 444:894-898(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15815621; DOI=10.1038/nature03466;
RA   Hillier L.W., Graves T.A., Fulton R.S., Fulton L.A., Pepin K.H.,
RA   Minx P., Wagner-McPherson C., Layman D., Wylie K., Sekhon M.,
RA   Becker M.C., Fewell G.A., Delehaunty K.D., Miner T.L., Nash W.E.,
RA   Kremitzki C., Oddy L., Du H., Sun H., Bradshaw-Cordum H., Ali J.,
RA   Carter J., Cordes M., Harris A., Isak A., van Brunt A., Nguyen C.,
RA   Du F., Courtney L., Kalicki J., Ozersky P., Abbott S., Armstrong J.,
RA   Belter E.A., Caruso L., Cedroni M., Cotton M., Davidson T., Desai A.,
RA   Elliott G., Erb T., Fronick C., Gaige T., Haakenson W., Haglund K.,
RA   Holmes A., Harkins R., Kim K., Kruchowski S.S., Strong C.M.,
RA   Grewal N., Goyea E., Hou S., Levy A., Martinka S., Mead K.,
RA   McLellan M.D., Meyer R., Randall-Maher J., Tomlinson C.,
RA   Dauphin-Kohlberg S., Kozlowicz-Reilly A., Shah N.,
RA   Swearengen-Shahid S., Snider J., Strong J.T., Thompson J., Yoakum M.,
RA   Leonard S., Pearman C., Trani L., Radionenko M., Waligorski J.E.,
RA   Wang C., Rock S.M., Tin-Wollam A.-M., Maupin R., Latreille P.,
RA   Wendl M.C., Yang S.-P., Pohl C., Wallis J.W., Spieth J., Bieri T.A.,
RA   Berkowicz N., Nelson J.O., Osborne J., Ding L., Meyer R., Sabo A.,
RA   Shotland Y., Sinha P., Wohldmann P.E., Cook L.L., Hickenbotham M.T.,
RA   Eldred J., Williams D., Jones T.A., She X., Ciccarelli F.D.,
RA   Izaurralde E., Taylor J., Schmutz J., Myers R.M., Cox D.R., Huang X.,
RA   McPherson J.D., Mardis E.R., Clifton S.W., Warren W.C.,
RA   Chinwalla A.T., Eddy S.R., Marra M.A., Ovcharenko I., Furey T.S.,
RA   Miller W., Eichler E.E., Bork P., Suyama M., Torrents D.,
RA   Waterston R.H., Wilson R.K.;
RT   "Generation and annotation of the DNA sequences of human chromosomes 2
RT   and 4.";
RL   Nature 434:724-731(2005).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 136-674 (ISOFORMS 1; 2; 3 AND 4), AND
RP   TISSUE SPECIFICITY.
RC   TISSUE=Spinal ganglion;
RX   PubMed=15302875; DOI=10.1074/jbc.M406387200;
RA   Raymond C.K., Castle J.C., Garrett-Engele P.W., Armour C.D., Kan Z.G.,
RA   Tsinoremas N.T., Johnson J.M.;
RT   "Expression of alternatively spliced sodium channel alpha-subunit
RT   genes: unique splicing patterns are observed in dorsal root ganglia.";
RL   J. Biol. Chem. 279:46234-46241(2004).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 150-264 AND 1340-1400.
RA   Diss J.K.J., Fraser S.P., Coombes R.C., Djamgoz M.B.A.;
RT   "Upregulation of voltage-gated Na+ channel expression and metastatic
RT   potential in human breast cancer: correlative studies on cell lines
RT   and biopsy tissues.";
RL   Submitted (APR-2001) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 840-958, AND VARIANTS PERYTHM
RP   THR-859 AND HIS-869.
RX   PubMed=14985375; DOI=10.1136/jmg.2003.012153;
RA   Yang Y., Wang Y., Li S., Xu Z., Li H., Ma L., Fan J., Bu D., Liu B.,
RA   Fan Z., Wu G., Jin J., Ding B., Zhu X., Shen Y.;
RT   "Mutations in SCN9A, encoding a sodium channel alpha subunit, in
RT   patients with primary erythermalgia.";
RL   J. Med. Genet. 41:171-174(2004).
RN   [7]
RP   TISSUE SPECIFICITY.
RX   PubMed=9169448; DOI=10.1074/jbc.272.23.14805;
RA   Sangameswaran L., Fish L.M., Koch B.D., Rabert D.K., Delgado S.G.,
RA   Ilnicka M., Jakeman L.B., Novakovic S., Wong K., Sze P., Tzoumaka E.,
RA   Stewart G.R., Herman R.C., Chan H., Eglen R.M., Hunter J.C.;
RT   "A novel tetrodotoxin-sensitive, voltage-gated sodium channel
RT   expressed in rat and human dorsal root ganglia.";
RL   J. Biol. Chem. 272:14805-14809(1997).
RN   [8]
RP   FUNCTION IN VOLTAGE-EVOKED DEPOLARIZATION, AND TISSUE SPECIFICITY.
RX   PubMed=15178348; DOI=10.1016/j.febslet.2004.04.092;
RA   Jo T., Nagata T., Iida H., Imuta H., Iwasawa K., Ma J., Hara K.,
RA   Omata M., Nagai R., Takizawa H., Nagase T., Nakajima T.;
RT   "Voltage-gated sodium channel expressed in cultured human smooth
RT   muscle cells: involvement of SCN9A.";
RL   FEBS Lett. 567:339-343(2004).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, SUBUNIT, PHOSPHORYLATION AT SER-1490,
RP   AND MUTAGENESIS OF SER-1490.
RX   PubMed=25240195; DOI=10.1016/j.febslet.2014.09.011;
RA   Tan Z.Y., Priest B.T., Krajewski J.L., Knopp K.L., Nisenbaum E.S.,
RA   Cummins T.R.;
RT   "Protein kinase C enhances human sodium channel hNav1.7 resurgent
RT   currents via a serine residue in the domain III-IV linker.";
RL   FEBS Lett. 588:3964-3969(2014).
RN   [10]
RP   INTERACTION WITH THE CONOTOXIN GVIIJ.
RX   PubMed=24497506; DOI=10.1073/pnas.1324189111;
RA   Gajewiak J., Azam L., Imperial J., Walewska A., Green B.R.,
RA   Bandyopadhyay P.K., Raghuraman S., Ueberheide B., Bern M., Zhou H.M.,
RA   Minassian N.A., Hagan R.H., Flinspach M., Liu Y., Bulaj G.,
RA   Wickenden A.D., Olivera B.M., Yoshikami D., Zhang M.M.;
RT   "A disulfide tether stabilizes the block of sodium channels by the
RT   conotoxin muO[section sign]-GVIIJ.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:2758-2763(2014).
RN   [11]
RP   X-RAY CRYSTALLOGRAPHY (3.53 ANGSTROMS) OF 1527-1559 AND 1581-1622,
RP   FUNCTION, SUBCELLULAR LOCATION, AND DOMAIN.
RX   PubMed=26680203; DOI=10.1126/science.aac5464;
RA   Ahuja S., Mukund S., Deng L., Khakh K., Chang E., Ho H., Shriver S.,
RA   Young C., Lin S., Johnson J.P. Jr., Wu P., Li J., Coons M., Tam C.,
RA   Brillantes B., Sampang H., Mortara K., Bowman K.K., Clark K.R.,
RA   Estevez A., Xie Z., Verschoof H., Grimwood M., Dehnhardt C.,
RA   Andrez J.C., Focken T., Sutherlin D.P., Safina B.S., Starovasnik M.A.,
RA   Ortwine D.F., Franke Y., Cohen C.J., Hackos D.H., Koth C.M.,
RA   Payandeh J.;
RT   "Structural basis of Nav1.7 inhibition by an isoform-selective small-
RT   molecule antagonist.";
RL   Science 350:0-0(2015).
RN   [12]
RP   CHARACTERIZATION OF VARIANTS PERYTHM THR-859 AND HIS-869, FUNCTION,
RP   AND SUBCELLULAR LOCATION.
RX   PubMed=15385606; DOI=10.1523/JNEUROSCI.2695-04.2004;
RA   Cummins T.R., Dib-Hajj S.D., Waxman S.G.;
RT   "Electrophysiological properties of mutant Nav1.7 sodium channels in a
RT   painful inherited neuropathy.";
RL   J. Neurosci. 24:8232-8236(2004).
RN   [13]
RP   VARIANT PERYTHM THR-241.
RX   PubMed=16216943; DOI=10.1001/archneur.62.10.1587;
RA   Michiels J.J., te Morsche R.H.M., Jansen J.B.M.J., Drenth J.P.H.;
RT   "Autosomal dominant erythermalgia associated with a novel mutation in
RT   the voltage-gated sodium channel alpha subunit Nav1.7.";
RL   Arch. Neurol. 62:1587-1590(2005).
RN   [14]
RP   VARIANT PERYTHM VAL-1460, AND CHARACTERIZATION OF VARIANT PERYTHM
RP   VAL-1460.
RX   PubMed=15958509; DOI=10.1093/brain/awh514;
RA   Dib-Hajj S.D., Rush A.M., Cummins T.R., Hisama F.M., Novella S.,
RA   Tyrrell L., Marshall L., Waxman S.G.;
RT   "Gain-of-function mutation in Nav1.7 in familial erythromelalgia
RT   induces bursting of sensory neurons.";
RL   Brain 128:1847-1854(2005).
RN   [15]
RP   VARIANTS PERYTHM SER-216; LYS-395; THR-859 AND PHE-869, AND VARIANT
RP   ARG-1161.
RX   PubMed=15955112; DOI=10.1111/j.0022-202X.2005.23737.x;
RA   Drenth J.P., te Morsche R.H., Guillet G., Taieb A., Kirby R.L.,
RA   Jansen J.B.;
RT   "SCN9A mutations define primary erythermalgia as a neuropathic
RT   disorder of voltage gated sodium channels.";
RL   J. Invest. Dermatol. 124:1333-1338(2005).
RN   [16]
RP   VARIANT PERYTHM PHE-869, AND CHARACTERIZATION OF VARIANT PERYTHM
RP   PHE-869.
RX   PubMed=16392115; DOI=10.1002/ana.20776;
RA   Han C., Rush A.M., Dib-Hajj S.D., Li S., Xu Z., Wang Y., Tyrrell L.,
RA   Wang X., Yang Y., Waxman S.G.;
RT   "Sporadic onset of erythermalgia: a gain-of-function mutation in
RT   Nav1.7.";
RL   Ann. Neurol. 59:553-558(2006).
RN   [17]
RP   CHARACTERIZATION OF VARIANT PERYTHM SER-216, FUNCTION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=16988069; DOI=10.1212/01.wnl.0000231514.33603.1e;
RA   Choi J.S., Dib-Hajj S.D., Waxman S.G.;
RT   "Inherited erythermalgia: limb pain from an S4 charge-neutral Na
RT   channelopathy.";
RL   Neurology 67:1563-1567(2006).
RN   [18]
RP   VARIANTS PEPD CYS-1007; PHE-1309; ASP-1309; PHE-1310; THR-1472;
RP   VAL-1473; ILE-1475 AND LYS-1638, CHARACTERIZATION OF VARIANTS PEPD
RP   THR-1472; ILE-1475 AND LYS-1638, AND FUNCTION.
RX   PubMed=17145499; DOI=10.1016/j.neuron.2006.10.006;
RA   Fertleman C.R., Baker M.D., Parker K.A., Moffatt S., Elmslie F.V.,
RA   Abrahamsen B., Ostman J., Klugbauer N., Wood J.N., Gardiner R.M.,
RA   Rees M.;
RT   "SCN9A mutations in paroxysmal extreme pain disorder: allelic variants
RT   underlie distinct channel defects and phenotypes.";
RL   Neuron 52:767-774(2006).
RN   [19]
RP   CHARACTERIZATION OF VARIANT PERYTHM HIS-869.
RX   PubMed=16702558; DOI=10.1073/pnas.0602813103;
RA   Rush A.M., Dib-Hajj S.D., Liu S., Cummins T.R., Black J.A.,
RA   Waxman S.G.;
RT   "A single sodium channel mutation produces hyper- or hypoexcitability
RT   in different types of neurons.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:8245-8250(2006).
RN   [20]
RP   VARIANT PERYTHM GLU-1643, CHARACTERIZATION OF VARIANT PERYTHM
RP   GLU-1643, VARIANT PEPD GLU-1643, AND CHARACTERIZATION OF VARIANT PEPD
RP   GLU-1643.
RX   PubMed=18945915; DOI=10.1523/JNEUROSCI.3443-08.2008;
RA   Estacion M., Dib-Hajj S.D., Benke P.J., Te Morsche R.H., Eastman E.M.,
RA   Macala L.J., Drenth J.P., Waxman S.G.;
RT   "NaV1.7 gain-of-function mutations as a continuum: A1632E displays
RT   physiological changes associated with erythromelalgia and paroxysmal
RT   extreme pain disorder mutations and produces symptoms of both
RT   disorders.";
RL   J. Neurosci. 28:11079-11088(2008).
RN   [21]
RP   VARIANT PERYTHM ARG-10, CHARACTERIZATION OF VARIANTS PERYTHM ARG-10
RP   AND THR-859, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=19369487; DOI=10.1093/brain/awp078;
RA   Han C., Dib-Hajj S.D., Lin Z., Li Y., Eastman E.M., Tyrrell L.,
RA   Cao X., Yang Y., Waxman S.G.;
RT   "Early- and late-onset inherited erythromelalgia: genotype-phenotype
RT   correlation.";
RL   Brain 132:1711-1722(2009).
RN   [22]
RP   VARIANTS GEFS+7 TYR-641 AND ARG-666, VARIANTS FEB3B VAL-62 AND
RP   GLN-149, AND VARIANTS MET-228; ASN-490; LYS-519; MET-695; TYR-710;
RP   VAL-750; PHE-1134; GLN-1171 AND VAL-1278.
RX   PubMed=19763161; DOI=10.1371/journal.pgen.1000649;
RA   Singh N.A., Pappas C., Dahle E.J., Claes L.R., Pruess T.H.,
RA   De Jonghe P., Thompson J., Dixon M., Gurnett C., Peiffer A.,
RA   White H.S., Filloux F., Leppert M.F.;
RT   "A role of SCN9A in human epilepsies, as a cause of febrile seizures
RT   and as a potential modifier of Dravet syndrome.";
RL   PLoS Genet. 5:E1000649-E1000649(2009).
RN   [23]
RP   VARIANTS CIP GLN-907 AND 1381-ARG--LEU-1385 DEL, AND CHARACTERIZATION
RP   OF VARIANTS CIP GLN-907 AND 1381-ARG--LEU-1385 DEL.
RX   PubMed=20635406; DOI=10.1002/humu.21325;
RA   Cox J.J., Sheynin J., Shorer Z., Reimann F., Nicholas A.K.,
RA   Zubovic L., Baralle M., Wraige E., Manor E., Levy J., Woods C.G.,
RA   Parvari R.;
RT   "Congenital insensitivity to pain: novel SCN9A missense and in-frame
RT   deletion mutations.";
RL   Hum. Mutat. 31:E1670-E1686(2010).
RN   [24]
RP   VARIANT PEPD PRO-1623, AND CHARACTERIZATION OF VARIANT PEPD PRO-1623.
RX   PubMed=25285947; DOI=10.1097/ALN.0000000000000476;
RA   Suter M.R., Bhuiyan Z.A., Laedermann C.J., Kuntzer T., Schaller M.,
RA   Stauffacher M.W., Roulet E., Abriel H., Decosterd I., Wider C.;
RT   "p.L1612P, a novel voltage-gated sodium channel Nav1.7 mutation
RT   inducing a cold sensitive paroxysmal extreme pain disorder.";
RL   Anesthesiology 122:414-423(2015).
RN   [25]
RP   VARIANT PERYTHM THR-1643, CHARACTERIZATION OF VARIANT PERYTHM
RP   THR-1643, MUTAGENESIS OF ALA-1643, FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24311784; DOI=10.1074/jbc.M113.502211;
RA   Eberhardt M., Nakajima J., Klinger A.B., Neacsu C., Huhne K.,
RA   O'Reilly A.O., Kist A.M., Lampe A.K., Fischer K., Gibson J., Nau C.,
RA   Winterpacht A., Lampert A.;
RT   "Inherited pain: sodium channel Nav1.7 A1632T mutation causes
RT   erythromelalgia due to a shift of fast inactivation.";
RL   J. Biol. Chem. 289:1971-1980(2014).
CC   -!- FUNCTION: Mediates the voltage-dependent sodium ion permeability
CC       of excitable membranes. Assuming opened or closed conformations in
CC       response to the voltage difference across the membrane, the
CC       protein forms a sodium-selective channel through which Na(+) ions
CC       may pass in accordance with their electrochemical gradient
CC       (PubMed:7720699, PubMed:17167479, PubMed:25240195,
CC       PubMed:26680203, PubMed:15385606, PubMed:16988069,
CC       PubMed:17145499, PubMed:19369487, PubMed:24311784). It is a
CC       tetrodotoxin-sensitive Na(+) channel isoform (PubMed:7720699).
CC       Plays a role in pain mechanisms, especially in the development of
CC       inflammatory pain (PubMed:17167479, PubMed:17145499,
CC       PubMed:19369487, PubMed:24311784). {ECO:0000269|PubMed:15178348,
CC       ECO:0000269|PubMed:15385606, ECO:0000269|PubMed:16988069,
CC       ECO:0000269|PubMed:17145499, ECO:0000269|PubMed:17167479,
CC       ECO:0000269|PubMed:19369487, ECO:0000269|PubMed:24311784,
CC       ECO:0000269|PubMed:25240195, ECO:0000269|PubMed:26680203,
CC       ECO:0000269|PubMed:7720699}.
CC   -!- SUBUNIT: The sodium channel complex consists of a large, channel-
CC       forming alpha subunit and 2-3 smaller, ancillary beta subunits
CC       (PubMed:7720699, PubMed:17167479, PubMed:25240195). Interacts with
CC       NEDD4 and NEDD4L (By similarity). Interacts with the conotoxin
CC       GVIIJ (PubMed:24497506). {ECO:0000250|UniProtKB:Q62205,
CC       ECO:0000269|PubMed:17167479, ECO:0000269|PubMed:24497506,
CC       ECO:0000269|PubMed:25240195, ECO:0000269|PubMed:7720699}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:15385606,
CC       ECO:0000269|PubMed:17167479, ECO:0000269|PubMed:19369487,
CC       ECO:0000269|PubMed:24311784, ECO:0000269|PubMed:25240195,
CC       ECO:0000269|PubMed:26680203, ECO:0000269|PubMed:7720699}; Multi-
CC       pass membrane protein {ECO:0000305}. Cell projection
CC       {ECO:0000250|UniProtKB:O08562}. Note=In neurite terminals.
CC       {ECO:0000250|UniProtKB:O08562}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=4;
CC       Name=1;
CC         IsoId=Q15858-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q15858-2; Sequence=VSP_012028;
CC       Name=3;
CC         IsoId=Q15858-3; Sequence=VSP_012029;
CC       Name=4;
CC         IsoId=Q15858-4; Sequence=VSP_012028, VSP_012029;
CC   -!- TISSUE SPECIFICITY: Expressed strongly in dorsal root ganglion,
CC       with only minor levels elsewhere in the body, smooth muscle cells,
CC       MTC cell line and C-cell carcinoma. Isoform 1 is expressed
CC       preferentially in the central and peripheral nervous system.
CC       Isoform 2 is expressed preferentially in the dorsal root ganglion.
CC       {ECO:0000269|PubMed:15178348, ECO:0000269|PubMed:15302875,
CC       ECO:0000269|PubMed:7720699, ECO:0000269|PubMed:9169448}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position. {ECO:0000305|PubMed:26680203}.
CC   -!- PTM: Phosphorylation at Ser-1490 by PKC in a highly conserved
CC       cytoplasmic loop increases peak sodium currents.
CC       {ECO:0000269|PubMed:25240195}.
CC   -!- PTM: Ubiquitinated by NEDD4L; which may promote its endocytosis.
CC       Does not seem to be ubiquitinated by NEDD4.
CC       {ECO:0000250|UniProtKB:Q62205}.
CC   -!- DISEASE: Primary erythermalgia (PERYTHM) [MIM:133020]: Autosomal
CC       dominant disease characterized by recurrent episodes of severe
CC       pain associated with redness and warmth in the feet or hands.
CC       {ECO:0000269|PubMed:14985375, ECO:0000269|PubMed:15385606,
CC       ECO:0000269|PubMed:15955112, ECO:0000269|PubMed:15958509,
CC       ECO:0000269|PubMed:16216943, ECO:0000269|PubMed:16392115,
CC       ECO:0000269|PubMed:16702558, ECO:0000269|PubMed:16988069,
CC       ECO:0000269|PubMed:18945915, ECO:0000269|PubMed:19369487,
CC       ECO:0000269|PubMed:24311784}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Indifference to pain, congenital, autosomal recessive
CC       (CIP) [MIM:243000]: A disorder characterized by congenital
CC       inability to perceive any form of pain, in any part of the body.
CC       All other sensory modalities are preserved and the peripheral and
CC       central nervous systems are apparently intact. Patients perceive
CC       the sensations of touch, warm and cold temperature,
CC       proprioception, tickle and pressure, but not painful stimuli.
CC       There is no evidence of a motor or sensory neuropathy, either
CC       axonal or demyelinating. {ECO:0000269|PubMed:20635406}. Note=The
CC       disease is caused by mutations affecting the gene represented in
CC       this entry.
CC   -!- DISEASE: Paroxysmal extreme pain disorder (PEPD) [MIM:167400]:
CC       Autosomal dominant paroxysmal disorder of pain and autonomic
CC       dysfunction. The distinctive features are paroxysmal episodes of
CC       burning pain in the rectal, ocular, and mandibular areas
CC       accompanied by autonomic manifestations such as skin flushing.
CC       {ECO:0000269|PubMed:17145499, ECO:0000269|PubMed:18945915,
CC       ECO:0000269|PubMed:25285947}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Generalized epilepsy with febrile seizures plus 7
CC       (GEFS+7) [MIM:613863]: A rare autosomal dominant, familial
CC       condition with incomplete penetrance and large intrafamilial
CC       variability. Patients display febrile seizures persisting
CC       sometimes beyond the age of 6 years and/or a variety of afebrile
CC       seizure types. This disease combines febrile seizures, generalized
CC       seizures often precipitated by fever at age 6 years or more, and
CC       partial seizures, with a variable degree of severity.
CC       {ECO:0000269|PubMed:19763161}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Febrile seizures, familial, 3B (FEB3B) [MIM:613863]:
CC       Seizures associated with febrile episodes in childhood without any
CC       evidence of intracranial infection or defined pathologic or
CC       traumatic cause. It is a common condition, affecting 2-5% of
CC       children aged 3 months to 5 years. The majority are simple febrile
CC       seizures (generally defined as generalized onset, single seizures
CC       with a duration of less than 30 minutes). Complex febrile seizures
CC       are characterized by focal onset, duration greater than 30
CC       minutes, and/or more than one seizure in a 24 hour period. The
CC       likelihood of developing epilepsy following simple febrile
CC       seizures is low. Complex febrile seizures are associated with a
CC       moderately increased incidence of epilepsy.
CC       {ECO:0000269|PubMed:19763161}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.7/SCN9A subfamily. {ECO:0000305}.
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=SCN9A entry;
CC       URL="https://en.wikipedia.org/wiki/SCN9A";
CC   -!- WEB RESOURCE: Name=Protein Spotlight; Note=Silent pain - Issue 102
CC       of February 2009;
CC       URL="http://web.expasy.org/spotlight/back_issues/102";
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X82835; CAA58042.1; -; mRNA.
DR   EMBL; DQ857292; ABI51981.1; -; mRNA.
DR   EMBL; AC074101; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC107082; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC108146; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY682084; AAT85833.1; -; mRNA.
DR   EMBL; AY682085; AAT85834.1; -; mRNA.
DR   EMBL; AY682086; AAT85835.1; -; mRNA.
DR   EMBL; AJ310882; CAC84550.1; -; mRNA.
DR   EMBL; AJ310883; CAC84551.1; -; mRNA.
DR   EMBL; AJ310897; CAC84537.1; -; mRNA.
DR   EMBL; AJ580918; CAE45644.1; -; Genomic_DNA.
DR   EMBL; AJ580919; CAE45645.1; -; Genomic_DNA.
DR   CCDS; CCDS46441.1; -. [Q15858-3]
DR   PIR; S54771; S54771.
DR   RefSeq; NP_002968.1; NM_002977.3.
DR   RefSeq; XP_005246814.1; XM_005246757.2. [Q15858-1]
DR   RefSeq; XP_011509918.1; XM_011511616.2. [Q15858-1]
DR   RefSeq; XP_011509919.1; XM_011511617.2. [Q15858-2]
DR   RefSeq; XP_011509920.1; XM_011511618.2. [Q15858-4]
DR   UniGene; Hs.439145; -.
DR   PDB; 5EK0; X-ray; 3.53 A; A/B/C/D=1527-1559, A/B/C/D=1581-1622.
DR   PDBsum; 5EK0; -.
DR   ProteinModelPortal; Q15858; -.
DR   IntAct; Q15858; 2.
DR   STRING; 9606.ENSP00000386306; -.
DR   BindingDB; Q15858; -.
DR   ChEMBL; CHEMBL4296; -.
DR   DrugBank; DB06218; Lacosamide.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB00243; Ranolazine.
DR   DrugBank; DB06201; Rufinamide.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00909; Zonisamide.
DR   GuidetoPHARMACOLOGY; 584; -.
DR   TCDB; 1.A.1.10.5; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; Q15858; -.
DR   PhosphoSitePlus; Q15858; -.
DR   BioMuta; SCN9A; -.
DR   DMDM; 327478559; -.
DR   EPD; Q15858; -.
DR   PaxDb; Q15858; -.
DR   PeptideAtlas; Q15858; -.
DR   PRIDE; Q15858; -.
DR   Ensembl; ENST00000303354; ENSP00000304748; ENSG00000169432. [Q15858-1]
DR   Ensembl; ENST00000409435; ENSP00000386330; ENSG00000169432. [Q15858-1]
DR   Ensembl; ENST00000409672; ENSP00000386306; ENSG00000169432. [Q15858-3]
DR   GeneID; 6335; -.
DR   KEGG; hsa:6335; -.
DR   UCSC; uc002udr.2; human. [Q15858-1]
DR   CTD; 6335; -.
DR   DisGeNET; 6335; -.
DR   GeneCards; SCN9A; -.
DR   GeneReviews; SCN9A; -.
DR   HGNC; HGNC:10597; SCN9A.
DR   HPA; CAB013679; -.
DR   HPA; HPA061843; -.
DR   MalaCards; SCN9A; -.
DR   MIM; 133020; phenotype.
DR   MIM; 167400; phenotype.
DR   MIM; 243000; phenotype.
DR   MIM; 603415; gene.
DR   MIM; 613863; phenotype.
DR   neXtProt; NX_Q15858; -.
DR   OpenTargets; ENSG00000169432; -.
DR   Orphanet; 88642; Channelopathy-associated congenital insensitivity to pain.
DR   Orphanet; 33069; Dravet syndrome.
DR   Orphanet; 1956; Erythromelalgia.
DR   Orphanet; 36387; Generalized epilepsy with febrile seizures-plus.
DR   Orphanet; 970; Hereditary sensory and autonomic neuropathy type 2.
DR   Orphanet; 46348; Paroxysmal extreme pain disorder.
DR   Orphanet; 90026; Primary erythermalgia.
DR   Orphanet; 306577; Sodium channelopathy-related small fiber neuropathy.
DR   PharmGKB; PA35010; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q15858; -.
DR   KO; K04841; -.
DR   OMA; VSQNVRW; -.
DR   OrthoDB; EOG0903019Q; -.
DR   PhylomeDB; Q15858; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   GeneWiki; Nav1.7; -.
DR   GenomeRNAi; 6335; -.
DR   PRO; PR:Q15858; -.
DR   Proteomes; UP000005640; Chromosome 2.
DR   Bgee; ENSG00000169432; -.
DR   CleanEx; HS_SCN9A; -.
DR   ExpressionAtlas; Q15858; baseline and differential.
DR   Genevisible; Q15858; HS.
DR   GO; GO:0042995; C:cell projection; IEA:UniProtKB-SubCell.
DR   GO; GO:0005887; C:integral component of plasma membrane; IMP:UniProtKB.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:Ensembl.
DR   GO; GO:0031402; F:sodium ion binding; IEA:Ensembl.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IDA:UniProtKB.
DR   GO; GO:0048266; P:behavioral response to pain; IEA:Ensembl.
DR   GO; GO:0006954; P:inflammatory response; IEA:Ensembl.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0009791; P:post-embryonic development; IEA:Ensembl.
DR   GO; GO:0009636; P:response to toxic substance; IEA:Ensembl.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:UniProtKB.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IDA:UniProtKB.
DR   GO; GO:0006814; P:sodium ion transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR000048; IQ_motif_EF-hand-BS.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   InterPro; IPR024583; Na_trans_cytopl.
DR   InterPro; IPR028803; SCN9A.
DR   PANTHER; PTHR10037:SF235; PTHR10037:SF235; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   Pfam; PF11933; Na_trans_cytopl; 1.
DR   PRINTS; PR00170; NACHANNEL.
DR   SMART; SM00015; IQ; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell membrane; Cell projection;
KW   Complete proteome; Disease mutation; Disulfide bond; Epilepsy;
KW   Glycoprotein; Ion channel; Ion transport; Membrane; Phosphoprotein;
KW   Polymorphism; Reference proteome; Repeat; Sodium; Sodium channel;
KW   Sodium transport; Transmembrane; Transmembrane helix; Transport;
KW   Ubl conjugation; Voltage-gated channel.
FT   CHAIN         1   1988       Sodium channel protein type 9 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048502.
FT   TOPO_DOM      1    121       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    122    145       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    146    153       Extracellular. {ECO:0000255}.
FT   TRANSMEM    154    173       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    174    186       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    187    205       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    206    211       Extracellular. {ECO:0000255}.
FT   TRANSMEM    212    231       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000255}.
FT   TOPO_DOM    232    247       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    248    271       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    272    378       Extracellular. {ECO:0000255}.
FT   TRANSMEM    379    404       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    405    738       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    739    763       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    764    774       Extracellular. {ECO:0000255}.
FT   TRANSMEM    775    798       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    799    806       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    807    826       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    827    832       Extracellular. {ECO:0000255}.
FT   TRANSMEM    833    852       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000255}.
FT   TOPO_DOM    853    868       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    869    889       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    890    942       Extracellular. {ECO:0000255}.
FT   TRANSMEM    943    968       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    969   1187       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1188   1211       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1212   1224       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1225   1250       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1251   1256       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1257   1278       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1279   1282       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1283   1304       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000255}.
FT   TOPO_DOM   1305   1323       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1324   1351       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1352   1430       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1431   1457       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1458   1510       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1511   1534       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1535   1545       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1546   1569       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1570   1575       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1576   1599       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1600   1609       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1610   1631       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000255}.
FT   TOPO_DOM   1632   1646       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1647   1669       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1670   1735       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1736   1760       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1761   1988       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      112    410       I. {ECO:0000305}.
FT   REPEAT      726    989       II. {ECO:0000305}.
FT   REPEAT     1180   1488       III. {ECO:0000305}.
FT   REPEAT     1497   1795       IV. {ECO:0000305}.
FT   DOMAIN     1889   1918       IQ.
FT   MOD_RES    1490   1490       Phosphoserine; by PKC.
FT                                {ECO:0000269|PubMed:25240195}.
FT   CARBOHYD    209    209       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    283    283       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1352   1352       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1366   1366       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1375   1375       N-linked (GlcNAc...). {ECO:0000255}.
FT   DISULFID    895    895       Interchain; with SCN2B or SCN4B.
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   DISULFID    895    895       Interchain; with the conotoxin GVIIJ
FT                                (when the channel is not linked to SCN2B
FT                                or SCN4B; the bond to SCN2B or SCN4B
FT                                protects the channel from the inhibition
FT                                by toxin).
FT                                {ECO:0000250|UniProtKB:P04775}.
FT   VAR_SEQ     200    229       YLTEFVNLGNVSALRTFRVLRALKTISVIP -> YVTEFVD
FT                                LGNVSALRTFRVLRALKTISVIP (in isoform 2 and
FT                                isoform 4).
FT                                {ECO:0000303|PubMed:15302875}.
FT                                /FTId=VSP_012028.
FT   VAR_SEQ     648    658       Missing (in isoform 3 and isoform 4).
FT                                {ECO:0000303|PubMed:15302875,
FT                                ECO:0000303|PubMed:17167479,
FT                                ECO:0000303|PubMed:7720699}.
FT                                /FTId=VSP_012029.
FT   VARIANT      10     10       Q -> R (in PERYTHM; causes a
FT                                hyperpolarizing shift of -5.3 mV for the
FT                                midpoint of activation which is smaller
FT                                than that seen in other mutations causing
FT                                early-onset erythromelalgia mutations;
FT                                also causes a faster rate of activation
FT                                and slower deactivation compared to wild-
FT                                type; expression of the mutant protein
FT                                induced hyperexcitability in dorsal root
FT                                ganglion neurons but the increase is
FT                                smaller than that produced by Thr-859;
FT                                dbSNP:rs267607030).
FT                                {ECO:0000269|PubMed:19369487}.
FT                                /FTId=VAR_064595.
FT   VARIANT      62     62       I -> V (in FEB3B; dbSNP:rs121908920).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064596.
FT   VARIANT     149    149       P -> Q (in FEB3B; dbSNP:rs121908921).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064597.
FT   VARIANT     216    216       F -> S (in PERYTHM; hyperpolarizes the
FT                                voltage dependence of activation by 11
FT                                mV, accelerates activation, slows
FT                                deactivation and enhances the response to
FT                                slow, small depolarizations;
FT                                dbSNP:rs80356469).
FT                                {ECO:0000269|PubMed:15955112,
FT                                ECO:0000269|PubMed:16988069}.
FT                                /FTId=VAR_064598.
FT   VARIANT     228    228       I -> M (in dbSNP:rs71428908).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064599.
FT   VARIANT     241    241       S -> T (in PERYTHM; dbSNP:rs80356470).
FT                                {ECO:0000269|PubMed:16216943}.
FT                                /FTId=VAR_032014.
FT   VARIANT     395    395       N -> K (in PERYTHM; dbSNP:rs80356471).
FT                                {ECO:0000269|PubMed:15955112}.
FT                                /FTId=VAR_064600.
FT   VARIANT     406    406       E -> K (in PERYTHM).
FT                                /FTId=VAR_064601.
FT   VARIANT     490    490       S -> N (in dbSNP:rs58022607).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064602.
FT   VARIANT     519    519       E -> K (in dbSNP:rs187453572).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064603.
FT   VARIANT     641    641       N -> Y (in GEFS+7; dbSNP:rs121908918).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064604.
FT   VARIANT     666    666       K -> R (in GEFS+7; also found in a
FT                                patient with severe myoclonic epilepsy in
FT                                infancy; dbSNP:rs121908919).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064605.
FT   VARIANT     695    695       I -> M (in dbSNP:rs199588089).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064606.
FT   VARIANT     710    710       C -> Y (found in a patient with severe
FT                                myoclonic epilepsy in infancy;
FT                                dbSNP:rs201709980).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064607.
FT   VARIANT     750    750       I -> V (in dbSNP:rs182650126).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064608.
FT   VARIANT     859    859       I -> T (in PERYTHM; sporadic; activated
FT                                at more negative potentials; slower
FT                                inactivation kinetics than wild-type
FT                                channels; dbSNP:rs80356474).
FT                                {ECO:0000269|PubMed:14985375,
FT                                ECO:0000269|PubMed:15385606,
FT                                ECO:0000269|PubMed:15955112,
FT                                ECO:0000269|PubMed:19369487}.
FT                                /FTId=VAR_019947.
FT   VARIANT     869    869       L -> F (in PERYTHM; causes a
FT                                hyperpolarizing shift in channel
FT                                activation, a depolarizing shift of
FT                                inactivation and an 18-fold increase in
FT                                deactivation time compared to wild-type;
FT                                the mean ramp current amplitude in
FT                                response to slow depolarization is higher
FT                                in the mutant channels;
FT                                dbSNP:rs80356476).
FT                                {ECO:0000269|PubMed:15955112,
FT                                ECO:0000269|PubMed:16392115}.
FT                                /FTId=VAR_064609.
FT   VARIANT     869    869       L -> H (in PERYTHM; activated at more
FT                                negative potentials; slower inactivation
FT                                kinetics than wild-type channels;
FT                                dbSNP:rs80356475).
FT                                {ECO:0000269|PubMed:14985375,
FT                                ECO:0000269|PubMed:15385606,
FT                                ECO:0000269|PubMed:16702558}.
FT                                /FTId=VAR_019948.
FT   VARIANT     907    907       R -> Q (in CIP; significant reduction in
FT                                membrane localization of the mutant
FT                                protein compared to the wild-type;
FT                                complete loss of function of the sodium
FT                                channel). {ECO:0000269|PubMed:20635406}.
FT                                /FTId=VAR_064610.
FT   VARIANT     932    932       M -> L (in dbSNP:rs12478318).
FT                                /FTId=VAR_030444.
FT   VARIANT     943    943       M -> L (in dbSNP:rs12478318).
FT                                /FTId=VAR_055646.
FT   VARIANT    1007   1007       R -> C (in PEPD; dbSNP:rs121908910).
FT                                {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032015.
FT   VARIANT    1134   1134       L -> F (in dbSNP:rs200160858).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064611.
FT   VARIANT    1161   1161       W -> R (in dbSNP:rs6746030).
FT                                {ECO:0000269|PubMed:15955112,
FT                                ECO:0000269|PubMed:17167479,
FT                                ECO:0000269|PubMed:7720699}.
FT                                /FTId=VAR_019949.
FT   VARIANT    1171   1171       E -> Q (found in a patient with severe
FT                                myoclonic epilepsy in infancy).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064612.
FT   VARIANT    1278   1278       L -> V (in dbSNP:rs180922748).
FT                                {ECO:0000269|PubMed:19763161}.
FT                                /FTId=VAR_064613.
FT   VARIANT    1309   1309       V -> D (in PEPD; dbSNP:rs121908911).
FT                                {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032016.
FT   VARIANT    1309   1309       V -> F (in PEPD; dbSNP:rs121908912).
FT                                {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032017.
FT   VARIANT    1310   1310       V -> F (in PEPD; dbSNP:rs121908913).
FT                                {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032018.
FT   VARIANT    1381   1385       Missing (in CIP; significant reduction in
FT                                membrane localization of the mutant
FT                                protein compared to the wild-type;
FT                                complete loss of function of the sodium
FT                                channel). {ECO:0000269|PubMed:20635406}.
FT                                /FTId=VAR_064614.
FT   VARIANT    1460   1460       F -> V (in PERYTHM; produces a
FT                                hyperpolarizing shift in channel
FT                                activation and a depolarizing shift in
FT                                steady-state activation;
FT                                dbSNP:rs80356478).
FT                                {ECO:0000269|PubMed:15958509}.
FT                                /FTId=VAR_032019.
FT   VARIANT    1472   1472       I -> T (in PEPD; reduction in fast
FT                                inactivation leading to persistent sodium
FT                                current; dbSNP:rs121908914).
FT                                {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032020.
FT   VARIANT    1473   1473       F -> V (in PEPD).
FT                                {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032021.
FT   VARIANT    1475   1475       T -> I (in PEPD; reduction in fast
FT                                inactivation leading to persistent sodium
FT                                current; dbSNP:rs121908915).
FT                                {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032022.
FT   VARIANT    1623   1623       L -> P (in PEPD; depolarizes the voltage-
FT                                dependence of channel activation and
FT                                steady-state fast inactivation; increases
FT                                ramp current).
FT                                {ECO:0000269|PubMed:25285947}.
FT                                /FTId=VAR_072279.
FT   VARIANT    1638   1638       M -> K (in PEPD; reduction in fast
FT                                inactivation leading to persistent sodium
FT                                current). {ECO:0000269|PubMed:17145499}.
FT                                /FTId=VAR_032023.
FT   VARIANT    1643   1643       A -> E (in PERYTHM and PEPD;
FT                                hyperpolarizes voltage-dependence of
FT                                channel activation; depolarizes the
FT                                voltage-dependence of steady-state fast
FT                                inactivation; slows channel deactivation;
FT                                enhances persistent and resurgent
FT                                current; enhances neuronal
FT                                hyperexcitability in dorsal root ganglion
FT                                neurons). {ECO:0000269|PubMed:18945915,
FT                                ECO:0000269|PubMed:24311784}.
FT                                /FTId=VAR_072280.
FT   VARIANT    1643   1643       A -> T (in PERYTHM; no effect on voltage-
FT                                dependence of channel activation;
FT                                depolarizes the voltage dependence of
FT                                steady-state fast inactivation;
FT                                accelerates channel deactivation; no
FT                                increase in persistent and resurgent
FT                                currents; enhances neuronal
FT                                hyperexcitability in dorsal root ganglion
FT                                neurons). {ECO:0000269|PubMed:24311784}.
FT                                /FTId=VAR_072281.
FT   VARIANT    1919   1919       D -> G (in dbSNP:rs3750904).
FT                                /FTId=VAR_019950.
FT   MUTAGEN    1490   1490       S->A: Abolishes stimulation by agents
FT                                that stimulate PKC activity.
FT                                {ECO:0000269|PubMed:25240195}.
FT   MUTAGEN    1490   1490       S->D,E: Increases current amplitude.
FT                                {ECO:0000269|PubMed:25240195}.
FT   MUTAGEN    1643   1643       A->D: Depolarizes the voltage-dependence
FT                                of steady-state fast inactivation;
FT                                enhances persistent current.
FT                                {ECO:0000269|PubMed:24311784}.
FT   MUTAGEN    1643   1643       A->K: No effect on voltage-dependence of
FT                                steady-state fast inactivation.
FT                                {ECO:0000269|PubMed:24311784}.
FT   MUTAGEN    1643   1643       A->V: No effect on voltage-dependence of
FT                                steady-state fast inactivation.
FT                                {ECO:0000269|PubMed:24311784}.
FT   CONFLICT    267    267       F -> S (in Ref. 4; AAT85834).
FT                                {ECO:0000305}.
FT   CONFLICT    301    301       K -> R (in Ref. 4; AAT85835).
FT                                {ECO:0000305}.
FT   CONFLICT    309    309       S -> P (in Ref. 4; AAT85834).
FT                                {ECO:0000305}.
FT   CONFLICT    420    420       E -> G (in Ref. 4; AAT85834).
FT                                {ECO:0000305}.
FT   CONFLICT    430    430       L -> P (in Ref. 4; AAT85834).
FT                                {ECO:0000305}.
FT   CONFLICT    501    501       S -> P (in Ref. 4; AAT85835).
FT                                {ECO:0000305}.
FT   CONFLICT    610    610       P -> T (in Ref. 4; AAT85835).
FT                                {ECO:0000305}.
FT   CONFLICT    642    642       G -> R (in Ref. 4; AAT85835).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1988 AA;  226372 MW;  1BAEB8F32EBF5438 CRC64;
     MAMLPPPGPQ SFVHFTKQSL ALIEQRIAER KSKEPKEEKK DDDEEAPKPS SDLEAGKQLP
     FIYGDIPPGM VSEPLEDLDP YYADKKTFIV LNKGKTIFRF NATPALYMLS PFSPLRRISI
     KILVHSLFSM LIMCTILTNC IFMTMNNPPD WTKNVEYTFT GIYTFESLVK ILARGFCVGE
     FTFLRDPWNW LDFVVIVFAY LTEFVNLGNV SALRTFRVLR ALKTISVIPG LKTIVGALIQ
     SVKKLSDVMI LTVFCLSVFA LIGLQLFMGN LKHKCFRNSL ENNETLESIM NTLESEEDFR
     KYFYYLEGSK DALLCGFSTD SGQCPEGYTC VKIGRNPDYG YTSFDTFSWA FLALFRLMTQ
     DYWENLYQQT LRAAGKTYMI FFVVVIFLGS FYLINLILAV VAMAYEEQNQ ANIEEAKQKE
     LEFQQMLDRL KKEQEEAEAI AAAAAEYTSI RRSRIMGLSE SSSETSKLSS KSAKERRNRR
     KKKNQKKLSS GEEKGDAEKL SKSESEDSIR RKSFHLGVEG HRRAHEKRLS TPNQSPLSIR
     GSLFSARRSS RTSLFSFKGR GRDIGSETEF ADDEHSIFGD NESRRGSLFV PHRPQERRSS
     NISQASRSPP MLPVNGKMHS AVDCNGVVSL VDGRSALMLP NGQLLPEVII DKATSDDSGT
     TNQIHKKRRC SSYLLSEDML NDPNLRQRAM SRASILTNTV EELEESRQKC PPWWYRFAHK
     FLIWNCSPYW IKFKKCIYFI VMDPFVDLAI TICIVLNTLF MAMEHHPMTE EFKNVLAIGN
     LVFTGIFAAE MVLKLIAMDP YEYFQVGWNI FDSLIVTLSL VELFLADVEG LSVLRSFRLL
     RVFKLAKSWP TLNMLIKIIG NSVGALGNLT LVLAIIVFIF AVVGMQLFGK SYKECVCKIN
     DDCTLPRWHM NDFFHSFLIV FRVLCGEWIE TMWDCMEVAG QAMCLIVYMM VMVIGNLVVL
     NLFLALLLSS FSSDNLTAIE EDPDANNLQI AVTRIKKGIN YVKQTLREFI LKAFSKKPKI
     SREIRQAEDL NTKKENYISN HTLAEMSKGH NFLKEKDKIS GFGSSVDKHL MEDSDGQSFI
     HNPSLTVTVP IAPGESDLEN MNAEELSSDS DSEYSKVRLN RSSSSECSTV DNPLPGEGEE
     AEAEPMNSDE PEACFTDGCV WRFSCCQVNI ESGKGKIWWN IRKTCYKIVE HSWFESFIVL
     MILLSSGALA FEDIYIERKK TIKIILEYAD KIFTYIFILE MLLKWIAYGY KTYFTNAWCW
     LDFLIVDVSL VTLVANTLGY SDLGPIKSLR TLRALRPLRA LSRFEGMRVV VNALIGAIPS
     IMNVLLVCLI FWLIFSIMGV NLFAGKFYEC INTTDGSRFP ASQVPNRSEC FALMNVSQNV
     RWKNLKVNFD NVGLGYLSLL QVATFKGWTI IMYAAVDSVN VDKQPKYEYS LYMYIYFVVF
     IIFGSFFTLN LFIGVIIDNF NQQKKKLGGQ DIFMTEEQKK YYNAMKKLGS KKPQKPIPRP
     GNKIQGCIFD LVTNQAFDIS IMVLICLNMV TMMVEKEGQS QHMTEVLYWI NVVFIILFTG
     ECVLKLISLR HYYFTVGWNI FDFVVVIISI VGMFLADLIE TYFVSPTLFR VIRLARIGRI
     LRLVKGAKGI RTLLFALMMS LPALFNIGLL LFLVMFIYAI FGMSNFAYVK KEDGINDMFN
     FETFGNSMIC LFQITTSAGW DGLLAPILNS KPPDCDPKKV HPGSSVEGDC GNPSVGIFYF
     VSYIIISFLV VVNMYIAVIL ENFSVATEES TEPLSEDDFE MFYEVWEKFD PDATQFIEFS
     KLSDFAAALD PPLLIAKPNK VQLIAMDLPM VSGDRIHCLD ILFAFTKRVL GESGEMDSLR
     SQMEERFMSA NPSKVSYEPI TTTLKRKQED VSATVIQRAY RRYRLRQNVK NISSIYIKDG
     DRDDDLLNKK DMAFDNVNEN SSPEKTDATS STTSPPSYDS VTKPDKEKYE QDRTEKEDKG
     KDSKESKK
//
ID   SCNAA_HUMAN             Reviewed;        1956 AA.
AC   Q9Y5Y9; A6NDQ1;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   02-SEP-2008, sequence version 2.
DT   15-FEB-2017, entry version 137.
DE   RecName: Full=Sodium channel protein type 10 subunit alpha;
DE   AltName: Full=Peripheral nerve sodium channel 3;
DE            Short=PN3;
DE            Short=hPN3;
DE   AltName: Full=Sodium channel protein type X subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.8;
GN   Name=SCN10A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION IN VOLTAGE-EVOKED DEPOLARIZATION,
RP   TISSUE SPECIFICITY, AND VARIANTS ALA-1073 AND VAL-1713.
RC   TISSUE=Spinal ganglion;
RX   PubMed=9839820; DOI=10.1016/S0304-3959(98)00120-1;
RA   Rabert D.K., Koch B.D., Ilnicka M., Obernolte R.A., Naylor S.L.,
RA   Herman R.C., Eglen R.M., Hunter J.C., Sangameswaran L.;
RT   "A tetrodotoxin-resistant voltage-gated sodium channel from human
RT   dorsal root ganglia, hPN3/SCN10A.";
RL   Pain 78:107-114(1998).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [3]
RP   VARIANT TRP-916.
RX   PubMed=21248752; DOI=10.1038/nature09639;
RA   Varela I., Tarpey P., Raine K., Huang D., Ong C.K., Stephens P.,
RA   Davies H., Jones D., Lin M.L., Teague J., Bignell G., Butler A.,
RA   Cho J., Dalgliesh G.L., Galappaththige D., Greenman C., Hardy C.,
RA   Jia M., Latimer C., Lau K.W., Marshall J., McLaren S., Menzies A.,
RA   Mudie L., Stebbings L., Largaespada D.A., Wessels L.F.A., Richard S.,
RA   Kahnoski R.J., Anema J., Tuveson D.A., Perez-Mancera P.A.,
RA   Mustonen V., Fischer A., Adams D.J., Rust A., Chan-On W., Subimerb C.,
RA   Dykema K., Furge K., Campbell P.J., Teh B.T., Stratton M.R.,
RA   Futreal P.A.;
RT   "Exome sequencing identifies frequent mutation of the SWI/SNF complex
RT   gene PBRM1 in renal carcinoma.";
RL   Nature 469:539-542(2011).
RN   [4]
RP   VARIANTS FEPS2 PRO-554 AND THR-1304, CHARACTERIZATION OF VARIANTS
RP   FEPS2 PRO-554 AND THR-1304, VARIANTS LEU-939; LEU-940; ASN-1056;
RP   TYR-1523 AND SER-1662, AND CHARACTERIZATION OF VARIANT TYR-1523.
RX   PubMed=23115331; DOI=10.1073/pnas.1216080109;
RA   Faber C.G., Lauria G., Merkies I.S., Cheng X., Han C., Ahn H.S.,
RA   Persson A.K., Hoeijmakers J.G., Gerrits M.M., Pierro T., Lombardi R.,
RA   Kapetis D., Dib-Hajj S.D., Waxman S.G.;
RT   "Gain-of-function Nav1.8 mutations in painful neuropathy.";
RL   Proc. Natl. Acad. Sci. U.S.A. 109:19444-19449(2012).
CC   -!- FUNCTION: Tetrodotoxin-resistant channel that mediates the
CC       voltage-dependent sodium ion permeability of excitable membranes.
CC       Assuming opened or closed conformations in response to the voltage
CC       difference across the membrane, the protein forms a sodium-
CC       selective channel through which sodium ions may pass in accordance
CC       with their electrochemical gradient. Plays a role in neuropathic
CC       pain mechanisms. {ECO:0000269|PubMed:9839820}.
CC   -!- SUBUNIT: The channel consists of an ion conducting pore forming
CC       alpha-subunit regulated by one or more associated auxiliary
CC       subunits SCN1B, SCN2B and SCN3B; electrophysiological properties
CC       may vary depending on the type of the associated beta subunits.
CC       Found in a number of complexes with PRX, DYNLT1 and PDZD2.
CC       Interacts with proteins such as FSTL1, PRX, DYNLT1, PDZD2, S100A10
CC       and many others (By similarity). Interacts with NEDD4 and NEDD4L.
CC       {ECO:0000250}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}. Note=It can be translocated to the
CC       cell membrane through association with S100A10. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Expressed in the dorsal root ganglia and
CC       sciatic nerve. {ECO:0000269|PubMed:9839820}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- PTM: Ubiquitinated by NEDD4L; which promotes its endocytosis.
CC       {ECO:0000250}.
CC   -!- PTM: Phosphorylation at Ser-1451 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents. {ECO:0000250}.
CC   -!- PTM: Lacks the cysteine which covalently binds the conotoxin
CC       GVIIJ. This cysteine (position 816) is speculated in other sodium
CC       channel subunits alpha to be implied in covalent binding with the
CC       sodium channel subunit beta-2 or beta-4.
CC       {ECO:0000250|UniProtKB:P15389}.
CC   -!- DISEASE: Episodic pain syndrome, familial, 2 (FEPS2) [MIM:615551]:
CC       An autosomal dominant neurologic disorder characterized by adult-
CC       onset of paroxysmal pain mainly affecting the distal lower
CC       extremities. {ECO:0000269|PubMed:23115331}. Note=The disease is
CC       caused by mutations affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.8/SCN10A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF117907; AAD30863.1; -; mRNA.
DR   EMBL; AC116038; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC137625; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   CCDS; CCDS33736.1; -.
DR   RefSeq; NP_001280235.2; NM_001293306.2.
DR   RefSeq; NP_001280236.2; NM_001293307.2.
DR   RefSeq; NP_006505.3; NM_006514.3.
DR   UniGene; Hs.250443; -.
DR   ProteinModelPortal; Q9Y5Y9; -.
DR   STRING; 9606.ENSP00000390600; -.
DR   BindingDB; Q9Y5Y9; -.
DR   ChEMBL; CHEMBL5451; -.
DR   DrugBank; DB01086; Benzocaine.
DR   DrugBank; DB00297; Bupivacaine.
DR   DrugBank; DB01161; Chloroprocaine.
DR   DrugBank; DB00527; Cinchocaine.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB00645; Dyclonine.
DR   DrugBank; DB00473; Hexylcaine.
DR   DrugBank; DB06218; Lacosamide.
DR   DrugBank; DB01002; Levobupivacaine.
DR   DrugBank; DB00281; Lidocaine.
DR   DrugBank; DB00961; Mepivacaine.
DR   DrugBank; DB01173; Orphenadrine.
DR   DrugBank; DB00892; Oxybuprocaine.
DR   DrugBank; DB00721; Procaine.
DR   DrugBank; DB00807; Proparacaine.
DR   DrugBank; DB00296; Ropivacaine.
DR   DrugBank; DB00313; Valproic Acid.
DR   GuidetoPHARMACOLOGY; 585; -.
DR   iPTMnet; Q9Y5Y9; -.
DR   PhosphoSitePlus; Q9Y5Y9; -.
DR   BioMuta; SCN10A; -.
DR   DMDM; 205371821; -.
DR   PaxDb; Q9Y5Y9; -.
DR   PeptideAtlas; Q9Y5Y9; -.
DR   PRIDE; Q9Y5Y9; -.
DR   Ensembl; ENST00000449082; ENSP00000390600; ENSG00000185313.
DR   GeneID; 6336; -.
DR   KEGG; hsa:6336; -.
DR   UCSC; uc003ciq.4; human.
DR   CTD; 6336; -.
DR   DisGeNET; 6336; -.
DR   GeneCards; SCN10A; -.
DR   H-InvDB; HIX0030722; -.
DR   HGNC; HGNC:10582; SCN10A.
DR   MalaCards; SCN10A; -.
DR   MIM; 604427; gene.
DR   MIM; 615551; phenotype.
DR   neXtProt; NX_Q9Y5Y9; -.
DR   OpenTargets; ENSG00000185313; -.
DR   Orphanet; 88642; Channelopathy-associated congenital insensitivity to pain.
DR   Orphanet; 46348; Paroxysmal extreme pain disorder.
DR   Orphanet; 90026; Primary erythermalgia.
DR   Orphanet; 306577; Sodium channelopathy-related small fiber neuropathy.
DR   PharmGKB; PA35000; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOGENOM; HOG000231755; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q9Y5Y9; -.
DR   KO; K04842; -.
DR   OMA; MAMEHHG; -.
DR   OrthoDB; EOG090301B8; -.
DR   PhylomeDB; Q9Y5Y9; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   GeneWiki; SCN10A; -.
DR   GenomeRNAi; 6336; -.
DR   PRO; PR:Q9Y5Y9; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000185313; -.
DR   CleanEx; HS_SCN10A; -.
DR   Genevisible; Q9Y5Y9; HS.
DR   GO; GO:0071439; C:clathrin complex; IEA:Ensembl.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IDA:BHF-UCL.
DR   GO; GO:0044325; F:ion channel binding; IPI:BHF-UCL.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; IDA:BHF-UCL.
DR   GO; GO:0086016; P:AV node cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086043; P:bundle of His cell action potential; IMP:BHF-UCL.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0042475; P:odontogenesis of dentin-containing tooth; IEA:Ensembl.
DR   GO; GO:0060371; P:regulation of atrial cardiac muscle cell membrane depolarization; IMP:BHF-UCL.
DR   GO; GO:0055117; P:regulation of cardiac muscle contraction; IMP:BHF-UCL.
DR   GO; GO:0002027; P:regulation of heart rate; IMP:BHF-UCL.
DR   GO; GO:0034765; P:regulation of ion transmembrane transport; IDA:BHF-UCL.
DR   GO; GO:0007600; P:sensory perception; TAS:ProtInc.
DR   GO; GO:0019233; P:sensory perception of pain; IEA:Ensembl.
DR   GO; GO:0035725; P:sodium ion transmembrane transport; IDA:BHF-UCL.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR028809; Na_channel_a10su.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   PANTHER; PTHR10037:SF263; PTHR10037:SF263; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
PE   1: Evidence at protein level;
KW   Cell membrane; Complete proteome; Disease mutation; Glycoprotein;
KW   Ion channel; Ion transport; Membrane; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Sodium; Sodium channel; Sodium transport;
KW   Transmembrane; Transmembrane helix; Transport; Ubl conjugation;
KW   Voltage-gated channel.
FT   CHAIN         1   1956       Sodium channel protein type 10 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048507.
FT   TOPO_DOM      1    125       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    126    149       Helical; Name=S1 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    150    154       Extracellular. {ECO:0000255}.
FT   TRANSMEM    155    174       Helical; Name=S2 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    175    187       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    188    206       Helical; Name=S3 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    207    212       Extracellular. {ECO:0000255}.
FT   TRANSMEM    213    232       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000255}.
FT   TOPO_DOM    233    248       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    249    272       Helical; Name=S5 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    273    373       Extracellular. {ECO:0000255}.
FT   TRANSMEM    374    399       Helical; Name=S6 of repeat I.
FT                                {ECO:0000255}.
FT   TOPO_DOM    400    659       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    660    684       Helical; Name=S1 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    685    695       Extracellular. {ECO:0000255}.
FT   TRANSMEM    696    719       Helical; Name=S2 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    720    727       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    728    747       Helical; Name=S3 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    748    753       Extracellular. {ECO:0000255}.
FT   TRANSMEM    754    773       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000255}.
FT   TOPO_DOM    774    789       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    790    810       Helical; Name=S5 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    811    864       Extracellular. {ECO:0000255}.
FT   TRANSMEM    865    890       Helical; Name=S6 of repeat II.
FT                                {ECO:0000255}.
FT   TOPO_DOM    891   1147       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1148   1171       Helical; Name=S1 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1172   1184       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1185   1210       Helical; Name=S2 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1211   1216       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1217   1238       Helical; Name=S3 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1239   1242       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1243   1264       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000255}.
FT   TOPO_DOM   1265   1283       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1284   1311       Helical; Name=S5 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1312   1391       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1392   1418       Helical; Name=S6 of repeat III.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1419   1471       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1472   1495       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1496   1506       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1507   1530       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1531   1536       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1537   1560       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1561   1572       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1573   1594       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000255}.
FT   TOPO_DOM   1595   1609       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1610   1632       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1633   1697       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1698   1722       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000255}.
FT   TOPO_DOM   1723   1956       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      116    405       I. {ECO:0000305}.
FT   REPEAT      647    911       II. {ECO:0000305}.
FT   REPEAT     1140   1449       III. {ECO:0000305}.
FT   REPEAT     1458   1757       IV. {ECO:0000305}.
FT   DOMAIN     1851   1880       IQ.
FT   MOD_RES     441    441       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     444    444       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     467    467       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     479    479       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     612    612       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES     615    615       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:Q14524}.
FT   MOD_RES    1451   1451       Phosphoserine; by PKC. {ECO:0000250}.
FT   CARBOHYD    284    284       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    288    288       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    312    312       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    335    335       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    819    819       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1312   1312       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1328   1328       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1336   1336       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1686   1686       N-linked (GlcNAc...). {ECO:0000255}.
FT   VARIANT     509    509       S -> P (in dbSNP:rs7630989).
FT                                /FTId=VAR_020605.
FT   VARIANT     554    554       L -> P (in FEPS2; increases the
FT                                excitability of small DRG neurons;
FT                                dbSNP:rs138404783).
FT                                {ECO:0000269|PubMed:23115331}.
FT                                /FTId=VAR_070878.
FT   VARIANT     590    590       G -> R (in dbSNP:rs35332705).
FT                                /FTId=VAR_048696.
FT   VARIANT     916    916       R -> W (found in a renal cell carcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs370208223).
FT                                {ECO:0000269|PubMed:21248752}.
FT                                /FTId=VAR_064748.
FT   VARIANT     939    939       P -> L (in dbSNP:rs202174472).
FT                                {ECO:0000269|PubMed:23115331}.
FT                                /FTId=VAR_070879.
FT   VARIANT     940    940       Q -> L. {ECO:0000269|PubMed:23115331}.
FT                                /FTId=VAR_070880.
FT   VARIANT    1056   1056       D -> N (in dbSNP:rs751574392).
FT                                {ECO:0000269|PubMed:23115331}.
FT                                /FTId=VAR_070881.
FT   VARIANT    1073   1073       V -> A (in dbSNP:rs6795970).
FT                                {ECO:0000269|PubMed:9839820}.
FT                                /FTId=VAR_020606.
FT   VARIANT    1092   1092       L -> P (in dbSNP:rs12632942).
FT                                /FTId=VAR_020607.
FT   VARIANT    1304   1304       A -> T (in FEPS2; increases the
FT                                excitability of small DRG neurons;
FT                                dbSNP:rs142173735).
FT                                {ECO:0000269|PubMed:23115331}.
FT                                /FTId=VAR_070882.
FT   VARIANT    1523   1523       C -> Y (no gain in function in response
FT                                to depolarization; dbSNP:rs142217269).
FT                                {ECO:0000269|PubMed:23115331}.
FT                                /FTId=VAR_070883.
FT   VARIANT    1662   1662       G -> S (in dbSNP:rs151090729).
FT                                {ECO:0000269|PubMed:23115331}.
FT                                /FTId=VAR_070884.
FT   VARIANT    1713   1713       M -> V (in dbSNP:rs6599241).
FT                                {ECO:0000269|PubMed:9839820}.
FT                                /FTId=VAR_020608.
SQ   SEQUENCE   1956 AA;  220626 MW;  4A4A2C5E135B6685 CRC64;
     MEFPIGSLET NNFRRFTPES LVEIEKQIAA KQGTKKAREK HREQKDQEEK PRPQLDLKAC
     NQLPKFYGEL PAELIGEPLE DLDPFYSTHR TFMVLNKGRT ISRFSATRAL WLFSPFNLIR
     RTAIKVSVHS WFSLFITVTI LVNCVCMTRT DLPEKIEYVF TVIYTFEALI KILARGFCLN
     EFTYLRDPWN WLDFSVITLA YVGTAIDLRG ISGLRTFRVL RALKTVSVIP GLKVIVGALI
     HSVKKLADVT ILTIFCLSVF ALVGLQLFKG NLKNKCVKND MAVNETTNYS SHRKPDIYIN
     KRGTSDPLLC GNGSDSGHCP DGYICLKTSD NPDFNYTSFD SFAWAFLSLF RLMTQDSWER
     LYQQTLRTSG KIYMIFFVLV IFLGSFYLVN LILAVVTMAY EEQNQATTDE IEAKEKKFQE
     ALEMLRKEQE VLAALGIDTT SLHSHNGSPL TSKNASERRH RIKPRVSEGS TEDNKSPRSD
     PYNQRRMSFL GLASGKRRAS HGSVFHFRSP GRDISLPEGV TDDGVFPGDH ESHRGSLLLG
     GGAGQQGPLP RSPLPQPSNP DSRHGEDEHQ PPPTSELAPG AVDVSAFDAG QKKTFLSAEY
     LDEPFRAQRA MSVVSIITSV LEELEESEQK CPPCLTSLSQ KYLIWDCCPM WVKLKTILFG
     LVTDPFAELT ITLCIVVNTI FMAMEHHGMS PTFEAMLQIG NIVFTIFFTA EMVFKIIAFD
     PYYYFQKKWN IFDCIIVTVS LLELGVAKKG SLSVLRSFRL LRVFKLAKSW PTLNTLIKII
     GNSVGALGNL TIILAIIVFV FALVGKQLLG ENYRNNRKNI SAPHEDWPRW HMHDFFHSFL
     IVFRILCGEW IENMWACMEV GQKSICLILF LTVMVLGNLV VLNLFIALLL NSFSADNLTA
     PEDDGEVNNL QVALARIQVF GHRTKQALCS FFSRSCPFPQ PKAEPELVVK LPLSSSKAEN
     HIAANTARGS SGGLQAPRGP RDEHSDFIAN PTVWVSVPIA EGESDLDDLE DDGGEDAQSF
     QQEVIPKGQQ EQLQQVERCG DHLTPRSPGT GTSSEDLAPS LGETWKDESV PQVPAEGVDD
     TSSSEGSTVD CLDPEEILRK IPELADDLEE PDDCFTEGCI RHCPCCKLDT TKSPWDVGWQ
     VRKTCYRIVE HSWFESFIIF MILLSSGSLA FEDYYLDQKP TVKALLEYTD RVFTFIFVFE
     MLLKWVAYGF KKYFTNAWCW LDFLIVNISL ISLTAKILEY SEVAPIKALR TLRALRPLRA
     LSRFEGMRVV VDALVGAIPS IMNVLLVCLI FWLIFSIMGV NLFAGKFWRC INYTDGEFSL
     VPLSIVNNKS DCKIQNSTGS FFWVNVKVNF DNVAMGYLAL LQVATFKGWM DIMYAAVDSR
     EVNMQPKWED NVYMYLYFVI FIIFGGFFTL NLFVGVIIDN FNQQKKKLGG QDIFMTEEQK
     KYYNAMKKLG SKKPQKPIPR PLNKFQGFVF DIVTRQAFDI TIMVLICLNM ITMMVETDDQ
     SEEKTKILGK INQFFVAVFT GECVMKMFAL RQYYFTNGWN VFDFIVVVLS IASLIFSAIL
     KSLQSYFSPT LFRVIRLARI GRILRLIRAA KGIRTLLFAL MMSLPALFNI GLLLFLVMFI
     YSIFGMSSFP HVRWEAGIDD MFNFQTFANS MLCLFQITTS AGWDGLLSPI LNTGPPYCDP
     NLPNSNGTRG DCGSPAVGII FFTTYIIISF LIMVNMYIAV ILENFNVATE ESTEPLSEDD
     FDMFYETWEK FDPEATQFIT FSALSDFADT LSGPLRIPKP NRNILIQMDL PLVPGDKIHC
     LDILFAFTKN VLGESGELDS LKANMEEKFM ATNLSKSSYE PIATTLRWKQ EDISATVIQK
     AYRSYVLHRS MALSNTPCVP RAEEEAASLP DEGFVAFTAN ENCVLPDKSE TASATSFPPS
     YESVTRGLSD RVNMRTSSSI QNEDEATSME LIAPGP
//
ID   SCNBA_HUMAN             Reviewed;        1791 AA.
AC   Q9UI33; A6NN05; C9JD48; C9JR31; Q68K15; Q8NDX3; Q9UHE0; Q9UHM0;
DT   21-DEC-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 2.
DT   15-FEB-2017, entry version 132.
DE   RecName: Full=Sodium channel protein type 11 subunit alpha;
DE   AltName: Full=Peripheral nerve sodium channel 5;
DE            Short=PN5;
DE   AltName: Full=Sensory neuron sodium channel 2;
DE   AltName: Full=Sodium channel protein type XI subunit alpha;
DE   AltName: Full=Voltage-gated sodium channel subunit alpha Nav1.9;
DE   AltName: Full=hNaN;
GN   Name=SCN11A; Synonyms=SCN12A, SNS2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN VOLTAGE-EVOKED
RP   DEPOLARIZATION.
RC   TISSUE=Spinal ganglion;
RX   PubMed=10580103; DOI=10.1016/S0014-5793(99)01519-7;
RA   Dib-Hajj S.D., Tyrrell L., Cummins T.R., Black J.A., Wood P.M.,
RA   Waxman S.G.;
RT   "Two tetrodotoxin-resistant sodium channels in human dorsal root
RT   ganglion neurons.";
RL   FEBS Lett. 462:117-120(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), AND TISSUE SPECIFICITY.
RC   TISSUE=Brain;
RX   PubMed=10623608; DOI=10.1006/bbrc.1999.1916;
RA   Jeong S.-Y., Goto J., Hashida H., Suzuki T., Ogata K., Masuda M.,
RA   Hirai M., Isahara K., Uchiyama Y., Kanazawa I.;
RT   "Identification of a novel human voltage-gated sodium channel alpha
RT   subunit gene, SCN12A.";
RL   Biochem. Biophys. Res. Commun. 267:262-270(2000).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND FUNCTION IN
RP   NEUROTROPHIN-EVOKED DEPOLARIZATION.
RC   TISSUE=Neuroblastoma;
RX   PubMed=12384689; DOI=10.1038/nature01085;
RA   Blum R., Kafitz K.W., Konnerth A.;
RT   "Neurotrophin-evoked depolarization requires the sodium channel
RT   Nav1.9.";
RL   Nature 419:687-693(2002).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16641997; DOI=10.1038/nature04728;
RA   Muzny D.M., Scherer S.E., Kaul R., Wang J., Yu J., Sudbrak R.,
RA   Buhay C.J., Chen R., Cree A., Ding Y., Dugan-Rocha S., Gill R.,
RA   Gunaratne P., Harris R.A., Hawes A.C., Hernandez J., Hodgson A.V.,
RA   Hume J., Jackson A., Khan Z.M., Kovar-Smith C., Lewis L.R.,
RA   Lozado R.J., Metzker M.L., Milosavljevic A., Miner G.R., Morgan M.B.,
RA   Nazareth L.V., Scott G., Sodergren E., Song X.-Z., Steffen D., Wei S.,
RA   Wheeler D.A., Wright M.W., Worley K.C., Yuan Y., Zhang Z., Adams C.Q.,
RA   Ansari-Lari M.A., Ayele M., Brown M.J., Chen G., Chen Z.,
RA   Clendenning J., Clerc-Blankenburg K.P., Chen R., Chen Z., Davis C.,
RA   Delgado O., Dinh H.H., Dong W., Draper H., Ernst S., Fu G.,
RA   Gonzalez-Garay M.L., Garcia D.K., Gillett W., Gu J., Hao B.,
RA   Haugen E., Havlak P., He X., Hennig S., Hu S., Huang W., Jackson L.R.,
RA   Jacob L.S., Kelly S.H., Kube M., Levy R., Li Z., Liu B., Liu J.,
RA   Liu W., Lu J., Maheshwari M., Nguyen B.-V., Okwuonu G.O., Palmeiri A.,
RA   Pasternak S., Perez L.M., Phelps K.A., Plopper F.J., Qiang B.,
RA   Raymond C., Rodriguez R., Saenphimmachak C., Santibanez J., Shen H.,
RA   Shen Y., Subramanian S., Tabor P.E., Verduzco D., Waldron L., Wang J.,
RA   Wang J., Wang Q., Williams G.A., Wong G.K.-S., Yao Z., Zhang J.,
RA   Zhang X., Zhao G., Zhou J., Zhou Y., Nelson D., Lehrach H.,
RA   Reinhardt R., Naylor S.L., Yang H., Olson M., Weinstock G.,
RA   Gibbs R.A.;
RT   "The DNA sequence, annotation and analysis of human chromosome 3.";
RL   Nature 440:1194-1198(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 924-1114 (ISOFORM 3), AND TISSUE
RP   SPECIFICITY.
RC   TISSUE=Spinal ganglion;
RX   PubMed=15302875; DOI=10.1074/jbc.M406387200;
RA   Raymond C.K., Castle J.C., Garrett-Engele P.W., Armour C.D., Kan Z.G.,
RA   Tsinoremas N.T., Johnson J.M.;
RT   "Expression of alternatively spliced sodium channel alpha-subunit
RT   genes: unique splicing patterns are observed in dorsal root ganglia.";
RL   J. Biol. Chem. 279:46234-46241(2004).
RN   [6]
RP   REVIEW.
RX   PubMed=12536125; DOI=10.1016/S0166-2236(02)00030-9;
RA   Delmas P., Coste B.;
RT   "Na+ channel Nav1.9: in search of a gating mechanism.";
RL   Trends Neurosci. 26:55-57(2003).
RN   [7]
RP   VARIANTS FEPS3 CYS-225 AND GLY-808.
RX   PubMed=24207120; DOI=10.1016/j.ajhg.2013.09.016;
RA   Zhang X.Y., Wen J., Yang W., Wang C., Gao L., Zheng L.H., Wang T.,
RA   Ran K., Li Y., Li X., Xu M., Luo J., Feng S., Ma X., Ma H., Chai Z.,
RA   Zhou Z., Yao J., Zhang X., Liu J.Y.;
RT   "Gain-of-function mutations in SCN11A cause familial episodic pain.";
RL   Am. J. Hum. Genet. 93:957-966(2013).
RN   [8]
RP   VARIANT HSAN7 PRO-811, AND CHARACTERIZATION VARIANT HSAN7 PRO-811.
RX   PubMed=24036948; DOI=10.1038/ng.2767;
RA   Leipold E., Liebmann L., Korenke G.C., Heinrich T., Giesselmann S.,
RA   Baets J., Ebbinghaus M., Goral R.O., Stodberg T., Hennings J.C.,
RA   Bergmann M., Altmuller J., Thiele H., Wetzel A., Nurnberg P.,
RA   Timmerman V., De Jonghe P., Blum R., Schaible H.G., Weis J.,
RA   Heinemann S.H., Hubner C.A., Kurth I.;
RT   "A de novo gain-of-function mutation in SCN11A causes loss of pain
RT   perception.";
RL   Nat. Genet. 45:1399-1404(2013).
RN   [9]
RP   VARIANTS FEPS3 THR-381 AND PRO-1158, VARIANTS ASN-419; THR-582;
RP   ASP-681; PRO-842 AND LEU-1689, AND CHARACTERIZATION OF VARIANTS FEPS3
RP   THR-381 AND PRO-1158.
RX   PubMed=24776970; DOI=10.1093/brain/awu079;
RG   PROPANE Study Group;
RA   Huang J., Han C., Estacion M., Vasylyev D., Hoeijmakers J.G.,
RA   Gerrits M.M., Tyrrell L., Lauria G., Faber C.G., Dib-Hajj S.D.,
RA   Merkies I.S., Waxman S.G.;
RT   "Gain-of-function mutations in sodium channel Na(v)1.9 in painful
RT   neuropathy.";
RL   Brain 137:1627-1642(2014).
RN   [10]
RP   VARIANT HSAN7 ALA-1184, AND CHARACTERIZATION OF VARIANTS HSAN7 PRO-811
RP   AND ALA-1184.
RX   PubMed=26645915; DOI=10.1038/ncomms10049;
RA   Leipold E., Hanson-Kahn A., Frick M., Gong P., Bernstein J.A.,
RA   Voigt M., Katona I., Oliver Goral R., Altmueller J., Nuernberg P.,
RA   Weis J., Huebner C.A., Heinemann S.H., Kurth I.;
RT   "Cold-aggravated pain in humans caused by a hyperactive NaV1.9 channel
RT   mutant.";
RL   Nat. Commun. 6:10049-10049(2015).
RN   [11]
RP   VARIANT FEPS3 ARG-699, AND CHARACTERIZATION OF VARIANT FEPS3 ARG-699.
RX   PubMed=25791876; DOI=10.1007/s12017-015-8347-9;
RA   Han C., Yang Y., de Greef B.T., Hoeijmakers J.G., Gerrits M.M.,
RA   Verhamme C., Qu J., Lauria G., Merkies I.S., Faber C.G.,
RA   Dib-Hajj S.D., Waxman S.G.;
RT   "The domain II S4-S5 linker in Nav1.9: a missense mutation enhances
RT   activation, impairs fast inactivation, and produces human painful
RT   neuropathy.";
RL   NeuroMolecular Med. 17:158-169(2015).
RN   [12]
RP   VARIANTS FEPS3 HIS-222 AND SER-222, AND VARIANTS LEU-308; ILE-909 AND
RP   ILE-1609.
RX   PubMed=27224030; DOI=10.1371/journal.pone.0154827;
RA   Okuda H., Noguchi A., Kobayashi H., Kondo D., Harada K.H.,
RA   Youssefian S., Shioi H., Kabata R., Domon Y., Kubota K., Kitano Y.,
RA   Takayama Y., Hitomi T., Ohno K., Saito Y., Asano T., Tominaga M.,
RA   Takahashi T., Koizumi A.;
RT   "Infantile pain episodes associated with novel Nav1.9 mutations in
RT   familial episodic pain syndrome in japanese families.";
RL   PLoS ONE 11:E0154827-E0154827(2016).
CC   -!- FUNCTION: This protein mediates the voltage-dependent sodium ion
CC       permeability of excitable membranes. Assuming opened or closed
CC       conformations in response to the voltage difference across the
CC       membrane, the protein forms a sodium-selective channel through
CC       which sodium ions may pass in accordance with their
CC       electrochemical gradient. It is a tetrodotoxin-resistant sodium
CC       channel isoform. Also involved, with the contribution of the
CC       receptor tyrosine kinase NTRK2, in rapid BDNF-evoked neuronal
CC       depolarization. {ECO:0000269|PubMed:10580103,
CC       ECO:0000269|PubMed:12384689}.
CC   -!- SUBUNIT: The voltage-resistant sodium channel consists of an ion
CC       conducting pore forming alpha-subunit regulated by one or more
CC       auxiliary subunits SCN1B, SCN2B and SCN3B.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000250}; Multi-pass
CC       membrane protein {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q9UI33-1; Sequence=Displayed;
CC       Name=2; Synonyms=Scn12a-s;
CC         IsoId=Q9UI33-2; Sequence=VSP_012260, VSP_012261;
CC       Name=3;
CC         IsoId=Q9UI33-3; Sequence=VSP_012259;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in the dorsal root ganglia and
CC       trigeminal ganglia, olfactory bulb, hippocampus, cerebellar
CC       cortex, spinal cord, spleen, small intestine and placenta.
CC       {ECO:0000269|PubMed:10623608, ECO:0000269|PubMed:15302875}.
CC   -!- DOMAIN: The sequence contains 4 internal repeats, each with 5
CC       hydrophobic segments (S1,S2,S3,S5,S6) and one positively charged
CC       segment (S4). Segments S4 are probably the voltage-sensors and are
CC       characterized by a series of positively charged amino acids at
CC       every third position.
CC   -!- PTM: Phosphorylation at Ser-1341 by PKC in a highly conserved
CC       cytoplasmic loop slows inactivation of the sodium channel and
CC       reduces peak sodium currents. {ECO:0000250}.
CC   -!- DISEASE: Neuropathy, hereditary sensory and autonomic, 7 (HSAN7)
CC       [MIM:615548]: A form of hereditary sensory and autonomic
CC       neuropathy, a genetically and clinically heterogeneous group of
CC       disorders characterized by degeneration of dorsal root and
CC       autonomic ganglion cells, and by sensory and/or autonomic
CC       abnormalities. HSAN7 is characterized by congenital inability to
CC       experience pain resulting in self-mutilations, slow-healing
CC       wounds, and multiple painless fractures. mild muscle weakness,
CC       delayed motor development, slightly reduced motor and sensory
CC       nerve conduction velocities, hyperhidrosis and gastrointestinal
CC       dysfunction. {ECO:0000269|PubMed:24036948,
CC       ECO:0000269|PubMed:26645915}. Note=The disease is caused by
CC       mutations affecting the gene represented in this entry.
CC   -!- DISEASE: Episodic pain syndrome, familial, 3 (FEPS3) [MIM:615552]:
CC       An autosomal dominant neurologic disorder characterized by
CC       paroxysmal pain mainly affecting the distal lower extremities and
CC       occasionally the upper body, especially the joints of fingers and
CC       arms. The pain is exacerbated with fatigue.
CC       {ECO:0000269|PubMed:24207120, ECO:0000269|PubMed:24776970,
CC       ECO:0000269|PubMed:25791876, ECO:0000269|PubMed:27224030}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the sodium channel (TC 1.A.1.10) family.
CC       Nav1.9/SCN11A subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF188679; AAF17480.1; -; mRNA.
DR   EMBL; AF109737; AAF24976.1; -; mRNA.
DR   EMBL; AF150882; AAF24980.1; -; mRNA.
DR   EMBL; AJ417790; CAD10507.1; -; mRNA.
DR   EMBL; AC116038; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AY686224; AAT95434.1; -; mRNA.
DR   CCDS; CCDS33737.1; -. [Q9UI33-1]
DR   RefSeq; NP_001274152.1; NM_001287223.1. [Q9UI33-1]
DR   RefSeq; NP_054858.2; NM_014139.2. [Q9UI33-1]
DR   RefSeq; XP_016861138.1; XM_017005649.1. [Q9UI33-1]
DR   RefSeq; XP_016861139.1; XM_017005650.1. [Q9UI33-1]
DR   UniGene; Hs.591657; -.
DR   ProteinModelPortal; Q9UI33; -.
DR   IntAct; Q9UI33; 1.
DR   STRING; 9606.ENSP00000307599; -.
DR   BindingDB; Q9UI33; -.
DR   ChEMBL; CHEMBL5167; -.
DR   DrugBank; DB00907; Cocaine.
DR   DrugBank; DB00313; Valproic Acid.
DR   DrugBank; DB00909; Zonisamide.
DR   TCDB; 1.A.1.10.9; the voltage-gated ion channel (vic) superfamily.
DR   iPTMnet; Q9UI33; -.
DR   PhosphoSitePlus; Q9UI33; -.
DR   BioMuta; SCN11A; -.
DR   DMDM; 124053649; -.
DR   PaxDb; Q9UI33; -.
DR   PeptideAtlas; Q9UI33; -.
DR   PRIDE; Q9UI33; -.
DR   Ensembl; ENST00000302328; ENSP00000307599; ENSG00000168356. [Q9UI33-1]
DR   Ensembl; ENST00000444237; ENSP00000408028; ENSG00000168356. [Q9UI33-2]
DR   Ensembl; ENST00000456224; ENSP00000416757; ENSG00000168356. [Q9UI33-3]
DR   GeneID; 11280; -.
DR   KEGG; hsa:11280; -.
DR   UCSC; uc003cis.2; human. [Q9UI33-1]
DR   CTD; 11280; -.
DR   DisGeNET; 11280; -.
DR   GeneCards; SCN11A; -.
DR   HGNC; HGNC:10583; SCN11A.
DR   HPA; HPA036746; -.
DR   HPA; HPA036747; -.
DR   MalaCards; SCN11A; -.
DR   MIM; 604385; gene.
DR   MIM; 615548; phenotype.
DR   MIM; 615552; phenotype.
DR   neXtProt; NX_Q9UI33; -.
DR   OpenTargets; ENSG00000168356; -.
DR   Orphanet; 88642; Channelopathy-associated congenital insensitivity to pain.
DR   Orphanet; 391392; Familial episodic pain syndrome with predominantly lower limb involvement.
DR   Orphanet; 391397; Hereditary sensory and autonomic neuropathy type 7.
DR   Orphanet; 46348; Paroxysmal extreme pain disorder.
DR   Orphanet; 90026; Primary erythermalgia.
DR   Orphanet; 306577; Sodium channelopathy-related small fiber neuropathy.
DR   PharmGKB; PA35001; -.
DR   eggNOG; KOG2301; Eukaryota.
DR   eggNOG; ENOG410XNP6; LUCA.
DR   GeneTree; ENSGT00830000128242; -.
DR   HOVERGEN; HBG053100; -.
DR   InParanoid; Q9UI33; -.
DR   KO; K04843; -.
DR   OMA; LENFNTA; -.
DR   OrthoDB; EOG0903026U; -.
DR   PhylomeDB; Q9UI33; -.
DR   TreeFam; TF323985; -.
DR   Reactome; R-HSA-445095; Interaction between L1 and Ankyrins.
DR   Reactome; R-HSA-5576892; Phase 0 - rapid depolarisation.
DR   ChiTaRS; SCN11A; human.
DR   GeneWiki; Nav1.9; -.
DR   GenomeRNAi; 11280; -.
DR   PRO; PR:Q9UI33; -.
DR   Proteomes; UP000005640; Chromosome 3.
DR   Bgee; ENSG00000168356; -.
DR   CleanEx; HS_SCN11A; -.
DR   Genevisible; Q9UI33; HS.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; IBA:GO_Central.
DR   GO; GO:0001518; C:voltage-gated sodium channel complex; IEA:InterPro.
DR   GO; GO:0005248; F:voltage-gated sodium channel activity; TAS:ProtInc.
DR   GO; GO:0086010; P:membrane depolarization during action potential; IBA:GO_Central.
DR   GO; GO:0019228; P:neuronal action potential; IBA:GO_Central.
DR   GO; GO:0051930; P:regulation of sensory perception of pain; ISS:UniProtKB.
DR   GO; GO:0042493; P:response to drug; TAS:ProtInc.
DR   GO; GO:0006814; P:sodium ion transport; TAS:ProtInc.
DR   Gene3D; 1.20.120.350; -; 4.
DR   InterPro; IPR027359; Channel_four-helix_dom.
DR   InterPro; IPR005821; Ion_trans_dom.
DR   InterPro; IPR028821; Na_channel_a11su.
DR   InterPro; IPR001696; Na_channel_asu.
DR   InterPro; IPR010526; Na_trans_assoc.
DR   PANTHER; PTHR10037:SF229; PTHR10037:SF229; 1.
DR   Pfam; PF00520; Ion_trans; 4.
DR   Pfam; PF06512; Na_trans_assoc; 1.
DR   PRINTS; PR00170; NACHANNEL.
PE   1: Evidence at protein level;
KW   Alternative splicing; Cell membrane; Complete proteome;
KW   Disease mutation; Glycoprotein; Ion channel; Ion transport; Membrane;
KW   Neurodegeneration; Neuropathy; Phosphoprotein; Polymorphism;
KW   Reference proteome; Repeat; Sodium; Sodium channel; Sodium transport;
KW   Transmembrane; Transmembrane helix; Transport; Voltage-gated channel.
FT   CHAIN         1   1791       Sodium channel protein type 11 subunit
FT                                alpha.
FT                                /FTId=PRO_0000048510.
FT   TOPO_DOM      1    126       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    127    148       Helical; Name=S1 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    149    156       Extracellular. {ECO:0000255}.
FT   TRANSMEM    157    180       Helical; Name=S2 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    181    192       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    193    212       Helical; Name=S3 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    213    219       Extracellular. {ECO:0000255}.
FT   TRANSMEM    220    239       Helical; Voltage-sensor; Name=S4 of
FT                                repeat I. {ECO:0000250}.
FT   TOPO_DOM    240    255       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    256    269       Helical; Name=S5 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    270    376       Extracellular. {ECO:0000255}.
FT   TRANSMEM    377    402       Helical; Name=S6 of repeat I.
FT                                {ECO:0000250}.
FT   TOPO_DOM    403    572       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    573    596       Helical; Name=S1 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    597    607       Extracellular. {ECO:0000255}.
FT   TRANSMEM    608    631       Helical; Name=S2 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    632    639       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    640    659       Helical; Name=S3 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    660    667       Extracellular. {ECO:0000255}.
FT   TRANSMEM    668    687       Helical; Voltage-sensor; Name=S4 of
FT                                repeat II. {ECO:0000250}.
FT   TOPO_DOM    688    702       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM    703    725       Helical; Name=S5 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    726    785       Extracellular. {ECO:0000255}.
FT   TRANSMEM    786    811       Helical; Name=S6 of repeat II.
FT                                {ECO:0000250}.
FT   TOPO_DOM    812   1051       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1052   1074       Helical; Name=S1 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1075   1088       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1089   1114       Helical; Name=S2 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1115   1120       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1121   1138       Helical; Name=S3 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1139   1139       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1140   1161       Helical; Voltage-sensor; Name=S4 of
FT                                repeat III. {ECO:0000250}.
FT   TOPO_DOM   1162   1180       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1181   1202       Helical; Name=S5 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1203   1281       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1282   1308       Helical; Name=S6 of repeat III.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1309   1361       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1362   1385       Helical; Name=S1 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1386   1396       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1397   1420       Helical; Name=S2 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1421   1426       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1427   1450       Helical; Name=S3 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1451   1461       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1462   1484       Helical; Voltage-sensor; Name=S4 of
FT                                repeat IV. {ECO:0000250}.
FT   TOPO_DOM   1485   1499       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM   1500   1522       Helical; Name=S5 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1523   1579       Extracellular. {ECO:0000255}.
FT   TRANSMEM   1580   1604       Helical; Name=S6 of repeat IV.
FT                                {ECO:0000250}.
FT   TOPO_DOM   1605   1791       Cytoplasmic. {ECO:0000255}.
FT   REPEAT      115    408       I. {ECO:0000305}.
FT   REPEAT      559    833       II. {ECO:0000305}.
FT   REPEAT     1044   1339       III. {ECO:0000305}.
FT   REPEAT     1348   1639       IV. {ECO:0000305}.
FT   MOD_RES    1341   1341       Phosphoserine; by PKC. {ECO:0000250}.
FT   CARBOHYD    290    290       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    338    338       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD    781    781       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1209   1209       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1216   1216       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1222   1222       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1230   1230       N-linked (GlcNAc...). {ECO:0000255}.
FT   CARBOHYD   1568   1568       N-linked (GlcNAc...). {ECO:0000255}.
FT   VAR_SEQ     946    983       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:15302875}.
FT                                /FTId=VSP_012259.
FT   VAR_SEQ    1444   1444       T -> K (in isoform 2).
FT                                {ECO:0000303|PubMed:10623608}.
FT                                /FTId=VSP_012260.
FT   VAR_SEQ    1445   1791       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:10623608}.
FT                                /FTId=VSP_012261.
FT   VARIANT     222    222       R -> H (in FEPS3).
FT                                {ECO:0000269|PubMed:27224030}.
FT                                /FTId=VAR_076679.
FT   VARIANT     222    222       R -> S (in FEPS3).
FT                                {ECO:0000269|PubMed:27224030}.
FT                                /FTId=VAR_076680.
FT   VARIANT     225    225       R -> C (in FEPS3; dbSNP:rs138607170).
FT                                {ECO:0000269|PubMed:24207120}.
FT                                /FTId=VAR_070919.
FT   VARIANT     308    308       P -> L (in dbSNP:rs751477540).
FT                                {ECO:0000269|PubMed:27224030}.
FT                                /FTId=VAR_076681.
FT   VARIANT     381    381       I -> T (in FEPS3; causes
FT                                hyperexcitability of dorsal root ganglion
FT                                neurons; depolarizes resting membrane
FT                                potential; enhances spontaneous firing;
FT                                hyperpolarizes channel activation; slows
FT                                deactivation; decreases rates of current
FT                                decay; does not change slow-inactivation;
FT                                dbSNP:rs606231280).
FT                                {ECO:0000269|PubMed:24776970}.
FT                                /FTId=VAR_076682.
FT   VARIANT     419    419       K -> N (in dbSNP:rs150269814).
FT                                {ECO:0000269|PubMed:24776970}.
FT                                /FTId=VAR_076683.
FT   VARIANT     481    481       G -> E (in dbSNP:rs13059805).
FT                                /FTId=VAR_030002.
FT   VARIANT     582    582       A -> T (in dbSNP:rs141228634).
FT                                {ECO:0000269|PubMed:24776970}.
FT                                /FTId=VAR_076684.
FT   VARIANT     681    681       A -> D. {ECO:0000269|PubMed:24776970}.
FT                                /FTId=VAR_076685.
FT   VARIANT     699    699       G -> R (in FEPS3; causes
FT                                hyperexcitability of dorsal root ganglion
FT                                neurons; hyperpolarizes channel
FT                                activation; slows deactivation;
FT                                depolarizes steady-state fast-
FT                                inactivation; dbSNP:rs145734191).
FT                                {ECO:0000269|PubMed:25791876}.
FT                                /FTId=VAR_076686.
FT   VARIANT     777    777       M -> R (in dbSNP:rs4302324).
FT                                /FTId=VAR_030003.
FT   VARIANT     808    808       A -> G (in FEPS3; dbSNP:rs483352921).
FT                                {ECO:0000269|PubMed:24207120}.
FT                                /FTId=VAR_070920.
FT   VARIANT     811    811       L -> P (in HSAN7; results in excessive
FT                                channel activity at resting voltages;
FT                                causes sustained depolarization of
FT                                nociceptors and impaired generation of
FT                                action potentials; causes aberrant
FT                                synaptic transmission; causes transient
FT                                hyperexcitability of dorsal root ganglion
FT                                neurons; dbSNP:rs483352920).
FT                                {ECO:0000269|PubMed:24036948,
FT                                ECO:0000269|PubMed:26645915}.
FT                                /FTId=VAR_070921.
FT   VARIANT     842    842       A -> P. {ECO:0000269|PubMed:24776970}.
FT                                /FTId=VAR_076687.
FT   VARIANT     909    909       V -> I (in dbSNP:rs33985936).
FT                                {ECO:0000269|PubMed:27224030}.
FT                                /FTId=VAR_048697.
FT   VARIANT    1158   1158       L -> P (in FEPS3; slows deactivation;
FT                                depolarizes resting membrane potential;
FT                                enhances spontaneous firing; decreases
FT                                rates of current decay; does not change
FT                                fast-inactivation; does not change slow-
FT                                inactivation; dbSNP:rs141686175).
FT                                {ECO:0000269|PubMed:24776970}.
FT                                /FTId=VAR_076688.
FT   VARIANT    1184   1184       V -> A (in HSAN7; cold-aggravated
FT                                peripheral pain seen in some patients;
FT                                enhances the channel activity by shifting
FT                                the voltage dependence of channel opening
FT                                to hyperpolarized potentials thereby
FT                                giving rise to hyperexcitability of
FT                                nociceptors; causes hyperexcitability and
FT                                reduced cold-sensitivity of dorsal root
FT                                ganglion neurons).
FT                                {ECO:0000269|PubMed:26645915}.
FT                                /FTId=VAR_075250.
FT   VARIANT    1198   1198       Y -> H (in dbSNP:rs12638601).
FT                                /FTId=VAR_030004.
FT   VARIANT    1609   1609       T -> I (in dbSNP:rs72869687).
FT                                {ECO:0000269|PubMed:27224030}.
FT                                /FTId=VAR_076689.
FT   VARIANT    1689   1689       F -> L (in dbSNP:rs201107889).
FT                                {ECO:0000269|PubMed:24776970}.
FT                                /FTId=VAR_076690.
FT   CONFLICT    576    576       D -> G (in Ref. 3; CAD10507).
FT                                {ECO:0000305}.
FT   CONFLICT    703    703       S -> N (in Ref. 2; AAF24976/AAF24980).
FT                                {ECO:0000305}.
FT   CONFLICT    847    847       R -> G (in Ref. 3; CAD10507).
FT                                {ECO:0000305}.
FT   CONFLICT   1086   1086       I -> T (in Ref. 5; AAT95434).
FT                                {ECO:0000305}.
SQ   SEQUENCE   1791 AA;  204922 MW;  DE38680BFB639ED1 CRC64;
     MDDRCYPVIF PDERNFRPFT SDSLAAIEKR IAIQKEKKKS KDQTGEVPQP RPQLDLKASR
     KLPKLYGDIP RELIGKPLED LDPFYRNHKT FMVLNRKRTI YRFSAKHALF IFGPFNSIRS
     LAIRVSVHSL FSMFIIGTVI INCVFMATGP AKNSNSNNTD IAECVFTGIY IFEALIKILA
     RGFILDEFSF LRDPWNWLDS IVIGIAIVSY IPGITIKLLP LRTFRVFRAL KAISVVSRLK
     VIVGALLRSV KKLVNVIILT FFCLSIFALV GQQLFMGSLN LKCISRDCKN ISNPEAYDHC
     FEKKENSPEF KMCGIWMGNS ACSIQYECKH TKINPDYNYT NFDNFGWSFL AMFRLMTQDS
     WEKLYQQTLR TTGLYSVFFF IVVIFLGSFY LINLTLAVVT MAYEEQNKNV AAEIEAKEKM
     FQEAQQLLKE EKEALVAMGI DRSSLTSLET SYFTPKKRKL FGNKKRKSFF LRESGKDQPP
     GSDSDEDCQK KPQLLEQTKR LSQNLSLDHF DEHGDPLQRQ RALSAVSILT ITMKEQEKSQ
     EPCLPCGENL ASKYLVWNCC PQWLCVKKVL RTVMTDPFTE LAITICIIIN TVFLAMEHHK
     MEASFEKMLN IGNLVFTSIF IAEMCLKIIA LDPYHYFRRG WNIFDSIVAL LSFADVMNCV
     LQKRSWPFLR SFRVLRVFKL AKSWPTLNTL IKIIGNSVGA LGSLTVVLVI VIFIFSVVGM
     QLFGRSFNSQ KSPKLCNPTG PTVSCLRHWH MGDFWHSFLV VFRILCGEWI ENMWECMQEA
     NASSSLCVIV FILITVIGKL VVLNLFIALL LNSFSNEERN GNLEGEARKT KVQLALDRFR
     RAFCFVRHTL EHFCHKWCRK QNLPQQKEVA GGCAAQSKDI IPLVMEMKRG SETQEELGIL
     TSVPKTLGVR HDWTWLAPLA EEEDDVEFSG EDNAQRITQP EPEQQAYELH QENKKPTSQR
     VQSVEIDMFS EDEPHLTIQD PRKKSDVTSI LSECSTIDLQ DGFGWLPEMV PKKQPERCLP
     KGFGCCFPCC SVDKRKPPWV IWWNLRKTCY QIVKHSWFES FIIFVILLSS GALIFEDVHL
     ENQPKIQELL NCTDIIFTHI FILEMVLKWV AFGFGKYFTS AWCCLDFIIV IVSVTTLINL
     MELKSFRTLR ALRPLRALSQ FEGMKVVVNA LIGAIPAILN VLLVCLIFWL VFCILGVYFF
     SGKFGKCING TDSVINYTII TNKSQCESGN FSWINQKVNF DNVGNAYLAL LQVATFKGWM
     DIIYAAVDST EKEQQPEFES NSLGYIYFVV FIIFGSFFTL NLFIGVIIDN FNQQQKKLGG
     QDIFMTEEQK KYYNAMKKLG SKKPQKPIPR PLNKCQGLVF DIVTSQIFDI IIISLIILNM
     ISMMAESYNQ PKAMKSILDH LNWVFVVIFT LECLIKIFAL RQYYFTNGWN LFDCVVVLLS
     IVSTMISTLE NQEHIPFPPT LFRIVRLARI GRILRLVRAA RGIRTLLFAL MMSLPSLFNI
     GLLLFLIMFI YAILGMNWFS KVNPESGIDD IFNFKTFASS MLCLFQISTS AGWDSLLSPM
     LRSKESCNSS SENCHLPGIA TSYFVSYIII SFLIVVNMYI AVILENFNTA TEESEDPLGE
     DDFDIFYEVW EKFDPEATQF IKYSALSDFA DALPEPLRVA KPNKYQFLVM DLPMVSEDRL
     HCMDILFAFT ARVLGGSDGL DSMKAMMEEK FMEANPLKKL YEPIVTTTKR KEEERGAAII
     QKAFRKYMMK VTKGDQGDQN DLENGPHSPL QTLCNGDLSS FGVAKGKVHC D
//
